<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="review-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Immunol</journal-id><journal-id journal-id-type="iso-abbrev">Front Immunol</journal-id><journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id><journal-title-group><journal-title>Frontiers in Immunology</journal-title></journal-title-group><issn pub-type="epub">1664-3224</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40012912</article-id><article-id pub-id-type="pmc">PMC11861071</article-id><article-id pub-id-type="doi">10.3389/fimmu.2024.1376654</article-id><article-categories><subj-group subj-group-type="heading"><subject>Immunology</subject><subj-group><subject>Review</subject></subj-group></subj-group></article-categories><title-group><article-title>Immunologic and inflammatory consequences of SARS-CoV-2 infection and its implications in renal disease</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Naiditch</surname><given-names>Hiam</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/2604060"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/visualization/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>Betts</surname><given-names>Michael R.</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>Larman</surname><given-names>H. Benjamin</given-names></name><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/1185217"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>Levi</surname><given-names>Moshe</given-names></name><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Rosenberg</surname><given-names>Avi Z.</given-names></name><xref rid="aff5" ref-type="aff">
<sup>5</sup>
</xref><xref rid="fn001" ref-type="author-notes">
<sup>*</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/1191562"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib></contrib-group><aff id="aff1">
<sup>1</sup>
<institution>Department of Pulmonary, Allergy, Critical Care and Sleep Medicine, University of Pittsburgh</institution>, <addr-line>Pittsburgh, PA</addr-line>, <country>United States</country>
</aff><aff id="aff2">
<sup>2</sup>
<institution>Department of Microbiology and Institute of Immunology, Perelman School of Medicine, University of Pennsylvania</institution>, <addr-line>Philadelphia, PA</addr-line>, <country>United States</country>
</aff><aff id="aff3">
<sup>3</sup>
<institution>Institute for Cell Engineering, Division of Immunology, Department of Pathology, Johns Hopkins University</institution>, <addr-line>Baltimore, MD</addr-line>, <country>United States</country>
</aff><aff id="aff4">
<sup>4</sup>
<institution>Department of Biochemistry and Molecular &#x00026; Cellular Biology, Georgetown University</institution>, <addr-line>Washington, DC</addr-line>, <country>United States</country>
</aff><aff id="aff5">
<sup>5</sup>
<institution>Department of Pathology, Johns Hopkins University</institution>, <addr-line>Baltimore, MD</addr-line>, <country>United States</country>
</aff><author-notes><fn fn-type="edited-by"><p>Edited by: Stelvio Tonello, University of Eastern Piedmont, Italy</p></fn><fn fn-type="edited-by"><p>Reviewed by: Xavier Contreras, Universit&#x000e9; Toulouse III Paul Sabatier, France</p><p>Xi-Chen Zhao, The Central Hospital of Qingdao West Coast New Area, China</p><p>Nicole Vercellino, Universit&#x000e0; degli Studi del Piemonte Orientale, Italy</p></fn><corresp id="fn001">*Correspondence: Avi Z. Rosenberg, <email xlink:href="mailto:arosen34@jhmi.edu">arosen34@jhmi.edu</email>
</corresp></author-notes><pub-date pub-type="epub"><day>12</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2024</year></pub-date><volume>15</volume><elocation-id>1376654</elocation-id><history><date date-type="received"><day>30</day><month>1</month><year>2024</year></date><date date-type="accepted"><day>23</day><month>12</month><year>2024</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2025 Naiditch, Betts, Larman, Levi and Rosenberg</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Naiditch, Betts, Larman, Levi and Rosenberg</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><p>The emergence of the COVID-19 pandemic made it critical to understand the immune and inflammatory responses to the SARS-CoV-2 virus. It became increasingly recognized that the immune response was a key mediator of illness severity and that its mechanisms needed to be better understood. Early infection of both tissue and immune cells, such as macrophages, leading to pyroptosis-mediated inflammasome production in an organ system critical for systemic oxygenation likely plays a central role in the morbidity wrought by SARS-CoV-2. Delayed transcription of Type I and Type III interferons by SARS-CoV-2 may lead to early disinhibition of viral replication. Cytokines such as interleukin-1 (IL-1), IL-6, IL-12, and tumor necrosis factor &#x003b1; (TNF&#x003b1;), some of which may be produced through mechanisms involving nuclear factor kappa B (NF-&#x003ba;B), likely contribute to the hyperinflammatory state in patients with severe COVID-19. Lymphopenia, more apparent among natural killer (NK) cells, CD8+ T-cells, and B-cells, can contribute to disease severity and may reflect direct cytopathic effects of SARS-CoV-2 or end-organ sequestration. Direct infection and immune activation of endothelial cells by SARS-CoV-2 may be a critical mechanism through which end-organ systems are impacted. In this context, endovascular neutrophil extracellular trap (NET) formation and microthrombi development can be seen in the lungs and other critical organs throughout the body, such as the heart, gut, and brain. The kidney may be among the most impacted extrapulmonary organ by SARS-CoV-2 infection owing to a high concentration of ACE2 and exposure to systemic SARS-CoV-2. In the kidney, acute tubular injury, early myofibroblast activation, and collapsing glomerulopathy in select populations likely account for COVID-19-related AKI and CKD development. The development of COVID-19-associated nephropathy (COVAN), in particular, may be mediated through IL-6 and signal transducer and activator of transcription 3 (STAT3) signaling, suggesting a direct connection between the COVID-19-related immune response and the development of chronic disease. Chronic manifestations of COVID-19 also include systemic conditions like Multisystem Inflammatory Syndrome in Children (MIS-C) and Adults (MIS-A) and post-acute sequelae of&#x000a0;COVID-19 (PASC), which may reflect a spectrum of clinical presentations of persistent immune dysregulation. The lessons learned and those undergoing continued study likely have broad implications for understanding viral infections&#x02019; immunologic and inflammatory consequences beyond coronaviruses.</p></abstract><kwd-group><kwd>SARS-CoV-2</kwd><kwd>COVID-19</kwd><kwd>PASC</kwd><kwd>long COVID</kwd><kwd>inflammasome</kwd><kwd>inflammation</kwd><kwd>AKI</kwd></kwd-group><funding-group><funding-statement>The author(s) declare financial support was received for the research, authorship, and/or publication of this article. HN is the recipient of T32 grant 5T32HL007563-35 and F32 grant 1F32MD019534-01.</funding-statement></funding-group><counts><fig-count count="4"/><table-count count="3"/><equation-count count="0"/><ref-count count="415"/><page-count count="30"/><word-count count="17881"/></counts><custom-meta-group><custom-meta><meta-name>section-in-acceptance</meta-name><meta-value>Viral Immunology</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="s1"><label>1</label><title>Introduction</title><p>On March 11, 2020, as healthcare systems worldwide saw rising SARS-CoV-2 cases, COVID-19 was declared a pandemic (<xref rid="B1" ref-type="bibr">1</xref>). The infectivity of the virus and the severity of COVID-19 in many patients led to the accelerated study of the disease (<xref rid="B2" ref-type="bibr">2</xref>). It became increasingly apparent that the immune milieu generated by SARS-CoV-2 was unique, even among similar coronaviruses (<xref rid="B3" ref-type="bibr">3</xref>). Peripheral lymphopenia, elevated inflammatory markers (<xref rid="B4" ref-type="bibr">4</xref>), endothelial damage, and microthrombosis characterized some early findings in COVID-19 (<xref rid="B5" ref-type="bibr">5</xref>). In the years that followed, the immune response to COVID-19 has been further elucidated, allowing for the identification of effective vaccines (<xref rid="B6" ref-type="bibr">6</xref>, <xref rid="B7" ref-type="bibr">7</xref>), monoclonal antibodies (<xref rid="B8" ref-type="bibr">8</xref>), and other therapies (<xref rid="B9" ref-type="bibr">9</xref>, <xref rid="B10" ref-type="bibr">10</xref>). The emergence of syndromes associated with post-infectious immune dysregulation such as Multisystem Inflammatory Syndrome in children (MIS-C) (<xref rid="B11" ref-type="bibr">11</xref>, <xref rid="B12" ref-type="bibr">12</xref>) or adults (MIS-A) (<xref rid="B13" ref-type="bibr">13</xref>, <xref rid="B14" ref-type="bibr">14</xref>) further propelled the study of the disease. A compelling association with autoimmune disease, perhaps related to the development of autoantibodies in the presence of SARS-CoV-2-mediated pyroptosis, further exemplified the complex interplay between the immunologic response in COVID-19 and chronic disease (<xref rid="B15" ref-type="bibr">15</xref>).</p><p>Among the organ systems studied, a high concentration of ACE2 in a highly vascular structure readily exposed to systemic pathogens highlights the human kidney as a unique model for the systemic effects of SARS-CoV-2 (<xref rid="B16" ref-type="bibr">16</xref>). Prior to infection, there is a paucity of immune cells in the human kidney; most of these are CD4+ and CD8+ T cells, with a smaller percentage of NK cells, B cells (<xref rid="B17" ref-type="bibr">17</xref>), and CD14+, CD16+ and CD68+ myeloid cells (<xref rid="B18" ref-type="bibr">18</xref>). Following infection with SARS-CoV-2, an upregulation in proinflammatory genes such as HSPA1A in podocytes and JUN1 in mesenchymal clusters (<xref rid="B19" ref-type="bibr">19</xref>) can accompany selective immune suppression of lymphocytes mediated through T-cell immunoglobulin and mucin-domain containing-3 (TIM-3) and Programmed cell death protein 1 (PD-1) (<xref rid="B20" ref-type="bibr">20</xref>). Resident immune cells may mediate inflammation by TNF&#x003b1; release, IL-34-mediated necrosis, and NLRP3 inflammasome production (<xref rid="B266" ref-type="bibr">266</xref>). Myeloid cell activation is a hallmark of COVID-19 and is associated with immune dysregulation in COVID-19, particularly in severe disease (<xref rid="B21" ref-type="bibr">21</xref>). Moreover, early post-mortem studies revealed compelling evidence for direct infection of predominantly ACE2-positive renal tubular cells by SARS-CoV-2 (<xref rid="B16" ref-type="bibr">16</xref>). Intriguingly, the upregulation of TGF-&#x003b2;, PI3K/Akt, MAPK, and WNT signaling can be associated with tubule interstitial fibrosis and may also point to a mechanism of COVID-19-related CKD (<xref rid="B19" ref-type="bibr">19</xref>).</p><p>The following represents a comprehensive review of the immunologic and inflammatory consequences of SARS-CoV-2 infection, synthesizing the molecular immune response to the acute and chronic end-organ dysfunction in both acute and chronic forms of COVID-19. Among the organ systems studied, particular attention is paid to the kidney and recently described pathophysiology in COVID-19.</p><sec id="s1_1"><label>1.1</label><title>Initial infection with SARS-CoV-2</title><p>SARS-CoV-2 infection occurs predominantly in the upper respiratory tract via ACE2 and TMPRSS2.</p><p>Coronaviruses likely originated in bats and rodents and eventually evolved to affect other animals and humans &#x0fffc;. Their pathogenicity was not fully appreciated until 2002, when the sudden acute respiratory syndrome (SARS) broke out in Guangdong Province, China (<xref rid="B22" ref-type="bibr">22</xref>). Since that time, coronaviruses have been implicated in Middle East respiratory syndrome (MERS) and other less overtly severe clinical entities (<xref rid="B22" ref-type="bibr">22</xref>). Approximately seven years after MERS, SARS-CoV-2 emerged as a public health threat, spurring research into its structure, infectivity, and the immune response it provokes.</p><p>SARS-CoV-2 is a betacoronavirus with an envelope containing an envelope (E) protein, a membrane (M) protein, and a spike (S) protein interspersed within a lipid membrane (<xref rid="B5" ref-type="bibr">5</xref>). The nucleus contains a positive-sense single-stranded RNA molecule bound to the nucleocapsid (N) protein (<xref rid="B23" ref-type="bibr">23</xref>). The bulk of the ssRNA has two open reading frames at the 5&#x02019; end, ORF1a and ORF1b, which are the transcriptional precursors of the viral replication and transcription complex (RTC) (<xref rid="B23" ref-type="bibr">23</xref>). SARS-CoV-2 is transmitted by respiratory and aerosolized droplets from infected individuals actively shedding the virus (<xref rid="B24" ref-type="bibr">24</xref>&#x02013;<xref rid="B26" ref-type="bibr">26</xref>). Virions can contact areas of high angiotensin-converting enzyme 2 (ACE2) and transmembrane protease serine 2 (TMPRSS2) co-expression, namely in goblet secretory cells in the nasopharynx, epithelial cells of the oral mucosa, airway, and alveoli including Type II pneumocytes, and lung macrophages (<xref rid="B27" ref-type="bibr">27</xref>, <xref rid="B28" ref-type="bibr">28</xref>). Viral entry into host cells is facilitated by binding the S protein to ACE2, followed by proteolytic cleavage at the S1/S2 and S&#x02019; sites by TMPRSS2, a process that allows for virus-host membrane fusion (<xref rid="B29" ref-type="bibr">29</xref>). Expression of ACE2 and TMPRSS2 has also been noted in endothelial cells, enterocytes (<xref rid="B27" ref-type="bibr">27</xref>), and podocytes in the kidney glomerulus (<xref rid="B5" ref-type="bibr">5</xref>).</p><p>The importance of ACE2 has been confirmed through GWAS identification of variants (such as X-linked rs190509934) associated with reduced ACE2 expression and reduced likelihood of infection with SARS-CoV-2 (<xref rid="B30" ref-type="bibr">30</xref>, <xref rid="B31" ref-type="bibr">31</xref>). Likewise, increased susceptibility to infection is associated with <italic>SLC6A20</italic> on chromosome 3p21.1, which encodes a protein [sodium-imino acid transporter 1 (SIT1)] that is associated with ACE2 (<xref rid="B30" ref-type="bibr">30</xref>, <xref rid="B31" ref-type="bibr">31</xref>). Dipeptidyl peptidase-4 (DPP-4) has been identified as another possible candidate for SARS-CoV-2 binding <italic>in silico</italic>, albeit of unclear clinical significance (<xref rid="B32" ref-type="bibr">32</xref>&#x02013;<xref rid="B36" ref-type="bibr">36</xref>). In addition to TMPRSS2, proteolysis can also be performed by endosomal cathepsin B (catB) and cathepsin L (catL) (<xref rid="B23" ref-type="bibr">23</xref>). Following fusion, the release and subsequent translation of ORF1a and ORF1b lead to the production of polypeptides pp1a and pp1ab, which are eventually processed into 16 non-structural proteins that comprise the viral RTC (<xref rid="B23" ref-type="bibr">23</xref>) (<xref rid="f1" ref-type="fig">
<bold>Figures&#x000a0;1A, B</bold>
</xref>). Structural proteins are encoded from interspersed ORFs at the 3&#x02019; end of the ssRNA and are eventually processed in the endoplasmic reticulum and Golgi apparatus with modifications including N- and O-glycosylation, which are thought to be critical to virion infectivity (<xref rid="B23" ref-type="bibr">23</xref>, <xref rid="B37" ref-type="bibr">37</xref>). Among the proteins produced during acute infection are replicase proteins, which help form replication complexes within the endoplasmic reticulum (<xref rid="B38" ref-type="bibr">38</xref>).</p><fig position="float" id="f1"><label>Figure&#x000a0;1</label><caption><p>Early immune response to SARS-CoV-2 infection. <bold>(A)</bold> SARS-CoV-2 virions are inhaled through respiratory and aerosolized droplets (<xref rid="B24" ref-type="bibr">24</xref>&#x02013;<xref rid="B26" ref-type="bibr">26</xref>). Infection of susceptible cell types, particularly those bearing ACE2 and TMPRSS, such as Type II pneumocytes, can occur (<xref rid="B27" ref-type="bibr">27</xref>, <xref rid="B28" ref-type="bibr">28</xref>). <bold>(B)</bold> Viral entry can occur through mechanisms including host-membrane fusion (<xref rid="B29" ref-type="bibr">29</xref>). Entry is followed by the release and translation of ORF1a and ORF1b of SARS-CoV-2 ssRNA, formation of the viral replication and transcription complex (<xref rid="B23" ref-type="bibr">23</xref>), and production of new SARS-CoV-2 virions, which are eventually exocytosed. <bold>(C)</bold> Resident macrophages are likely among the first immune cells to encounter SARS-CoV-2 through both direct infection and indirect immune activation. As with other cells, TLR- and RLR-mediated recognition are accompanied by downstream effects through Myd88 activation, TRIF binding (<xref rid="B43" ref-type="bibr">43</xref>, <xref rid="B45" ref-type="bibr">45</xref>, <xref rid="B50" ref-type="bibr">50</xref>), MAVS activation (<xref rid="B45" ref-type="bibr">45</xref>), and NF-&#x003ba;B activation (<xref rid="B45" ref-type="bibr">45</xref>, <xref rid="B52" ref-type="bibr">52</xref>). <bold>(D)</bold> Production of Type I and Type III interferons appears to be blunted in the early immune response (<xref rid="B42" ref-type="bibr">42</xref>, <xref rid="B89" ref-type="bibr">89</xref>) despite their antiviral potential. <bold>(E)</bold> Infection and activation with SARS-CoV-2 may induce inflammasome production and macrophage pyroptosis, which may be a key early driver of a heightened immune response following SARS-CoV-2 infection (<xref rid="B57" ref-type="bibr">57</xref>). <bold>(F)</bold> One such mechanism is through cytokine and chemokine release (<xref rid="B70" ref-type="bibr">70</xref>, <xref rid="B103" ref-type="bibr">103</xref>, <xref rid="B104" ref-type="bibr">104</xref>), including TNF&#x003b1;, TGF-&#x003b2;, CCL2/3, CXCL9/10, IL-1&#x003b2;, IL-2, IL-6, IL-10, IL-17, IL-21, and IL-22 (see text for references). <bold>(G)</bold> The early immune response may also be mediated by pre-existing cross-reactive antibodies (<xref rid="B174" ref-type="bibr">174</xref>&#x02013;<xref rid="B177" ref-type="bibr">177</xref>) and plasmablast development (<xref rid="B173" ref-type="bibr">173</xref>). <bold>(H)</bold> Endothelial cell infection may also occur (<xref rid="B207" ref-type="bibr">207</xref>); endothelial cell activation may be associated with a hypercoagulable state (<xref rid="B210" ref-type="bibr">210</xref>, <xref rid="B211" ref-type="bibr">211</xref>). <bold>(I)</bold> Early neutrophil responses include the production of immature neutrophils through emergency myelopoiesis (<xref rid="B115" ref-type="bibr">115</xref>, <xref rid="B400" ref-type="bibr">400</xref>) and neutrophil extracellular trap (NET) formation, which may also contribute to microvascular thrombosis (<xref rid="B111" ref-type="bibr">111</xref>, <xref rid="B117" ref-type="bibr">117</xref>). <bold>(J)</bold> Soluble pattern recognition molecules such as mannose-binding lectin (MBL) and pentraxin three can bind to SARS-CoV-2 spike and nucleocapsid proteins, respectively (<xref rid="B96" ref-type="bibr">96</xref>). <bold>(K)</bold> Lymphopenia, which often accompanies COVID-19 (<xref rid="B408" ref-type="bibr">408</xref>), can include the peripheral depletion of cell types such as Innate Lymphoid Cells (ILC) (<xref rid="B126" ref-type="bibr">126</xref>, <xref rid="B127" ref-type="bibr">127</xref>), MAIT (<xref rid="B127" ref-type="bibr">127</xref>), NK-cells (<xref rid="B124" ref-type="bibr">124</xref>, <xref rid="B398" ref-type="bibr">398</xref>), and &#x003b3;&#x003b4;-T-cells (<xref rid="B136" ref-type="bibr">136</xref>).</p></caption><graphic xlink:href="fimmu-15-1376654-g001" position="float"/></fig><p>One mechanism of protection from pattern recognition receptors (PRRs), such as melanoma differentiation-associated protein 5 (MDA5), includes the formation of double-membrane vesicles (<xref rid="B38" ref-type="bibr">38</xref>). Relatively unchecked viral replication and an immune response that can be in disarray in severe disease can lead to the eventual dissemination through deeper inhalation of upper respiratory virus-containing particles or contiguous spread from the site of infection (<xref rid="B38" ref-type="bibr">38</xref>). Further dissemination of SARS-CoV-2 to other organ systems can be mediated through viremia, which is associated with adverse clinical outcomes (<xref rid="B39" ref-type="bibr">39</xref>). SARS-CoV-2 can evolve within a host to develop enhanced infectivity, immune evasion, and transmissibility, all of which can translate to pathogenicity and disease severity on the individual and population levels (<xref rid="B40" ref-type="bibr">40</xref>). A mutation rate of approximately 1&#x02009;&#x000d7;&#x02009;10<sup>&#x02013;6</sup> to 2&#x02009;&#x000d7;&#x02009;10<sup>&#x02013;6</sup>&#x02009;mutations per nucleotide per replication cycle is one characteristic of SARS-CoV-2 evolution (<xref rid="B40" ref-type="bibr">40</xref>). Selection pressures such as innate immune defense mechanisms like those mediated by the apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like (APOBEC) family provoke the formation of C-&#x0003e;U mutations, which can alter phenotypic properties of the virus &#x0fffc;, which can, in turn, lead to the development of variants of concern (VOC). Transmissibility resulting from molecular evolution represents a bottleneck for mutations to pass from one host to another and in turn the likelihood of a virus like SARS-CoV-2 to cause an epidemic or pandemic (<xref rid="B40" ref-type="bibr">40</xref>). As a virus enters and uses the host cell for its own propagation, a response is elicited in the human host to fight for its own preservation. In the subsequent sections, that response&#x02014;characterized by distinct but often overlapping cellular and extracellular mechanisms that accompany each stage of infection with SARS-CoV-2&#x02014;will be elucidated.</p></sec></sec><sec id="s2"><label>2</label><title>Acute immunologic and inflammatory response to SARS-CoV-2</title><sec id="s2_1"><label>2.1</label><title>Innate immune responses to acute infection with SARS-CoV-2</title><p>The innate immune response to SARS-CoV-2 is the first line of defense against the virus (<xref rid="B41" ref-type="bibr">41</xref>) and also represents a crossroad at which immune cell recruitment and coordination can be pathologically skewed. Inflammatory cytokine disarray with concomitantly delayed IFN-I and IFN-III responses may be primary mediators of immune dysregulation in severe disease (<xref rid="B42" ref-type="bibr">42</xref>). Dysregulated innate immune responses comprise one of the critical features of COVID-19 (<xref rid="B42" ref-type="bibr">42</xref>).</p><sec id="s2_1_1"><label>2.1.1</label><title>Host cell viral recognition</title><p>Early pattern recognition receptor and Toll-like receptor activation in SARS-CoV-2.</p><p>In normal physiologic conditions, the entry of viral RNA into a host cell does not go unnoticed. The newly released viral ssRNA contains pathogen-associated molecular patterns (PAMPs) recognized as foreign entities by pattern recognition receptors (PRRs) in the cytoplasm and along the cell membrane and endosomal surfaces (<xref rid="B43" ref-type="bibr">43</xref>&#x02013;<xref rid="B45" ref-type="bibr">45</xref>). PRRs include cytoplasmic retinoic acid-inducible gene I-like receptors (RLRs) and membrane-bound Toll-like receptors (TLRs), with subclasses that recognize a wide array of viral nucleic acid assortments (<xref rid="B44" ref-type="bibr">44</xref>, <xref rid="B45" ref-type="bibr">45</xref>). As a positive-sense ssRNA, the viral RNA from SARS-CoV-2 is recognized by the RLRs retinoic acid-inducible gene (RIG-I) and MDA5 by its uncapped 5&#x02019; triphosphate terminus (<xref rid="B43" ref-type="bibr">43</xref>). The activation of RIG-I and MDA5 and their association with mitochondrial antiviral signaling protein (MAVS) eventually leads to the transcription of type I interferons, which are likely dependent on nuclear factor kappa-light-chain enhancer of activated B cells (NF-&#x003ba;B) (<xref rid="B45" ref-type="bibr">45</xref>).</p><p>Positive-sense ssRNA also activates endosomal TLR7 (as well as TLR8), which, in conjunction with myeloid differentiation primary-response gene 88 (MyD88), typically leads to the production of both type I and type III interferons (IFNs) (<xref rid="B46" ref-type="bibr">46</xref>, <xref rid="B47" ref-type="bibr">47</xref>). The TLR7/MyD88 pathway mediates immunity in plasmacytoid dendritic cells (pDCs) in multiple viral infections and is also likely relevant in airway epithelial cells infected with SARS-CoV-2 (<xref rid="B48" ref-type="bibr">48</xref>, <xref rid="B49" ref-type="bibr">49</xref>). Furthermore, the severity of illness in young male patients with loss-of-function variants in the X-linked <italic>TLR7</italic>, as well as the associated defects in type I and type II interferon production, suggest a critical role of this pathway in the innate response to SARS-CoV-2 infection (<xref rid="B46" ref-type="bibr">46</xref>). Endosomal TLR3 may also be activated in the presence of SARS-CoV-2, perhaps due to transient dsRNA produced in the viral replication process (<xref rid="B43" ref-type="bibr">43</xref>, <xref rid="B49" ref-type="bibr">49</xref>). TLR3 binds to TIR-domain-containing adapter-inducing interferon-&#x003b2; (TRIF), which also can lead to type I and type III interferon production via IFN regulatory factor 3 (IRF3) as well as robust NF-&#x003ba;B activation (<xref rid="B43" ref-type="bibr">43</xref>, <xref rid="B45" ref-type="bibr">45</xref>, <xref rid="B50" ref-type="bibr">50</xref>). MyD88 activation can polarize macrophages towards a pro-inflammatory M1 phenotype in mouse models (<xref rid="B51" ref-type="bibr">51</xref>). In addition to the above mechanisms, human airway epithelial cells infected with SARS-CoV-2 have also been shown to have decreased transcription of dual-specificity phosphatase 1 and 5 (<italic>DUSP1</italic> and <italic>DUSP5</italic>), which may lead to unbalanced activation of NF-&#x003ba;B (<xref rid="B52" ref-type="bibr">52</xref>).</p></sec><sec id="s2_1_2"><label>2.1.2</label><title>Compounded inflammation in acute SARS-CoV-2 infection at the level of the host cell</title><p>SARS-CoV-2 provokes the release of pro-inflammatory cytokines via NF-&#x003ba;B, inflammasome production, and pyroptosis.</p><p>Cytopathic viral infection of airway epithelial cells can trigger inflammasome activation, pyroptosis, necroptosis, and apoptosis (<xref rid="B28" ref-type="bibr">28</xref>, <xref rid="B53" ref-type="bibr">53</xref>&#x02013;<xref rid="B55" ref-type="bibr">55</xref>). Early studies during the pandemic revealed intense NLRP3 inflammasome expression in the lungs of patients with fatal COVID-19 (<xref rid="B56" ref-type="bibr">56</xref>), suggesting a pivotal role for pyroptosis in severe COVID-19 (<xref rid="B57" ref-type="bibr">57</xref>). SARS-CoV-2 may promote pyroptosis through non-structural protein 6 (nsp6) (<xref rid="B58" ref-type="bibr">58</xref>). The subsequent release of damage-associated molecular patterns (DAMPs) and activation of IL-1&#x003b2; may be one of the first events leading to the inflammatory cascade that characterizes COVID-19 (<xref rid="B28" ref-type="bibr">28</xref>). The release of DAMPs and IL-1&#x003b2; promotes the release of additional inflammatory cytokines such as macrophage inflammatory protein 1&#x003b1; (MIP1&#x003b1;), MIP1&#x003b2;, IL-6, and interferon gamma-induced protein 10 (IP-10) from adjacent alveolar macrophages, epithelial cells, and endothelial cells (<xref rid="B28" ref-type="bibr">28</xref>, <xref rid="B59" ref-type="bibr">59</xref>). TGF-&#x003b2; production may also be enhanced in severe disease (<xref rid="B60" ref-type="bibr">60</xref>).</p><p>An essential function of ACE2 is to degrade angiotensin II (Ang II) into Ang- (<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B7" ref-type="bibr">7</xref>, <xref rid="B61" ref-type="bibr">61</xref>). As SARS-CoV-2 binds to ACE2 and the complex is endocytosed or incorporated through other mechanisms (<xref rid="B62" ref-type="bibr">62</xref>), less ACE2 is available to perform its typical functions, and levels of Ang II rise. The increasing levels of Ang II provide excess stimulation to the Ang II Type 1 receptor (AT1R), which&#x02014;in addition to vasoconstriction&#x02014;promotes the activation of NF-&#x00138;&#x003b2; through ADAM17 cleavage of TNF&#x003b1;, membrane-bound EGF (<xref rid="B63" ref-type="bibr">63</xref>), and IL-6R&#x003b1; into their soluble forms (<xref rid="B61" ref-type="bibr">61</xref>). Subsequent activation of TNF&#x003b1;R and EGFR also leads to downstream NF-&#x003ba;B activation (<xref rid="B61" ref-type="bibr">61</xref>, <xref rid="B63" ref-type="bibr">63</xref>). The activation of gp130 by the IL6R-&#x003b1;-IL-6 complex further activates a JAK/STAT pathway, amplifying the NF-&#x003ba;B response via STAT3 (<xref rid="B63" ref-type="bibr">63</xref>).</p><p>NF-&#x003ba;B plays a pivotal role in the upregulation of the immune response (<xref rid="B64" ref-type="bibr">64</xref>). It has been hypothesized that the benefits of corticosteroids such as dexamethasone may be partially due to the downregulation of NF-&#x003ba;B pathways (<xref rid="B65" ref-type="bibr">65</xref>). In airway epithelial cells, NF-&#x003ba;B promotes the production of IL-6, G-CSF, GM-CSF, and MIP2 k&#x003b2; (<xref rid="B66" ref-type="bibr">66</xref>). In M1 alveolar macrophages, NF-&#x003ba;B promotes the production of an array of inflammatory cytokines, including IL-1&#x003b2;, IL-6, IL-12, and TNF&#x003b1; (<xref rid="B64" ref-type="bibr">64</xref>). NF-&#x003ba;B in SARS-CoV-2-infected hosts has also been shown to trigger NLRP3 (<xref rid="B57" ref-type="bibr">57</xref>) inflammasome formation and pyroptosis in monocytes through a caspase-1 mechanism with resultant production of DAMPs and cytokines such as IL-1&#x003b2; (<xref rid="B67" ref-type="bibr">67</xref>, <xref rid="B68" ref-type="bibr">68</xref>). DAMP-mediated signaling itself leads to a conformational change in NLRP3 and caspase-1-mediated cleavage of the inhibitory C-terminus of gasdermin D, which is the main effector of pyroptosis (<xref rid="B57" ref-type="bibr">57</xref>). Gasdermin D can then traffic to the cell membrane and polymerize into &#x003b2;-barrel pores, promoting ion (namely, Ca2+) and protein flux and the eventual loss of the mitochondrial membrane potential and IL-1 and IL-18 activation and IL-1&#x003b2; release (<xref rid="B57" ref-type="bibr">57</xref>).</p><p>Other cytokines include IL-2, IL-17, IL-8, macrophage inflammatory protein 1 (MIP-1), monocyte chemoattractant protein 1 (MCP-1), and chemokine ligands (e.g. CCL2, CCL3, and CCL7) including C-X-C motif chemokine ligands (e.g. CXCL2 and CXCL10) (<xref rid="B65" ref-type="bibr">65</xref>). The clinical significance of cytokine release was demonstrated in a 2021 single-cell and bulk RNA-seq analysis of specimens from patients with COVID-19, which showed that upregulation of IL-2, IL-6, IL-8, IL-17A, and NF-&#x003ba;B was correlated with the severity of COVID-19 (<xref rid="B69" ref-type="bibr">69</xref>). The function of several such cytokines and chemokines in COVID-19 are summarized in <xref rid="T1" ref-type="table">
<bold>Table&#x000a0;1</bold>
</xref>. The release of cytokines in COVID-19 is associated with a hyperinflammatory state, leading to what some have called a &#x0201c;cytokine storm&#x0201d; that characterizes severe COVID-19 and its associated end-organ dysfunction syndromes (<xref rid="B61" ref-type="bibr">61</xref>, <xref rid="B63" ref-type="bibr">63</xref>), similar to that seen in other hyperimmune responses characterized by cytokine release syndromes (CRS) related to chimeric antigen receptor-modified T (CAR-T) cell therapy, macrophage activation syndrome (MAS), and hemophagocytic lymphohistiocytosis (HLH) (<xref rid="B70" ref-type="bibr">70</xref>, <xref rid="B71" ref-type="bibr">71</xref>).</p><table-wrap position="float" id="T1"><label>Table&#x000a0;1</label><caption><p>Cytokine and chemokine response in COVID-19.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Cytokine/Chemokine</th><th valign="top" align="left" rowspan="1" colspan="1">Function</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">IL-1&#x003b2;</td><td valign="top" align="left" rowspan="1" colspan="1">Proinflammatory (<xref rid="B383" ref-type="bibr">383</xref>); evidence of inflammasome activation (<xref rid="B384" ref-type="bibr">384</xref>); may induce ACE2 shedding (<xref rid="B383" ref-type="bibr">383</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">IL-1RA</td><td valign="top" align="left" rowspan="1" colspan="1">Evidence of inflammasome activation (<xref rid="B99" ref-type="bibr">99</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">IL-2</td><td valign="top" align="left" rowspan="1" colspan="1">Upregulation correlates with severity of COVID-19 (<xref rid="B69" ref-type="bibr">69</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">IL-6</td><td valign="top" align="left" rowspan="1" colspan="1">Levels highly correlated with SARS-CoV-2 RNAemia (<xref rid="B385" ref-type="bibr">385</xref>) and COVID-19 severity (<xref rid="B69" ref-type="bibr">69</xref>, <xref rid="B386" ref-type="bibr">386</xref>); differentiation of monocytes to macrophages (<xref rid="B70" ref-type="bibr">70</xref>); mediates differentiation of T<sub>H</sub>17-cells (<xref rid="B60" ref-type="bibr">60</xref>, <xref rid="B153" ref-type="bibr">153</xref>, <xref rid="B154" ref-type="bibr">154</xref>); correlates with increase in DN2 B-cell population (<xref rid="B181" ref-type="bibr">181</xref>); persistent elevation (at least 8 months following infection) may be seen in PASC (<xref rid="B301" ref-type="bibr">301</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">IL-7</td><td valign="top" align="left" rowspan="1" colspan="1">Elevated in COVID-19 (<xref rid="B387" ref-type="bibr">387</xref>); important in T-cell development and survival (<xref rid="B387" ref-type="bibr">387</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">IL-8</td><td valign="top" align="left" rowspan="1" colspan="1">Proinflammatory via neutrophil recruitment (<xref rid="B388" ref-type="bibr">388</xref>); upregulation correlates with severity of COVID-19 in some studies (<xref rid="B69" ref-type="bibr">69</xref>, <xref rid="B388" ref-type="bibr">388</xref>); may be associated with duration with illness (<xref rid="B388" ref-type="bibr">388</xref>); may be elevated in PASC (<xref rid="B389" ref-type="bibr">389</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">IL-10</td><td valign="top" align="left" rowspan="1" colspan="1">Key anti-inflammatory mediator which may also blunt anti-SARS-CoV-2 response (<xref rid="B386" ref-type="bibr">386</xref>); associated with COVID-19 severity (<xref rid="B386" ref-type="bibr">386</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">IL-17</td><td valign="top" align="left" rowspan="1" colspan="1">Pro-inflammatory; associated with neutrophil attraction (<xref rid="B311" ref-type="bibr">311</xref>); upregulation of IL-17A correlates with severity of COVID-19 (<xref rid="B69" ref-type="bibr">69</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">IL-18</td><td valign="top" align="left" rowspan="1" colspan="1">Evidence of inflammasome activation (<xref rid="B99" ref-type="bibr">99</xref>, <xref rid="B384" ref-type="bibr">384</xref>); induces IFN-&#x003b3; production (<xref rid="B384" ref-type="bibr">384</xref>); high levels seen in MAS, of note (<xref rid="B384" ref-type="bibr">384</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">IL-21</td><td valign="top" align="left" rowspan="1" colspan="1">Released by T<sub>H</sub>17 (<xref rid="B155" ref-type="bibr">155</xref>); may interact with IFN-&#x003b3; to facilitate DN2 B-cell differentiation (<xref rid="B181" ref-type="bibr">181</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">IL-22</td><td valign="top" align="left" rowspan="1" colspan="1">Released by T<sub>H</sub>1, T<sub>H</sub>17 (<xref rid="B155" ref-type="bibr">155</xref>, <xref rid="B390" ref-type="bibr">390</xref>), and NK cells (<xref rid="B390" ref-type="bibr">390</xref>); anti-inflammatory (<xref rid="B390" ref-type="bibr">390</xref>), anti-apoptotic, and anti-oxidant properties specifically on epithelial cells and fibroblasts (<xref rid="B391" ref-type="bibr">391</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">IFN-&#x003b1; (T1 IFN)</td><td valign="top" align="left" rowspan="1" colspan="1">Critical component of antiviral response (<xref rid="B392" ref-type="bibr">392</xref>); significant impairment (low levels) in severe and critical COVID-19 (<xref rid="B94" ref-type="bibr">94</xref>, <xref rid="B393" ref-type="bibr">393</xref>); IgG autoantibodies to IFN-&#x003b1;2 (<xref rid="B285" ref-type="bibr">285</xref>, <xref rid="B309" ref-type="bibr">309</xref>) may be seen in patients with critical COVID-19 (<xref rid="B309" ref-type="bibr">309</xref>) which may persist for at least 2-3 months after infection (<xref rid="B285" ref-type="bibr">285</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">IFN-&#x003b2; (T1 IFN)</td><td valign="top" align="left" rowspan="1" colspan="1">Critical component of antiviral response (<xref rid="B392" ref-type="bibr">392</xref>); significant impairment [absent, in at least one study (<xref rid="B94" ref-type="bibr">94</xref>)] in severe and critical COVID-19 (<xref rid="B94" ref-type="bibr">94</xref>, <xref rid="B393" ref-type="bibr">393</xref>); persistent elevation (at least 8 months following infection) may be seen in PASC (<xref rid="B301" ref-type="bibr">301</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">IFN-&#x003b3; (T2 IFN)</td><td valign="top" align="left" rowspan="1" colspan="1">May be a key component of cytokine-mediated inflammatory cell death and shock state together with TNF&#x003b1; (<xref rid="B394" ref-type="bibr">394</xref>); Drives extrafollicular B cells to antiviral antibody production (<xref rid="B181" ref-type="bibr">181</xref>, <xref rid="B395" ref-type="bibr">395</xref>); persistent elevation (at least 8 months following infection) may be seen in PASC (<xref rid="B301" ref-type="bibr">301</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">TGF-&#x003b2;</td><td valign="top" align="left" rowspan="1" colspan="1">Induces peripheral plasmablast antibody production (namely, IgG1 and IgA1) (<xref rid="B396" ref-type="bibr">396</xref>) mediates differentiation of T<sub>H</sub>17-cells (<xref rid="B60" ref-type="bibr">60</xref>, <xref rid="B153" ref-type="bibr">153</xref>, <xref rid="B154" ref-type="bibr">154</xref>); may inopportunely suppress NK cell function in severe COVID-19 (<xref rid="B397" ref-type="bibr">397</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">TNF&#x003b1;</td><td valign="top" align="left" rowspan="1" colspan="1">Proinflammatory (<xref rid="B383" ref-type="bibr">383</xref>); may induce ACE2 shedding (<xref rid="B383" ref-type="bibr">383</xref>); may be a key component of cytokine-mediated inflammatory cell death and shock state (<xref rid="B394" ref-type="bibr">394</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">CCL2/MCP-1</td><td valign="top" align="left" rowspan="1" colspan="1">Elevated in COVID-19 patients compared to matched healthy controls (<xref rid="B311" ref-type="bibr">311</xref>); may indicate monocyte chemoattraction to affected lung (<xref rid="B94" ref-type="bibr">94</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">CCL3/MIP1&#x003b1;</td><td valign="top" align="left" rowspan="1" colspan="1">Elevated in COVID-19 patients compared to matched healthy controls (<xref rid="B311" ref-type="bibr">311</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">CCL4/MIP1&#x003b2;</td><td valign="top" align="left" rowspan="1" colspan="1">Elevated in COVID-19 patients compared to matched healthy controls (<xref rid="B311" ref-type="bibr">311</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">CXCL9</td><td valign="top" align="left" rowspan="1" colspan="1">IFN-&#x003b3;-induced (<xref rid="B384" ref-type="bibr">384</xref>); may be elevated in cytokine storm syndromes (<xref rid="B384" ref-type="bibr">384</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">CXCL10/IP-10</td><td valign="top" align="left" rowspan="1" colspan="1">Correlates with disease progression (<xref rid="B82" ref-type="bibr">82</xref>) and an increase in DN2 B-cell population (<xref rid="B181" ref-type="bibr">181</xref>); may remain elevated throughout viral infection, which may be unique to severe coronavirus infections (<xref rid="B82" ref-type="bibr">82</xref>); associated with an increase in EF B cells (<xref rid="B181" ref-type="bibr">181</xref>)</td></tr></tbody></table></table-wrap><p>Hyperinflammatory immune responses are not necessarily unique to SARS-CoV-2 (<xref rid="B72" ref-type="bibr">72</xref>, <xref rid="B73" ref-type="bibr">73</xref>): High levels of IL-6 have been noted in patients with acute respiratory distress (ARDS) before the COVID-19 pandemic (<xref rid="B74" ref-type="bibr">74</xref>). Others have suggested that lymphocyte depletion and exhaustion, delayed interferon response, and decreased TNF&#x003b1; production in certain phases of the disease are indicators of immune suppression (<xref rid="B75" ref-type="bibr">75</xref>). Although a more precise depiction of the cytokine-mediated inflammatory response in COVID-19 may be suggested by the term &#x0201c;cytokine disharmony&#x0201d; or other terms denoting dysregulation, by and large, the immune response in severe forms of COVID-19 appears to skew towards a hyperinflammatory cytokine dysregulation (<xref rid="B76" ref-type="bibr">76</xref>&#x02013;<xref rid="B81" ref-type="bibr">81</xref>), with early outcomes in severe disease perhaps attributable to cytokines preferentially elevated in SARS-CoV-2 (<xref rid="B73" ref-type="bibr">73</xref>, <xref rid="B82" ref-type="bibr">82</xref>), interferon I dysregulation (<xref rid="B83" ref-type="bibr">83</xref>), and local microthrombi formation (<xref rid="B74" ref-type="bibr">74</xref>, <xref rid="B84" ref-type="bibr">84</xref>), as will be discussed in further detail.</p></sec><sec id="s2_1_3"><label>2.1.3</label><title>The role of interferons</title><p>Interferon release is suppressed early in the course of SARS-CoV-2 infection.</p><p>Interferons are integral to the antiviral immune armamentarium and have been shown to have potent anti-SARS-CoV-2 activity (<xref rid="B85" ref-type="bibr">85</xref>). Critical illness in COVID-19 is associated with inborn errors of genes involved in Type I interferon production (<xref rid="B86" ref-type="bibr">86</xref>). While IFN-&#x003b1; and IFN-&#x003b2; can contribute to inflammation in SARS-CoV-2 through IFNR-mediated downstream activation of NF-&#x003ba;B, the simultaneous stimulation of interferon-stimulated genes (ISGs) can promote the development of a potent antiviral state (<xref rid="B87" ref-type="bibr">87</xref>, <xref rid="B88" ref-type="bibr">88</xref>). First, IFN acts to increase PRRs, which can improve viral detection (<xref rid="B88" ref-type="bibr">88</xref>). In tandem, many proteins are produced via ISGs, which can inhibit nearly every step in viral infection and replication (<xref rid="B88" ref-type="bibr">88</xref>).</p><p>Despite their seemingly potent anti-SARS-CoV-2 activity, the transcription of crucial interferon genes for type I and type III interferons (<italic>IFNB, IFNK, IFNA5</italic>, and <italic>IFNL1-5</italic>) is suppressed early in the course of SARS-CoV-2 infection, particularly in severe disease (<xref rid="B42" ref-type="bibr">42</xref>, <xref rid="B89" ref-type="bibr">89</xref>). Mechanisms may include suppression of sequential steps along the pathway of ISG production, similar to that mediated by other coronaviruses such as SARS-CoV-1 [mediated in part by Nsp1 (<xref rid="B90" ref-type="bibr">90</xref>)] and MERS-CoV in humans and murine hepatitis virus (MHV) in mice (<xref rid="B91" ref-type="bibr">91</xref>&#x02013;<xref rid="B93" ref-type="bibr">93</xref>). This phenomenon, among others, may help to explain the pathogenicity and associated immune dysregulation of SARS-CoV-2 (<xref rid="B85" ref-type="bibr">85</xref>, <xref rid="B89" ref-type="bibr">89</xref>, <xref rid="B94" ref-type="bibr">94</xref>, <xref rid="B95" ref-type="bibr">95</xref>).</p></sec><sec id="s2_1_4"><label>2.1.4</label><title>Soluble pattern recognition molecules</title><p>Soluble pattern recognition molecules (PRMs) have antibody-like functions representing a key component of humoral immunity (<xref rid="B96" ref-type="bibr">96</xref>). These include collectins (e.g., mannose-binding lectin (MBL), which activates the complement system via the lectin pathway), pentraxins [e.g., C-reactive protein (CRP)], C1q, and ficolins (<xref rid="B96" ref-type="bibr">96</xref>). Systemic complement activation was upregulated in patients with COVID-19, with sC5b-9 and C4d found to be higher in those patients with respiratory failure (<xref rid="B97" ref-type="bibr">97</xref>). A 2022 study revealed that MBL and pentraxin 3 (PTX3) play critical roles in humoral immunity against SARS-CoV-2, with MBL binding to spike (S) protein in a glycan-dependent manner prompting complement activation via the lectin pathway and with PTX3 binding to nucleocapsid (<xref rid="B96" ref-type="bibr">96</xref>) (<xref rid="f1" ref-type="fig">
<bold>Figure&#x000a0;1J</bold>
</xref>). Furthermore, single nucleotide polymorphisms (SNPs) of the <italic>MBL2</italic> gene, particularly rs10824845, suggest an association with the severity of COVID-19 (<xref rid="B96" ref-type="bibr">96</xref>). Interestingly, despite its apparent association with clinical outcomes, CRP was not shown to bind to any of the SARS-CoV-2 proteins tested, which included S, N, and E (<xref rid="B96" ref-type="bibr">96</xref>, <xref rid="B98" ref-type="bibr">98</xref>).</p></sec><sec id="s2_1_5"><label>2.1.5</label><title>Monocytes and macrophages</title><p>Monocytes and macrophages play a prominent role in the dysregulated immune response to SARS-CoV-2 (<xref rid="B71" ref-type="bibr">71</xref>). Macrophages express ACE2 receptors and represent targets for SARS-CoV-2 viral entry [which may also occur via the Fc receptor CD16 (<xref rid="B99" ref-type="bibr">99</xref>)], viral replication (<xref rid="B99" ref-type="bibr">99</xref>) and spread (<xref rid="B100" ref-type="bibr">100</xref>, <xref rid="B101" ref-type="bibr">101</xref>), and associated immune responses (<xref rid="B102" ref-type="bibr">102</xref>). Responsiveness to TLR associated with suppressing IL-1R-associated kinase (IRAK)-M expression points to hyperinflammatory phenotype (<xref rid="B102" ref-type="bibr">102</xref>). Macrophages mediate cytokine release in COVID-19 through STAT1 signaling and pDC activation and may be associated with a dampened IFN-I response (<xref rid="B103" ref-type="bibr">103</xref>, <xref rid="B104" ref-type="bibr">104</xref>). Once activated during SARS-CoV-2 infection, macrophages showed signs of inflammasome activation as evidenced by an associated speck-like protein containing a CARD (ASC) co-localization with NLR family pyrin domain containing 3 (NLRP3) and activated caspase-1, as shown in a recently published <italic>in vivo</italic> murine model with a humanized immune system (<xref rid="B99" ref-type="bibr">99</xref>). IL-18 and IL-1RA (considered downstream evidence of inflammasome activation) were upregulated (with IL-1&#x003b2; also evident <italic>in vitro</italic>), as was chemokine CXCL10 expression (<xref rid="B99" ref-type="bibr">99</xref>). Finally, pyroptosis was also increased in this model as measured by LDH and gasdermin D levels (<xref rid="B99" ref-type="bibr">99</xref>). Similar results were seen in <italic>in vitro</italic> studies of monocytes (<xref rid="B67" ref-type="bibr">67</xref>). IL-6 further promotes the differentiation of monocytes to macrophages (<xref rid="B70" ref-type="bibr">70</xref>). Perhaps owing to the ubiquity of macrophages in tissues (<xref rid="B105" ref-type="bibr">105</xref>), macrophage-induced inflammation&#x02014;mediated in part by direct viral infection, inflammasome activation, pyroptosis (<xref rid="B57" ref-type="bibr">57</xref>), and cytokine release (<xref rid="B70" ref-type="bibr">70</xref>, <xref rid="B103" ref-type="bibr">103</xref>, <xref rid="B104" ref-type="bibr">104</xref>)&#x02014;appears to be a prominent driver of the SARS-CoV-2-mediated immune response (<xref rid="B101" ref-type="bibr">101</xref>, <xref rid="B106" ref-type="bibr">106</xref>) (<xref rid="f1" ref-type="fig">
<bold>Figures&#x000a0;1C&#x02013;F</bold>
</xref>).</p></sec><sec id="s2_1_6"><label>2.1.6</label><title>Plasmacytoid dendritic cells</title><p>Plasmacytoid dendritic cells (pDCs) help drive the immune response to viral infections such as coronaviruses (<xref rid="B107" ref-type="bibr">107</xref>). pDCs are more likely to be directly infected with SARS-CoV-2 than macrophages (<xref rid="B104" ref-type="bibr">104</xref>), and emerging evidence has shown that pDCs are the predominant cell type involved in the production of Type I and Type III interferons (<xref rid="B108" ref-type="bibr">108</xref>). COVID-19 severity is inversely correlated with a pDC-driven IFN&#x003b1; response (<xref rid="B108" ref-type="bibr">108</xref>). The presence of pDCs was seen in the lungs of patients with SARS-CoV-2 and was associated with IFN-I signaling, itself correlated with macrophage inflammatory response (<xref rid="B104" ref-type="bibr">104</xref>). pDCs have been shown to enhance TLR signaling in macrophages via IFN-1; RNAseq studies have additionally shown mediation of transcriptional changes in macrophages that correlate with a more robust inflammatory response to SARS-CoV-2 than to LPS (<xref rid="B104" ref-type="bibr">104</xref>). A 2021 study showed that both myeloid and plasmacytoid dendritic cells show an alteration in DC homing and activation markers such as PDL-1, CD86, and CCR7 that correlated with hospitalization status (<xref rid="B109" ref-type="bibr">109</xref>). Given the central importance of macrophages in COVID-19, the mechanistic pathways involving pDCs are likely a critical first step in developing the hyperinflammatory cytokine response accompanying macrophage activation in severe disease. Functional alterations of DCs and deficiency of pDCs (as well as CD1c+ mDCs) may persist seven months after acute SARS-CoV-2 infection (<xref rid="B109" ref-type="bibr">109</xref>).</p></sec><sec id="s2_1_7"><label>2.1.7</label><title>Neutrophils</title><p>In addition to their overt role in bacterial and fungal infections, neutrophils can contribute to the immune response to viruses (<xref rid="B110" ref-type="bibr">110</xref>). They may additionally exhibit enhanced trafficking to highly vascularized organs such as the lungs and kidneys (<xref rid="B111" ref-type="bibr">111</xref>). Neutrophilia (<xref rid="B112" ref-type="bibr">112</xref>) and a high neutrophil-to-lymphocyte ratio are associated with severe COVID-19 (<xref rid="B113" ref-type="bibr">113</xref>, <xref rid="B114" ref-type="bibr">114</xref>). Early studies using single-cell transcriptomics and proteomics from peripheral blood mononuclear cells (PBMC) of patients with COVID-19 showed altered myelopoiesis in patients with severe disease (<xref rid="B115" ref-type="bibr">115</xref>). Immature neutrophils expressing CD24, DEFA3, DEFA4, and PGLYRP1 were a prominent cell population in that study (<xref rid="B115" ref-type="bibr">115</xref>). Another study showed a reduction in the neutrophil maturation marker CD-10, associated with emergency myelopoiesis (<xref rid="B400" ref-type="bibr">400</xref>) and poor clinical outcomes (<xref rid="B116" ref-type="bibr">116</xref>). Among the mechanisms studied, the formation of neutrophil extracellular traps (NETs) (aggregates of extracellular DNA, histones, neutrophil elastase, myeloperoxidase, and other molecules such as tissue factor) (<xref rid="B111" ref-type="bibr">111</xref>) are thought to play a prominent role in COVID-19 pathogenesis, mediated in part through target-organ microvascular occlusion (<xref rid="B111" ref-type="bibr">111</xref>) and associated immunothrombosis (<xref rid="B111" ref-type="bibr">111</xref>, <xref rid="B117" ref-type="bibr">117</xref>) (<xref rid="f1" ref-type="fig">
<bold>Figure&#x000a0;1I</bold>
</xref>).</p></sec><sec id="s2_1_8"><label>2.1.8</label><title>Natural killer cells</title><p>Acknowledging the innate-adaptive overlap exhibited by natural killer (NK) cells (<xref rid="B118" ref-type="bibr">118</xref>), NK cells play an essential role in innate antiviral responses (<xref rid="B119" ref-type="bibr">119</xref>, <xref rid="B120" ref-type="bibr">120</xref>). While an increased frequency of activated NKG2C<sup>+</sup>CD57<sup>+</sup> CD56<sup>dim</sup> NK cell phenotypes may be seen in severe COVID-19 (<xref rid="B121" ref-type="bibr">121</xref>), severe infection is associated with peripheral NK cell depletion and an exhausted phenotype based on LAG3, PDCD1, and HAVCR2 expression, which may be mediated by aberrant TGF-&#x003b2; production and homing to lung tissue (<xref rid="B121" ref-type="bibr">121</xref>, <xref rid="B122" ref-type="bibr">122</xref>). NK cell quiescence manifesting as decreased perforin and granzyme production has also been demonstrated in COVID-19. This may be mediated by increased IL-6 (<xref rid="B123" ref-type="bibr">123</xref>) and TNF&#x003b1;, both part of the cytokine milieu characterizing the syndrome (<xref rid="B124" ref-type="bibr">124</xref>).</p></sec><sec id="s2_1_9"><label>2.1.9</label><title>Innate lymphoid cells</title><p>Innate lymphoid cells (ILC) are more recently described subsets of lymphocytes that can participate in innate immune responses that mirror type 1, type 2, and type 3 immune responses (<xref rid="B125" ref-type="bibr">125</xref>). Studies have shown that illness severity in COVID-19 is inversely associated with ILC count (<xref rid="B126" ref-type="bibr">126</xref>, <xref rid="B127" ref-type="bibr">127</xref>). ILC-mediated amphiregulin production has been proposed as one mechanism of immune tolerance (<xref rid="B126" ref-type="bibr">126</xref>). Of note, a proportionally higher number of amphiregulin-producing ILC was seen in healthy controls vs patients hospitalized with COVID-19 and in females versus males (<xref rid="B126" ref-type="bibr">126</xref>).</p></sec><sec id="s2_1_10"><label>2.1.10</label><title>Mucosal-associated invariant T-cells</title><p>Mucosal-associated invariant T-cells (MAIT) are innate-like T cells that recognize non-specific riboflavin metabolites of bacteria at mucosal surfaces, including those lining the bronchial tree, which are also activated during viral infections (<xref rid="B128" ref-type="bibr">128</xref>, <xref rid="B129" ref-type="bibr">129</xref>)and can inhibit viral replication (<xref rid="B130" ref-type="bibr">130</xref>). While the specificity and significance of this cell type in COVID-19 is still under study, heightened activation of circulating CD8+ MAIT cells (<xref rid="B127" ref-type="bibr">127</xref>, <xref rid="B128" ref-type="bibr">128</xref>) may correlate with illness severity as measured by Simplified Acute Physiology (SAPS) II score (<xref rid="B128" ref-type="bibr">128</xref>).</p></sec><sec id="s2_1_11"><label>2.1.11</label><title>&#x003b3;&#x003b4;-T-cells</title><p>&#x003b3;&#x003b4;-T-cells are another subset of T-lymphocytes with innate-like functionality with the potential to induce strong antiviral responses independent of MHC-mediated antigen presentation (<xref rid="B122" ref-type="bibr">122</xref>, <xref rid="B131" ref-type="bibr">131</xref>, <xref rid="B132" ref-type="bibr">132</xref>). Their use in cancer immunotherapy (<xref rid="B122" ref-type="bibr">122</xref>, <xref rid="B133" ref-type="bibr">133</xref>) and presence at mucosal barrier sites (<xref rid="B134" ref-type="bibr">134</xref>) stimulated interest in their role in COVID-19 (<xref rid="B133" ref-type="bibr">133</xref>, <xref rid="B134" ref-type="bibr">134</xref>). In SARS-CoV-1, they appear to be active members of the immune milieu (<xref rid="B133" ref-type="bibr">133</xref>, <xref rid="B135" ref-type="bibr">135</xref>). However, their role in SARS-CoV-2 appears to be muted (<xref rid="B131" ref-type="bibr">131</xref>) compared to SARS-CoV-1<sup>120</sup>. In addition to their peripheral depletion, as with other T-cell subsets (<xref rid="B136" ref-type="bibr">136</xref>), &#x003b3;&#x003b4;-T cells could not mount a potent immune response to spike or nucleocapsid antigen <italic>in vitro</italic> studies (<xref rid="B131" ref-type="bibr">131</xref>). The depletion of various innate-like lymphocyte subtypes is portrayed as a component of the early immune response to SARS-CoV-2 in <xref rid="f1" ref-type="fig">
<bold>Figure&#x000a0;1K</bold>
</xref>.</p></sec></sec><sec id="s2_2"><label>2.2</label><title>Adaptive immune responses to SARS-CoV-2 infection</title><p>Components of the innate immune response to SARS-CoV-2 infection can help in the immediacy of their response while simultaneously perpetuating detrimental non-specific inflammatory signaling. The adaptive immune response generally follows the innate immune response and provides an additional layer of nuanced and potentially potent protection in patients with and recovering from COVID-19. In addition, the memory adaptive response induced by both natural infection and vaccination, as discussed below, plays a crucial role in protection from reinfection, limiting disease severity and hastening resolution in the event of reinfection.</p><p>The adaptive immune response plays an important role in viral infections, primarily consisting of CD4+ T-cells, CD8+ T-cells, and B-cells (<xref rid="B137" ref-type="bibr">137</xref>). Despite this role, lymphopenia is a hallmark of COVID-19 and may correlate with disease severity and severe lung injury (<xref rid="B127" ref-type="bibr">127</xref>, <xref rid="B138" ref-type="bibr">138</xref>, <xref rid="B139" ref-type="bibr">139</xref>) (<xref rid="f2" ref-type="fig">
<bold>Figure&#x000a0;2A</bold>
</xref>). In addition to the direct cytopathic effects of SARS-CoV-2 (<xref rid="B140" ref-type="bibr">140</xref>), early studies showed significant damage to lymphoid tissue and lymphocyte apoptosis in the lymph nodes and spleen of deceased patients with COVID-19 (<xref rid="B141" ref-type="bibr">141</xref>). Additional mechanisms may involve sequestration or recruitment of lymphocytes to actively inflamed tissues such as the lung and other target organs (<xref rid="B127" ref-type="bibr">127</xref>, <xref rid="B142" ref-type="bibr">142</xref>). Lymphopenia also appears to be inversely related to levels of IL-6 and therapeutically targeted IL-6 inhibition can lead to the correction of circulating lymphocyte counts (<xref rid="B143" ref-type="bibr">143</xref>, <xref rid="B144" ref-type="bibr">144</xref>).</p><fig position="float" id="f2"><label>Figure&#x000a0;2</label><caption><p>Lymphocyte response in acute and post-acute SARS-COV-2. <bold>(A)</bold> Lymphopenia is a hallmark of COVID-19 (<xref rid="B408" ref-type="bibr">408</xref>). <bold>(B)</bold> Among the cell types present, CD4+ T-cells skew towards T<sub>H1</sub> and T<sub>FH</sub> phenotypes with associated effector functions (<xref rid="B145" ref-type="bibr">145</xref>, <xref rid="B151" ref-type="bibr">151</xref>); germinal center T<sub>FH</sub> may be decreased (<xref rid="B151" ref-type="bibr">151</xref>). Upregulation of T<sub>H</sub>17-cells can occur [in contrast to T<sub>reg</sub> (<xref rid="B156" ref-type="bibr">156</xref>)] and may be accompanied by the pro-inflammatory release of IFN-&#x003b3;, GM-CSF, IL-10, IL-17A, IL-17F, IL-21, and IL-22 (<xref rid="B155" ref-type="bibr">155</xref>). <bold>(C)</bold> CD8+ cells exhibit activated phenotypes with preserved effector function and a potential role in macrophage-mediated cytokine release in acute COVID-19 (<xref rid="B137" ref-type="bibr">137</xref>, <xref rid="B161" ref-type="bibr">161</xref>, <xref rid="B163" ref-type="bibr">163</xref>) despite showing peripheral depletion (<xref rid="B139" ref-type="bibr">139</xref>, <xref rid="B144" ref-type="bibr">144</xref>, <xref rid="B159" ref-type="bibr">159</xref>, <xref rid="B160" ref-type="bibr">160</xref>). <bold>(D)</bold> B-cells are also peripherally depleted in COVID-19 (<xref rid="B173" ref-type="bibr">173</xref>, <xref rid="B181" ref-type="bibr">181</xref>). Plasmablast development occurs at first in extrafollicular zones (<xref rid="B173" ref-type="bibr">173</xref>), initially with less sophisticated targeting (<xref rid="B173" ref-type="bibr">173</xref>, <xref rid="B181" ref-type="bibr">181</xref>) via DN2 and DN3 B-cells (<xref rid="B181" ref-type="bibr">181</xref>), but later [at approximately seven days post-infection (<xref rid="B181" ref-type="bibr">181</xref>)] with more robust class-switching, somatic hypermutation and affinity maturation (<xref rid="B173" ref-type="bibr">173</xref>) from germinal center (GC) cells. <bold>(E)</bold> Autoantibody development, including those directed towards interferons, can develop at this time (<xref rid="B309" ref-type="bibr">309</xref>) and may later be associated with PASC (<xref rid="B285" ref-type="bibr">285</xref>). <bold>(F)</bold> In the post-acute phase, effector CD4+ T-cell subtypes may remain active for at least 2-3 months (<xref rid="B285" ref-type="bibr">285</xref>). Decreased levels of na&#x000ef;ve CD4+ T-cells suggest ongoing activation (<xref rid="B301" ref-type="bibr">301</xref>). Memory T-cells (which can develop early in the course of infection) can include those of the CD4+ and CD8+ T-cells and subtypes (<xref rid="B165" ref-type="bibr">165</xref>, <xref rid="B406" ref-type="bibr">406</xref>), and may be detected at least one year post-infection (<xref rid="B165" ref-type="bibr">165</xref>). S-specific CXCR3-/CXCR5-/CCR6+ T<sub>H</sub>17-cells can have a half-life of 4.9 years (<xref rid="B405" ref-type="bibr">405</xref>). Memory T-cells may be important drivers of vaccine-mediated immunity (<xref rid="B194" ref-type="bibr">194</xref>, <xref rid="B195" ref-type="bibr">195</xref>). <bold>(G)</bold> CD8+ T-cells may continue to exhibit markers of activation and exhaustion (PD-1 and TIM-3) at three months, particularly in patients with PASC, and have been observed to persist for up to 8 months (<xref rid="B301" ref-type="bibr">301</xref>). Memory CD8+ T-cells may have a half-life of one year (<xref rid="B405" ref-type="bibr">405</xref>); this can vary by disease severity (<xref rid="B405" ref-type="bibr">405</xref>). <bold>(H)</bold> Depletion of na&#x000ef;ve B-cells suggests ongoing activation at eight months (<xref rid="B301" ref-type="bibr">301</xref>). Memory B-cell (MBC) frequency may correlate with decreased symptom duration (<xref rid="B403" ref-type="bibr">403</xref>) and may also have a role in vaccine-mediate immunity, even as antibody levels subside (<xref rid="B192" ref-type="bibr">192</xref>). MBC associated with autoantibody or SARS-CoV-2-directed antibody production may also be associated with varying PASC symptomatology (<xref rid="B285" ref-type="bibr">285</xref>). Of note, autoantibody production may occur early and may precede COVID-19 diagnosis (<xref rid="B285" ref-type="bibr">285</xref>).</p></caption><graphic xlink:href="fimmu-15-1376654-g002" position="float"/></fig><sec id="s2_2_1"><label>2.2.1</label><title>CD4+ T-cells</title><p>CD4+ T-cells are integral to developing a targeted adaptive immune response by recognizing foreign antigens on MHC Class II molecules and activating other immune cells, including CD8+ T-cells, B-cells, and NK cells (<xref rid="B145" ref-type="bibr">145</xref>). Specific viral targets of CD4+ T-cells include M, N, and S, nsp3 and ORF3, and others, albeit to a smaller degree (<xref rid="B137" ref-type="bibr">137</xref>, <xref rid="B146" ref-type="bibr">146</xref>). Tan et&#x000a0;al. and others showed that a robust CD4+ T-cell response is important for viral clearance in SARS-CoV-2 (<xref rid="B147" ref-type="bibr">147</xref>) and that the relative absence of such a response could be fatal (<xref rid="B148" ref-type="bibr">148</xref>). Early studies showed a more prominent CD4+ T-cell response than CD8+ T-cells (<xref rid="B137" ref-type="bibr">137</xref>), with increased expression of CD38 in moderate-to-severe disease indicative of an activated phenotype (<xref rid="B149" ref-type="bibr">149</xref>). An increased proportion of cytotoxic CD4+ T helper (CTL-T<sub>H</sub>) cells and follicular T<sub>FH</sub>-cells (which have a role in B-cell affinity maturation and antibody production) were seen in hospitalized patients with COVID-19 relative to regulatory T-cell (T<sub>reg</sub>) populations (<xref rid="B145" ref-type="bibr">145</xref>). Curiously, another study showed a positive correlation of specifically CD8+ T<sub>reg</sub> cells with increased CD4+ cells in patients with acute SARS-CoV-2 infection (<xref rid="B150" ref-type="bibr">150</xref>), a finding potentially indicative of a compensatory anti-inflammatory program (<xref rid="B89" ref-type="bibr">89</xref>).</p><p>As noted, depletion of T-cells, particularly in the peripheral blood, is a hallmark of severe COVID-19 (<xref rid="B144" ref-type="bibr">144</xref>, <xref rid="B149" ref-type="bibr">149</xref>). T-cells exhibit enhanced expression of apoptotic pathways and T-cell immunoglobulin and mucin-domain containing-3 (Tim-3) and programmed cell death protein 1 (PD-1), which&#x02014;while expressed in activated states&#x02014;can also be markers of T-cell exhaustion (<xref rid="B139" ref-type="bibr">139</xref>). In addition, germinal centers&#x02014;which are important sites of T-cell and B-cell interaction&#x02014;are lost in thoracic lymph nodes of patients with acute COVID-19, with an associated loss of germinal center CD4+ Bcl-6+ T<sub>FH</sub>-cells and an increased proportion of T<sub>H1</sub>-cells (<xref rid="B151" ref-type="bibr">151</xref>), which are responsible for IFN&#x003b3; production. Bcl-6 is a transcriptional repressor that can allow for the development of high-affinity immunoglobulins in both T and B-cells (<xref rid="B152" ref-type="bibr">152</xref>). Taken together, T-cell lymphopenia, exhaustion, and associated immune sequelae likely contribute to the immune dysregulation in COVID-19 (<xref rid="f2" ref-type="fig">
<bold>Figure&#x000a0;2B</bold>
</xref>).</p></sec><sec id="s2_2_2"><label>2.2.2</label><title>T<sub>H</sub>17 cells</title><p>T<sub>H</sub>17 cells are a distinct lineage of CD4+ T-cells that are typically involved in the clearance of extracellular pathogens (<xref rid="B153" ref-type="bibr">153</xref>). Their differentiation is mediated through TGF-&#x003b2; and IL-6 (<xref rid="B153" ref-type="bibr">153</xref>), both of which are upregulated in severe COVID-19 (<xref rid="B60" ref-type="bibr">60</xref>, <xref rid="B154" ref-type="bibr">154</xref>). T<sub>H</sub>17 cells may contribute to acute inflammation in COVID-19 through the release of IFN-&#x003b3;, GM-CSF, IL-10, IL-17A, IL-17F, IL-21, and IL-22 (<xref rid="B155" ref-type="bibr">155</xref>) (<xref rid="f2" ref-type="fig">
<bold>Figure&#x000a0;2B</bold>
</xref>). An increased T<sub>H</sub>17/T<sub>reg</sub> ratio and their associated factors (e.g., RAR-related orphan receptor gamma (ROR&#x003b3;t)/Forkhead box protein P3 (FoxP3) appear to correlate with SARS-CoV-2 infection as well as clinical outcome (<xref rid="B156" ref-type="bibr">156</xref>). As will be discussed, T<sub>H</sub>17 cells have been implicated in chronic autoimmune and inflammatory conditions and thus may represent an important link between acute and chronic immunity in patients with COVID-19 (<xref rid="B153" ref-type="bibr">153</xref>).</p></sec><sec id="s2_2_3"><label>2.2.3</label><title>CD8+ T-cells</title><p>CD8+ T-cells target cells infected with intracellular pathogens, including viruses such as SARS-CoV-2, by detecting foreign antigens on MHC-1 (<xref rid="B137" ref-type="bibr">137</xref>, <xref rid="B157" ref-type="bibr">157</xref>). CD8+ T-cells can target numerous proteins derived from SARS-CoV-2, depending on expressed HLA class I types (<xref rid="B146" ref-type="bibr">146</xref>). While widely viewed as critical for disease resolution and subsequent protection from re-infection (<xref rid="B137" ref-type="bibr">137</xref>), SARS-CoV-2-specific CD8+ T cell responses in the blood tend to be relatively low in frequency (compared to influenza or Epstein-Barr virus) in most infected or resolved individuals (<xref rid="B158" ref-type="bibr">158</xref>). Several studies have confirmed a decrease in circulating CD8+ T-cells in COVID-19 (<xref rid="B139" ref-type="bibr">139</xref>, <xref rid="B144" ref-type="bibr">144</xref>, <xref rid="B159" ref-type="bibr">159</xref>, <xref rid="B160" ref-type="bibr">160</xref>). Those CD8+ T-cells that were present were found to be highly activated in a subset of COVID-19 patients as measured by KI67 and HLA-DR+CD38 expression (<xref rid="B161" ref-type="bibr">161</xref>) and appear to retain their cytotoxic capacity as measured by IFN&#x003b3;, granzyme B, perforin, and CD107a production or expression (<xref rid="B137" ref-type="bibr">137</xref>) (<xref rid="f2" ref-type="fig">
<bold>Figure&#x000a0;2C</bold>
</xref>). In addition, pre-existing cross-reactive nucleocapsid-specific memory CD8+ T-cells that recognize seasonal coronaviruses (<xref rid="B162" ref-type="bibr">162</xref>) may provide some level of protection from primary SARS-CoV-2 infection or disease severity, depending on the specificity and HLA haplotype. CD8+ T-cells have also been implicated in non-COVID cytokine release syndromes such as macrophage activation syndrome (MAS) (<xref rid="B163" ref-type="bibr">163</xref>) and may play a similar role in the exacerbated immune response in COVID-19.</p></sec><sec id="s2_2_4"><label>2.2.4</label><title>Memory T-cells</title><p>Memory T-cells can recognize and aid in clearing viruses to which a host may be re-exposed (<xref rid="B164" ref-type="bibr">164</xref>). Given the novelty of SARS-CoV-2, the duration of detectable memory T-cells responsive to SARS-CoV-2 remains the subject of ongoing study. Highly reactive, polyclonal CD8+ T-cells have been detected in the serum of patients with a history of mild COVID-19 up to one year after infection (<xref rid="B165" ref-type="bibr">165</xref>), with recent studies supporting at least this duration for SARS-CoV-2-specific CD8+ T-cells expressing CD45RA, IL-7R-&#x003b1;, T cell factor 1, and low CCR7 (<xref rid="B166" ref-type="bibr">166</xref>). This phenotype suggests tissue recirculating effector memory CD8+ T cells that retain high proliferative potential yet traffic through lymphoid and non-lymphoid tissues (<xref rid="B167" ref-type="bibr">167</xref>). Of note, memory T-cells have been detected in patients with SARS-CoV-1 beyond 17 years (<xref rid="B164" ref-type="bibr">164</xref>). Importantly, SARS-CoV-2-specific stem-cell-like memory T-cell populations appear to be maintained regardless of disease severity (<xref rid="B164" ref-type="bibr">164</xref>) (<xref rid="f2" ref-type="fig">
<bold>Figures&#x000a0;2F, G</bold>
</xref>). While the clinical significance of memory cell phenotypes remains to be determined, particularly in the context of viral variants (<xref rid="B89" ref-type="bibr">89</xref>), evidence suggests that CD8+ T-cells generated through natural immunity (<xref rid="B168" ref-type="bibr">168</xref>) or vaccination (<xref rid="B169" ref-type="bibr">169</xref>) can cross-recognize viral antigens despite a significant number of mutations in the viral genome (<xref rid="B169" ref-type="bibr">169</xref>).</p></sec><sec id="s2_2_5"><label>2.2.5</label><title>B-cell-mediated immune response: humoral immunity</title><p>B-lymphocytes are a critical component of adaptive immunity. Antibodies secreted by B-cell-derived plasma cells can serve multiple roles through antigen binding: Neutralization by preventing pathogen entry, immune cell recruitment and/or activation, and enhancement of antigen uptake and processing by antigen-presenting cells to other immune cells (<xref rid="B170" ref-type="bibr">170</xref>). Antibodies have also historically provided a measurable immune response that can serve as an imperfect but established benchmark for immunity (<xref rid="B170" ref-type="bibr">170</xref>&#x02013;<xref rid="B172" ref-type="bibr">172</xref>).</p></sec><sec id="s2_2_6"><label>2.2.6</label><title>Naturally occurring antibodies</title><p>Pre-existing antibodies to SARS-CoV-2 in humans were predominantly non-neutralizing, directed towards the N-protein and, to a lesser extent, the largely conserved S2 component of the S protein, which does not contain the receptor binding domain (RBD) (<xref rid="B173" ref-type="bibr">173</xref>, <xref rid="B174" ref-type="bibr">174</xref>), with the latter suggesting some degree of cross-reactivity from endemic coronaviruses (<xref rid="B174" ref-type="bibr">174</xref>, <xref rid="B175" ref-type="bibr">175</xref>) (<xref rid="f1" ref-type="fig">
<bold>Figure&#x000a0;1G</bold>
</xref>). Anti-glycan antibodies&#x02014;by and large of the IgM class (<xref rid="B176" ref-type="bibr">176</xref>)&#x02014;may also be found in humans at baseline and can be targeted towards glycans found on enveloped viruses (<xref rid="B176" ref-type="bibr">176</xref>). Lower risk of COVID-19 in patients with blood type O (<xref rid="B177" ref-type="bibr">177</xref>) may have contributed to the hypothesis that certain blood types may be more protective against SARS-CoV-2 infection, perhaps by anti-glycan ABO antibodies (<xref rid="B177" ref-type="bibr">177</xref>). Early GWAS of COVID-19 patients provided a biologically plausible mechanism for this proposed phenomenon by identifying a reproducible association of susceptibility to COVID-19 with locus 9q34.2, which coincides with the ABO locus (<xref rid="B178" ref-type="bibr">178</xref>, <xref rid="B179" ref-type="bibr">179</xref>). However, observational data since the discovery of the virus have been mixed (<xref rid="B176" ref-type="bibr">176</xref>, <xref rid="B180" ref-type="bibr">180</xref>), perhaps owing to the difference between susceptibility and clinical severity of the disease (<xref rid="B179" ref-type="bibr">179</xref>).</p></sec><sec id="s2_2_7"><label>2.2.7</label><title>Acute B-cell response to SARS-CoV-2 Infection</title><p>The acute phase of SARS-CoV-2 infection is accompanied by B-cell lymphopenia and early plasmablast development from extrafollicular sites, a response typically occurring within 3-5 days (<xref rid="B173" ref-type="bibr">173</xref>, <xref rid="B181" ref-type="bibr">181</xref>). In contrast to other infections, early antibody responses to SARS-CoV-2 include IgG, IgA, and IgM production (<xref rid="B173" ref-type="bibr">173</xref>) directed predominantly toward the N and S proteins (<xref rid="B173" ref-type="bibr">173</xref>). Somatic hypermutation and affinity maturation are less likely to occur at this stage (<xref rid="B173" ref-type="bibr">173</xref>, <xref rid="B181" ref-type="bibr">181</xref>), and plasma cells produced during this time tend to be short-lived (<xref rid="B173" ref-type="bibr">173</xref>). The degree of extrafollicular B cell activation is characterized by an increase in CD11c<sup>+</sup> activated naive (aN) B-cells which are precursors to IgD<sup>-</sup>CD27<sup>-</sup>, C-X-C chemokine receptor type 5 (CXCR5)<sup>-</sup>CD21<sup>-</sup> [double-negative 2 (DN2)] B-cells in addition to more recently discovered Cd11<sup>-</sup>CD21<sup>-</sup> (DN3) B-cell populations in severe COVID-19, which correlates with an increase in antibody-secreting cell populations (<xref rid="B181" ref-type="bibr">181</xref>) (<xref rid="f2" ref-type="fig">
<bold>Figure&#x000a0;2D</bold>
</xref>). The differentiation of these cells is TLR7-independent and is mediated through IFN&#x003b3;-IL-21 interactions, with the increase in DN2 B-cells additionally found to correlate with levels of IL-6 and IP-10 (<xref rid="B181" ref-type="bibr">181</xref>). Notably, an increase in endogenous neutralizing antibodies correlates with severe disease (<xref rid="B181" ref-type="bibr">181</xref>) and thus may suggest a raging battle rather than a victorious immune response. Curiously, a similar B-cell activation phenotype has been found in active SLE (<xref rid="B181" ref-type="bibr">181</xref>).</p><p>Approximately seven days after infection (<xref rid="B181" ref-type="bibr">181</xref>), a more nuanced and durable B-cell follicular response begins to develop from germinal center (GC) cells in lymphoid tissue via class-switching, affinity maturation, and somatic hypermutation (<xref rid="B173" ref-type="bibr">173</xref>). IgM and IgG anti-N, anti-S (<xref rid="B182" ref-type="bibr">182</xref>), and specifically anti-RBD (<xref rid="B183" ref-type="bibr">183</xref>)-defined seroconversion typically occur at a median of 11-13 days after symptom onset (<xref rid="B173" ref-type="bibr">173</xref>, <xref rid="B182" ref-type="bibr">182</xref>, <xref rid="B183" ref-type="bibr">183</xref>). In severe COVID-19, however, the GC response may be markedly blunted: Post-mortem specimens revealed an <italic>absence</italic> of germinal centers in the thoracic lymph nodes of patients with acute COVID-19 (<xref rid="B151" ref-type="bibr">151</xref>). A reduction of Bcl-6<sup>+</sup> GC B-cells was seen in the same patient population (<xref rid="B151" ref-type="bibr">151</xref>). As previous research points to a quantitatively robust and seemingly adequate neutralizing capacity of the early extrafollicular antibody response (<xref rid="B181" ref-type="bibr">181</xref>), it is conceivable that the sustained production of meticulously targeted antibodies may be adversely impacted. However, the mechanism underlying this relationship likely requires further study (<xref rid="B184" ref-type="bibr">184</xref>).</p></sec><sec id="s2_2_8"><label>2.2.8</label><title>Memory B-cells</title><p>Memory B-cells (MBCs) provide an immune reservoir for clonal expansion after infection (<xref rid="B185" ref-type="bibr">185</xref>, <xref rid="B186" ref-type="bibr">186</xref>). In acute SARS-CoV-2 infection, the extrafollicular B-cell response includes the development of transient non-class-switched MBC with low rates of somatic hypermutation and class-switching (<xref rid="B173" ref-type="bibr">173</xref>). In tandem, pre-existing MBC populations with cross-reactivity to conserved S2 regions can proliferate, as evidenced by a robust initial IgG response to S2 (<xref rid="B174" ref-type="bibr">174</xref>). B-cells that enter germinal centers of secondary lymphoid organs can develop a more nuanced immune memory through class switching and somatic hypermutation later in the course of infection (<xref rid="B173" ref-type="bibr">173</xref>). Patients who recover from COVID-19 have an increased proportion of tissue-like memory (TLM) IgG+ S1-specific MBC (<xref rid="B187" ref-type="bibr">187</xref>) and circulating resting IgDloCD20+ MBC sustained for at least seven months after acute infection (<xref rid="B188" ref-type="bibr">188</xref>) (<xref rid="f2" ref-type="fig">
<bold>Figure&#x000a0;2H</bold>
</xref>). The process of MBC generation likely requires CD4+ T-cells and can be affected by the severity of illness (<xref rid="B187" ref-type="bibr">187</xref>). Among the various immunoglobulin subtypes, IgG MBC eventually predominates in recovered individuals, along with a minor population of IgA MBC (<xref rid="B171" ref-type="bibr">171</xref>, <xref rid="B173" ref-type="bibr">173</xref>).</p></sec><sec id="s2_2_9"><label>2.2.9</label><title>Long-lived bone marrow plasma cells</title><p>Long-lived CD19<sup>&#x02212;</sup>CD38<sup>hi</sup>CD138<sup>+</sup> bone marrow plasma cells (BMPC) are another component of the humoral memory (<xref rid="B173" ref-type="bibr">173</xref>, <xref rid="B189" ref-type="bibr">189</xref>) and may be the primary source of circulating antibodies years after a viral infection (<xref rid="B188" ref-type="bibr">188</xref>). Their presence has been detected at least seven months following infection with SARS-CoV-2 (<xref rid="B188" ref-type="bibr">188</xref>).</p><p>A summary of several important cell types and their function in acute and post-acute COVID-19 is shown in <xref rid="T2" ref-type="table">
<bold>Table&#x000a0;2</bold>
</xref>. Of note, while neutralizing antibody titers may suggest protective immunity early in the post-infectious period (<xref rid="B172" ref-type="bibr">172</xref>), the relative contributions of various immune memory cells to sterilizing or protective immunity in SARS-CoV-2 remain the subject of further study, making such immunity challenging to define at this time.</p><table-wrap position="float" id="T2"><label>Table&#x000a0;2</label><caption><p>Innate and adaptive immune responses to COVID-19.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1"/><th valign="top" align="left" rowspan="1" colspan="1">Cell Type or Molecular Immune Response</th><th valign="top" align="left" rowspan="1" colspan="1">Expression and Function in Early COVID-19</th><th valign="top" colspan="2" align="left" rowspan="1">Expression and Function in Post-Infectious COVID-19</th></tr></thead><tbody><tr><td valign="top" rowspan="3" align="left" colspan="1">Innate/Humoral Immune Responses</td><td valign="top" align="left" rowspan="1" colspan="1">NK cells</td><td valign="top" align="left" rowspan="1" colspan="1">Depleted number with exhausted phenotype in COVID-19 (<xref rid="B124" ref-type="bibr">124</xref>, <xref rid="B398" ref-type="bibr">398</xref>) despite antiviral potential (<xref rid="B119" ref-type="bibr">119</xref>, <xref rid="B120" ref-type="bibr">120</xref>)</td><td valign="top" colspan="2" align="left" rowspan="1">Memory-like NK cell at 2-3 months correlates with cough symptoms of PASC (<xref rid="B285" ref-type="bibr">285</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Innate Lymphoid Cells (ILC)</td><td valign="top" align="left" rowspan="1" colspan="1">Depleted in severe illness (<xref rid="B126" ref-type="bibr">126</xref>, <xref rid="B127" ref-type="bibr">127</xref>) in spite of amphiregulin-mediated immune tolerance potential (<xref rid="B126" ref-type="bibr">126</xref>)</td><td valign="top" colspan="2" align="left" rowspan="1">Further research needed</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">MAIT</td><td valign="top" align="left" rowspan="1" colspan="1">Peripherally depleted in severe illness (<xref rid="B127" ref-type="bibr">127</xref>); effector functions (primarily TNF&#x003b1; and IL-17A production) altered in COVID-19 (<xref rid="B128" ref-type="bibr">128</xref>) in one study, with heightened activation and cytotoxic phenotypes seen in another study (<xref rid="B129" ref-type="bibr">129</xref>) correlating with severity of disease</td><td valign="top" colspan="2" align="left" rowspan="1">Cell levels normalize in convalescent phase albeit with suppression of CXCR3 levels, particularly in severe disease (<xref rid="B399" ref-type="bibr">399</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">&#x003b3;&#x003b4;-T-cells</td><td valign="top" align="left" rowspan="1" colspan="1">-Peripherally depleted in COVID-19 (<xref rid="B136" ref-type="bibr">136</xref>) and unable to mount potent responses to spike and nucleocapsid antigens (<xref rid="B131" ref-type="bibr">131</xref>)</td><td valign="top" colspan="2" align="left" rowspan="1">Innate-like CD3+CD4&#x02212;CD8&#x02212; T cells (which may include &#x003b3;&#x003b4;-T-cells), found absent at 3 months in patients with PASC (<xref rid="B301" ref-type="bibr">301</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">B-cells</td><td valign="top" align="left" rowspan="1" colspan="1">Cross-reactive, naturally-occurring antibodies may confer some degree of protection (<xref rid="B174" ref-type="bibr">174</xref>&#x02013;<xref rid="B177" ref-type="bibr">177</xref>);<break/>Peripherally depleted in COVID-19 (<xref rid="B173" ref-type="bibr">173</xref>, <xref rid="B181" ref-type="bibr">181</xref>) albeit with activated responses (<xref rid="B181" ref-type="bibr">181</xref>);<break/>Early plasmablast development and antibody response in extrafollicular cells includes IgM, IgG and IgA (<xref rid="B173" ref-type="bibr">173</xref>) to N and S proteins (<xref rid="B173" ref-type="bibr">173</xref>)<break/>DN2 and DN3 cells characterize the EF response with adequate neutralizing capacity (<xref rid="B181" ref-type="bibr">181</xref>);<break/>Autoantibodies to type I and type III IFNs (e.g.) can be seen in COVID-19 patients (<xref rid="B309" ref-type="bibr">309</xref>, <xref rid="B415" ref-type="bibr">415</xref>)</td><td valign="top" colspan="2" align="left" rowspan="1">Autoantibodies may be seen in convalescence (<xref rid="B285" ref-type="bibr">285</xref>) and may play a role in PASC (<xref rid="B285" ref-type="bibr">285</xref>);<break/>Na&#x000ef;ve CD127<sup>low</sup>TIM-3<sup>&#x02212;</sup>CD38<sup>low</sup>CD27<sup>&#x02212;</sup>IgD<sup>+</sup> B-cell populations diminished in the post-acute phase, suggesting ongoing activation (<xref rid="B301" ref-type="bibr">301</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Monocytes/Macrophages</td><td valign="top" align="left" rowspan="1" colspan="1">AACE2 and CD16&#x02013;mediated viral infection (<xref rid="B99" ref-type="bibr">99</xref>, <xref rid="B102" ref-type="bibr">102</xref>);<break/>Downregulation of IRAK-M expression (<xref rid="B102" ref-type="bibr">102</xref>)<break/>Inflammasome activation (<xref rid="B99" ref-type="bibr">99</xref>)</td><td valign="top" colspan="2" align="left" rowspan="1">Monocytes continue to be polyfunctional throughout the convalescent phase (at least at 2-3 months) across multiple subgroups (<xref rid="B285" ref-type="bibr">285</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Plasmacytoid Dendritic Cells (pDCs)</td><td valign="top" align="left" rowspan="1" colspan="1">Direct infection; production of Type I and Type III interferons (<xref rid="B108" ref-type="bibr">108</xref>); inverse correlation with COVID-19 severity (<xref rid="B108" ref-type="bibr">108</xref>); enhance TLR signaling in macrophages via IFN-1</td><td valign="top" colspan="2" align="left" rowspan="1">Persistent reduction 7 months post hospitalization (<xref rid="B109" ref-type="bibr">109</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Neutrophils</td><td valign="top" align="left" rowspan="1" colspan="1">Emergency myelopoiesis may produce immature subtypes (<xref rid="B115" ref-type="bibr">115</xref>, <xref rid="B400" ref-type="bibr">400</xref>) with resultant pro-inflammatory and thrombogenic NET formation (<xref rid="B111" ref-type="bibr">111</xref>, <xref rid="B117" ref-type="bibr">117</xref>); increased numbers and NLR may be associated with severe disease (<xref rid="B113" ref-type="bibr">113</xref>, <xref rid="B114" ref-type="bibr">114</xref>)</td><td valign="top" colspan="2" align="left" rowspan="1">Total neutrophil count and levels of MPO are increased in patients with post-COVID-19 interstitial lung abnormalities (<xref rid="B401" ref-type="bibr">401</xref>); NET formation may be associated with lung fibrogenesis (<xref rid="B401" ref-type="bibr">401</xref>); NETosis-associated immunothrombosis may be associated with long-term effects of COVID-19 (<xref rid="B402" ref-type="bibr">402</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Memory B-cells</td><td valign="top" align="left" rowspan="1" colspan="1">May be source of initial IgG response in SARS-CoV-2 na&#x000ef;ve patients by cross-reactivity to conserved antigens (<xref rid="B174" ref-type="bibr">174</xref>)<break/>Initially with low rates of somatic hypermutation and class-switching (<xref rid="B173" ref-type="bibr">173</xref>); Production likely requires CD4+ T-cells (<xref rid="B187" ref-type="bibr">187</xref>)</td><td valign="top" colspan="2" align="left" rowspan="1">Increased frequency of MBC, IgM+, and class-switched MBC associated with decreased symptom duration in convalescent patients (<xref rid="B403" ref-type="bibr">403</xref>); likely role in vaccine-mediated immunity even as antibody levels decline (<xref rid="B192" ref-type="bibr">192</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">BMPC</td><td valign="top" align="left" rowspan="1" colspan="1">Likely source of circulating antibodies years after infection with other viruses (<xref rid="B173" ref-type="bibr">173</xref>, <xref rid="B189" ref-type="bibr">189</xref>)</td><td valign="top" colspan="2" align="left" rowspan="1">Detected at least 7 months after SARS-CoV-2 infection (<xref rid="B188" ref-type="bibr">188</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Soluble Pattern Recognition Molecules</td><td valign="top" align="left" rowspan="1" colspan="1">Unclear for CRP (<xref rid="B98" ref-type="bibr">98</xref>)<break/>Systemic complement activation (<xref rid="B97" ref-type="bibr">97</xref>)<break/>MBL binds to spike protein (<xref rid="B96" ref-type="bibr">96</xref>); deficiency may be associated with severity (<xref rid="B404" ref-type="bibr">404</xref>)PTX3 binds to nucleocapsid (<xref rid="B96" ref-type="bibr">96</xref>)</td><td valign="top" colspan="2" align="left" rowspan="1">MBL deficiency more frequent in PASC compared to historical controls (<xref rid="B389" ref-type="bibr">389</xref>)</td></tr><tr><td valign="top" rowspan="2" align="left" colspan="1">Adaptive/Cellular Immune Responses</td><td valign="top" align="left" rowspan="1" colspan="1">CD4+ T-cells</td><td valign="top" align="left" rowspan="1" colspan="1">Important role in viral clearance (<xref rid="B147" ref-type="bibr">147</xref>) with activated phenotypes (<xref rid="B149" ref-type="bibr">149</xref>); skew towards T<sub>H1</sub> and T<sub>FH</sub> phenotypes with associated effector functions (<xref rid="B145" ref-type="bibr">145</xref>, <xref rid="B151" ref-type="bibr">151</xref>), albeit with quantitative loss of germinal center T<sub>FH</sub>-cells (<xref rid="B151" ref-type="bibr">151</xref>);<break/>Likely important in generation of MBC (<xref rid="B187" ref-type="bibr">187</xref>)</td><td valign="top" colspan="2" align="left" rowspan="1">Na&#x000ef;ve CD4+ cell populations diminished in the post-acute phase, suggesting ongoing activation (<xref rid="B301" ref-type="bibr">301</xref>); clonal expansion of cytotoxic CD4+ cells may continue 2-3 months following infection and may be associated with GI symptoms (<xref rid="B285" ref-type="bibr">285</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">T<sub>H</sub>17 cells</td><td valign="top" align="left" rowspan="1" colspan="1">May contribute to acute inflammation through release of IFN-&#x003b3;, GM-CSF, IL-10, IL-17A, IL-17F, IL-21, and IL-22 (<xref rid="B155" ref-type="bibr">155</xref>);<break/>Appear to be proportionally upregulated in COVID-19 (as compared to T<sub>reg</sub> (<xref rid="B156" ref-type="bibr">156</xref>), which may be associated with clinical outcome (<xref rid="B156" ref-type="bibr">156</xref>); may be a mechanism for COVID-19-related autoimmunity (<xref rid="B155" ref-type="bibr">155</xref>)</td><td valign="top" colspan="2" align="left" rowspan="1">Half-life of S-specific T<sub>H</sub>17-like (CXCR3-/CXCR5-/CCR6+) cells is approximately 4.9 years, longer than T<sub>H</sub>1-, T<sub>H2</sub>-, and T<sub>FH</sub>-like cells (<xref rid="B405" ref-type="bibr">405</xref>); increase in proportion of T<sub>H</sub>17 central memory cells seen at least 24 weeks post-infection (<xref rid="B406" ref-type="bibr">406</xref>); noted role in autoimmune conditions like SLE (<xref rid="B153" ref-type="bibr">153</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" colspan="2" align="left" rowspan="1">CD8+ T-cells</td><td valign="top" align="left" rowspan="1" colspan="1">Peripherally depleted in COVID-19 (<xref rid="B139" ref-type="bibr">139</xref>, <xref rid="B144" ref-type="bibr">144</xref>, <xref rid="B159" ref-type="bibr">159</xref>, <xref rid="B160" ref-type="bibr">160</xref>) albeit with activated phenotype (<xref rid="B161" ref-type="bibr">161</xref>) and preserved effector function (<xref rid="B137" ref-type="bibr">137</xref>); possible role in macrophage activation-related cytokine release (<xref rid="B163" ref-type="bibr">163</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">Na&#x000ef;ve CD8+ cell populations diminished in the post-acute phase, suggesting ongoing activation (<xref rid="B301" ref-type="bibr">301</xref>); Clonal expansion of cytotoxic CD8+ cells may continue 2-3 months following infection and may be associated with GI symptoms (<xref rid="B285" ref-type="bibr">285</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Memory T-cells</td><td valign="top" align="left" rowspan="1" colspan="1">CD8+ T-cells present at least 1 year post-infection (<xref rid="B165" ref-type="bibr">165</xref>) and likely longer (<xref rid="B164" ref-type="bibr">164</xref>); may be an important driver of vaccine-mediated immunity (<xref rid="B194" ref-type="bibr">194</xref>, <xref rid="B195" ref-type="bibr">195</xref>)</td><td valign="top" colspan="2" align="left" rowspan="1">May the predominant mediator of immunity following decay of neutralizing antibody titers (<xref rid="B407" ref-type="bibr">407</xref>) and across pre-Omicron variants (<xref rid="B407" ref-type="bibr">407</xref>); S-specific CD8+ and CD4+ central and effector memory T-cells also shown to be likely predominant in vaccine-mediated immunity against Omicron variant (<xref rid="B195" ref-type="bibr">195</xref>); increase in proportion of CD4+ T<sub>H</sub>17 central memory cells seen at least 24 weeks post-infection (<xref rid="B406" ref-type="bibr">406</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Regulatory T-cells</td><td valign="top" align="left" rowspan="1" colspan="1">Appear to be proportionally downregulated in COVID-19 (as compared to T<sub>H</sub>17 (<xref rid="B156" ref-type="bibr">156</xref>), which may be associated with clinical outcome (<xref rid="B156" ref-type="bibr">156</xref>)</td><td valign="top" colspan="2" align="left" rowspan="1">Increase in TEMRA (effector memory with acquired CD45RA) Tregs at 16 weeks and na&#x000ef;ve Treg to at least 24 weeks post infection with associated decreased in central memory, effector memory, T<sub>H</sub>R2, T<sub>FH</sub>R to 16 weeks and T<sub>H</sub>R22, T<sub>H</sub>R2/22 to 24 weeks post-infection (<xref rid="B406" ref-type="bibr">406</xref>)</td></tr></tbody></table></table-wrap></sec><sec id="s2_2_10"><label>2.2.10</label><title>Vaccine-mediated adaptive immunity</title><p>The severity of the COVID-19 pandemic spurred the development of highly effective vaccines with the benefit of low-risk immunity across a population. Currently, available SARS-CoV-2 vaccines contain mRNA (or DNA in adenovirus vaccines) encoding the S protein, which can be further cleaved into its subunits S1 and S2 (<xref rid="B190" ref-type="bibr">190</xref>). Initial studies with mRNA vaccines established immunogenicity based on clinical efficacy (<xref rid="B6" ref-type="bibr">6</xref>), IgG response to RBD or S1, and at least 50% neutralization titers (<xref rid="B191" ref-type="bibr">191</xref>). Later studies further showed the durability of vaccine-induced immune memory, as evidenced by an increase in CD71+ MBC cells 3-6 months post-vaccination, even as antibody levels to S and the RBD declined (<xref rid="B192" ref-type="bibr">192</xref>). Notably, MBCs were cross-reactive to alpha, beta, and delta variants per data available then (<xref rid="B192" ref-type="bibr">192</xref>). More recent findings highlight the effect of sequential vaccine boosters as promoting refined MBC antibody-mediated immunity that targets both the ACE2 binding site of SARS-CoV-2 spike protein as well as more conserved components of the RBD (i.e., Type 1/4 antibodies), which correlate with increasing potency of SARS-CoV-2 neutralization (<xref rid="B185" ref-type="bibr">185</xref>).</p><p>While not suited for neutralizing and preventing viral entry into host cells, T-cell responses can help prevent the spread of infection within a host and consequently can impact illness severity and virus transmissibility (<xref rid="B193" ref-type="bibr">193</xref>). Omicron variant vaccine efficacy has been shown to be adversely affected by Omicron-specific CD8+ T-cell responses despite moderate levels of neutralizing antibodies in macaques (<xref rid="B194" ref-type="bibr">194</xref>). More recent studies also suggest conserved vaccine-mediated cellular immunity across variants, including Omicron, despite a diminished neutralizing antibody response (<xref rid="B195" ref-type="bibr">195</xref>). While the authors would be remiss if we did not mention vaccine-mediated immunity, the topic itself warrants further exploration beyond this paper&#x02019;s scope.</p><p>The immune response evoked by infection with SARS-CoV-2 at the molecular level is often accompanied by the clinical syndrome known as COVID-19. COVID-19 is widely recognized as a predominantly respiratory disease manifesting as fever and cough (<xref rid="B196" ref-type="bibr">196</xref>). It is also recognized that the virus and its inflammatory response can affect multiple organ systems outside of the respiratory tract, as described in the following section.</p></sec></sec><sec id="s2_3"><label>2.3</label><title>Acute immune-mediated end-organ injury following SARS-CoV-2 infection</title><p>Acute SARS-CoV-2 infection can lead to end organ damage through direct viral infection associated with localized immune activation and systemic immune responses. In addition to the lung, ACE2 receptors can be found in the heart (<xref rid="B197" ref-type="bibr">197</xref>), brain (<xref rid="B198" ref-type="bibr">198</xref>), kidney (<xref rid="B199" ref-type="bibr">199</xref>), testis (<xref rid="B199" ref-type="bibr">199</xref>), liver (<xref rid="B200" ref-type="bibr">200</xref>), colon (<xref rid="B199" ref-type="bibr">199</xref>, <xref rid="B201" ref-type="bibr">201</xref>), and other organs (<xref rid="B199" ref-type="bibr">199</xref>, <xref rid="B202" ref-type="bibr">202</xref>) (<xref rid="f3" ref-type="fig">
<bold>Figure&#x000a0;3A</bold>
</xref>). While the clinical significance of such expression has not yet been fully elucidated, SARS-CoV-2 viremia can lead to end-organ infection and associated dysfunction by developing local pathologic inflammatory responses. Furthermore, the presence of ACE2 on endothelial cells (<xref rid="B203" ref-type="bibr">203</xref>, <xref rid="B204" ref-type="bibr">204</xref>) and the known association with endotheliitis (<xref rid="B197" ref-type="bibr">197</xref>, <xref rid="B205" ref-type="bibr">205</xref>) and microthrombi (<xref rid="B203" ref-type="bibr">203</xref>, <xref rid="B206" ref-type="bibr">206</xref>) may allow for SARS-CoV-2 to affect multiple organs through disruption of the normal functioning of the microvasculature (<xref rid="B197" ref-type="bibr">197</xref>).</p><fig position="float" id="f3"><label>Figure&#x000a0;3</label><caption><p>Acute, post-acute and chronic end organ manifestations of SARS-CoV-2 infection. SARS-CoV-2 may have adverse clinicopathophysiological impacts on multiple organ systems throughout the body. <bold>(A)</bold> Early effects are shown here and may include delirium, stroke, cardiomyopathy, myocardial infarction, pneumonia, ARDS, and AKI. <bold>(B)</bold> Postacute and chronic end-organ manifestations of SARS-CoV-2 infection can include neuropsychiatric symptoms such as fatigue and POTS (which may be features of PASC), in addition to myocarditis, interstitial lung disease and CKD.</p></caption><graphic xlink:href="fimmu-15-1376654-g003" position="float"/></fig><sec id="s2_3_1"><label>2.3.1</label><title>Endothelial cell infection, microangiopathy, and microthrombi mediate end-organ dysfunction in COVID-19</title><p>ACE2 expression on endothelial cells may allow for viral infection to impact multiple organs, including the lung and kidney (<xref rid="B207" ref-type="bibr">207</xref>). Early pathologic specimens from COVID-19 patients revealed direct viral infection of endothelial cells in a transplanted kidney, with inflammatory lymphocytic infiltration noted in microvasculature of the heart, lung, kidney, and liver (<xref rid="B207" ref-type="bibr">207</xref>). While endotheliitis and hypercoagulation can be found with other viral infections, additional studies revealed the presence of intracapillary microthrombi in the pulmonary vasculature, as well as intussusceptive angiogenesis likely resulting from loss of normal microvascular architecture, which was seen more often in SARS-CoV-2 when compared to H1N1 influenza A (<xref rid="B208" ref-type="bibr">208</xref>, <xref rid="B209" ref-type="bibr">209</xref>). Endothelial cell activation is associated with a hypercoagulable state in COVID-19 (<xref rid="B210" ref-type="bibr">210</xref>, <xref rid="B211" ref-type="bibr">211</xref>), with proposed mechanisms including exocytosis of granules containing von Willebrand factor (vWF) and P-selectin (<xref rid="B211" ref-type="bibr">211</xref>) in addition to alteration in plasminogen activator inhibitor 1 (PAI-1) and tissue factor pathway inhibitor (TFPI) levels and upregulating cell adhesion molecules like VCAM and ICAM, which facilitates extravasation of circulating white blood cells (<xref rid="B212" ref-type="bibr">212</xref>) (<xref rid="f1" ref-type="fig">
<bold>Figure&#x000a0;1H</bold>
</xref>).</p><p>The hypercoagulable state of COVID-19 may be a function of the complex interplay between immune cells and endothelial cells. Early polymorphonuclear (PMN) cell activation may lead to neutrophil extracellular traps (NETs) forming via NETosis, as suggested by increased plasma NET formation in intubated patients with COVID-19 (<xref rid="B213" ref-type="bibr">213</xref>). Colocalization of citrullinated histone H3+ neutrophils with platelets in blood vessels suggests that NET formation is implicated in the development of microthrombi in COVID-19 patients (<xref rid="B213" ref-type="bibr">213</xref>) (<xref rid="f1" ref-type="fig">
<bold>Figure&#x000a0;1I</bold>
</xref>). Macrophages and monocytes in which inflammasomes and pyroptosis are activated may release microparticles containing tissue factor (TF) (<xref rid="B214" ref-type="bibr">214</xref>, <xref rid="B215" ref-type="bibr">215</xref>), a critical first step in the coagulation cascade (<xref rid="B216" ref-type="bibr">216</xref>). IL-6 may further enhance the release of TF from monocytes (<xref rid="B217" ref-type="bibr">217</xref>). Of note, while not unique to COVID-19, severe infections can also promote the development of disseminated intravascular coagulation (DIC), the mechanisms of which have been well-studied (<xref rid="B218" ref-type="bibr">218</xref>).</p></sec><sec id="s2_3_2"><label>2.3.2</label><title>Acute lung injury</title><p>The lungs are among the earliest and most overtly affected organs in COVID-19 (<xref rid="B219" ref-type="bibr">219</xref>), with symptoms ranging from mild [and sometimes relatively asymptomatic (<xref rid="B220" ref-type="bibr">220</xref>, <xref rid="B221" ref-type="bibr">221</xref>)] to severe hypoxemic respiratory failure requiring mechanical ventilation (<xref rid="B222" ref-type="bibr">222</xref>). Despite comparatively low ACE2 expression in the lung overall, type II alveolar epithelial cells (<xref rid="B223" ref-type="bibr">223</xref>) are preferentially targeted by SARS-CoV-2 (<xref rid="B69" ref-type="bibr">69</xref>). Early infection is typically characterized by viral pneumonia of varying severity (<xref rid="B219" ref-type="bibr">219</xref>, <xref rid="B224" ref-type="bibr">224</xref>), which may progress to COVID-19-related acute respiratory distress syndrome (ARDS) (<xref rid="B224" ref-type="bibr">224</xref>) with a predominance of CD-3+ and CD-4+ T lymphocytes in precapillary and postcapillary blood vessels (<xref rid="B208" ref-type="bibr">208</xref>). As with other organ systems, the anatomic and clinical sequelae of viral infections within the lungs are related both to the infection and to the inflammatory response with which it is accompanied (<xref rid="B225" ref-type="bibr">225</xref>). Findings in early COVID-19 typically manifest as bilateral peripheral ground-glass opacities and consolidations, which may reflect diffuse alveolar damage when examined histologically (<xref rid="B225" ref-type="bibr">225</xref>). As with other viruses, organizing pneumonia can also be seen, as well as bronchiolitis, manifesting as bronchial wall thickening, centrilobular nodules, and tree-in-bud opacities (<xref rid="B225" ref-type="bibr">225</xref>). While early studies hypothesized a unique trajectory of lung compliance changes in COVID-19 ARDS (<xref rid="B226" ref-type="bibr">226</xref>), later studies suggest that COVID-19 ARDS is a heterogeneous entity composed of pathophysiologic phenotypes that may be managed similarly to previously described phenotypes of ARDS (<xref rid="B227" ref-type="bibr">227</xref>&#x02013;<xref rid="B231" ref-type="bibr">231</xref>). The overlap with typical ARDS in severe COVID-19 may explain the benefit of dexamethasone in hospitalized patients with an increased supplemental oxygen requirement (<xref rid="B232" ref-type="bibr">232</xref>), similar to a recent trial studying dexamethasone in ARDS (<xref rid="B233" ref-type="bibr">233</xref>). Of note, the development of endotheliitis and microthrombi (<xref rid="B208" ref-type="bibr">208</xref>, <xref rid="B234" ref-type="bibr">234</xref>) in COVID-19 does appear to be unique to SARS-CoV-2 as compared to other viral illnesses such as influenza H1N1 (<xref rid="B208" ref-type="bibr">208</xref>, <xref rid="B235" ref-type="bibr">235</xref>), a finding which may reflect SARS-CoV-2 tropism for ACE2 on endothelial cells (<xref rid="B197" ref-type="bibr">197</xref>, <xref rid="B203" ref-type="bibr">203</xref>, <xref rid="B205" ref-type="bibr">205</xref>, <xref rid="B206" ref-type="bibr">206</xref>) exacerbated by an inflammation-related hypercoagulable state (<xref rid="B236" ref-type="bibr">236</xref>). In line with such pathophysiology, the initiation of therapeutic-dose anticoagulation in non-critically ill patients has been shown to be effective in preventing the need for mechanical ventilation and improving survival to hospital discharge (<xref rid="B237" ref-type="bibr">237</xref>). Initiation of anticoagulation during critical illness, in contrast, has not been shown to improve survival, which may be due to the timing of microthrombi development and the momentum of the inflammation-related hypercoagulable state (<xref rid="B238" ref-type="bibr">238</xref>). Of note, overt pulmonary emboli (PE) have a pooled incidence of 21% in hospitalized patients with COVID-19 (<xref rid="B239" ref-type="bibr">239</xref>); treatment for PE in such scenarios involves standard anticoagulation.</p></sec><sec id="s2_3_3"><label>2.3.3</label><title>Acute cardiac dysfunction</title><p>Although the phenomenon itself is probably rare (<xref rid="B240" ref-type="bibr">240</xref>), numerous studies have revealed associations of COVID-19 to myocarditis (<xref rid="B197" ref-type="bibr">197</xref>, <xref rid="B240" ref-type="bibr">240</xref>&#x02013;<xref rid="B243" ref-type="bibr">243</xref>). One US hospital administrative database study among patients hospitalized from March 2020 to January 2021 showed that the risk for myocarditis was 0.146% for patients with COVID-19 compared to 0.009%, with an estimated 15.7 times increased risk for the syndrome (<xref rid="B244" ref-type="bibr">244</xref>). In several such cases, SARS-CoV-2 mRNA was shown to be present in the myocardium and was associated with an intense inflammatory response comprised of macrophages and CD8+ cytotoxic T-cells (<xref rid="B245" ref-type="bibr">245</xref>, <xref rid="B246" ref-type="bibr">246</xref>). At least one patient exhibited no overt evidence of pulmonary SARS-CoV-2 infection (<xref rid="B245" ref-type="bibr">245</xref>). Other mechanisms of acute cardiac involvement may include stress-related (Takutsobu) cardiomyopathy (<xref rid="B242" ref-type="bibr">242</xref>) and myocardial infarction (<xref rid="B240" ref-type="bibr">240</xref>, <xref rid="B247" ref-type="bibr">247</xref>) related to supply-and-demand mismatch (<xref rid="B248" ref-type="bibr">248</xref>) or overt coronary occlusion (<xref rid="B249" ref-type="bibr">249</xref>). COVID-19-associated IL-6 production can also affect cardiac function: IL-6 has been shown to exacerbate viral myocarditis (<xref rid="B240" ref-type="bibr">240</xref>), and a recently submitted study using cardiac organoids stimulated with IL-1&#x003b2; suggests cardiac dysfunction may be due to downregulation of sarcomere components, reduced sarcomere width, contraction amplitude, increased cardiac fibrosis, and prothrombotic vasculature, irrespective of direct infection with SARS-CoV-2 (<xref rid="B250" ref-type="bibr">250</xref>).</p></sec><sec id="s2_3_4"><label>2.3.4</label><title>Acute neurologic and psychiatric dysfunction</title><p>Neurological manifestations of COVID-19 appear to portend a worse outcome in terms of in-hospital mortality, hospital length of stay, and persistent functional disability (<xref rid="B251" ref-type="bibr">251</xref>). Neurological manifestations were estimated to occur in as many as 80% of patients hospitalized with COVID-19 (<xref rid="B252" ref-type="bibr">252</xref>), with the most common self-reported symptoms including headache (37%) and anosmia/ageusia (26%) and the most common syndromes including encephalopathy (49%), coma (17%) and stroke (6%) (<xref rid="B252" ref-type="bibr">252</xref>). Ischemic stroke appears to be more prevalent in SARS-CoV-2 infection (1.6%; 95% CI 1.1-2.3%) (<xref rid="B253" ref-type="bibr">253</xref>) than in influenza (0.2%; 95% CI, 0.0%-0.6%) (<xref rid="B253" ref-type="bibr">253</xref>, <xref rid="B254" ref-type="bibr">254</xref>). COVID-19 patients with co-morbid pre-existing dementia are at exceptionally high risk for in-hospital delirium, itself associated with prolonged hospitalization, intensive care unit (ICU) admission, or in-hospital mortality (<xref rid="B251" ref-type="bibr">251</xref>). Other disorders include seizures, hypoxic/ischemic brain injury (<xref rid="B251" ref-type="bibr">251</xref>), encephalitis (<xref rid="B255" ref-type="bibr">255</xref>), critical illness neuropathy/myopathy, myalgias, and dizziness (<xref rid="B251" ref-type="bibr">251</xref>). Psychiatric disorders including psychosis (<xref rid="B255" ref-type="bibr">255</xref>), anxiety, depression and post-traumatic stress disorder (PTSD) were also reported in COVID-19 patients (<xref rid="B256" ref-type="bibr">256</xref>). Single-cell CSF analysis in patients with neurological manifestations demonstrated a dampened interferon response, an increase in de-differentiated monocyte populations, and exhausted CD4+ T-cell phenotypes (<xref rid="B257" ref-type="bibr">257</xref>). Other proposed mechanisms of neurological dysfunction include endothelial damage, local inflammation (<xref rid="B258" ref-type="bibr">258</xref>), direct effect on choroid plexus epithelium, glial cell tropism, retrograde transportation into the CNS from the olfactory bulb (<xref rid="B256" ref-type="bibr">256</xref>), and hypoxic-ischemic injury to the CNS (<xref rid="B256" ref-type="bibr">256</xref>).</p></sec><sec id="s2_3_5"><label>2.3.5</label><title>Immunologic effects on the kidney accompanying SARS-CoV-2 infection acute kidney injury</title><p>The kidney is unique in its high concentration of ACE2, its increased vascularity, and its exposure to systemic pathogens (<xref rid="B16" ref-type="bibr">16</xref>). ACE2 is co-expressed with TMPRSS2 in podocytes and tubule epithelial cells as it is in the lungs (<xref rid="B259" ref-type="bibr">259</xref>). Furin and CD147, which bind SARS-CoV-2, are likewise expressed in the kidney (<xref rid="B260" ref-type="bibr">260</xref>). Immune cells in the healthy human kidney are sparse and are primarily CD4+ and CD8+ T cells, with a smaller percentage of NK cells, B cells (<xref rid="B17" ref-type="bibr">17</xref>), and CD14+, CD16+ and CD68+ myeloid cells (<xref rid="B18" ref-type="bibr">18</xref>). Infection with SARS-CoV-2, a shift occurs from an upregulation in proinflammatory genes such as HSPA1A in podocytes and JUN1 in mesenchymal clusters (<xref rid="B19" ref-type="bibr">19</xref>) can accompany selective immune suppression of lymphocytes mediated through T-cell immunoglobulin and mucin-domain containing-3 (TIM-3) and Programmed cell death protein 1 (PD-1) (<xref rid="B20" ref-type="bibr">20</xref>). A 2022 review suggests that resident immune cells may mediate inflammation by TNF&#x003b1; release, IL-34-mediated necrosis, and NLRP3 inflammasome production (<xref rid="B266" ref-type="bibr">266</xref>). ICAM-1, E- and P-selectin upregulation may be associated with neutrophil and circulating immune cell recruitment, platelet activation, NETosis (<xref rid="B266" ref-type="bibr">266</xref>), and immunothrombosis. While tropism for the kidney had previously been debated (<xref rid="B255" ref-type="bibr">255</xref>), the detection of SARS-CoV-2 RNA in a case series of kidney autopsies (<xref rid="B264" ref-type="bibr">264</xref>) suggests a role for direct infection. One elegant study built on the finding of increased extracellular matrix (ECM) in pathological specimens to explore an association with tubule-interstitial nephrosis (<xref rid="B260" ref-type="bibr">260</xref>). In this study, single-cell RNA sequencing of SARS-CoV-2-infected human-induced pluripotent stem-cell-derived kidney organoids confirmed the presence of SARS-CoV-2 in podocytes, proximal tubular cells, and myofibroblasts. Increased collagen one protein expression was seen in SARS-CoV-2 infected organoids compared to controls, a finding abrogated with a TGF-&#x003b2; blocker (SB431542). Moreover, the upregulation of HSPA1A, NRF21, S100A9, and TMSB10 proinflammatory genes was seen in podocytes, as was CCN1, JUN, and NFKBIA in mesenchymal clusters. Pathways upregulated among SARS-CoV-2-infected cells included TGF-&#x003b2;, PI3K/Akt, MAPK, and WNT signaling in proximal tubular cells and mesenchymal clusters (<xref rid="B260" ref-type="bibr">260</xref>). Upregulated IL-6 and STAT3 signaling may be important in COVAN-mediated disease (<xref rid="B265" ref-type="bibr">265</xref>). These results support a hypothesis that SARS-CoV-2 promotes tubule interstitial fibrosis through profibrotic pathways, at least in severe disease (<xref rid="f4" ref-type="fig">
<bold>Figure&#x000a0;4</bold>
</xref>).</p><fig position="float" id="f4"><label>Figure&#x000a0;4</label><caption><p>Inflammatory and immunologic consequences of SARS-CoV-2 in the kidney. <bold>(A)</bold> Histological and pathological mechanisms of acute kidney injury (AKI) in SARS-CoV-2 infection include collapsing glomerulonephritis, myoglobin cast nephropathy, proliferative glomerulonephritis with monoclonal IgG deposits, sequelae of nephrotoxic agents, acute tubular injury and necrosis (<xref rid="B267" ref-type="bibr">267</xref>), and perfusion pressure changes. More recent studies suggest that early tubule-interstitial fibrosis can occur in the setting of upregulated pro-fibrotic and pro-inflammatory mechanisms accompanied by myofibroblast activation, collagen, and ECM deposition. <bold>(B)</bold> Mechanisms of the development of chronic kidney disease (CKD) can include natural progression from AKI (<xref rid="B414" ref-type="bibr">414</xref>), which may occur as a result of maladaptive repair manifesting as early myofibroblast activation through proinflammatory pathways such as TGF-&#x003b2;, decreased Ang 1-7 production, and concomitant ongoing ECM and collagen deposition through mechanisms set off during the COVID-19 AKI phase. Direct damage to podocytes and proximal convoluted tubules via SARS-CoV-2 colocalization with Le<sup>x</sup> and sialyl-Le<sup>x</sup> (CD15s) in addition to ACE2 in the setting of chronic replication of SARS-CoV-2 may occur in immunocompromised hosts (<xref rid="B365" ref-type="bibr">365</xref>). Progression of pre-existing CKD may occur following COVID-19. In renal PASC, mildly decreased eGFR is likely to occur as a less clinically significant manifestation of SARS-CoV-2 infection. Additional mechanisms include CKD as a sequela of the array of etiologies of AKI in acute infection (<xref rid="B414" ref-type="bibr">414</xref>). Long-term sequelae of COVID-19 may also include subclinical decreased creatinine clearance (<xref rid="B366" ref-type="bibr">366</xref>), presumably through the mechanisms described for more overt CKD phenotypes. Persistent viral RNA may be present in immunocompetent patients and has been suggested as one mechanism for PASC (<xref rid="B291" ref-type="bibr">291</xref>).</p></caption><graphic xlink:href="fimmu-15-1376654-g004" position="float"/></fig><p>Of note, patients with ESRD may already exhibit exhausted T-cell phenotypes (<xref rid="B259" ref-type="bibr">259</xref>). As discussed above, infection with SARS-CoV-2 is likewise associated with lymphopenia and exhausted T-cell phenotypes (<xref rid="B260" ref-type="bibr">260</xref>), which may indicate exacerbated immune dysregulation in such patients. Patients with ESRD have been shown to produce durable antibody anti-nucleocapsid and anti-RBD antibodies at least 6 months post-infection (<xref rid="B261" ref-type="bibr">261</xref>, <xref rid="B262" ref-type="bibr">262</xref>), although this was not found to correlate with a decreased likelihood of reinfection in patients undergoing hemodialysis (<xref rid="B263" ref-type="bibr">263</xref>). While not the subject of this review, a more recent study noted that patients with both mRNA-1273 vaccination as well as prior infection with SARS-CoV-2 exhibited more robust neutralizing antibody production and S-specific B-cells were higher among patients with chronic kidney disease, and that the percentage of S-specific memory CD4+ and CD8+ T-cells were higher among patients who were dialysis-dependent than healthy hybrid controls (<xref rid="B264" ref-type="bibr">264</xref>).</p><p>Early studies in China suggested an incidence of AKI in 4.7% of all patients presenting with SARS-CoV-2 infection by Kidney Disease: Improving Global Outcomes (KDIGO) Criteria (<xref rid="B265" ref-type="bibr">265</xref>, <xref rid="B266" ref-type="bibr">266</xref>). In another study, AKI was reported in approximately 25% of hospitalized patients with COVID-19 (<xref rid="B267" ref-type="bibr">267</xref>). The International Severe Acute Respiratory and Emerging Infections Consortium (ISARIC) World Health Organization (WHO) Clinical Characterisation Protocol UK (CCP-UK) for Severe Emerging Infections was among the largest epidemiological studies performed during the COVID-19 pandemic (<xref rid="B268" ref-type="bibr">268</xref>). Among the 85687 patients in this multicenter cohort, 2198 (2.6%) ultimately underwent acute renal replacement therapy (RRT) (long-term dialysis patients were excluded.) Among 41294 patients with available serum creatinine, 13000 (31.5%) had biochemical AKI: 8562 had stage 1 (65.9%), 2609 stage 2 (20.1%) and 1829 stage 3 (14.1%), with a concurrent increased risk in 28-day mortality by AKI severity (stage 1: aOR 1.58 (1.49&#x02013;1.67); stage 2: aOR 2.41 (2.20&#x02013;2.64); stage 3 aOR 3.50 (3.14&#x02013;3.91); and RRT aOR 3.06 (2.75&#x02013;3.39) (<xref rid="B268" ref-type="bibr">268</xref>). As summarized in the 2022 study, predominant risk factors for RRT were chronic kidney disease (CKD) (aOR 3.41; 95% CI=3.06&#x02013;3.81), male sex (aOR 2.43; CI=2.18&#x02013;2.71) and Black race (aOR 2.17; CI=1.79&#x02013;2.63). Primary risk factors for biochemical AKI were admission respiratory rate &#x0003e;30 breaths per minute (aOR 1.68; CI=1.56&#x02013;1.81), CKD (aOR 1.66; CI=1.57&#x02013;1.76), and Black race (aOR 1.44; CI=1.28&#x02013;1.61) (<xref rid="B268" ref-type="bibr">268</xref>).</p><p>In addition to the acute effect of COVID-19 and its consequences on the kidney, an early phenome-wide association study (PheWAS) of patients showed a significant increase in the likelihood of hospitalization among those patients with stage 4 CKD and above (Stage 4 CKD: OR 2.90, 95% CI: 1.47, 5.74), stage 5 CKD or dialysis (OR 8.83, 95% CI: 2.76, 28.27) (<xref rid="B269" ref-type="bibr">269</xref>). The odds of hospitalization were especially high among kidney transplant recipients (OR 14.98, 95% CI: 2.77, 80.8) (<xref rid="B269" ref-type="bibr">269</xref>), with plausible mechanisms including transplant rejection as seen in a 2021 biopsy series (<xref rid="B270" ref-type="bibr">270</xref>).</p><p>In the largest biopsy series among patients with SARS-CoV-2 infection (45.4% with AKI and 42.6% for proteinuria with or without AKI), among whom 44.6% were African American, the most common diagnosis was collapsing glomerulopathy (25.8%) (<xref rid="B270" ref-type="bibr">270</xref>). Of those patients, 91.7% had high-risk <italic>APOL1</italic> genotypes (<xref rid="B270" ref-type="bibr">270</xref>) [G1/G1, G1/G2, or G2/G2 (<xref rid="B271" ref-type="bibr">271</xref>)]. Increased rates of myoglobin cast nephropathy (3.3%), proliferative glomerulonephritis with monoclonal IgG deposits (PMIG) (1.7%), and rejection among transplant patients (61.4% of transplant patients) were also seen when compared to historical controls (<xref rid="f4" ref-type="fig">
<bold>Figure&#x000a0;4A</bold>
</xref>) (<xref rid="B270" ref-type="bibr">270</xref>). Lower rates of arterionephrosclerosis, diabetic nephropathy, and IgA nephropathy were also noted within this cohort (<xref rid="B270" ref-type="bibr">270</xref>). Only 3.7% of biopsy specimens within this series exhibited SARS-CoV-2 N protein by immunohistochemistry, none of which were positive by <italic>in situ</italic> hybridization (<xref rid="B272" ref-type="bibr">272</xref>).</p><p>The unique association of COVID-19 and collapsing glomerulopathy has led to the identification of an entity known as COVID-19 associated nephropathy (COVAN), which is thought to be similar to HIV-associated nephropathy (HIVAN) (<xref rid="B273" ref-type="bibr">273</xref>). Mechanisms of COVID-19-induced collapsing glomerulopathy&#x02014;a variant of focal segmental glomerulosclerosis (FSGS) characterized by collapse of the glomerular capillaries with hypertrophy of the overlying podocytes (<xref rid="B271" ref-type="bibr">271</xref>)&#x02014;may include direct infection as well as thrombotic microangiopathy or other ischemic insults (<xref rid="B271" ref-type="bibr">271</xref>). In addition to the above-mentioned immunologic processes, mechanisms of COVID-19-related AKI include acute tubular injury (ATI) and acute tubular necrosis (ATN) from various etiologies, including systemic hemodynamic instability (<xref rid="B267" ref-type="bibr">267</xref>). Proteinuria can occur in COVID-19-related AKI and is typically low molecular weight, indicative of tubular injury (<xref rid="B267" ref-type="bibr">267</xref>). Other proposed mechanisms include intravascular hypovolemia, increased right heart filling pressures secondary to pulmonary pathology with associated renal venous vascular congestion, rhabdomyolysis, glomerulonephritis, and collapsing glomerulopathy (<xref rid="B267" ref-type="bibr">267</xref>). Additional patho-etiologies include endothelial inflammation, microthrombi formation, and thrombotic microangiopathy (<xref rid="B267" ref-type="bibr">267</xref>). NET-related immunothrombosis may be implicated, particularly in patients with proteinuria (<xref rid="B111" ref-type="bibr">111</xref>). Nephrotoxic agents administered during the course of hospitalization may also cause AKI through varied mechanisms (<xref rid="B267" ref-type="bibr">267</xref>) (<xref rid="f4" ref-type="fig">
<bold>Figure&#x000a0;4</bold>
</xref>).</p></sec><sec id="s2_3_6"><label>2.3.6</label><title>Gastrointestinal damage and dysfunction</title><p>Up to 50% of patients with COVID-19 develop GI symptoms such as nausea, abdominal pain, and diarrhea (<xref rid="B274" ref-type="bibr">274</xref>). SARS-CoV-2 can be detected in the stool, suggesting a role for fecal-oral transmission (<xref rid="B275" ref-type="bibr">275</xref>). Enterocytes can be directly infected with SARS-CoV-2 (<xref rid="B276" ref-type="bibr">276</xref>). Inflammatory infiltration of the intestine comprised of neutrophils, macrophages, and lymphocytes may be seen in severe COVID-19 (<xref rid="B276" ref-type="bibr">276</xref>). Studies in human small intestinal organoids reveal a response similar to that seen in the lungs (<xref rid="B277" ref-type="bibr">277</xref>), with low levels of interferons I and III and high levels of chemokines such as IP-10 and CXCL10 (<xref rid="B278" ref-type="bibr">278</xref>) skewing the immune response towards inflammation with less potent antiviral activity (<xref rid="B274" ref-type="bibr">274</xref>, <xref rid="B277" ref-type="bibr">277</xref>). Systemic inflammation, including cytokine release, can induce leakiness in the gut mucosal barrier, leading to exposure to LPS and &#x003b2;-D-glucan and the development of neutrophil extracellular traps (NETs) (<xref rid="B279" ref-type="bibr">279</xref>). Alterations in the gut microbiome in SARS-CoV-2 infection are thought to contribute to COVID-19-mediate inflammation, including through increased gut permeability and associated endotoxemia (<xref rid="B280" ref-type="bibr">280</xref>). In one study of metagenomic and metaproteomic profiles of COVID-19 patients, an increase in opportunistic pathogenic species such as Burkholderia contaminans was seen along with a decrease in commensal bacteria and was associated with illness severity, highlighting the role of the microbiome (<xref rid="B281" ref-type="bibr">281</xref>). Other studies showed increases in Escherichia coli, Klebsiella pneumoniae and Enterococcus faecalis (<xref rid="B282" ref-type="bibr">282</xref>). Antibiotic use during the pandemic is also likely to have contributed to microbial dysbiosis (<xref rid="B282" ref-type="bibr">282</xref>). The reduction in short-chain fatty acids, metabolites of a normal microbiome that can serve as fuel for enterocytes and regulators of innate and adaptive immunity, may help to explain COVID-19-related microbial dysbiosis (<xref rid="B282" ref-type="bibr">282</xref>).</p></sec></sec></sec><sec id="s3"><label>3</label><title>Post-acute and chronic immunologic and inflammatory response to SARS-CoV-2</title><p>Early waves of the pandemic were followed by the growth of a population of patients who continued to suffer from physical and neuropsychiatric symptoms (<xref rid="B283" ref-type="bibr">283</xref>) as well as overt organ damage (<xref rid="B284" ref-type="bibr">284</xref>). In the UK&#x02019;s National Health System (NHS), for instance, approximately one-third of patients who were hospitalized with COVID-19 were readmitted to the hospital within 5 months (<xref rid="B284" ref-type="bibr">284</xref>), implying a substantial individual and public health burden. A collection of symptoms, including shortness of breath, fatigue, memory loss, GI distress, and anosmia, has come to be called &#x0201c;long COVID&#x0201d; or post-acute sequelae of COVID-19 (PASC) (<xref rid="B285" ref-type="bibr">285</xref>). In a recent meta-analysis that alluded to substantial study heterogeneity (I<sup>2</sup> = 100%, P &#x0003c; 0.001), global pooled prevalence of any post-COVID-19 condition is estimated to be approximately 43% (95% CI, 39-46%) (<xref rid="B283" ref-type="bibr">283</xref>), with fatigue being the most common symptom reported (23%; 95% CI, 17-30%) and with symptoms more likely to be present in patients who were hospitalized with COVID-19 (<xref rid="B283" ref-type="bibr">283</xref>). Other studies reported at least one PASC symptom in half of all survivors of COVID-19, extending to at least 6 months following hospitalization (median 54.0% (IQR 31.0%-67.0%) (<xref rid="B286" ref-type="bibr">286</xref>). Pre-existing comorbidities likely predispose patients to PASC: A recent study showed a prevalence of 2.8% to 5.5% in people with pre-existing health conditions as compared with 1.8% in healthy controls (<xref rid="B287" ref-type="bibr">287</xref>). Mechanisms of post-COVID organ dysfunction and PASC are an area of current and active interest (<xref rid="B285" ref-type="bibr">285</xref>, <xref rid="B288" ref-type="bibr">288</xref>) with definitions of PASC being in a state of flux likely accounting for the heterogeneous findings (<xref rid="B283" ref-type="bibr">283</xref>).</p><sec id="s3_1"><label>3.1</label><title>Systemic inflammatory response to COVID-19: long-term effects from acute response and long-term immune response</title><sec id="s3_1_1"><label>3.1.1</label><title>Persistent viral RNA</title><p>Pathological studies have shown that SARS-CoV-2 viral RNA can persist and replicate throughout the body in multiple organs, including the heart, lung, brain, small intestine, and adrenal gland, for at least seven months post-infection (<xref rid="B289" ref-type="bibr">289</xref>). Circulating spike protein has been detected in approximately 60% of patients diagnosed with PASC for up to 12 months post-infection compared to those not diagnosed with PASC (<xref rid="B290" ref-type="bibr">290</xref>). While the clinical implications are unclear (<xref rid="B289" ref-type="bibr">289</xref>), the above findings and several other studies have fueled the hypothesis that PASC may be related to viral persistence (<xref rid="B291" ref-type="bibr">291</xref>). The presence of antibodies to spike antigen in 60% of COVID-19 survivors with PASC, in contrast to 0% of such antibodies in patients without PASC, indirectly points to a viral reservoir promoting persistent inflammation (<xref rid="B290" ref-type="bibr">290</xref>, <xref rid="B292" ref-type="bibr">292</xref>). Of note, although less common than with DNA viruses, the phenomenon of persistent RNA virus is not unique to SARS-CoV-2 (<xref rid="B293" ref-type="bibr">293</xref>, <xref rid="B294" ref-type="bibr">294</xref>) and has been seen with adenovirus, enterovirus, parvovirus B19 (<xref rid="B293" ref-type="bibr">293</xref>, <xref rid="B294" ref-type="bibr">294</xref>), rhinovirus, respiratory syncytial virus (RSV) and others, and correlated with cardiomyopathy, asthma, and chronic pulmonary disease (<xref rid="B293" ref-type="bibr">293</xref>). The attention to virus-associated clinicopathology that the SARS-CoV-2 pandemic has spurred may thus prove impactful for many chronic illnesses.</p></sec><sec id="s3_1_2"><label>3.1.2</label><title>Altered immune activation with co-presentation of EBV</title><p>Among the mechanisms studied for persistent symptoms in patients who have recovered from acute COVID-19 is altered immune activation to co-persistent Epstein-Barr Virus (EBV) (<xref rid="B291" ref-type="bibr">291</xref>). A 2021 study found that those patients who suffered from PASC symptoms were more likely to have evidence of EBV reactivation manifesting as early antigen diffuse (EA-D) IgG or viral capsid IgM (<xref rid="B295" ref-type="bibr">295</xref>). A later study showed that detection of EBV DNA was more than twice as common (27.1% vs. 12.5%) in patients diagnosed with COVID-19 (<xref rid="B296" ref-type="bibr">296</xref>). In another study, EBV viremia was seen in 14% of patients diagnosed with acute COVID-19 (<xref rid="B285" ref-type="bibr">285</xref>). In that same study, EBV viremia was associated with specific symptoms of PASC such as fatigue (<xref rid="B285" ref-type="bibr">285</xref>). Given the association of EBV with a number of clinical conditions ranging from chronic fatigue syndrome and multiple sclerosis (<xref rid="B297" ref-type="bibr">297</xref>), it&#x02019;s role in acute and chronic forms of COVID-19 should not be ignored. Of note, re-activation of dormant infections is likely not unique to EBV in COVID-19. Similar phenomena have been suggested with tuberculosis (<xref rid="B298" ref-type="bibr">298</xref>) and toxoplasmosis (<xref rid="B299" ref-type="bibr">299</xref>), and may yet be the subject of further study.</p></sec><sec id="s3_1_3"><label>3.1.3</label><title>Persistent cytokine release and the role of inflammasomes</title><p>Cytokines such as IL-2, IL-6, IL-17, TNF&#x003b1;, and IFN-&#x003b3; may be persistently elevated for weeks during active acute COVID-19 (<xref rid="B139" ref-type="bibr">139</xref>) and may continue to be elevated in the early post-acute phase of COVID-19 (<xref rid="B300" ref-type="bibr">300</xref>, <xref rid="B301" ref-type="bibr">301</xref>). In particular, IL-6, IFN-&#x003b2;, IFN-&#x003b3;, and IFN-&#x003bb;2/3 are associated with symptoms of PASC at least eight months after acute infection (<xref rid="B301" ref-type="bibr">301</xref>). Macrophages and monocytes may be responsible for the ongoing release of IL-1&#x003b2;, IL-6, and TNF (<xref rid="B302" ref-type="bibr">302</xref>). Hypotheses about the relevance of persistently elevated cytokines in PASC include low-grade chronic peripheral inflammation leading to microglia dysfunction and neuro-inflammation, which may explain &#x0201c;brain fog&#x0201d; and similar symptoms. This mechanism has yet to be proven (<xref rid="B303" ref-type="bibr">303</xref>). Among the mechanisms of cytokine release, the inflammasome-mediated pyroptosis pathway has been implicated in COVID-19 (<xref rid="B67" ref-type="bibr">67</xref>) and may involve NLRP3 (<xref rid="B304" ref-type="bibr">304</xref>). NLRP3 is associated with the development of such autoimmune conditions as rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), systemic sclerosis (SSc), and inflammatory bowel disease (IBD) (<xref rid="B305" ref-type="bibr">305</xref>). Therefore, persistent NLRP3-mediated inflammation via IL-1&#x003b2; may be at play in patients with PASC (<xref rid="B306" ref-type="bibr">306</xref>). In a study among PASC patients with lung fibrosis, activation of the Absent in Melanoma 2 (AIM2) inflammasome was associated with the release of IL-1&#x003b1;, IFN-&#x003b1; and TGF-&#x003b2;, a finding not seen in non-PASC patients (<xref rid="B306" ref-type="bibr">306</xref>). Of note, in that same study, the provocation of NLRP3 with LPS or ATP did not induce IL-1&#x003b1; release (<xref rid="B306" ref-type="bibr">306</xref>). The significance of inflammasomes in acute and chronic forms of COVID-19 remains the subject of ongoing study (<xref rid="B307" ref-type="bibr">307</xref>).</p></sec><sec id="s3_1_4"><label>3.1.4</label><title>Autoantibodies</title><p>Autoantibody development may be associated with the emergence of PASC (<xref rid="B285" ref-type="bibr">285</xref>). Several patients can develop autoantibodies early in the course of illness (<xref rid="B308" ref-type="bibr">308</xref>), as well as convalescent patients (<xref rid="B285" ref-type="bibr">285</xref>) (<xref rid="f2" ref-type="fig">
<bold>Figure&#x000a0;2E</bold>
</xref>). Among a cohort of patients with life-threatening COVID-19, 10.2% were found to have IgG autoantibodies to type I IFNs IFN-&#x003b1;2 and IFN-&#x003c9; (<xref rid="B309" ref-type="bibr">309</xref>). A unique sequencing technique called Molecular Indexing of Proteins by Self-Assembly (MIPSA) further identified type III-anti-IFN-&#x003bb;3 autoantibodies in patients with severe COVID-19 (<xref rid="B415" ref-type="bibr">415</xref>). Another study revealed that one out of every four hospitalized patients with COVID-19 in their cohort had anti-nuclear antibodies (ANA) of various titers and patterns (<xref rid="B308" ref-type="bibr">308</xref>). Following acute infection, autoantibodies can linger or develop anew. In a recent study, 44% of patients with symptoms of PASC were found to have autoantibodies, including the ANAs Jo-1, Ro/SS-A, La/SS-B, U1-snRNP, P1, and anti-IFN-&#x003b1;2, approximately 2-3 months after initial symptom onset (<xref rid="B285" ref-type="bibr">285</xref>). Intriguingly, immune profiles of patients with PASC may be similar to those with SLE (<xref rid="B285" ref-type="bibr">285</xref>, <xref rid="B310" ref-type="bibr">310</xref>). While it is difficult to ignore the possibility of pre-existing autoantibodies in certain patients before the development of COVID-19, a 2022 study points out that few of the patients found to have autoantibodies early in the course of illness had clinical evidence of autoimmune disease before COVID-19, suggesting a pre-existing subclinical autoimmune process that COVID-19 exacerbates (<xref rid="B285" ref-type="bibr">285</xref>).</p></sec><sec id="s3_1_5"><label>3.1.5</label><title>T-cell and B-cell subpopulations</title><p>In the early post-recovery phase, lymphopenia may persist (<xref rid="B300" ref-type="bibr">300</xref>). Following acute infection, CD4+ and CD8+ T-cell populations that upregulate genes associated with inflammatory regulation are preferentially expanded, and those associated with effector functions are contracted (<xref rid="B285" ref-type="bibr">285</xref>). In some patients, however&#x02014;particularly those experiencing GI symptoms of PASC&#x02014;populations of cytotoxic CD4+ and CD8+ T-cells continue to evolve into new clones, suggesting a role for T-cell-mediated inflammation in PASC (<xref rid="B285" ref-type="bibr">285</xref>). Additional studies have shown that naive CD127<sup>low</sup>GzmB<sup>&#x02212;</sup>CCR7<sup>+</sup>CD45RA<sup>+</sup>CD27<sup>+</sup>CD8<sup>+</sup> T-cells, naive CD127<sup>low</sup>TIM-3<sup>&#x02212;</sup>CCR7<sup>+</sup>CD45 RA<sup>+</sup>CD27<sup>+</sup>CD4<sup>+</sup> T-cells, and naive CD127<sup>low</sup>TIM-3<sup>&#x02212;</sup>CD38<sup>low</sup>CD27<sup>&#x02212;</sup>IgD<sup>+</sup> B cells are absent eight months post-infection in patients with PASC, suggesting ongoing activation of normally na&#x000ef;ve T-cell and B-cell subsets (<xref rid="B301" ref-type="bibr">301</xref>). As noted above, T<sub>H</sub>17 cells may be preferentially expressed in the hyperinflammatory environment in COVID-19, which includes TGF-&#x003b2; and IL-6 (<xref rid="B153" ref-type="bibr">153</xref>, <xref rid="B311" ref-type="bibr">311</xref>). T<sub>H</sub>17 cells have been associated with several autoimmune diseases, including asthma, multiple sclerosis, SLE, and RA (<xref rid="B153" ref-type="bibr">153</xref>). Specific cell signatures in T-cells, B-cells, and NK cells have defined different immune endophenotypes among patients with PASC (<xref rid="B285" ref-type="bibr">285</xref>). The interplay between T-cells and other viruses in a patient&#x02019;s virome (<xref rid="B312" ref-type="bibr">312</xref>), such as EBV and CMV, may also affect the development of PASC symptoms (<xref rid="B285" ref-type="bibr">285</xref>). Additional research can help further describe clinical and endophenotypes following infection with SARS-CoV-2 and elucidate the significance of these findings.</p></sec></sec><sec id="s3_2"><label>3.2</label><title>Post-acute and delayed inflammation-related end-organ injury following SARS-CoV-2 infection</title><sec id="s3_2_1"><label>3.2.1</label><title>Multisystem inflammatory syndrome in children and adults (MIS-C; MIS-A)</title><p>Multisystem inflammatory syndrome in children (MIS-C) and adults (MIS-A) are distinct acute hyperinflammatory illnesses involving end-organ dysfunction (<xref rid="B313" ref-type="bibr">313</xref>) that can occur 2-12 weeks after acute infection with SARS-CoV-2 (<xref rid="B314" ref-type="bibr">314</xref>). Diagnostic criteria for MIS-C vary but typically include age &#x0003c;21 years, persistent fever, involvement of &#x02265;2 organ systems [e.g., cardiac dysfunction (seen in 86.5% in one study), dermatologic or mucocutaneous involvement (70.9%), and GI involvement (90.9%) (<xref rid="B315" ref-type="bibr">315</xref>)] and inflammatory markers in the context of a preceding SARS-CoV-2 infection (<xref rid="B313" ref-type="bibr">313</xref>). Diagnostic criteria for MIS-A presently include severe cardiac illness, dermatologic and conjunctival manifestations, and elevated inflammatory markers in the context of recently positive SARS-CoV-2 PCR, antigen, or antibody testing in patients &#x0003e;21 (<xref rid="B316" ref-type="bibr">316</xref>). It is important to note that these two syndromes, while similar in name, likely reflect distinct pathological processes. MIS-C is more common than MIS-A and exhibits strong similarities to Kawasaki Disease (<xref rid="B313" ref-type="bibr">313</xref>). Both MIS-C and MIS-A exhibit similarities to macrophage activation syndrome (MAS), secondary hemophagocytic lymphohistiocytosis (HLH), and toxic shock syndrome (<xref rid="B317" ref-type="bibr">317</xref>) and may be equivalent to an immunologic aftershock following a sometimes-benign initial infection (<xref rid="B317" ref-type="bibr">317</xref>). MIS-C may be distinguishable from severe COVID-19 by cytokine profile differences such as increased IL-10 in MIS-C (<xref rid="B317" ref-type="bibr">317</xref>). Coronary artery aneurysms have been reported in MIS-C (<xref rid="B318" ref-type="bibr">318</xref>); both MIS-C and MIS-A can be associated with myocarditis (<xref rid="B319" ref-type="bibr">319</xref>&#x02013;<xref rid="B321" ref-type="bibr">321</xref>), which can progress to cardiogenic shock (<xref rid="B321" ref-type="bibr">321</xref>) and may respond to immunosuppressive agents (<xref rid="B13" ref-type="bibr">13</xref>, <xref rid="B320" ref-type="bibr">320</xref>, <xref rid="B321" ref-type="bibr">321</xref>).</p></sec></sec><sec id="s3_3"><label>3.3</label><title>Chronic end-organ dysfunction following infection with SARS-CoV-2</title><p>The early effects of SARS-CoV-2 infection and the associated immune response can have a long-term impact on multiple organ systems. Post-acute sequelae of COVID-19 (PASC), also called Long COVID, long-haul COVID, and other names, is now widely recognized as a clinical entity carrying its own <italic>International Classification of Diseases, Tenth Revision, Clinical Modification</italic> (ICD-10-CM) diagnosis (U09.9 Post COVID-19 condition, unspecified) (<xref rid="B322" ref-type="bibr">322</xref>). The convenience of a unifying diagnostic code belies the sundry manifestations of this condition. Patients who have recovered from COVID-19 may display clinical and pathological evidence of end-organ dysfunction, which may overlap those underlying PASC (<xref rid="f3" ref-type="fig">
<bold>Figure&#x000a0;3B</bold>
</xref>). Pre-existing factors such as older age, female gender, higher BMI, and previous hospitalization are associated with the development of symptoms of PASC (<xref rid="B323" ref-type="bibr">323</xref>).</p><sec id="s3_3_1"><label>3.3.1</label><title>Cardiac dysfunction</title><p>A large US Veterans&#x02019; study found that the risk of cardiovascular disease, including inflammatory heart disease, was increased beyond 30 days after acute SARS-CoV-2 infection, even when mild (<xref rid="B324" ref-type="bibr">324</xref>). COVID-19 in the acute phase (defined as &#x02264; 21 days) and in the post-acute phase (&#x0003e; 21 days) were shown to be associated with an increased risk of cardiovascular disease than contemporary controls [hazard ratio (HR) for acute phase: 4.3 (CI=2.6-6.9); HR for post-acute phase: 1.4 (CI=1.2-1.8)], findings which also held for historical controls whose population health was not overtly impacted by COVID-19 as a whole (<xref rid="B325" ref-type="bibr">325</xref>, <xref rid="B326" ref-type="bibr">326</xref>). The risk of ischemic heart disease, heart failure, myocardial infarction, MACE, myocarditis, and pericarditis were all increased in the 12 months following acute SARS-CoV-2 infection (<xref rid="B324" ref-type="bibr">324</xref>). The risks of atrial fibrillation, ventricular arrhythmias, and other dysrhythmias were also higher (<xref rid="B324" ref-type="bibr">324</xref>). Myocarditis carried the highest risk (HR 5.38; CI: 3.80-7.59) of all such outcomes, which remained increased for COVID-19 patients even when vaccination was accounted for (<xref rid="B324" ref-type="bibr">324</xref>). A retrospective cohort study from a US health plan reported similarly increased risks in several of the outcomes mentioned above, as well as an increase in the diagnosis of hypertension (<xref rid="B327" ref-type="bibr">327</xref>). The risk of cerebrovascular disorders like stroke and TIA was also increased (<xref rid="B324" ref-type="bibr">324</xref>). While the impact of pre-existing comorbidities should not be ignored (<xref rid="B287" ref-type="bibr">287</xref>), subgroup analyses of the 2022 Veteran study suggested that COVID-19 was itself a risk factor for future cardiovascular disease <italic>regardless of pre-COVID-19 risk</italic> (<xref rid="B324" ref-type="bibr">324</xref>, <xref rid="B328" ref-type="bibr">328</xref>). Moreover, COVID-19 disrupted the care of patients with cardiovascular disease and was associated with an overall increase in mortality due to these conditions (<xref rid="B326" ref-type="bibr">326</xref>).</p></sec><sec id="s3_3_2"><label>3.3.2</label><title>Pulmonary dysfunction</title><p>Pulmonary hypertension (and associated right-sided cardiac dysfunction) (<xref rid="B329" ref-type="bibr">329</xref>) can be observed as a result of pulmonary fibrosis (<xref rid="B330" ref-type="bibr">330</xref>) and prior pulmonary emboli (i.e., Group 3 and Group 4 pulmonary hypertension, respectively) (<xref rid="B331" ref-type="bibr">331</xref>). Patients with pulmonary emboli may exhibit functional limitations and dyspnea (<xref rid="B332" ref-type="bibr">332</xref>) even in the absence of overt pulmonary hypertension. Notably, the risk of new-onset PE [as defined by hazard ratio (HR) (<xref rid="B324" ref-type="bibr">324</xref>)] and a new diagnosis of pulmonary hypertension (<xref rid="B327" ref-type="bibr">327</xref>) have also been found to be higher in patients who have had COVID-19. On imaging, early infection with SARS-CoV-2 can give way to air trapping in patients with PASC seen in a post-COVID-19 clinic 42-204 days after diagnosis (<xref rid="B333" ref-type="bibr">333</xref>). This CT finding suggests persistent small airway disease (<xref rid="B333" ref-type="bibr">333</xref>), presumably reflective of post-viral constrictive bronchiolitis, and is typically not associated with large airway obstruction on pulmonary function tests (PFTs) (<xref rid="B333" ref-type="bibr">333</xref>, <xref rid="B334" ref-type="bibr">334</xref>). Patients with more severe infections (i.e., those requiring an ICU stay) were additionally found to have GGOs, architectural distortion, honeycombing, scar, or traction bronchiectasis accompanied by restrictive lung physiology and a reduction in DLCO (<xref rid="B333" ref-type="bibr">333</xref>, <xref rid="B335" ref-type="bibr">335</xref>). Pulmonary fibrosis and interstitial lung disease (ILD) following COVID-19 (<xref rid="B336" ref-type="bibr">336</xref>&#x02013;<xref rid="B338" ref-type="bibr">338</xref>) may be due to an initial hyperproliferation of pathologic fibroblasts acting via TGF-&#x003b2; signaling (<xref rid="B339" ref-type="bibr">339</xref>). Post-COVID pulmonary complications are likely to be related to disease severity, as suggested by an association with the inflammatory markers ESR and CRP (<xref rid="B340" ref-type="bibr">340</xref>), as well as to pre-existing comorbidities (<xref rid="B287" ref-type="bibr">287</xref>). Observational studies are now underway to elucidate the mechanisms and clinical trajectory of post-COVID-19 ILD (<xref rid="B336" ref-type="bibr">336</xref>). The risk of a new diagnosis of sleep apnea appears to be higher following hospitalization for COVID-19 (<xref rid="B327" ref-type="bibr">327</xref>).</p></sec><sec id="s3_3_3"><label>3.3.3</label><title>Neuropsychiatric symptoms</title><p>Neuropsychiatric symptoms can be a prominent component of PASC and are typically characterized by fatigue, cognitive dysfunction, and post-exertional malaise (<xref rid="B341" ref-type="bibr">341</xref>). A recent survey study confirmed similarities between fibromyalgia and chronic fatigue syndrome with respect to self-reported fatigue, cognitive function, anxiety, depression, kinesiophobia, pain, and physical dysfunction, although patients with PASC had lower levels of fatigue and pain (<xref rid="B342" ref-type="bibr">342</xref>). Neurocognitive testing confirmed impairments in 46% of this preselected group of patients (<xref rid="B343" ref-type="bibr">343</xref>) and has been reported in other populations (<xref rid="B344" ref-type="bibr">344</xref>). Persistent neuroinflammation and endothelial injury are among the proposed mechanisms for this phenomenon (<xref rid="B345" ref-type="bibr">345</xref>).</p><p>Laboratory abnormalities among patients with PASC include reduced cortisol levels (<xref rid="B346" ref-type="bibr">346</xref>) and a reduced circulating serotonin level (<xref rid="B347" ref-type="bibr">347</xref>). A compensatory increase in ACTH was not seen among patients with low cortisol, which may reflect a blunted stress response in patients with PASC (<xref rid="B346" ref-type="bibr">346</xref>). The correlation between viral-RNA-induced type I interferons and reduced serotonin is thought to be mediated by reduced tryptophan uptake and storage and hypercoagulability, as shown in a recent elegant study from 2023 (<xref rid="B347" ref-type="bibr">347</xref>). In that same study&#x02014;which opened the door to a compelling mechanism underlying PASC&#x02014;cognitive dysfunction correlated with peripheral serotonin depletion (<xref rid="B347" ref-type="bibr">347</xref>).</p><p>In post-hospital discharge patients with symptoms of PASC, the most common MRI finding was scattered white matter lesions (<xref rid="B343" ref-type="bibr">343</xref>). An increased risk of incident ischemic and hemorrhagic stroke, encephalitis, encephalopathy, migraine, seizures, sensory disorders, peripheral nervous system disorders, musculoskeletal disorders, Guillain-Barre Syndrome, and extrapyramidal disorders was seen among patients followed for 12 months following acute SARS-CoV-2 infection, with an estimated HR for any neurologic sequela of 1.42 (1.38-1.47) (<xref rid="B344" ref-type="bibr">344</xref>). In one comprehensive NIH study of 12 patients with neurologic sequelae of SARS-CoV-2 infection, mild cognitive impairment (Montreal Cognitive Assessment Score (MoCA) &#x0003c; 26) was seen in half of the patients, with deficits predominantly seen in short-term memory (<xref rid="B348" ref-type="bibr">348</xref>). No MRI abnormalities were seen in those patients. Immunophenotyping of CSF revealed higher frequencies of antibody-secreting B cells and PD-L1-expressing monocytes and lower frequencies of CD4+ and CD8+ effector memory cells (<xref rid="B348" ref-type="bibr">348</xref>). It should be noted that one-third of patients included in the study had a prior history of resolved long-term disability due to a preceding infection (amoebiasis due to <italic>Entamoeba histolytica</italic>, infectious mononucleosis, Lyme disease, and severe sepsis due to group A Streptococcus) (<xref rid="B348" ref-type="bibr">348</xref>).</p></sec><sec id="s3_3_4"><label>3.3.4</label><title>Persistent renal dysfunction and chronic kidney disease</title><p>In a US health plan cohort, renal dysfunction, as defined by a composite of AKI and CKD, was found to be more likely after a diagnosis of COVID-19 in hospitalized patients with a pre-existing condition (<xref rid="B327" ref-type="bibr">327</xref>). Other studies reported an increased likelihood of a new diagnosis of CKD within the first 4-6 months following COVID-19 in addition to AKI (<xref rid="B284" ref-type="bibr">284</xref>, <xref rid="B349" ref-type="bibr">349</xref>). A large VA health system study also revealed an increase in the diagnosis of CKD following COVID-19 infection in hospitalized and intensive care unit patients (HR, hospitalized patients=1.36 (CI=1.24-1.49), and HR for ICU patients=1.88 (1.66-2.13) (<xref rid="B350" ref-type="bibr">350</xref>).</p><p>CKD is known to be associated with altered immunity. ESRD has likewise been defined in part as a state of &#x0201c;acquired immunodeficiency&#x0201d; by Vanholder and Ringoir in 1993 (<xref rid="B351" ref-type="bibr">351</xref>), although simultaneously heightened levels of inflammation and immune activation have also been described noted (<xref rid="B352" ref-type="bibr">352</xref>). In ESRD patients, CD14+CD16+ monocyte populations are expanded, cytokine production and chemokine expression is increased, as is basal ROS production (<xref rid="B352" ref-type="bibr">352</xref>, <xref rid="B353" ref-type="bibr">353</xref>). LDL likewise elicits a stronger pro-inflammatory response (<xref rid="B354" ref-type="bibr">354</xref>). In contrast, a decreased number of DCs with impaired function (<xref rid="B355" ref-type="bibr">355</xref>) are seen, circulating PMNs have decreased phagocytic capacity, na&#x000ef;ve and central memory T cells are depleted (with a reduced CD4+/CD8+ T cell ratio), CD4+CD25bright+FoxP3+ Treg populations are both diminished and impaired, and B cell populations are likewise diminished (<xref rid="B352" ref-type="bibr">352</xref>).</p><p>An early PheWAS study cited above pointed to a strong association between pre-existing Stage 4 CKD, Stage 5 CKD, and dialysis with the likelihood of hospitalization with even higher odds among kidney transplant recipients &#x0fffc;, suggesting a disproportionate impact among those with pre-existing renal disease as well as the bidirectional interplay between COVID-19 and CKD (<xref rid="B356" ref-type="bibr">356</xref>). Among 758 patients in the Health Outcome Predictive Evaluation of COVID-19 (HOPE COVID-19) Study, an eGFR of &#x0003c; 60 ml/min/1.73m<sup>2</sup> was associated with a higher risk of in-hospital mortality (eGFR &#x0003e; 60: 18.4%; eGFR 30-60: 56.5%; and eGFR &#x0003c; 30: 65.5%; p &#x0003c; 0.001), multi-organ failure, and sepsis (<xref rid="B356" ref-type="bibr">356</xref>, <xref rid="B357" ref-type="bibr">357</xref>). Notably, while only 8.5% of the HOPE-COVID-19 cohort had documented CKD on admission, 30.6% (N=322) presented with eGFR &#x0003c; 60 ml/min/1.73m<sup>2</sup>, suggesting a role in the development of AKI as described above (<xref rid="B356" ref-type="bibr">356</xref>, <xref rid="B357" ref-type="bibr">357</xref>).</p><p>Mechanisms of the development of CKD in the general population include the progression of changes set in motion through COVID-19 AKI, particularly as the development of AKI itself can be associated with the eventual development of CKD (<xref rid="B358" ref-type="bibr">358</xref>). Acknowledging the unique etiological mechanisms of the initial AKI insult (<xref rid="B359" ref-type="bibr">359</xref>, <xref rid="B360" ref-type="bibr">360</xref>), injury of proximal tubule cells in severe AKI may result in cell cycle arrest in the G2/M phase, which leads to the secretion of TGF-&#x003b2; and connective tissue growth factor, both of which mediate fibrosis through c-jun NH2-terminal kinase (JNK) signaling (<xref rid="B359" ref-type="bibr">359</xref>, <xref rid="B361" ref-type="bibr">361</xref>). Following AKI, animal models have shown that aberrant activation of developmental pathways such as Hedgehog and Wnt/&#x003b2;-catenin can also promote fibrosis (<xref rid="B359" ref-type="bibr">359</xref>). Persistent mitochondrial dysfunction following the initial insult may also play a role in developing fibrosis and persistent inflammation (<xref rid="B359" ref-type="bibr">359</xref>). Resident <italic>P0-Cre</italic> fibroblasts in the renal cortex and medulla (<xref rid="B359" ref-type="bibr">359</xref>) may transdifferentiate into &#x003b1;SMA-positive myofibroblasts and promote fibrosis (<xref rid="B359" ref-type="bibr">359</xref>); <italic>Gli1-Cre</italic> fibroblasts are likewise related to end-organ fibrosis and may be therapeutically targeted (<xref rid="B362" ref-type="bibr">362</xref>).</p><p>A 2022 study reviewed a biopsy series and confirmed the presence of tubule interstitial fibrosis in patients with COVID-19 as compared to age, sex, and comorbidity-matched controls &#x0fffc;; in an elegant study described above for AKI, infection of human iPSC-derived organoids elucidated SARS-CoV-2-specific pathways of tubule-interstitial fibrosis mediated through direct infection (<xref rid="B19" ref-type="bibr">19</xref>). Early pro-inflammatory, fibroblast activation, and myofibroblast differentiation, including those mediated by TGF-&#x003b2;, NF&#x003ba;B, and JAK-STAT, were upregulated in podocytes, proximal tubule cells (PTC), and fibroblasts, with a concomitant increase in ECM and collagen deposition (<xref rid="B19" ref-type="bibr">19</xref>). Additional mechanisms are described above. Further, the initial binding of SARS-CoV-2 with ACE2 in the kidney in acute infection limits its bioavailability for Ang1-7 production, leading to fibrosis (<xref rid="B363" ref-type="bibr">363</xref>) and maladaptive repair (<xref rid="B359" ref-type="bibr">359</xref>, <xref rid="B364" ref-type="bibr">364</xref>). Mechanisms in immunocompromised patients may involve direct damage to podocytes and proximal convoluted tubules via SARS-CoV-2 colocalization with Le<sup>x</sup> and sialyl-Le<sup>x</sup> (CD15s) in addition to ACE2 in the setting of chronic replication of SARS-CoV-2 as seen on biopsy from a patient with splenic marginal cell lymphoma (<xref rid="B365" ref-type="bibr">365</xref>).</p><p>Much of the research on COVID-19 AKI and CKD has been performed among patients with more severe illness. A 2022 study of a primarily ambulatory cohort of patients in Hamburg, Germany, showed a decreased eGFR (regression estimate -2.35mL/min/1.73m<sup>2</sup> (CI= -4.28, -0.42); Bonferroni adjusted p=0.019) as compared to matched controls (<xref rid="B366" ref-type="bibr">366</xref>). Mechanisms or histological specimens were not described in this study. However, it is conceivable that SARS-CoV-2-mediated AKI and subsequent CKD exist on a spectrum, and likely that if so, the above mechanisms are at play in what may be considered &#x0201c;renal PASC.&#x0201d; As noted above, persistent viral RNA may be among the mechanisms in renal PASC (<xref rid="B291" ref-type="bibr">291</xref>).</p></sec><sec id="s3_3_5"><label>3.3.5</label><title>Other organ systems</title><p>In a large cohort of post-discharge patients in the UK&#x02019;s NHS, the rate of new diagnoses of chronic liver disease increased following hospitalization for COVID-19 (<xref rid="B284" ref-type="bibr">284</xref>). Diagnosis of diabetes was also increased (<xref rid="B284" ref-type="bibr">284</xref>). A large VA cohort identified an excess burden of diabetes beyond thirty days after COVID-19 diagnosis in non-hospitalized patients, in addition to lipid disorders and obesity (<xref rid="B350" ref-type="bibr">350</xref>). An increased burden of esophageal disorders, gastrointestinal disorders, and dysphagia was also seen, as was incident elevated alanine aminotransferase (ALT) levels (<xref rid="B350" ref-type="bibr">350</xref>). As described above in the context of acute infection, mechanisms of excess inflammation in post-infectious symptoms include alterations in the gut microbiome, with acute and post-infectious inflammation possibly reflecting perturbations in the gastrointestinal mucosal barrier (<xref rid="B367" ref-type="bibr">367</xref>). An extra burden of skin disorders, arthralgias, and arthritis was also seen in the VA cohort (<xref rid="B350" ref-type="bibr">350</xref>). Thyrotoxicosis related to both subacute thyroiditis and Graves&#x02019; Disease has been reported (<xref rid="B368" ref-type="bibr">368</xref>). Reports of hormonal changes in male and female patients vary; an increase in menstrual cycle has been reported (<xref rid="B368" ref-type="bibr">368</xref>, <xref rid="B369" ref-type="bibr">369</xref>). Orchitis and epidydimo-orchitis may occur in acute COVID-19 (<xref rid="B368" ref-type="bibr">368</xref>). The immunologic changes that accompany SARS-CoV-2 may also prove to be associated with long-term pathophysiology in bone (<xref rid="B370" ref-type="bibr">370</xref>). Finally, vasculitis (<xref rid="B371" ref-type="bibr">371</xref>), myositis (<xref rid="B371" ref-type="bibr">371</xref>, <xref rid="B372" ref-type="bibr">372</xref>), and rhabdomyolysis (<xref rid="B371" ref-type="bibr">371</xref>) have been reported in acute COVID-19; arthritis (<xref rid="B350" ref-type="bibr">350</xref>), including inflammatory arthritis (<xref rid="B371" ref-type="bibr">371</xref>), has been reported in the post-infectious period. A comprehensive summary of the end-organ effects on various organ systems affected in both acute and post-infectious COVID-19 is shown in <xref rid="T3" ref-type="table">
<bold>Table&#x000a0;3</bold>
</xref> and <xref rid="f3" ref-type="fig">
<bold>Figure&#x000a0;3</bold>
</xref>.</p><table-wrap position="float" id="T3"><label>Table&#x000a0;3</label><caption><p>Acute and post-acute end-organ dysfunction in COVID-19.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Organ system</th><th valign="top" align="left" rowspan="1" colspan="1">Acute effects</th><th valign="top" align="left" rowspan="1" colspan="1">Post-acute effects</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Cardiovascular</td><td valign="top" align="left" rowspan="1" colspan="1">Myocarditis (<xref rid="B197" ref-type="bibr">197</xref>, <xref rid="B240" ref-type="bibr">240</xref>&#x02013;<xref rid="B243" ref-type="bibr">243</xref>); stress cardiomyopathy (<xref rid="B242" ref-type="bibr">242</xref>); myocardial infarction (<xref rid="B240" ref-type="bibr">240</xref>, <xref rid="B247" ref-type="bibr">247</xref>&#x02013;<xref rid="B249" ref-type="bibr">249</xref>); pericardial effusion, tamponade (<xref rid="B371" ref-type="bibr">371</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">Shortness of breath (<xref rid="B285" ref-type="bibr">285</xref>); coronary artery aneurysms (MIS-C) (<xref rid="B318" ref-type="bibr">318</xref>); myocarditis [in the absence of (<xref rid="B324" ref-type="bibr">324</xref>) or presence of MIS-C or MIS-A (<xref rid="B319" ref-type="bibr">319</xref>&#x02013;<xref rid="B321" ref-type="bibr">321</xref>)]; risk of ischemic heart disease, MI, MACE, heart failure, atrial fibrillation, ventricular and other arrhythmias may be increased beyond acute infection (<xref rid="B324" ref-type="bibr">324</xref>); increased likelihood of diagnosis of hypertension (<xref rid="B327" ref-type="bibr">327</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Respiratory</td><td valign="top" align="left" rowspan="1" colspan="1">Hypoxemic respiratory failure (<xref rid="B222" ref-type="bibr">222</xref>); pneumonia (<xref rid="B219" ref-type="bibr">219</xref>, <xref rid="B224" ref-type="bibr">224</xref>); ARDS (<xref rid="B224" ref-type="bibr">224</xref>); PE (<xref rid="B239" ref-type="bibr">239</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">Shortness of breath (<xref rid="B285" ref-type="bibr">285</xref>); pulmonary fibrosis (<xref rid="B330" ref-type="bibr">330</xref>, <xref rid="B336" ref-type="bibr">336</xref>); ILD (<xref rid="B336" ref-type="bibr">336</xref>), pulmonary hypertension (<xref rid="B327" ref-type="bibr">327</xref>, <xref rid="B329" ref-type="bibr">329</xref>); PE (<xref rid="B324" ref-type="bibr">324</xref>); diagnosis of sleep apnea (<xref rid="B327" ref-type="bibr">327</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Renal</td><td valign="top" align="left" rowspan="1" colspan="1">AKI (<xref rid="B267" ref-type="bibr">267</xref>, <xref rid="B327" ref-type="bibr">327</xref>); proteinuria, tubular injury (<xref rid="B267" ref-type="bibr">267</xref>); hematuria (<xref rid="B371" ref-type="bibr">371</xref>); need for RRT (<xref rid="B367" ref-type="bibr">367</xref>); hyponatremia (<xref rid="B368" ref-type="bibr">368</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">CKD (<xref rid="B327" ref-type="bibr">327</xref>), decreased eGFR, ESRD (<xref rid="B310" ref-type="bibr">310</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Nervous/Psychiatric</td><td valign="top" align="left" rowspan="1" colspan="1">Headache, anosmia/ageusia, encephalopathy, coma, stroke (<xref rid="B252" ref-type="bibr">252</xref>); encephalitis (<xref rid="B255" ref-type="bibr">255</xref>); delirium (<xref rid="B251" ref-type="bibr">251</xref>); ischemic stroke (<xref rid="B253" ref-type="bibr">253</xref>, <xref rid="B254" ref-type="bibr">254</xref>); anxiety, depression (<xref rid="B251" ref-type="bibr">251</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">Memory loss, fatigue (<xref rid="B285" ref-type="bibr">285</xref>, <xref rid="B341" ref-type="bibr">341</xref>), neurocognitive impairment (<xref rid="B341" ref-type="bibr">341</xref>, <xref rid="B344" ref-type="bibr">344</xref>), encephalopathy, encephalitis (<xref rid="B344" ref-type="bibr">344</xref>), migraine headache (<xref rid="B344" ref-type="bibr">344</xref>), anosmia (<xref rid="B285" ref-type="bibr">285</xref>), post-exertional malaise (<xref rid="B341" ref-type="bibr">341</xref>), risk of TIA, risk of stroke (<xref rid="B324" ref-type="bibr">324</xref>) [both ischemic and hemorrhagic (<xref rid="B344" ref-type="bibr">344</xref>)], seizures (<xref rid="B344" ref-type="bibr">344</xref>), extrapyramidal disorders (<xref rid="B344" ref-type="bibr">344</xref>), peripheral nervous system disorders (<xref rid="B344" ref-type="bibr">344</xref>), Guillan-Barre Syndrome (<xref rid="B344" ref-type="bibr">344</xref>); dysautonomia, postural tachycardia syndrome (POTS) (<xref rid="B310" ref-type="bibr">310</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Enteral</td><td valign="top" align="left" rowspan="1" colspan="1">Nausea, abdominal pain, diarrhea (<xref rid="B274" ref-type="bibr">274</xref>); perturbation in GI mucosal barrier may be implicated in both acute COVID-19 and PASC (<xref rid="B310" ref-type="bibr">310</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">Diagnosis of esophageal disorders, dysphagia, gastrointestinal disorders (<xref rid="B350" ref-type="bibr">350</xref>), chronic liver disease (<xref rid="B284" ref-type="bibr">284</xref>); elevated ALT (<xref rid="B350" ref-type="bibr">350</xref>); potential for alteration of gut microbiome (<xref rid="B367" ref-type="bibr">367</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Hematologic</td><td valign="top" align="left" rowspan="1" colspan="1">Lymphopenia (<xref rid="B408" ref-type="bibr">408</xref>); neutrophilia, prolonged PT 34783405} and aPTT (<xref rid="B409" ref-type="bibr">409</xref>), decreased fibrinogen, elevated D-dimer (<xref rid="B408" ref-type="bibr">408</xref>), hypercoagulability (<xref rid="B409" ref-type="bibr">409</xref>), VTE (<xref rid="B239" ref-type="bibr">239</xref>), thrombocytopenia, disseminated intravascular coagulation (DIC), cytokine abnormalities (<xref rid="B409" ref-type="bibr">409</xref>, <xref rid="B410" ref-type="bibr">410</xref>); hyperferritinemia (<xref rid="B410" ref-type="bibr">410</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">Increase in amyloid deposits in plasma (<xref rid="B411" ref-type="bibr">411</xref>), VTE/PE (<xref rid="B324" ref-type="bibr">324</xref>, <xref rid="B412" ref-type="bibr">412</xref>);</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Endocrine</td><td valign="top" align="left" rowspan="1" colspan="1">Pituitary apoplexy (particularly in patients with pre-existing macroadenoma) (<xref rid="B368" ref-type="bibr">368</xref>); subacute thyroiditis- and Graves&#x02019;-associated thyrotoxicosis (<xref rid="B368" ref-type="bibr">368</xref>); low TSH and low T3 (<xref rid="B368" ref-type="bibr">368</xref>), adrenal insufficiency, adrenal hemorrhage, adrenal infarction (<xref rid="B368" ref-type="bibr">368</xref>); alterations in serum cortisol, with higher levels associated with more severe disease (<xref rid="B368" ref-type="bibr">368</xref>); new onset type 1 diabetes mellitus (<xref rid="B368" ref-type="bibr">368</xref>); decreased menstrual volume, prolonged menstrual cycle (33288478; 34543404}; varying reports of E2, progresterone, AMH, and testosterone levels in female sex (<xref rid="B368" ref-type="bibr">368</xref>); epidydimo-orchitis, hypogonadism (possibly physiologic response to stressor) (<xref rid="B368" ref-type="bibr">368</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">Persistent hyperglycemia (<xref rid="B368" ref-type="bibr">368</xref>); diagnosis of diabetes (<xref rid="B284" ref-type="bibr">284</xref>, <xref rid="B350" ref-type="bibr">350</xref>, <xref rid="B368" ref-type="bibr">368</xref>); diagnosis of lipid disorders and obesity (<xref rid="B350" ref-type="bibr">350</xref>); possible effect on bone density (<xref rid="B370" ref-type="bibr">370</xref>); cortisol downregulation may be associated with PASC (<xref rid="B285" ref-type="bibr">285</xref>, <xref rid="B288" ref-type="bibr">288</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Rheumatologic</td><td valign="top" align="left" rowspan="1" colspan="1">Production of pro-inflammatory cytokines (<xref rid="B410" ref-type="bibr">410</xref>); arthralgia, myalgia (<xref rid="B371" ref-type="bibr">371</xref>); myositis (<xref rid="B371" ref-type="bibr">371</xref>, <xref rid="B372" ref-type="bibr">372</xref>); rhabdomyolysis (<xref rid="B371" ref-type="bibr">371</xref>); vasculitis (small, medium and large vessel) (<xref rid="B371" ref-type="bibr">371</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">Arthralgias, arthritis (<xref rid="B350" ref-type="bibr">350</xref>) (including inflammatory arthritis (<xref rid="B371" ref-type="bibr">371</xref>); autoantibodies to IFN-I, ANA (Ro, La, Jo-1, P1, and U1-snRNP) may be seen in PASC (<xref rid="B310" ref-type="bibr">310</xref>); SLE (<xref rid="B371" ref-type="bibr">371</xref>); MIS-C (<xref rid="B367" ref-type="bibr">367</xref>); MIS-A (<xref rid="B413" ref-type="bibr">413</xref>)</td></tr></tbody></table></table-wrap></sec></sec></sec><sec id="s4"><label>4</label><title>The impact of SARS-CoV-2 variants</title><p>The impact of variants throughout the pandemic is a subject of ongoing interest, particularly concerning ongoing vaccine development (<xref rid="B373" ref-type="bibr">373</xref>). Mutations in the S protein are likely to be the most important in determining viral tropism, infectivity, and mortality (<xref rid="B374" ref-type="bibr">374</xref>). However, mutations in other proteins, such as R203K and G204R in N, may also impact viral fitness (<xref rid="B375" ref-type="bibr">375</xref>). A 2022 study compared the impact of Delta and Omicron SARS-CoV-2 variants in a cohort of 65 patients admitted to an intensive care unit. A higher mortality rate was seen with Omicron (52.9% vs. 41.9% with Delta), although the study acknowledges a higher rate of comorbidities among Omicron patients (<xref rid="B376" ref-type="bibr">376</xref>). Similar PaO2/FiO2 ratios (partial pressure of oxygen in arteries to the fraction of inspired oxygen) were seen [Omicron: 156.57, SD 65.98 vs. Delta: 157.31, SD 84.56 (p=0.971)], suggesting a role for extrapulmonary pathophysiology. Organ-specific sequelae may also relate to SARS-CoV-2 variants: Cardiovascular mortality was higher during the pandemic period, ranging from March to June 2020 (likely the D614G variant) and during the Delta wave (June to December 2021) (<xref rid="B326" ref-type="bibr">326</xref>). Rates of AKI were higher among Omicron patients than Delta (13 (38.24%) vs. 3 (9.7%), OR 5.78; CI 1.46&#x02013;22.9, p=0.0172) (<xref rid="B376" ref-type="bibr">376</xref>), which may be due to a higher rate of comorbidities among Omicron patients admitted to the ICU rather than being reflective of virus-specific effects.</p><p>One meta-analysis examined the impact of variants on post-COVID symptomatology by pooled estimates of several studies, reporting CT abnormalities (60.5%; 95% CI: 40.4-80.6%) and sleep difficulty (24.5%; 95%: 17.5-31.5%) to be the most common PASC symptom following infection with wild-type SARS-CoV-2, fatigue most common among survivors of the Alpha variant, and myalgia among survivors of the Omicron variant (11.7% (95% CI: 8.3-15.1%) in Omicron compared to 9.4% (95% CI: 6.3-12.5%) in wild-type) (<xref rid="B377" ref-type="bibr">377</xref>). In that same study, the Alpha and Gamma variants had higher rates of dyspnea (34.2% (8.3-60.1%) and 43.0% (35.3, 50.8%), respectively). The Alpha variant was found to have a higher rate of patients with greater than one general symptom of PASC and fatigue (<xref rid="B377" ref-type="bibr">377</xref>). As noted by the authors and as suggested by recent meta-analyses, vaccination is likely to have attenuated the risk of PASC among survivors of COVID-19 (<xref rid="B323" ref-type="bibr">323</xref>, <xref rid="B378" ref-type="bibr">378</xref>, <xref rid="B379" ref-type="bibr">379</xref>). As pointed out by the authors of a recent study on pooled survivors of COVID-19 across SARS-CoV-2 variants (<xref rid="B323" ref-type="bibr">323</xref>), however, it is difficult to parse out the interaction of vaccines with individual variants, which may be the subject of future studies.</p><p>Mechanisms underlying responses to variants of concern may vary. Studies in zebrafish models showed that the wild-type (WT)/Wuhan SARS-CoV-2 variant activated emergency myelopoiesis and recruited neutrophils and macrophages through inflammasome production (<xref rid="B380" ref-type="bibr">380</xref>). Deficiency of ACE2 led to exacerbation of inflammation, which was reversed with Ang 1-7 injection, suggesting a role for this pathway in WT-SARS-CoV-2 (<xref rid="B380" ref-type="bibr">380</xref>). S1&#x000a0;from the Gamma (P.1) variant (S1&#x003b3;) and from the Beta variant (S1&#x003b2; from B.1.351) produced higher levels of inflammation, and S1&#x003b4; (Delta variant; B.1.617.2) produced lower levels of inflammation as measured by macrophage and neutrophil recruitment as well as NF-&#x003ba;B activity in this study (<xref rid="B380" ref-type="bibr">380</xref>). A study published in November 2021 showed evidence of microvascular dysfunction among patients infected with SARS-CoV-2 (exact variants unknown) (<xref rid="B381" ref-type="bibr">381</xref>), which was not seen in a follow-up study among patients infected with Omicron (<xref rid="B382" ref-type="bibr">382</xref>). A complete discussion regarding variant-specific mechanisms of virulence is outside of the scope of this review and will likely be the subject of ongoing study [see, e.g. (<xref rid="B375" ref-type="bibr">375</xref>)].</p></sec><sec sec-type="conclusions" id="s5"><label>5</label><title>Conclusions</title><p>In conclusion, the immune response to novel SARS-CoV-2 involves a complex milieu of cytokines, macrophages, lymphocytes, and other immune cells skewed towards a pathologically hyperactivated response. Organized but immunostimulatory pyroptosis and inflammasome production may be at play in an environment that lacks crucial early antiviral interferon production, which, along with the development of immune-mediated microthrombi, may be associated with the severity of disease in COVID-19. In the kidney, these mechanisms, as well as acute tubular injury, early myofibroblast activation, and collapsing glomerulopathy in select populations, are likely to account for COVID-19-related AKI and CKD development.</p><p>Among the limitations of this review is a thorough discussion regarding variant-specific mechanisms of immune responses, particularly as subsequent waves of the pandemic met longitudinal populations of varying degrees of immunity mediated through vaccination and natural infection. Typical immune responses to SARS-CoV-2 continue to change as the novelty of the virus changes.</p><p>It is still unclear whether the acute and long-term sequelae and associated pathophysiology following SARS-CoV-2 infection are unique to the virus or whether this reflects the unprecedented focus of research brought about by the pandemic. In any case, the pace of research in the COVID-19 era has led to a greater understanding of the components of a regulated immune response to SARS-CoV-2 and perhaps to viral infections more generally.</p></sec></body><back><ack><title>Acknowledgments</title><p>Images were created using <uri xlink:href="https://BioRender.com/">BioRender.com</uri>.</p></ack><sec sec-type="author-contributions" id="s6"><title>Author contributions</title><p>HN: Conceptualization, Visualization, Writing &#x02013; original draft, Writing &#x02013; review &#x00026; editing. MB: Writing &#x02013; review &#x00026; editing. HL: Writing &#x02013; review &#x00026; editing. ML: Writing &#x02013; review &#x00026; editing. AR: Conceptualization, Supervision, Writing &#x02013; review &#x00026; editing.</p></sec><sec sec-type="COI-statement" id="s8"><title>Conflict of interest</title><p>The authors declare that the research was conducted without any commercial or financial relationships that could potentially create a conflict of interest.</p></sec><sec sec-type="disclaimer" id="s9"><title>Publisher&#x02019;s note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec><ref-list><title>References</title><ref id="B1"><label>1</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cucinotta</surname><given-names>D</given-names></name><name><surname>Vanelli</surname><given-names>M</given-names></name></person-group>. <article-title>WHO declares COVID-19 a pandemic</article-title>. <source>Acta Biomed</source>. (<year>2020</year>) <volume>91</volume>:<page-range>157&#x02013;60</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.23750/abm.v91i1.9397</pub-id>
</mixed-citation></ref><ref id="B2"><label>2</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mather</surname><given-names>N</given-names></name></person-group>. <article-title>How we accelerated clinical trials in the age of coronavirus</article-title>. <source>Nature</source>. (<year>2020</year>) <volume>584</volume>:<fpage>326</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/d41586-020-02416-z</pub-id>
<pub-id pub-id-type="pmid">32812005</pub-id>
</mixed-citation></ref><ref id="B3"><label>3</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wu</surname><given-names>Z</given-names></name><name><surname>Harrich</surname><given-names>D</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Hu</surname><given-names>D</given-names></name><name><surname>Li</surname><given-names>D</given-names></name></person-group>. <article-title>The unique features of SARS-CoV-2 transmission: Comparison with SARS-CoV, MERS-CoV and 2009 H1N1 pandemic influenza virus</article-title>. <source>Rev Med Virol</source>. (<year>2021</year>) <volume>31</volume>:<elocation-id>e2171</elocation-id>. doi: <pub-id pub-id-type="doi">10.1002/rmv.2171</pub-id>
<pub-id pub-id-type="pmid">33350025</pub-id>
</mixed-citation></ref><ref id="B4"><label>4</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ji</surname><given-names>P</given-names></name><name><surname>Zhu</surname><given-names>J</given-names></name><name><surname>Zhong</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Pang</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Association of elevated inflammatory markers and severe COVID-19: A meta-analysis</article-title>. <source>Med (Baltimore)</source>. (<year>2020</year>) <volume>99</volume>:<elocation-id>e23315</elocation-id>. doi: <pub-id pub-id-type="doi">10.1097/MD.0000000000023315</pub-id>
</mixed-citation></ref><ref id="B5"><label>5</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Perico</surname><given-names>L</given-names></name><name><surname>Benigni</surname><given-names>A</given-names></name><name><surname>Casiraghi</surname><given-names>F</given-names></name><name><surname>Ng</surname><given-names>LFP</given-names></name><name><surname>Renia</surname><given-names>L</given-names></name><name><surname>Remuzzi</surname><given-names>G</given-names></name></person-group>. <article-title>Immunity, endothelial injury and complement-induced coagulopathy in COVID-19</article-title>. <source>Nat Rev Nephrol</source>. (<year>2021</year>) <volume>17</volume>:<fpage>46</fpage>&#x02013;<lpage>64</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41581-020-00357-4</pub-id>
<pub-id pub-id-type="pmid">33077917</pub-id>
</mixed-citation></ref><ref id="B6"><label>6</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Polack</surname><given-names>FP</given-names></name><name><surname>Thomas</surname><given-names>SJ</given-names></name><name><surname>Kitchin</surname><given-names>N</given-names></name><name><surname>Absalon</surname><given-names>J</given-names></name><name><surname>Gurtman</surname><given-names>A</given-names></name><name><surname>Lockhart</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine</article-title>. <source>N Engl J Med</source>. (<year>2020</year>) <volume>383</volume>:<page-range>2603&#x02013;15</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1056/NEJMoa2034577</pub-id>
</mixed-citation></ref><ref id="B7"><label>7</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Anderson</surname><given-names>EJ</given-names></name><name><surname>Rouphael</surname><given-names>NG</given-names></name><name><surname>Widge</surname><given-names>AT</given-names></name><name><surname>Jackson</surname><given-names>LA</given-names></name><name><surname>Roberts</surname><given-names>PC</given-names></name><name><surname>Makhene</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Safety and immunogenicity of SARS-coV-2 mRNA-1273 vaccine in older adults</article-title>. <source>N Engl J Med</source>. (<year>2020</year>) <volume>383</volume>:<page-range>2427&#x02013;38</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1056/NEJMoa2028436</pub-id>
</mixed-citation></ref><ref id="B8"><label>8</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Taylor</surname><given-names>PC</given-names></name><name><surname>Adams</surname><given-names>AC</given-names></name><name><surname>Hufford</surname><given-names>MM</given-names></name><name><surname>de la Torre</surname><given-names>I</given-names></name><name><surname>Winthrop</surname><given-names>K</given-names></name><name><surname>Gottlieb</surname><given-names>RL</given-names></name></person-group>. <article-title>Neutralizing monoclonal antibodies for treatment of COVID-19</article-title>. <source>Nat Rev Immunol</source>. (<year>2021</year>) <volume>21</volume>:<page-range>382&#x02013;93</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41577-021-00542-x</pub-id>
</mixed-citation></ref><ref id="B9"><label>9</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Owen</surname><given-names>DR</given-names></name><name><surname>Allerton</surname><given-names>CMN</given-names></name><name><surname>Anderson</surname><given-names>AS</given-names></name><name><surname>Aschenbrenner</surname><given-names>L</given-names></name><name><surname>Avery</surname><given-names>M</given-names></name><name><surname>Berritt</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>An oral SARS-CoV-2 M(pro) inhibitor clinical candidate for the treatment of COVID-19</article-title>. <source>Science</source>. (<year>2021</year>) <volume>374</volume>:<page-range>1586&#x02013;93</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1126/science.abl4784</pub-id>
</mixed-citation></ref><ref id="B10"><label>10</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jayk Bernal</surname><given-names>A</given-names></name><name><surname>Gomes da Silva</surname><given-names>MM</given-names></name><name><surname>Musungaie</surname><given-names>DB</given-names></name><name><surname>Kovalchuk</surname><given-names>E</given-names></name><name><surname>Gonzalez</surname><given-names>A</given-names></name><name><surname>Delos Reyes</surname><given-names>V</given-names></name><etal/></person-group>. <article-title>Molnupiravir for oral treatment of covid-19 in nonhospitalized patients</article-title>. <source>N Engl J Med</source>. (<year>2022</year>) <volume>386</volume>:<page-range>509&#x02013;20</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1056/NEJMoa2116044</pub-id>
</mixed-citation></ref><ref id="B11"><label>11</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Aldawas</surname><given-names>A</given-names></name><name><surname>Ishfaq</surname><given-names>M</given-names></name></person-group>. <article-title>COVID-19: multisystem inflammatory syndrome in children (MIS-C)</article-title>. <source>Cureus</source>. (<year>2022</year>) <volume>14</volume>:<elocation-id>e21064</elocation-id>. doi: <pub-id pub-id-type="doi">10.7759/cureus.21064</pub-id>
<pub-id pub-id-type="pmid">35165539</pub-id>
</mixed-citation></ref><ref id="B12"><label>12</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kashyap</surname><given-names>H</given-names></name><name><surname>Kumar</surname><given-names>RNS</given-names></name><name><surname>Gautam</surname><given-names>S</given-names></name><name><surname>Gupta</surname><given-names>A</given-names></name><name><surname>Gupta</surname><given-names>S</given-names></name><name><surname>Tiwari</surname><given-names>PK</given-names></name></person-group>. <article-title>Multisystem inflammatory syndrome in children (MIS-C) associated with COVID-19 infection</article-title>. <source>Indian J Pediatr</source>. (<year>2021</year>) <volume>88</volume>:<fpage>1053</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1007/s12098-021-03832-3</pub-id>
<pub-id pub-id-type="pmid">34269987</pub-id>
</mixed-citation></ref><ref id="B13"><label>13</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cattaneo</surname><given-names>P</given-names></name><name><surname>Volpe</surname><given-names>A</given-names></name><name><surname>Cardellino</surname><given-names>CS</given-names></name><name><surname>Riccardi</surname><given-names>N</given-names></name><name><surname>Bertoli</surname><given-names>G</given-names></name><name><surname>Ursini</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Multisystem inflammatory syndrome in an adult (MIS-A) successfully treated with anakinra and glucocorticoids</article-title>. <source>Microorganisms</source>. (<year>2021</year>) <volume>9</volume>:<fpage>1393</fpage>. doi: <pub-id pub-id-type="doi">10.3390/microorganisms9071393</pub-id>
<pub-id pub-id-type="pmid">34203277</pub-id>
</mixed-citation></ref><ref id="B14"><label>14</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Patel</surname><given-names>P</given-names></name><name><surname>DeCuir</surname><given-names>J</given-names></name><name><surname>Abrams</surname><given-names>J</given-names></name><name><surname>Campbell</surname><given-names>AP</given-names></name><name><surname>Godfred-Cato</surname><given-names>S</given-names></name><name><surname>Belay</surname><given-names>ED</given-names></name></person-group>. <article-title>Clinical characteristics of multisystem inflammatory syndrome in adults: A systematic review</article-title>. <source>JAMA Netw Open</source>. (<year>2021</year>) <volume>4</volume>:<elocation-id>e2126456</elocation-id>. doi: <pub-id pub-id-type="doi">10.1001/jamanetworkopen.2021.26456</pub-id>
<pub-id pub-id-type="pmid">34550381</pub-id>
</mixed-citation></ref><ref id="B15"><label>15</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gracia-Ramos</surname><given-names>AE</given-names></name><name><surname>Martin-Nares</surname><given-names>E</given-names></name><name><surname>Hernandez-Molina</surname><given-names>G</given-names></name></person-group>. <article-title>New onset of autoimmune diseases following COVID-19 diagnosis</article-title>. <source>Cells</source>. (<year>2021</year>) <volume>10</volume>:<fpage>3592</fpage>. doi: <pub-id pub-id-type="doi">10.3390/cells10123592</pub-id>
<pub-id pub-id-type="pmid">34944099</pub-id>
</mixed-citation></ref><ref id="B16"><label>16</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Diao</surname><given-names>B</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>R</given-names></name><name><surname>Feng</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Human kidney is a target for novel severe acute respiratory syndrome coronavirus 2 infection</article-title>. <source>Nat Commun</source>. (<year>2021</year>) <volume>12</volume>:<fpage>2506</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41467-021-22781-1</pub-id>
<pub-id pub-id-type="pmid">33947851</pub-id>
</mixed-citation></ref><ref id="B17"><label>17</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>McEvoy</surname><given-names>CM</given-names></name><name><surname>Murphy</surname><given-names>JM</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Clotet-Freixas</surname><given-names>S</given-names></name><name><surname>Mathews</surname><given-names>JA</given-names></name><name><surname>An</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Single-cell profiling of healthy human kidney reveals features of sex-based transcriptional programs and tissue-specific immunity</article-title>. <source>Nat Commun</source>. (<year>2022</year>) <volume>13</volume>:<fpage>7634</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41467-022-35297-z</pub-id>
<pub-id pub-id-type="pmid">36496458</pub-id>
</mixed-citation></ref><ref id="B18"><label>18</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Park</surname><given-names>JG</given-names></name><name><surname>Na</surname><given-names>M</given-names></name><name><surname>Kim</surname><given-names>MG</given-names></name><name><surname>Park</surname><given-names>SH</given-names></name><name><surname>Lee</surname><given-names>HJ</given-names></name><name><surname>Kim</surname><given-names>DK</given-names></name><etal/></person-group>. <article-title>Immune cell composition in normal human kidneys</article-title>. <source>Sci Rep</source>. (<year>2020</year>) <volume>10</volume>:<fpage>15678</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41598-020-72821-x</pub-id>
<pub-id pub-id-type="pmid">32973321</pub-id>
</mixed-citation></ref><ref id="B19"><label>19</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jansen</surname><given-names>J</given-names></name><name><surname>Reimer</surname><given-names>KC</given-names></name><name><surname>Nagai</surname><given-names>JS</given-names></name><name><surname>Varghese</surname><given-names>FS</given-names></name><name><surname>Overheul</surname><given-names>GJ</given-names></name><name><surname>de Beer</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>SARS-CoV-2 infects the human kidney and drives fibrosis in kidney organoids</article-title>. <source>Cell Stem Cell</source>. (<year>2022</year>) <volume>29</volume>:<fpage>217</fpage>&#x02013;<lpage>31.e8</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.stem.2021.12.010</pub-id>
<pub-id pub-id-type="pmid">35032430</pub-id>
</mixed-citation></ref><ref id="B20"><label>20</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wu</surname><given-names>H</given-names></name><name><surname>He</surname><given-names>P</given-names></name><name><surname>Ren</surname><given-names>Y</given-names></name><name><surname>Xiao</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><etal/></person-group>. <article-title>Postmortem high-dimensional immune profiling of severe COVID-19 patients reveals distinct patterns of immunosuppression and immunoactivation</article-title>. <source>Nat Commun</source>. (<year>2022</year>) <volume>13</volume>:<fpage>269</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41467-021-27723-5</pub-id>
<pub-id pub-id-type="pmid">35022412</pub-id>
</mixed-citation></ref><ref id="B21"><label>21</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Qin</surname><given-names>G</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Yu</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name></person-group>. <article-title>Myeloid cells in COVID-19 microenvironment</article-title>. <source>Signal Transduct Target Ther</source>. (<year>2021</year>) <volume>6</volume>:<fpage>372</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41392-021-00792-0</pub-id>
<pub-id pub-id-type="pmid">34707085</pub-id>
</mixed-citation></ref><ref id="B22"><label>22</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cui</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>F</given-names></name><name><surname>Shi</surname><given-names>ZL</given-names></name></person-group>. <article-title>Origin and evolution of pathogenic coronaviruses</article-title>. <source>Nat Rev Microbiol</source>. (<year>2019</year>) <volume>17</volume>:<page-range>181&#x02013;92</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41579-018-0118-9</pub-id>
</mixed-citation></ref><ref id="B23"><label>23</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>V&#x02019;Kovski</surname><given-names>P</given-names></name><name><surname>Kratzel</surname><given-names>A</given-names></name><name><surname>Steiner</surname><given-names>S</given-names></name><name><surname>Stalder</surname><given-names>H</given-names></name><name><surname>Thiel</surname><given-names>V</given-names></name></person-group>. <article-title>Coronavirus biology and replication: implications for SARS-CoV-2</article-title>. <source>Nat Rev Microbiol</source>. (<year>2021</year>) <volume>19</volume>:<page-range>155&#x02013;70</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41579-020-00468-6</pub-id>
</mixed-citation></ref><ref id="B24"><label>24</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hawks</surname><given-names>SA</given-names></name><name><surname>Prussin</surname><given-names>AJ</given-names><suffix>2nd</suffix></name><name><surname>Kuchinsky</surname><given-names>SC</given-names></name><name><surname>Pan</surname><given-names>J</given-names></name><name><surname>Marr</surname><given-names>LC</given-names></name><name><surname>Duggal</surname><given-names>NK</given-names></name></person-group>. <article-title>Infectious SARS-coV-2 is emitted in aerosol particles</article-title>. <source>mBio</source>. (<year>2021</year>) <volume>12</volume>:<fpage>e0252721</fpage>. doi: <pub-id pub-id-type="doi">10.1128/mBio.02527-21</pub-id>
<pub-id pub-id-type="pmid">34663099</pub-id>
</mixed-citation></ref><ref id="B25"><label>25</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Richard</surname><given-names>M</given-names></name><name><surname>Kok</surname><given-names>A</given-names></name><name><surname>de Meulder</surname><given-names>D</given-names></name><name><surname>Bestebroer</surname><given-names>TM</given-names></name><name><surname>Lamers</surname><given-names>MM</given-names></name><name><surname>Okba</surname><given-names>NMA</given-names></name><etal/></person-group>. <article-title>SARS-CoV-2 is transmitted via contact and via the air between ferrets</article-title>. <source>Nat Commun</source>. (<year>2020</year>) <volume>11</volume>:<fpage>3496</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41467-020-17367-2</pub-id>
<pub-id pub-id-type="pmid">32641684</pub-id>
</mixed-citation></ref><ref id="B26"><label>26</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Azimi</surname><given-names>P</given-names></name><name><surname>Keshavarz</surname><given-names>Z</given-names></name><name><surname>Cedeno Laurent</surname><given-names>JG</given-names></name><name><surname>Stephens</surname><given-names>B</given-names></name><name><surname>Allen</surname><given-names>JG</given-names></name></person-group>. <article-title>Mechanistic transmission modeling of COVID-19 on the Diamond Princess cruise ship demonstrates the importance of aerosol transmission</article-title>. <source>Proc Natl Acad Sci U S A</source>. (<year>2021</year>) <volume>118</volume>:<elocation-id>e2015482118</elocation-id>. doi: <pub-id pub-id-type="doi">10.1073/pnas.2015482118</pub-id>
<pub-id pub-id-type="pmid">33536312</pub-id>
</mixed-citation></ref><ref id="B27"><label>27</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ziegler</surname><given-names>CGK</given-names></name><name><surname>Allon</surname><given-names>SJ</given-names></name><name><surname>Nyquist</surname><given-names>SK</given-names></name><name><surname>Mbano</surname><given-names>IM</given-names></name><name><surname>Miao</surname><given-names>VN</given-names></name><name><surname>Tzouanas</surname><given-names>CN</given-names></name><etal/></person-group>. <article-title>SARS-coV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues</article-title>. <source>Cell</source>. (<year>2020</year>) <volume>181</volume>:<fpage>1016</fpage>&#x02013;<lpage>35 e19</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.cell.2020.04.035</pub-id>
<pub-id pub-id-type="pmid">32413319</pub-id>
</mixed-citation></ref><ref id="B28"><label>28</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tay</surname><given-names>MZ</given-names></name><name><surname>Poh</surname><given-names>CM</given-names></name><name><surname>Renia</surname><given-names>L</given-names></name><name><surname>MacAry</surname><given-names>PA</given-names></name><name><surname>Ng</surname><given-names>LFP</given-names></name></person-group>. <article-title>The trinity of COVID-19: immunity, inflammation and intervention</article-title>. <source>Nat Rev Immunol</source>. (<year>2020</year>) <volume>20</volume>:<page-range>363&#x02013;74</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41577-020-0311-8</pub-id>
</mixed-citation></ref><ref id="B29"><label>29</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Senapati</surname><given-names>S</given-names></name><name><surname>Banerjee</surname><given-names>P</given-names></name><name><surname>Bhagavatula</surname><given-names>S</given-names></name><name><surname>Kushwaha</surname><given-names>PP</given-names></name><name><surname>Kumar</surname><given-names>S</given-names></name></person-group>. <article-title>Contributions of human ACE2 and TMPRSS2 in determining host-pathogen interaction of COVID-19</article-title>. <source>J Genet</source>. (<year>2021</year>) <volume>100</volume>:<fpage>12</fpage>. doi: <pub-id pub-id-type="doi">10.1007/s12041-021-01262-w</pub-id>
<pub-id pub-id-type="pmid">33707363</pub-id>
</mixed-citation></ref><ref id="B30"><label>30</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Horowitz</surname><given-names>JE</given-names></name><name><surname>Kosmicki</surname><given-names>JA</given-names></name><name><surname>Damask</surname><given-names>A</given-names></name><name><surname>Sharma</surname><given-names>D</given-names></name><name><surname>Roberts</surname><given-names>GHL</given-names></name><name><surname>Justice</surname><given-names>AE</given-names></name><etal/></person-group>. <article-title>Genome-wide analysis provides genetic evidence that ACE2 influences COVID-19 risk and yields risk scores associated with severe disease</article-title>. <source>Nat Genet</source>. (<year>2022</year>) <volume>54</volume>:<page-range>382&#x02013;92</page-range>. doi: <pub-id pub-id-type="doi">10.1038/s41588-021-01006-7</pub-id>
</mixed-citation></ref><ref id="B31"><label>31</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Karlsen</surname><given-names>TH</given-names></name></person-group>. <article-title>Understanding COVID-19 through genome-wide association studies</article-title>. <source>Nat Genet</source>. (<year>2022</year>) <volume>54</volume>:<page-range>368&#x02013;9</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41588-021-00985-x</pub-id>
</mixed-citation></ref><ref id="B32"><label>32</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Scheen</surname><given-names>AJ</given-names></name></person-group>. <article-title>DPP-4 inhibition and COVID-19: From initial concerns to recent expectations</article-title>. <source>Diabetes Metab</source>. (<year>2021</year>) <volume>47</volume>:<fpage>101213</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.diabet.2020.11.005</pub-id>
<pub-id pub-id-type="pmid">33249199</pub-id>
</mixed-citation></ref><ref id="B33"><label>33</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Eleftheriou</surname><given-names>P</given-names></name><name><surname>Amanatidou</surname><given-names>D</given-names></name><name><surname>Petrou</surname><given-names>A</given-names></name><name><surname>Geronikaki</surname><given-names>A</given-names></name></person-group>. <article-title>In silico evaluation of the effectivity of approved protease inhibitors against the main protease of the novel SARS-coV-2 virus</article-title>. <source>Molecules</source>. (<year>2020</year>) <volume>25</volume>:<fpage>2529</fpage>. doi: <pub-id pub-id-type="doi">10.3390/molecules25112529</pub-id>
<pub-id pub-id-type="pmid">32485894</pub-id>
</mixed-citation></ref><ref id="B34"><label>34</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Letko</surname><given-names>M</given-names></name><name><surname>Marzi</surname><given-names>A</given-names></name><name><surname>Munster</surname><given-names>V</given-names></name></person-group>. <article-title>Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses</article-title>. <source>Nat Microbiol</source>. (<year>2020</year>) <volume>5</volume>:<page-range>562&#x02013;9</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41564-020-0688-y</pub-id>
</mixed-citation></ref><ref id="B35"><label>35</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Xiong</surname><given-names>Y</given-names></name><name><surname>Delic</surname><given-names>D</given-names></name><name><surname>Zeng</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Chu</surname><given-names>C</given-names></name><name><surname>Hasan</surname><given-names>AA</given-names></name><etal/></person-group>. <article-title>Regulation of SARS CoV-2 host factors in the kidney and heart in rats with 5/6 nephrectomy-effects of salt, ARB, DPP4 inhibitor and SGLT2 blocker</article-title>. <source>BMC Nephrol</source>. (<year>2022</year>) <volume>23</volume>:<fpage>117</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12882-022-02747-1</pub-id>
<pub-id pub-id-type="pmid">35331159</pub-id>
</mixed-citation></ref><ref id="B36"><label>36</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Xi</surname><given-names>CR</given-names></name><name><surname>Di Fazio</surname><given-names>A</given-names></name><name><surname>Nadvi</surname><given-names>NA</given-names></name><name><surname>Patel</surname><given-names>K</given-names></name><name><surname>Xiang</surname><given-names>MSW</given-names></name><name><surname>Zhang</surname><given-names>HE</given-names></name><etal/></person-group>. <article-title>A novel purification procedure for active recombinant human DPP4 and the inability of DPP4 to bind SARS-coV-2</article-title>. <source>Molecules</source>. (<year>2020</year>) <volume>25</volume>:<fpage>5392</fpage>. doi: <pub-id pub-id-type="doi">10.3390/molecules25225392</pub-id>
<pub-id pub-id-type="pmid">33218025</pub-id>
</mixed-citation></ref><ref id="B37"><label>37</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Reis</surname><given-names>CA</given-names></name><name><surname>Tauber</surname><given-names>R</given-names></name><name><surname>Blanchard</surname><given-names>V</given-names></name></person-group>. <article-title>Glycosylation is a key in SARS-CoV-2 infection</article-title>. <source>J Mol Med (Berl)</source>. (<year>2021</year>) <volume>99</volume>:<page-range>1023&#x02013;31</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1007/s00109-021-02092-0</pub-id>
</mixed-citation></ref><ref id="B38"><label>38</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lamers</surname><given-names>MM</given-names></name><name><surname>Haagmans</surname><given-names>BL</given-names></name></person-group>. <article-title>SARS-coV-2 pathogenesis</article-title>. <source>Nat Rev Microbiol</source>. (<year>2022</year>) <volume>20</volume>:<page-range>270&#x02013;84</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41579-022-00713-0</pub-id>
</mixed-citation></ref><ref id="B39"><label>39</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jacobs</surname><given-names>JL</given-names></name><name><surname>Bain</surname><given-names>W</given-names></name><name><surname>Naqvi</surname><given-names>A</given-names></name><name><surname>Staines</surname><given-names>B</given-names></name><name><surname>Castanha</surname><given-names>PMS</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Severe acute respiratory syndrome coronavirus 2 viremia is associated with coronavirus disease 2019 severity and predicts clinical outcomes</article-title>. <source>Clin Infect Dis</source>. (<year>2022</year>) <volume>74</volume>:<page-range>1525&#x02013;33</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1093/cid/ciab686</pub-id>
</mixed-citation></ref><ref id="B40"><label>40</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Markov</surname><given-names>PV</given-names></name><name><surname>Ghafari</surname><given-names>M</given-names></name><name><surname>Beer</surname><given-names>M</given-names></name><name><surname>Lythgoe</surname><given-names>K</given-names></name><name><surname>Simmonds</surname><given-names>P</given-names></name><name><surname>Stilianakis</surname><given-names>NI</given-names></name><etal/></person-group>. <article-title>The evolution of SARS-coV-2</article-title>. <source>Nat Rev Microbiol</source>. (<year>2023</year>) <volume>21</volume>:<page-range>361&#x02013;79</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41579-023-00878-2</pub-id>
</mixed-citation></ref><ref id="B41"><label>41</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schiuma</surname><given-names>G</given-names></name><name><surname>Beltrami</surname><given-names>S</given-names></name><name><surname>Bortolotti</surname><given-names>D</given-names></name><name><surname>Rizzo</surname><given-names>S</given-names></name><name><surname>Rizzo</surname><given-names>R</given-names></name></person-group>. <article-title>Innate immune response in SARS-coV-2 infection</article-title>. <source>Microorganisms</source>. (<year>2022</year>) <volume>10</volume>:<fpage>501</fpage>. doi: <pub-id pub-id-type="doi">10.3390/microorganisms10030501</pub-id>
<pub-id pub-id-type="pmid">35336077</pub-id>
</mixed-citation></ref><ref id="B42"><label>42</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lowery</surname><given-names>SA</given-names></name><name><surname>Sariol</surname><given-names>A</given-names></name><name><surname>Perlman</surname><given-names>S</given-names></name></person-group>. <article-title>Innate immune and inflammatory responses to SARS-CoV-2: Implications for COVID-19</article-title>. <source>Cell Host Microbe</source>. (<year>2021</year>) <volume>29</volume>:<page-range>1052&#x02013;62</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.chom.2021.05.004</pub-id>
</mixed-citation></ref><ref id="B43"><label>43</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Choi</surname><given-names>H</given-names></name><name><surname>Shin</surname><given-names>EC</given-names></name></person-group>. <article-title>Roles of type I and III interferons in COVID-19</article-title>. <source>Yonsei Med J</source>. (<year>2021</year>) <volume>62</volume>:<page-range>381&#x02013;90</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3349/ymj.2021.62.5.381</pub-id>
</mixed-citation></ref><ref id="B44"><label>44</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Iwasaki</surname><given-names>A</given-names></name></person-group>. <article-title>A virological view of innate immune recognition</article-title>. <source>Annu Rev Microbiol</source>. (<year>2012</year>) <volume>66</volume>:<page-range>177&#x02013;96</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1146/annurev-micro-092611-150203</pub-id>
</mixed-citation></ref><ref id="B45"><label>45</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Thompson</surname><given-names>MR</given-names></name><name><surname>Kaminski</surname><given-names>JJ</given-names></name><name><surname>Kurt-Jones</surname><given-names>EA</given-names></name><name><surname>Fitzgerald</surname><given-names>KA</given-names></name></person-group>. <article-title>Pattern recognition receptors and the innate immune response to viral infection</article-title>. <source>Viruses</source>. (<year>2011</year>) <volume>3</volume>:<page-range>920&#x02013;40</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3390/v3060920</pub-id>
</mixed-citation></ref><ref id="B46"><label>46</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>van der Made</surname><given-names>CI</given-names></name><name><surname>Simons</surname><given-names>A</given-names></name><name><surname>Schuurs-Hoeijmakers</surname><given-names>J</given-names></name><name><surname>van den Heuvel</surname><given-names>G</given-names></name><name><surname>Mantere</surname><given-names>T</given-names></name><name><surname>Kersten</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Presence of genetic variants among young men with severe COVID-19</article-title>. <source>JAMA</source>. (<year>2020</year>) <volume>324</volume>:<page-range>663&#x02013;73</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1001/jama.2020.13719</pub-id>
</mixed-citation></ref><ref id="B47"><label>47</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Akamatsu</surname><given-names>MA</given-names></name><name><surname>de Castro</surname><given-names>JT</given-names></name><name><surname>Takano</surname><given-names>CY</given-names></name><name><surname>Ho</surname><given-names>PL</given-names></name></person-group>. <article-title>Off balance: Interferons in COVID-19 lung infections</article-title>. <source>EBioMedicine</source>. (<year>2021</year>) <volume>73</volume>:<fpage>103642</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ebiom.2021.103642</pub-id>
<pub-id pub-id-type="pmid">34678609</pub-id>
</mixed-citation></ref><ref id="B48"><label>48</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gilliet</surname><given-names>M</given-names></name><name><surname>Cao</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>YJ</given-names></name></person-group>. <article-title>Plasmacytoid dendritic cells: sensing nucleic acids in viral infection and autoimmune diseases</article-title>. <source>Nat Rev Immunol</source>. (<year>2008</year>) <volume>8</volume>:<fpage>594</fpage>&#x02013;<lpage>606</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/nri2358</pub-id>
<pub-id pub-id-type="pmid">18641647</pub-id>
</mixed-citation></ref><ref id="B49"><label>49</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bortolotti</surname><given-names>D</given-names></name><name><surname>Gentili</surname><given-names>V</given-names></name><name><surname>Rizzo</surname><given-names>S</given-names></name><name><surname>Schiuma</surname><given-names>G</given-names></name><name><surname>Beltrami</surname><given-names>S</given-names></name><name><surname>Strazzabosco</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>TLR3 and TLR7 RNA sensor activation during SARS-coV-2 infection</article-title>. <source>Microorganisms</source>. (<year>2021</year>) <volume>9</volume>:<fpage>1820</fpage>. doi: <pub-id pub-id-type="doi">10.3390/microorganisms9091820</pub-id>
<pub-id pub-id-type="pmid">34576716</pub-id>
</mixed-citation></ref><ref id="B50"><label>50</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vabret</surname><given-names>N</given-names></name><name><surname>Britton</surname><given-names>GJ</given-names></name><name><surname>Gruber</surname><given-names>C</given-names></name><name><surname>Hegde</surname><given-names>S</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Kuksin</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Immunology of COVID-19: current state of the science</article-title>. <source>Immunity</source>. (<year>2020</year>) <volume>52</volume>:<page-range>910&#x02013;41</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.immuni.2020.05.002</pub-id>
</mixed-citation></ref><ref id="B51"><label>51</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yu</surname><given-names>M</given-names></name><name><surname>Zhou</surname><given-names>H</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Xiao</surname><given-names>N</given-names></name><name><surname>Roychowdhury</surname><given-names>S</given-names></name><name><surname>Schmitt</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>MyD88-dependent interplay between myeloid and endothelial cells in the initiation and progression of obesity-associated inflammatory diseases</article-title>. <source>J Exp Med</source>. (<year>2014</year>) <volume>211</volume>:<fpage>887</fpage>&#x02013;<lpage>907</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1084/jem.20131314</pub-id>
<pub-id pub-id-type="pmid">24752299</pub-id>
</mixed-citation></ref><ref id="B52"><label>52</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Goel</surname><given-names>S</given-names></name><name><surname>Saheb Sharif-Askari</surname><given-names>F</given-names></name><name><surname>Saheb Sharif Askari</surname><given-names>N</given-names></name><name><surname>Madkhana</surname><given-names>B</given-names></name><name><surname>Alwaa</surname><given-names>AM</given-names></name><name><surname>Mahboub</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>SARS-coV-2 switches &#x02018;on&#x02019; MAPK and NFkappaB signaling via the reduction of nuclear DUSP1 and DUSP5 expression</article-title>. <source>Front Pharmacol</source>. (<year>2021</year>) <volume>12</volume>:<fpage>631879</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3389/fphar.2021.631879</pub-id>
<pub-id pub-id-type="pmid">33995033</pub-id>
</mixed-citation></ref><ref id="B53"><label>53</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Guan</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Ye</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><etal/></person-group>. <article-title>SARS-CoV-2 triggers inflammatory responses and cell death through caspase-8 activation</article-title>. <source>Signal Transduct Target Ther</source>. (<year>2020</year>) <volume>5</volume>:<fpage>235</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41392-020-00334-0</pub-id>
<pub-id pub-id-type="pmid">33037188</pub-id>
</mixed-citation></ref><ref id="B54"><label>54</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nainu</surname><given-names>F</given-names></name><name><surname>Shiratsuchi</surname><given-names>A</given-names></name><name><surname>Nakanishi</surname><given-names>Y</given-names></name></person-group>. <article-title>Induction of apoptosis and subsequent phagocytosis of virus-infected cells as an antiviral mechanism</article-title>. <source>Front Immunol</source>. (<year>2017</year>) <volume>8</volume>:<fpage>1220</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3389/fimmu.2017.01220</pub-id>
<pub-id pub-id-type="pmid">29033939</pub-id>
</mixed-citation></ref><ref id="B55"><label>55</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ren</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>A</given-names></name><name><surname>Fang</surname><given-names>Y</given-names></name><name><surname>Shu</surname><given-names>T</given-names></name><name><surname>Wu</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>SARS-coV-2 membrane glycoprotein M triggers apoptosis with the assistance of nucleocapsid protein N in cells</article-title>. <source>Front Cell Infect Microbiol</source>. (<year>2021</year>) <volume>11</volume>:<fpage>706252</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3389/fcimb.2021.706252</pub-id>
<pub-id pub-id-type="pmid">34513728</pub-id>
</mixed-citation></ref><ref id="B56"><label>56</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Toldo</surname><given-names>S</given-names></name><name><surname>Bussani</surname><given-names>R</given-names></name><name><surname>Nuzzi</surname><given-names>V</given-names></name><name><surname>Bonaventura</surname><given-names>A</given-names></name><name><surname>Mauro</surname><given-names>AG</given-names></name><name><surname>Cannat&#x000e0;</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Inflammasome formation in the lungs of patients with fatal COVID-19</article-title>. <source>Inflamm Res</source>. (<year>2021</year>) <volume>70</volume>:<fpage>7</fpage>&#x02013;<lpage>10</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1007/s00011-020-01413-2</pub-id>
<pub-id pub-id-type="pmid">33079210</pub-id>
</mixed-citation></ref><ref id="B57"><label>57</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bittner</surname><given-names>ZA</given-names></name><name><surname>Schrader</surname><given-names>M</given-names></name><name><surname>George</surname><given-names>SE</given-names></name><name><surname>Amann</surname><given-names>R</given-names></name></person-group>. <article-title>Pyroptosis and its role in SARS-coV-2 infection</article-title>. <source>Cells</source>. (<year>2022</year>) <volume>11</volume>:<fpage>1717</fpage>. doi: <pub-id pub-id-type="doi">10.3390/cells11101717</pub-id>
<pub-id pub-id-type="pmid">35626754</pub-id>
</mixed-citation></ref><ref id="B58"><label>58</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sun</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Huang</surname><given-names>Z</given-names></name><name><surname>Xu</surname><given-names>W</given-names></name><name><surname>Hu</surname><given-names>W</given-names></name><name><surname>Yi</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>SARS-CoV-2 non-structural protein 6 triggers NLRP3-dependent pyroptosis by targeting ATP6AP1</article-title>. <source>Cell Death Differ</source>. (<year>2022</year>) <volume>29</volume>:<page-range>1240&#x02013;54</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41418-021-00916-7</pub-id>
</mixed-citation></ref><ref id="B59"><label>59</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hu</surname><given-names>G</given-names></name><name><surname>Christman</surname><given-names>JW</given-names></name></person-group>. <article-title>Editorial: alveolar macrophages in lung inflammation and resolution</article-title>. <source>Front Immunol</source>. (<year>2019</year>) <volume>10</volume>:<fpage>2275</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3389/fimmu.2019.02275</pub-id>
<pub-id pub-id-type="pmid">31616438</pub-id>
</mixed-citation></ref><ref id="B60"><label>60</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Barros-Martins</surname><given-names>J</given-names></name><name><surname>Forster</surname><given-names>R</given-names></name><name><surname>Bosnjak</surname><given-names>B</given-names></name></person-group>. <article-title>NK cell dysfunction in severe COVID-19: TGF-beta-induced downregulation of integrin beta-2 restricts NK cell cytotoxicity</article-title>. <source>Signal Transduct Target Ther</source>. (<year>2022</year>) <volume>7</volume>:<fpage>32</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41392-022-00892-5</pub-id>
<pub-id pub-id-type="pmid">35102142</pub-id>
</mixed-citation></ref><ref id="B61"><label>61</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>El-Arif</surname><given-names>G</given-names></name><name><surname>Khazaal</surname><given-names>S</given-names></name><name><surname>Farhat</surname><given-names>A</given-names></name><name><surname>Harb</surname><given-names>J</given-names></name><name><surname>Annweiler</surname><given-names>C</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Angiotensin II type I receptor (AT1R): the gate towards COVID-19-associated diseases</article-title>. <source>Molecules</source>. (<year>2022</year>) <volume>27</volume>:<fpage>2048</fpage>. doi: <pub-id pub-id-type="doi">10.3390/molecules27072048</pub-id>
<pub-id pub-id-type="pmid">35408447</pub-id>
</mixed-citation></ref><ref id="B62"><label>62</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Knyazev</surname><given-names>E</given-names></name><name><surname>Nersisyan</surname><given-names>S</given-names></name><name><surname>Tonevitsky</surname><given-names>A</given-names></name></person-group>. <article-title>Endocytosis and transcytosis of SARS-coV-2 across the intestinal epithelium and other tissue barriers</article-title>. <source>Front Immunol</source>. (<year>2021</year>) <volume>12</volume>:<fpage>636966</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3389/fimmu.2021.636966</pub-id>
<pub-id pub-id-type="pmid">34557180</pub-id>
</mixed-citation></ref><ref id="B63"><label>63</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hojyo</surname><given-names>S</given-names></name><name><surname>Uchida</surname><given-names>M</given-names></name><name><surname>Tanaka</surname><given-names>K</given-names></name><name><surname>Hasebe</surname><given-names>R</given-names></name><name><surname>Tanaka</surname><given-names>Y</given-names></name><name><surname>Murakami</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>How COVID-19 induces cytokine storm with high mortality</article-title>. <source>Inflammation Regen</source>. (<year>2020</year>) <volume>40</volume>:<fpage>37</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1186/s41232-020-00146-3</pub-id>
</mixed-citation></ref><ref id="B64"><label>64</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Liu</surname><given-names>T</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Joo</surname><given-names>D</given-names></name><name><surname>Sun</surname><given-names>SC</given-names></name></person-group>. <article-title>NF-kappaB signaling in inflammation</article-title>. <source>Signal Transduct Target Ther</source>. (<year>2017</year>) <volume>2</volume>:<fpage>17023</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/sigtrans.2017.23</pub-id>
<pub-id pub-id-type="pmid">29158945</pub-id>
</mixed-citation></ref><ref id="B65"><label>65</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Attiq</surname><given-names>A</given-names></name><name><surname>Yao</surname><given-names>LJ</given-names></name><name><surname>Afzal</surname><given-names>S</given-names></name><name><surname>Khan</surname><given-names>MA</given-names></name></person-group>. <article-title>The triumvirate of NF-kappaB, inflammation and cytokine storm in COVID-19</article-title>. <source>Int Immunopharmacol</source>. (<year>2021</year>) <volume>101</volume>:<fpage>108255</fpage>.<pub-id pub-id-type="pmid">34688149</pub-id>
</mixed-citation></ref><ref id="B66"><label>66</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cheng</surname><given-names>DS</given-names></name><name><surname>Han</surname><given-names>W</given-names></name><name><surname>Chen</surname><given-names>SM</given-names></name><name><surname>Sherrill</surname><given-names>TP</given-names></name><name><surname>Chont</surname><given-names>M</given-names></name><name><surname>Park</surname><given-names>GY</given-names></name><etal/></person-group>. <article-title>Airway epithelium controls lung inflammation and injury through the NF-kappa B pathway</article-title>. <source>J Immunol</source>. (<year>2007</year>) <volume>178</volume>:<page-range>6504&#x02013;13</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.4049/jimmunol.178.10.6504</pub-id>
</mixed-citation></ref><ref id="B67"><label>67</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ferreira</surname><given-names>AC</given-names></name><name><surname>Soares</surname><given-names>VC</given-names></name><name><surname>de Azevedo-Quintanilha</surname><given-names>IG</given-names></name><name><surname>Dias</surname><given-names>S</given-names></name><name><surname>Fintelman-Rodrigues</surname><given-names>N</given-names></name><name><surname>Sacramento</surname><given-names>CQ</given-names></name><etal/></person-group>. <article-title>SARS-CoV-2 engages inflammasome and pyroptosis in human primary monocytes</article-title>. <source>Cell Death Discovery</source>. (<year>2021</year>) <volume>7</volume>:<fpage>43</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41420-021-00428-w</pub-id>
<pub-id pub-id-type="pmid">33649297</pub-id>
</mixed-citation></ref><ref id="B68"><label>68</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rodrigues</surname><given-names>TS</given-names></name><name><surname>de Sa</surname><given-names>KSG</given-names></name><name><surname>Ishimoto</surname><given-names>AY</given-names></name><name><surname>Becerra</surname><given-names>A</given-names></name><name><surname>Oliveira</surname><given-names>S</given-names></name><name><surname>Almeida</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Inflammasomes are activated in response to SARS-CoV-2 infection and are associated with COVID-19 severity in patients</article-title>. <source>J Exp Med</source>. (<year>2021</year>) <volume>218</volume>:<elocation-id>e20201707</elocation-id>. doi: <pub-id pub-id-type="doi">10.1084/jem.20201707</pub-id>
<pub-id pub-id-type="pmid">33231615</pub-id>
</mixed-citation></ref><ref id="B69"><label>69</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bass</surname><given-names>A</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Dakshanamurthy</surname><given-names>S</given-names></name></person-group>. <article-title>Single-cell and bulk RNASeq profiling of COVID-19 patients reveal immune and inflammatory mechanisms of infection-induced organ damage</article-title>. <source>Viruses</source>. (<year>2021</year>) <volume>13</volume>:<fpage>2418</fpage>. doi: <pub-id pub-id-type="doi">10.3390/v13122418</pub-id>
<pub-id pub-id-type="pmid">34960687</pub-id>
</mixed-citation></ref><ref id="B70"><label>70</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gomez-Rial</surname><given-names>J</given-names></name><name><surname>Rivero-Calle</surname><given-names>I</given-names></name><name><surname>Salas</surname><given-names>A</given-names></name><name><surname>Martinon-Torres</surname><given-names>F</given-names></name></person-group>. <article-title>Role of monocytes/macrophages in covid-19 pathogenesis: implications for therapy</article-title>. <source>Infect Drug Resist</source>. (<year>2020</year>) <volume>13</volume>:<page-range>2485&#x02013;93</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.2147/IDR.S258639</pub-id>
</mixed-citation></ref><ref id="B71"><label>71</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Knoll</surname><given-names>R</given-names></name><name><surname>Schultze</surname><given-names>JL</given-names></name><name><surname>Schulte-Schrepping</surname><given-names>J</given-names></name></person-group>. <article-title>Monocytes and macrophages in COVID-19</article-title>. <source>Front Immunol</source>. (<year>2021</year>) <volume>12</volume>:<fpage>720109</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3389/fimmu.2021.720109</pub-id>
<pub-id pub-id-type="pmid">34367190</pub-id>
</mixed-citation></ref><ref id="B72"><label>72</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ryabkova</surname><given-names>VA</given-names></name><name><surname>Churilov</surname><given-names>LP</given-names></name><name><surname>Shoenfeld</surname><given-names>Y</given-names></name></person-group>. <article-title>Influenza infection, SARS, MERS and COVID-19: Cytokine storm - The common denominator and the lessons to be learned</article-title>. <source>Clin Immunol</source>. (<year>2021</year>) <volume>223</volume>:<fpage>108652</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.clim.2020.108652</pub-id>
<pub-id pub-id-type="pmid">33333256</pub-id>
</mixed-citation></ref><ref id="B73"><label>73</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pacheco-Hernandez</surname><given-names>LM</given-names></name><name><surname>Ramirez-Noyola</surname><given-names>JA</given-names></name><name><surname>Gomez-Garcia</surname><given-names>IA</given-names></name><name><surname>Ignacio-Cortes</surname><given-names>S</given-names></name><name><surname>Zuniga</surname><given-names>J</given-names></name><name><surname>Choreno-Parra</surname><given-names>JA</given-names></name></person-group>. <article-title>Comparing the cytokine storms of COVID-19 and pandemic influenza</article-title>. <source>J Interferon Cytokine Res</source>. (<year>2022</year>) <volume>42</volume>:<page-range>369&#x02013;92</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1089/jir.2022.0029</pub-id>
</mixed-citation></ref><ref id="B74"><label>74</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sinha</surname><given-names>P</given-names></name><name><surname>Matthay</surname><given-names>MA</given-names></name><name><surname>Calfee</surname><given-names>CS</given-names></name></person-group>. <article-title>Is a &#x0201c;Cytokine storm&#x0201d; Relevant to COVID-19</article-title>? <source>JAMA Intern Med</source>. (<year>2020</year>) <volume>180</volume>:<page-range>1152&#x02013;4</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1001/jamainternmed.2020.3313</pub-id>
</mixed-citation></ref><ref id="B75"><label>75</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Remy</surname><given-names>KE</given-names></name><name><surname>Mazer</surname><given-names>M</given-names></name><name><surname>Striker</surname><given-names>DA</given-names></name><name><surname>Ellebedy</surname><given-names>AH</given-names></name><name><surname>Walton</surname><given-names>AH</given-names></name><name><surname>Unsinger</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Severe immunosuppression and not a cytokine storm characterizes COVID-19 infections</article-title>. <source>JCI Insight</source>. (<year>2020</year>) <volume>5</volume>:<elocation-id>e140329</elocation-id>. doi: <pub-id pub-id-type="doi">10.1172/jci.insight.140329</pub-id>
<pub-id pub-id-type="pmid">32687484</pub-id>
</mixed-citation></ref><ref id="B76"><label>76</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Montazersaheb</surname><given-names>S</given-names></name><name><surname>Hosseiniyan Khatibi</surname><given-names>SM</given-names></name><name><surname>Hejazi</surname><given-names>MS</given-names></name><name><surname>Tarhriz</surname><given-names>V</given-names></name><name><surname>Farjami</surname><given-names>A</given-names></name><name><surname>Ghasemian Sorbeni</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>COVID-19 infection: an overview on cytokine storm and related interventions</article-title>. <source>Virol J</source>. (<year>2022</year>) <volume>19</volume>:<fpage>92</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12985-022-01814-1</pub-id>
<pub-id pub-id-type="pmid">35619180</pub-id>
</mixed-citation></ref><ref id="B77"><label>77</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gajjela</surname><given-names>BK</given-names></name><name><surname>Zhou</surname><given-names>MM</given-names></name></person-group>. <article-title>Calming the cytokine storm of COVID-19 through inhibition of JAK2/STAT3 signaling</article-title>. <source>Drug Discovery Today</source>. (<year>2022</year>) <volume>27</volume>:<fpage>390</fpage>&#x02013;<lpage>400</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.drudis.2021.10.016</pub-id>
<pub-id pub-id-type="pmid">34743903</pub-id>
</mixed-citation></ref><ref id="B78"><label>78</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cron</surname><given-names>RQ</given-names></name><name><surname>Caricchio</surname><given-names>R</given-names></name><name><surname>Chatham</surname><given-names>WW</given-names></name></person-group>. <article-title>Calming the cytokine storm in COVID-19</article-title>. <source>Nat Med</source>. (<year>2021</year>) <volume>27</volume>:<page-range>1674&#x02013;5</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41591-021-01500-9</pub-id>
</mixed-citation></ref><ref id="B79"><label>79</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Shen</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Yuan</surname><given-names>J</given-names></name><name><surname>Wei</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19</article-title>. <source>J Allergy Clin Immunol</source>. (<year>2020</year>) <volume>146</volume>:<fpage>119</fpage>&#x02013;<lpage>27 e4</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jaci.2020.04.027</pub-id>
<pub-id pub-id-type="pmid">32360286</pub-id>
</mixed-citation></ref><ref id="B80"><label>80</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Han</surname><given-names>H</given-names></name><name><surname>Ma</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>R</given-names></name><name><surname>Zhao</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><etal/></person-group>. <article-title>Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors</article-title>. <source>Emerg Microbes Infect</source>. (<year>2020</year>) <volume>9</volume>:<page-range>1123&#x02013;30</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1080/22221751.2020.1770129</pub-id>
</mixed-citation></ref><ref id="B81"><label>81</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Del Valle-Mendoza</surname><given-names>J</given-names></name><name><surname>Tarazona-Castro</surname><given-names>Y</given-names></name><name><surname>Merino-Luna</surname><given-names>A</given-names></name><name><surname>Carrillo-Ng</surname><given-names>H</given-names></name><name><surname>Kym</surname><given-names>S</given-names></name><name><surname>Aguilar-Luis</surname><given-names>MA</given-names></name><etal/></person-group>. <article-title>Comparison of cytokines levels among COVID-19 patients living at sea level and high altitude</article-title>. <source>BMC Infect Dis</source>. (<year>2022</year>) <volume>22</volume>:<fpage>96</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1186/s12879-022-07079-x</pub-id>
<pub-id pub-id-type="pmid">35090394</pub-id>
</mixed-citation></ref><ref id="B82"><label>82</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Buszko</surname><given-names>M</given-names></name><name><surname>Nita-Lazar</surname><given-names>A</given-names></name><name><surname>Park</surname><given-names>JH</given-names></name><name><surname>Schwartzberg</surname><given-names>PL</given-names></name><name><surname>Verthelyi</surname><given-names>D</given-names></name><name><surname>Young</surname><given-names>HA</given-names></name><etal/></person-group>. <article-title>Lessons learned: new insights on the role of cytokines in COVID-19</article-title>. <source>Nat Immunol</source>. (<year>2021</year>) <volume>22</volume>:<page-range>404&#x02013;11</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41590-021-00901-9</pub-id>
</mixed-citation></ref><ref id="B83"><label>83</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Olbei</surname><given-names>M</given-names></name><name><surname>Hautefort</surname><given-names>I</given-names></name><name><surname>Modos</surname><given-names>D</given-names></name><name><surname>Treveil</surname><given-names>A</given-names></name><name><surname>Poletti</surname><given-names>M</given-names></name><name><surname>Gul</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>SARS-coV-2 causes a different cytokine response compared to other cytokine storm-causing respiratory viruses in severely ill patients</article-title>. <source>Front Immunol</source>. (<year>2021</year>) <volume>12</volume>:<fpage>629193</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fimmu.2021.629193</pub-id>
<pub-id pub-id-type="pmid">33732251</pub-id>
</mixed-citation></ref><ref id="B84"><label>84</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fahmy</surname><given-names>OH</given-names></name><name><surname>Daas</surname><given-names>FM</given-names></name><name><surname>Salunkhe</surname><given-names>V</given-names></name><name><surname>Petrey</surname><given-names>JL</given-names></name><name><surname>Cosar</surname><given-names>EF</given-names></name><name><surname>Ramirez</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Is microthrombosis the main pathology in coronavirus disease 2019 severity?-A systematic review of the postmortem pathologic findings</article-title>. <source>Crit Care Explor</source>. (<year>2021</year>) <volume>3</volume>:<fpage>e0427</fpage>. doi: <pub-id pub-id-type="doi">10.1097/CCE.0000000000000427</pub-id>
<pub-id pub-id-type="pmid">34036278</pub-id>
</mixed-citation></ref><ref id="B85"><label>85</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hatton</surname><given-names>CF</given-names></name><name><surname>Botting</surname><given-names>RA</given-names></name><name><surname>Duenas</surname><given-names>ME</given-names></name><name><surname>Haq</surname><given-names>IJ</given-names></name><name><surname>Verdon</surname><given-names>B</given-names></name><name><surname>Thompson</surname><given-names>BJ</given-names></name><etal/></person-group>. <article-title>Delayed induction of type I and III interferons mediates nasal epithelial cell permissiveness to SARS-CoV-2</article-title>. <source>Nat Commun</source>. (<year>2021</year>) <volume>12</volume>:<fpage>7092</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41467-021-27318-0</pub-id>
<pub-id pub-id-type="pmid">34876592</pub-id>
</mixed-citation></ref><ref id="B86"><label>86</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Bastard</surname><given-names>P</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Le Pen</surname><given-names>J</given-names></name><name><surname>Moncada-Velez</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Inborn errors of type I IFN immunity in patients with life-threatening COVID-19</article-title>. <source>Science</source>. (<year>2020</year>) <volume>370</volume>:<elocation-id>eabd4570</elocation-id>. doi: <pub-id pub-id-type="doi">10.1126/science.abd4570</pub-id>
<pub-id pub-id-type="pmid">32972995</pub-id>
</mixed-citation></ref><ref id="B87"><label>87</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kehrer</surname><given-names>T</given-names></name><name><surname>Garcia-Sastre</surname><given-names>A</given-names></name><name><surname>Miorin</surname><given-names>L</given-names></name></person-group>. <article-title>Control of innate immune activation by severe acute respiratory syndrome coronavirus 2 and other coronaviruses</article-title>. <source>J Interferon Cytokine Res</source>. (<year>2021</year>) <volume>41</volume>:<page-range>205&#x02013;19</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1089/jir.2021.0060</pub-id>
</mixed-citation></ref><ref id="B88"><label>88</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schneider</surname><given-names>WM</given-names></name><name><surname>Chevillotte</surname><given-names>MD</given-names></name><name><surname>Rice</surname><given-names>CM</given-names></name></person-group>. <article-title>Interferon-stimulated genes: a complex web of host defenses</article-title>. <source>Annu Rev Immunol</source>. (<year>2014</year>) <volume>32</volume>:<page-range>513&#x02013;45</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1146/annurev-immunol-032713-120231</pub-id>
</mixed-citation></ref><ref id="B89"><label>89</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Moss</surname><given-names>P</given-names></name></person-group>. <article-title>The T cell immune response against SARS-CoV-2</article-title>. <source>Nat Immunol</source>. (<year>2022</year>) <volume>23</volume>:<page-range>186&#x02013;93</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41590-021-01122-w</pub-id>
</mixed-citation></ref><ref id="B90"><label>90</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Thoms</surname><given-names>M</given-names></name><name><surname>Buschauer</surname><given-names>R</given-names></name><name><surname>Ameismeier</surname><given-names>M</given-names></name><name><surname>Koepke</surname><given-names>L</given-names></name><name><surname>Denk</surname><given-names>T</given-names></name><name><surname>Hirschenberger</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Structural basis for translational shutdown and immune evasion by the Nsp1 protein of SARS-CoV-2</article-title>. <source>Science</source>. (<year>2020</year>) <volume>369</volume>:<page-range>1249&#x02013;55</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1126/science.abc8665</pub-id>
</mixed-citation></ref><ref id="B91"><label>91</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Park</surname><given-names>A</given-names></name><name><surname>Iwasaki</surname><given-names>A</given-names></name></person-group>. <article-title>Type I and type III interferons - induction, signaling, evasion, and application to combat COVID-19</article-title>. <source>Cell Host Microbe</source>. (<year>2020</year>) <volume>27</volume>:<page-range>870&#x02013;8</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.chom.2020.05.008</pub-id>
</mixed-citation></ref><ref id="B92"><label>92</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rose</surname><given-names>KM</given-names></name><name><surname>Elliott</surname><given-names>R</given-names></name><name><surname>Martinez-Sobrido</surname><given-names>L</given-names></name><name><surname>Garcia-Sastre</surname><given-names>A</given-names></name><name><surname>Weiss</surname><given-names>SR</given-names></name></person-group>. <article-title>Murine coronavirus delays expression of a subset of interferon-stimulated genes</article-title>. <source>J Virol</source>. (<year>2010</year>) <volume>84</volume>:<page-range>5656&#x02013;69</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1128/JVI.00211-10</pub-id>
</mixed-citation></ref><ref id="B93"><label>93</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhang</surname><given-names>R</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Cowley</surname><given-names>TJ</given-names></name><name><surname>Steinbrenner</surname><given-names>AD</given-names></name><name><surname>Phillips</surname><given-names>JM</given-names></name><name><surname>Yount</surname><given-names>BL</given-names></name><etal/></person-group>. <article-title>The nsp1, nsp13, and M proteins contribute to the hepatotropism of murine coronavirus JHM</article-title>. <source>WU. J Virol</source>. (<year>2015</year>) <volume>89</volume>:<page-range>3598&#x02013;609</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1128/JVI.03535-14</pub-id>
</mixed-citation></ref><ref id="B94"><label>94</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hadjadj</surname><given-names>J</given-names></name><name><surname>Yatim</surname><given-names>N</given-names></name><name><surname>Barnabei</surname><given-names>L</given-names></name><name><surname>Corneau</surname><given-names>A</given-names></name><name><surname>Boussier</surname><given-names>J</given-names></name><name><surname>Smith</surname><given-names>N</given-names></name><etal/></person-group>. <article-title>Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients</article-title>. <source>Science</source>. (<year>2020</year>) <volume>369</volume>:<page-range>718&#x02013;24</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1126/science.abc6027</pub-id>
</mixed-citation></ref><ref id="B95"><label>95</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hoagland</surname><given-names>DA</given-names></name><name><surname>Moller</surname><given-names>R</given-names></name><name><surname>Uhl</surname><given-names>SA</given-names></name><name><surname>Oishi</surname><given-names>K</given-names></name><name><surname>Frere</surname><given-names>J</given-names></name><name><surname>Golynker</surname><given-names>I</given-names></name><etal/></person-group>. <article-title>Leveraging the antiviral type I interferon system as a first line of defense against SARS-CoV-2 pathogenicity</article-title>. <source>Immunity</source>. (<year>2021</year>) <volume>54</volume>:<fpage>557</fpage>&#x02013;<lpage>70 e5</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.immuni.2021.01.017</pub-id>
<pub-id pub-id-type="pmid">33577760</pub-id>
</mixed-citation></ref><ref id="B96"><label>96</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Stravalaci</surname><given-names>M</given-names></name><name><surname>Pagani</surname><given-names>I</given-names></name><name><surname>Paraboschi</surname><given-names>EM</given-names></name><name><surname>Pedotti</surname><given-names>M</given-names></name><name><surname>Doni</surname><given-names>A</given-names></name><name><surname>Scavello</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>Recognition and inhibition of SARS-CoV-2 by humoral innate immunity pattern recognition molecules</article-title>. <source>Nat Immunol</source>. (<year>2022</year>) <volume>23</volume>:<page-range>275&#x02013;86</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41590-021-01114-w</pub-id>
</mixed-citation></ref><ref id="B97"><label>97</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Holter</surname><given-names>JC</given-names></name><name><surname>Pischke</surname><given-names>SE</given-names></name><name><surname>de Boer</surname><given-names>E</given-names></name><name><surname>Lind</surname><given-names>A</given-names></name><name><surname>Jenum</surname><given-names>S</given-names></name><name><surname>Holten</surname><given-names>AR</given-names></name><etal/></person-group>. <article-title>Systemic complement activation is associated with respiratory failure in COVID-19 hospitalized patients</article-title>. <source>Proc Natl Acad Sci U S A</source>. (<year>2020</year>) <volume>117</volume>:<page-range>25018&#x02013;25</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1073/pnas.2010540117</pub-id>
</mixed-citation></ref><ref id="B98"><label>98</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Smilowitz</surname><given-names>NR</given-names></name><name><surname>Kunichoff</surname><given-names>D</given-names></name><name><surname>Garshick</surname><given-names>M</given-names></name><name><surname>Shah</surname><given-names>B</given-names></name><name><surname>Pillinger</surname><given-names>M</given-names></name><name><surname>Hochman</surname><given-names>JS</given-names></name><etal/></person-group>. <article-title>C-reactive protein and clinical outcomes in patients with COVID-19</article-title>. <source>Eur Heart J</source>. (<year>2021</year>) <volume>42</volume>:<page-range>2270&#x02013;9</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1093/eurheartj/ehaa1103</pub-id>
</mixed-citation></ref><ref id="B99"><label>99</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sefik</surname><given-names>E</given-names></name><name><surname>Qu</surname><given-names>R</given-names></name><name><surname>Junqueira</surname><given-names>C</given-names></name><name><surname>Kaffe</surname><given-names>E</given-names></name><name><surname>Mirza</surname><given-names>H</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Inflammasome activation in infected macrophages drives COVID-19 pathology</article-title>. <source>Nature</source>. (<year>2022</year>) <volume>606</volume>:<page-range>585&#x02013;93</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41586-022-04802-1</pub-id>
</mixed-citation></ref><ref id="B100"><label>100</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Park</surname><given-names>MD</given-names></name></person-group>. <article-title>Macrophages: a trojan horse in COVID-19</article-title>? <source>Nat Rev Immunol</source>. (<year>2020</year>) <volume>20</volume>:<fpage>351</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41577-020-0317-2</pub-id>
</mixed-citation></ref><ref id="B101"><label>101</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Abassi</surname><given-names>Z</given-names></name><name><surname>Knaney</surname><given-names>Y</given-names></name><name><surname>Karram</surname><given-names>T</given-names></name><name><surname>Heyman</surname><given-names>SN</given-names></name></person-group>. <article-title>The lung macrophage in SARS-coV-2 infection: A friend or a foe</article-title>? <source>Front Immunol</source>. (<year>2020</year>) <volume>11</volume>:<fpage>1312</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3389/fimmu.2020.01312</pub-id>
<pub-id pub-id-type="pmid">32582222</pub-id>
</mixed-citation></ref><ref id="B102"><label>102</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pantazi</surname><given-names>I</given-names></name><name><surname>Al-Qahtani</surname><given-names>AA</given-names></name><name><surname>Alhamlan</surname><given-names>FS</given-names></name><name><surname>Alothaid</surname><given-names>H</given-names></name><name><surname>Matou-Nasri</surname><given-names>S</given-names></name><name><surname>Sourvinos</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>SARS-coV-2/ACE2 interaction suppresses IRAK-M expression and promotes pro-inflammatory cytokine production in macrophages</article-title>. <source>Front Immunol</source>. (<year>2021</year>) <volume>12</volume>:<fpage>683800</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3389/fimmu.2021.683800</pub-id>
<pub-id pub-id-type="pmid">34248968</pub-id>
</mixed-citation></ref><ref id="B103"><label>103</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yang</surname><given-names>D</given-names></name><name><surname>Chu</surname><given-names>H</given-names></name><name><surname>Hou</surname><given-names>Y</given-names></name><name><surname>Chai</surname><given-names>Y</given-names></name><name><surname>Shuai</surname><given-names>H</given-names></name><name><surname>Lee</surname><given-names>AC</given-names></name><etal/></person-group>. <article-title>Attenuated interferon and proinflammatory response in SARS-coV-2-infected human dendritic cells is associated with viral antagonism of STAT1 phosphorylation</article-title>. <source>J Infect Dis</source>. (<year>2020</year>) <volume>222</volume>:<page-range>734&#x02013;45</page-range>. doi: <pub-id pub-id-type="doi">10.1093/infdis/jiaa356</pub-id>
</mixed-citation></ref><ref id="B104"><label>104</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Laurent</surname><given-names>P</given-names></name><name><surname>Yang</surname><given-names>C</given-names></name><name><surname>Rendeiro</surname><given-names>AF</given-names></name><name><surname>Nilsson-Payant</surname><given-names>BE</given-names></name><name><surname>Carrau</surname><given-names>L</given-names></name><name><surname>Chandar</surname><given-names>V</given-names></name><etal/></person-group>. <article-title>Sensing of SARS-CoV-2 by pDCs and their subsequent production of IFN-I contribute to macrophage-induced cytokine storm during COVID-19</article-title>. <source>Sci Immunol</source>. (<year>2022</year>) <volume>7</volume>:<elocation-id>eadd4906</elocation-id>. doi: <pub-id pub-id-type="doi">10.1126/sciimmunol.add4906</pub-id>
<pub-id pub-id-type="pmid">36083891</pub-id>
</mixed-citation></ref><ref id="B105"><label>105</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gordon</surname><given-names>S</given-names></name><name><surname>Pluddemann</surname><given-names>A</given-names></name></person-group>. <article-title>Tissue macrophages: heterogeneity and functions</article-title>. <source>BMC Biol</source>. (<year>2017</year>) <volume>15</volume>:<fpage>53</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1186/s12915-017-0392-4</pub-id>
<pub-id pub-id-type="pmid">28662662</pub-id>
</mixed-citation></ref><ref id="B106"><label>106</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Xu</surname><given-names>Q</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Cai</surname><given-names>JJ</given-names></name></person-group>. <article-title>Association of pyroptosis and severeness of COVID-19 as revealed by integrated single-cell transcriptome data analysis</article-title>. <source>Immunoinformatics (Amst)</source>. (<year>2022</year>) <volume>6</volume>:<fpage>100013</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.immuno.2022.100013</pub-id>
<pub-id pub-id-type="pmid">35434695</pub-id>
</mixed-citation></ref><ref id="B107"><label>107</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cervantes-Barragan</surname><given-names>L</given-names></name><name><surname>Zust</surname><given-names>R</given-names></name><name><surname>Weber</surname><given-names>F</given-names></name><name><surname>Spiegel</surname><given-names>M</given-names></name><name><surname>Lang</surname><given-names>KS</given-names></name><name><surname>Akira</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Control of coronavirus infection through plasmacytoid dendritic-cell-derived type I interferon</article-title>. <source>Blood</source>. (<year>2007</year>) <volume>109</volume>:<page-range>1131&#x02013;7</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1182/blood-2006-05-023770</pub-id>
</mixed-citation></ref><ref id="B108"><label>108</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Venet</surname><given-names>M</given-names></name><name><surname>Ribeiro</surname><given-names>MS</given-names></name><name><surname>Decembre</surname><given-names>E</given-names></name><name><surname>Bellomo</surname><given-names>A</given-names></name><name><surname>Joshi</surname><given-names>G</given-names></name><name><surname>Nuovo</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Severe COVID-19 patients have impaired plasmacytoid dendritic cell-mediated control of SARS-CoV-2</article-title>. <source>Nat Commun</source>. (<year>2023</year>) <volume>14</volume>:<fpage>694</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41467-023-36140-9</pub-id>
<pub-id pub-id-type="pmid">36755036</pub-id>
</mixed-citation></ref><ref id="B109"><label>109</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Perez-Gomez</surname><given-names>A</given-names></name><name><surname>Vitalle</surname><given-names>J</given-names></name><name><surname>Gasca-Capote</surname><given-names>C</given-names></name><name><surname>Gutierrez-Valencia</surname><given-names>A</given-names></name><name><surname>Trujillo-Rodriguez</surname><given-names>M</given-names></name><name><surname>Serna-Gallego</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Dendritic cell deficiencies persist seven months after SARS-CoV-2 infection</article-title>. <source>Cell Mol Immunol</source>. (<year>2021</year>) <volume>18</volume>:<page-range>2128&#x02013;39</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41423-021-00728-2</pub-id>
</mixed-citation></ref><ref id="B110"><label>110</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Galani</surname><given-names>IE</given-names></name><name><surname>Andreakos</surname><given-names>E</given-names></name></person-group>. <article-title>Neutrophils in viral infections: Current concepts and caveats</article-title>. <source>J Leukoc Biol</source>. (<year>2015</year>) <volume>98</volume>:<page-range>557&#x02013;64</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1189/jlb.4VMR1114-555R</pub-id>
</mixed-citation></ref><ref id="B111"><label>111</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ackermann</surname><given-names>M</given-names></name><name><surname>Anders</surname><given-names>HJ</given-names></name><name><surname>Bilyy</surname><given-names>R</given-names></name><name><surname>Bowlin</surname><given-names>GL</given-names></name><name><surname>Daniel</surname><given-names>C</given-names></name><name><surname>De Lorenzo</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Patients with COVID-19: in the dark-NETs of neutrophils</article-title>. <source>Cell Death Differ</source>. (<year>2021</year>) <volume>28</volume>:<page-range>3125&#x02013;39</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41418-021-00805-z</pub-id>
</mixed-citation></ref><ref id="B112"><label>112</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wu</surname><given-names>C</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Cai</surname><given-names>Y</given-names></name><name><surname>Xia</surname><given-names>J</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Xu</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in wuhan, China</article-title>. <source>JAMA Intern Med</source>. (<year>2020</year>) <volume>180</volume>:<page-range>934&#x02013;43</page-range>. doi: <pub-id pub-id-type="doi">10.1001/jamainternmed.2020.0994</pub-id>
</mixed-citation></ref><ref id="B113"><label>113</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Prozan</surname><given-names>L</given-names></name><name><surname>Shusterman</surname><given-names>E</given-names></name><name><surname>Ablin</surname><given-names>J</given-names></name><name><surname>Mitelpunkt</surname><given-names>A</given-names></name><name><surname>Weiss-Meilik</surname><given-names>A</given-names></name><name><surname>Adler</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Prognostic value of neutrophil-to-lymphocyte ratio in COVID-19 compared with Influenza and respiratory syncytial virus infection</article-title>. <source>Sci Rep</source>. (<year>2021</year>) <volume>11</volume>:<fpage>21519</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41598-021-00927-x</pub-id>
<pub-id pub-id-type="pmid">34728719</pub-id>
</mixed-citation></ref><ref id="B114"><label>114</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Du</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Jin</surname><given-names>Y</given-names></name><name><surname>Peng</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>HHX</given-names></name><etal/></person-group>. <article-title>Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19</article-title>. <source>J Infect</source>. (<year>2020</year>) <volume>81</volume>:<fpage>e6</fpage>&#x02013;<lpage>e12</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jinf.2020.04.002</pub-id>
</mixed-citation></ref><ref id="B115"><label>115</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schulte-Schrepping</surname><given-names>J</given-names></name><name><surname>Reusch</surname><given-names>N</given-names></name><name><surname>Paclik</surname><given-names>D</given-names></name><name><surname>Bassler</surname><given-names>K</given-names></name><name><surname>Schlickeiser</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Severe COVID-19 is marked by a dysregulated myeloid cell compartment</article-title>. <source>Cell</source>. (<year>2020</year>) <volume>182</volume>:<fpage>1419</fpage>&#x02013;<lpage>40 e23</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.cell.2020.08.001</pub-id>
<pub-id pub-id-type="pmid">32810438</pub-id>
</mixed-citation></ref><ref id="B116"><label>116</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>O&#x02019;Driscoll</surname><given-names>DN</given-names></name></person-group>. <article-title>Emergency myelopoiesis in critical illness: lessons from the COVID-19 pandemic</article-title>. <source>Ir J Med Sci</source>. (<year>2022</year>) <volume>192</volume>:<page-range>831&#x02013;2</page-range>. doi: <pub-id pub-id-type="doi">10.1007/s11845-022-03068-w</pub-id>
</mixed-citation></ref><ref id="B117"><label>117</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Arcanjo</surname><given-names>A</given-names></name><name><surname>Logullo</surname><given-names>J</given-names></name><name><surname>Menezes</surname><given-names>CCB</given-names></name><name><surname>de Souza Carvalho Giangiarulo</surname><given-names>TC</given-names></name><name><surname>Dos Reis</surname><given-names>MC</given-names></name><name><surname>de Castro</surname><given-names>GMM</given-names></name><etal/></person-group>. <article-title>The emerging role of neutrophil extracellular traps in severe acute respiratory syndrome coronavirus 2 (COVID-19)</article-title>. <source>Sci Rep</source>. (<year>2020</year>) <volume>10</volume>:<fpage>19630</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41598-020-76781-0</pub-id>
<pub-id pub-id-type="pmid">33184506</pub-id>
</mixed-citation></ref><ref id="B118"><label>118</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vivier</surname><given-names>E</given-names></name><name><surname>Raulet</surname><given-names>DH</given-names></name><name><surname>Moretta</surname><given-names>A</given-names></name><name><surname>Caligiuri</surname><given-names>MA</given-names></name><name><surname>Zitvogel</surname><given-names>L</given-names></name><name><surname>Lanier</surname><given-names>LL</given-names></name><etal/></person-group>. <article-title>Innate or adaptive immunity? The example of natural killer cells</article-title>. <source>Science</source>. (<year>2011</year>) <volume>331</volume>:<page-range>44&#x02013;9</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1126/science.1198687</pub-id>
</mixed-citation></ref><ref id="B119"><label>119</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pituch-Noworolska</surname><given-names>AM</given-names></name></person-group>. <article-title>NK cells in SARS-CoV-2 infection</article-title>. <source>Cent Eur J Immunol</source>. (<year>2022</year>) <volume>47</volume>:<fpage>95</fpage>&#x02013;<lpage>101</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.5114/ceji.2022.113078</pub-id>
<pub-id pub-id-type="pmid">35600151</pub-id>
</mixed-citation></ref><ref id="B120"><label>120</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Diaz-Salazar</surname><given-names>C</given-names></name><name><surname>Sun</surname><given-names>JC</given-names></name></person-group>. <article-title>Coordinated viral control by cytotoxic lymphocytes ensures optimal adaptive NK cell responses</article-title>. <source>Cell Rep</source>. (<year>2020</year>) <volume>32</volume>:<fpage>108186</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.celrep.2020.108186</pub-id>
<pub-id pub-id-type="pmid">32966792</pub-id>
</mixed-citation></ref><ref id="B121"><label>121</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Maucourant</surname><given-names>C</given-names></name><name><surname>Filipovic</surname><given-names>I</given-names></name><name><surname>Ponzetta</surname><given-names>A</given-names></name><name><surname>Aleman</surname><given-names>S</given-names></name><name><surname>Cornillet</surname><given-names>M</given-names></name><name><surname>Hertwig</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Natural killer cell immunotypes related to COVID-19 disease severity</article-title>. <source>Sci Immunol</source>. (<year>2020</year>) <volume>5</volume>:<elocation-id>eabd6832</elocation-id>. doi: <pub-id pub-id-type="doi">10.1126/sciimmunol.abd6832</pub-id>
<pub-id pub-id-type="pmid">32826343</pub-id>
</mixed-citation></ref><ref id="B122"><label>122</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bjorkstrom</surname><given-names>NK</given-names></name><name><surname>Ponzetta</surname><given-names>A</given-names></name></person-group>. <article-title>Natural killer cells and unconventional T cells in COVID-19</article-title>. <source>Curr Opin Virol</source>. (<year>2021</year>) <volume>49</volume>:<page-range>176&#x02013;82</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.coviro.2021.06.005</pub-id>
</mixed-citation></ref><ref id="B123"><label>123</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cifaldi</surname><given-names>L</given-names></name><name><surname>Prencipe</surname><given-names>G</given-names></name><name><surname>Caiello</surname><given-names>I</given-names></name><name><surname>Bracaglia</surname><given-names>C</given-names></name><name><surname>Locatelli</surname><given-names>F</given-names></name><name><surname>De Benedetti</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>Inhibition of natural killer cell cytotoxicity by interleukin-6: implications for the pathogenesis of macrophage activation syndrome</article-title>. <source>Arthritis Rheumatol</source>. (<year>2015</year>) <volume>67</volume>:<page-range>3037&#x02013;46</page-range>. doi: <pub-id pub-id-type="doi">10.1002/art.39295</pub-id>
</mixed-citation></ref><ref id="B124"><label>124</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gustine</surname><given-names>JN</given-names></name><name><surname>Jones</surname><given-names>D</given-names></name></person-group>. <article-title>Immunopathology of hyperinflammation in COVID-19</article-title>. <source>Am J Pathol</source>. (<year>2021</year>) <volume>191</volume>:<fpage>4</fpage>&#x02013;<lpage>17</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.ajpath.2020.08.009</pub-id>
<pub-id pub-id-type="pmid">32919977</pub-id>
</mixed-citation></ref><ref id="B125"><label>125</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Eberl</surname><given-names>G</given-names></name><name><surname>Colonna</surname><given-names>M</given-names></name><name><surname>Di Santo</surname><given-names>JP</given-names></name><name><surname>McKenzie</surname><given-names>AN</given-names></name></person-group>. <article-title>Innate lymphoid cells. Innate lymphoid cells: a new paradigm in immunology</article-title>. <source>Science</source>. (<year>2015</year>) <volume>348</volume>:<fpage>aaa6566</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1126/science.aaa6566</pub-id>
<pub-id pub-id-type="pmid">25999512</pub-id>
</mixed-citation></ref><ref id="B126"><label>126</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Silverstein</surname><given-names>NJ</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Manickas-Hill</surname><given-names>Z</given-names></name><name><surname>Carbone</surname><given-names>C</given-names></name><name><surname>Dauphin</surname><given-names>A</given-names></name><name><surname>Boribong</surname><given-names>BP</given-names></name><etal/></person-group>. <article-title>Innate lymphoid cells and COVID-19 severity in SARS-CoV-2 infection</article-title>. <source>Elife</source>. (<year>2022</year>) <volume>11</volume>:<elocation-id>e74681</elocation-id>. doi: <pub-id pub-id-type="doi">10.7554/eLife.74681</pub-id>
<pub-id pub-id-type="pmid">35275061</pub-id>
</mixed-citation></ref><ref id="B127"><label>127</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kuri-Cervantes</surname><given-names>L</given-names></name><name><surname>Pampena</surname><given-names>MB</given-names></name><name><surname>Meng</surname><given-names>W</given-names></name><name><surname>Rosenfeld</surname><given-names>AM</given-names></name><name><surname>Ittner</surname><given-names>CAG</given-names></name><name><surname>Weisman</surname><given-names>AR</given-names></name><etal/></person-group>. <article-title>Comprehensive mapping of immune perturbations associated with severe COVID-19</article-title>. <source>Sci Immunol</source>. (<year>2020</year>) <volume>5</volume>:<elocation-id>eabd7114</elocation-id>. doi: <pub-id pub-id-type="doi">10.1126/sciimmunol.abd7114</pub-id>
<pub-id pub-id-type="pmid">32669287</pub-id>
</mixed-citation></ref><ref id="B128"><label>128</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Deschler</surname><given-names>S</given-names></name><name><surname>Kager</surname><given-names>J</given-names></name><name><surname>Erber</surname><given-names>J</given-names></name><name><surname>Fricke</surname><given-names>L</given-names></name><name><surname>Koyumdzhieva</surname><given-names>P</given-names></name><name><surname>Georgieva</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Mucosal-associated invariant T (MAIT) cells are highly activated and functionally impaired in COVID-19 patients</article-title>. <source>Viruses</source>. (<year>2021</year>) <volume>13</volume>:<fpage>241</fpage>. doi: <pub-id pub-id-type="doi">10.3390/v13020241</pub-id>
<pub-id pub-id-type="pmid">33546489</pub-id>
</mixed-citation></ref><ref id="B129"><label>129</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Flament</surname><given-names>H</given-names></name><name><surname>Rouland</surname><given-names>M</given-names></name><name><surname>Beaudoin</surname><given-names>L</given-names></name><name><surname>Toubal</surname><given-names>A</given-names></name><name><surname>Bertrand</surname><given-names>L</given-names></name><name><surname>Lebourgeois</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Outcome of SARS-CoV-2 infection is linked to MAIT cell activation and cytotoxicity</article-title>. <source>Nat Immunol</source>. (<year>2021</year>) <volume>22</volume>:<page-range>322&#x02013;35</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41590-021-00870-z</pub-id>
</mixed-citation></ref><ref id="B130"><label>130</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Toubal</surname><given-names>A</given-names></name><name><surname>Nel</surname><given-names>I</given-names></name><name><surname>Lotersztajn</surname><given-names>S</given-names></name><name><surname>Lehuen</surname><given-names>A</given-names></name></person-group>. <article-title>Mucosal-associated invariant T cells and disease</article-title>. <source>Nat Rev Immunol</source>. (<year>2019</year>) <volume>19</volume>:<page-range>643&#x02013;57</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41577-019-0191-y</pub-id>
</mixed-citation></ref><ref id="B131"><label>131</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Singh</surname><given-names>K</given-names></name><name><surname>Cogan</surname><given-names>S</given-names></name><name><surname>Elekes</surname><given-names>S</given-names></name><name><surname>Murphy</surname><given-names>DM</given-names></name><name><surname>Cummins</surname><given-names>S</given-names></name><name><surname>Curran</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>SARS-CoV-2 spike and nucleocapsid proteins fail to activate human dendritic cells or gammadelta T cells</article-title>. <source>PloS One</source>. (<year>2022</year>) <volume>17</volume>:<elocation-id>e0271463</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1371/journal.pone.0271463</pub-id>
<pub-id pub-id-type="pmid">35834480</pub-id>
</mixed-citation></ref><ref id="B132"><label>132</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lo Presti</surname><given-names>E</given-names></name><name><surname>Dieli</surname><given-names>F</given-names></name><name><surname>Meraviglia</surname><given-names>S</given-names></name></person-group>. <article-title>Lymphopenia in COVID-19: gammadelta T cells-based therapeutic opportunities</article-title>. <source>Vaccines (Basel)</source>. (<year>2021</year>) <volume>9</volume>:<fpage>562</fpage>. doi: <pub-id pub-id-type="doi">10.3390/vaccines9060562</pub-id>
<pub-id pub-id-type="pmid">34071430</pub-id>
</mixed-citation></ref><ref id="B133"><label>133</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>von Massow</surname><given-names>G</given-names></name><name><surname>Oh</surname><given-names>S</given-names></name><name><surname>Lam</surname><given-names>A</given-names></name><name><surname>Gustafsson</surname><given-names>K</given-names></name></person-group>. <article-title>Gamma delta T cells and their involvement in COVID-19 virus infections</article-title>. <source>Front Immunol</source>. (<year>2021</year>) <volume>12</volume>:<fpage>741218</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3389/fimmu.2021.741218</pub-id>
<pub-id pub-id-type="pmid">34777353</pub-id>
</mixed-citation></ref><ref id="B134"><label>134</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yazdanifar</surname><given-names>M</given-names></name><name><surname>Mashkour</surname><given-names>N</given-names></name><name><surname>Bertaina</surname><given-names>A</given-names></name></person-group>. <article-title>Making a case for using gammadelta T cells against SARS-CoV-2</article-title>. <source>Crit Rev Microbiol</source>. (<year>2020</year>) <volume>46</volume>:<fpage>689</fpage>&#x02013;<lpage>702</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1080/1040841X.2020.1822279</pub-id>
<pub-id pub-id-type="pmid">33023358</pub-id>
</mixed-citation></ref><ref id="B135"><label>135</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Poccia</surname><given-names>F</given-names></name><name><surname>Agrati</surname><given-names>C</given-names></name><name><surname>Castilletti</surname><given-names>C</given-names></name><name><surname>Bordi</surname><given-names>L</given-names></name><name><surname>Gioia</surname><given-names>C</given-names></name><name><surname>Horejsh</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Anti-severe acute respiratory syndrome coronavirus immune responses: the role played by V gamma 9V delta 2 T cells</article-title>. <source>J Infect Dis</source>. (<year>2006</year>) <volume>193</volume>:<page-range>1244&#x02013;9</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1086/502975</pub-id>
</mixed-citation></ref><ref id="B136"><label>136</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lei</surname><given-names>L</given-names></name><name><surname>Qian</surname><given-names>H</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>D</given-names></name><name><surname>Dai</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>The phenotypic changes of gammadelta T cells in COVID-19 patients</article-title>. <source>J Cell Mol Med</source>. (<year>2020</year>) <volume>24</volume>:<page-range>11603&#x02013;6</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1111/jcmm.15620</pub-id>
</mixed-citation></ref><ref id="B137"><label>137</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sette</surname><given-names>A</given-names></name><name><surname>Crotty</surname><given-names>S</given-names></name></person-group>. <article-title>Adaptive immunity to SARS-coV-2 and COVID-19</article-title>. <source>Cell</source>. (<year>2021</year>) <volume>184</volume>:<page-range>861&#x02013;80</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.cell.2021.01.007</pub-id>
</mixed-citation></ref><ref id="B138"><label>138</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tan</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Zhang</surname><given-names>D</given-names></name><name><surname>Ding</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>Q</given-names></name><name><surname>Tang</surname><given-names>YQ</given-names></name><etal/></person-group>. <article-title>Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study</article-title>. <source>Signal Transduct Target Ther</source>. (<year>2020</year>) <volume>5</volume>:<fpage>33</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41392-020-0148-4</pub-id>
<pub-id pub-id-type="pmid">32296069</pub-id>
</mixed-citation></ref><ref id="B139"><label>139</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yao</surname><given-names>C</given-names></name><name><surname>Bora</surname><given-names>SA</given-names></name><name><surname>Parimon</surname><given-names>T</given-names></name><name><surname>Zaman</surname><given-names>T</given-names></name><name><surname>Friedman</surname><given-names>OA</given-names></name><name><surname>Palatinus</surname><given-names>JA</given-names></name><etal/></person-group>. <article-title>Cell-type-specific immune dysregulation in severely ill COVID-19 patients</article-title>. <source>Cell Rep</source>. (<year>2021</year>) <volume>34</volume>:<fpage>108590</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.celrep.2020.108590</pub-id>
<pub-id pub-id-type="pmid">33357411</pub-id>
</mixed-citation></ref><ref id="B140"><label>140</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gupta</surname><given-names>A</given-names></name><name><surname>Madhavan</surname><given-names>MV</given-names></name><name><surname>Sehgal</surname><given-names>K</given-names></name><name><surname>Nair</surname><given-names>N</given-names></name><name><surname>Mahajan</surname><given-names>S</given-names></name><name><surname>Sehrawat</surname><given-names>TS</given-names></name><etal/></person-group>. <article-title>Extrapulmonary manifestations of COVID-19</article-title>. <source>Nat Med</source>. (<year>2020</year>) <volume>26</volume>:<page-range>1017&#x02013;32</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41591-020-0968-3</pub-id>
</mixed-citation></ref><ref id="B141"><label>141</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Xiang</surname><given-names>Q</given-names></name><name><surname>Feng</surname><given-names>Z</given-names></name><name><surname>Diao</surname><given-names>B</given-names></name><name><surname>Tu</surname><given-names>C</given-names></name><name><surname>Qiao</surname><given-names>Q</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>SARS-coV-2 induces lymphocytopenia by promoting inflammation and decimates secondary lymphoid organs</article-title>. <source>Front Immunol</source>. (<year>2021</year>) <volume>12</volume>:<fpage>661052</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3389/fimmu.2021.661052</pub-id>
<pub-id pub-id-type="pmid">33995382</pub-id>
</mixed-citation></ref><ref id="B142"><label>142</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Huang</surname><given-names>I</given-names></name><name><surname>Pranata</surname><given-names>R</given-names></name></person-group>. <article-title>Lymphopenia in severe coronavirus disease-2019 (COVID-19): systematic review and meta-analysis</article-title>. <source>J Intensive Care</source>. (<year>2020</year>) <volume>8</volume>:<fpage>36</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s40560-020-00453-4</pub-id>
<pub-id pub-id-type="pmid">32483488</pub-id>
</mixed-citation></ref><ref id="B143"><label>143</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Xu</surname><given-names>X</given-names></name><name><surname>Han</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>T</given-names></name><name><surname>Sun</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Fu</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Effective treatment of severe COVID-19 patients with tocilizumab</article-title>. <source>Proc Natl Acad Sci U S A</source>. (<year>2020</year>) <volume>117</volume>:<page-range>10970&#x02013;5</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1073/pnas.2005615117</pub-id>
</mixed-citation></ref><ref id="B144"><label>144</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Diao</surname><given-names>B</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Tan</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Ning</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19)</article-title>. <source>Front Immunol</source>. (<year>2020</year>) <volume>11</volume>:<fpage>827</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3389/fimmu.2020.00827</pub-id>
<pub-id pub-id-type="pmid">32425950</pub-id>
</mixed-citation></ref><ref id="B145"><label>145</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Meckiff</surname><given-names>BJ</given-names></name><name><surname>Ramirez-Suastegui</surname><given-names>C</given-names></name><name><surname>Fajardo</surname><given-names>V</given-names></name><name><surname>Chee</surname><given-names>SJ</given-names></name><name><surname>Kusnadi</surname><given-names>A</given-names></name><name><surname>Simon</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Imbalance of regulatory and cytotoxic SARS-coV-2-reactive CD4(+) T cells in COVID-19</article-title>. <source>Cell</source>. (<year>2020</year>) <volume>183</volume>:<fpage>1340</fpage>&#x02013;<lpage>53 e16</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.cell.2020.10.001</pub-id>
<pub-id pub-id-type="pmid">33096020</pub-id>
</mixed-citation></ref><ref id="B146"><label>146</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Grifoni</surname><given-names>A</given-names></name><name><surname>Weiskopf</surname><given-names>D</given-names></name><name><surname>Ramirez</surname><given-names>SI</given-names></name><name><surname>Mateus</surname><given-names>J</given-names></name><name><surname>Dan</surname><given-names>JM</given-names></name><name><surname>Moderbacher</surname><given-names>CR</given-names></name><etal/></person-group>. <article-title>Targets of T cell responses to SARS-coV-2 coronavirus in humans with COVID-19 disease and unexposed individuals</article-title>. <source>Cell</source>. (<year>2020</year>) <volume>181</volume>:<fpage>1489</fpage>&#x02013;<lpage>501 e15</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.cell.2020.05.015</pub-id>
<pub-id pub-id-type="pmid">32473127</pub-id>
</mixed-citation></ref><ref id="B147"><label>147</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tan</surname><given-names>AT</given-names></name><name><surname>Linster</surname><given-names>M</given-names></name><name><surname>Tan</surname><given-names>CW</given-names></name><name><surname>Le Bert</surname><given-names>N</given-names></name><name><surname>Chia</surname><given-names>WN</given-names></name><name><surname>Kunasegaran</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients</article-title>. <source>Cell Rep</source>. (<year>2021</year>) <volume>34</volume>:<fpage>108728</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.celrep.2021.108728</pub-id>
<pub-id pub-id-type="pmid">33516277</pub-id>
</mixed-citation></ref><ref id="B148"><label>148</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rydyznski Moderbacher</surname><given-names>C</given-names></name><name><surname>Ramirez</surname><given-names>SI</given-names></name><name><surname>Dan</surname><given-names>JM</given-names></name><name><surname>Grifoni</surname><given-names>A</given-names></name><name><surname>Hastie</surname><given-names>KM</given-names></name><name><surname>Weiskopf</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Antigen-specific adaptive immunity to SARS-coV-2 in acute COVID-19 and associations with age and disease severity</article-title>. <source>Cell</source>. (<year>2020</year>) <volume>183</volume>:<fpage>996</fpage>&#x02013;<lpage>1012 e19</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.cell.2020.09.038</pub-id>
<pub-id pub-id-type="pmid">33010815</pub-id>
</mixed-citation></ref><ref id="B149"><label>149</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sekine</surname><given-names>T</given-names></name><name><surname>Perez-Potti</surname><given-names>A</given-names></name><name><surname>Rivera-Ballesteros</surname><given-names>O</given-names></name><name><surname>Stralin</surname><given-names>K</given-names></name><name><surname>Gorin</surname><given-names>JB</given-names></name><name><surname>Olsson</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19</article-title>. <source>Cell</source>. (<year>2020</year>) <volume>183</volume>:<fpage>158</fpage>&#x02013;<lpage>68 e14</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.cell.2020.08.017</pub-id>
<pub-id pub-id-type="pmid">32979941</pub-id>
</mixed-citation></ref><ref id="B150"><label>150</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gao</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Guo</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Fan</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Regulatory CD4(+) and CD8(+) T cells are negatively correlated with CD4(+)/CD8(+) T cell ratios in patients acutely infected with SARS-CoV-2</article-title>. <source>J Leukoc Biol</source>. (<year>2021</year>) <volume>109</volume>:<page-range>91&#x02013;7</page-range>. doi: <pub-id pub-id-type="doi">10.1002/JLB.5COVA0720-421RR</pub-id>
</mixed-citation></ref><ref id="B151"><label>151</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kaneko</surname><given-names>N</given-names></name><name><surname>Kuo</surname><given-names>HH</given-names></name><name><surname>Boucau</surname><given-names>J</given-names></name><name><surname>Farmer</surname><given-names>JR</given-names></name><name><surname>Allard-Chamard</surname><given-names>H</given-names></name><name><surname>Mahajan</surname><given-names>VS</given-names></name><etal/></person-group>. <article-title>Loss of bcl-6-expressing T follicular helper cells and germinal centers in COVID-19</article-title>. <source>Cell</source>. (<year>2020</year>) <volume>183</volume>:<fpage>143</fpage>&#x02013;<lpage>57 e13</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.cell.2020.08.025</pub-id>
<pub-id pub-id-type="pmid">32877699</pub-id>
</mixed-citation></ref><ref id="B152"><label>152</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Basso</surname><given-names>K</given-names></name><name><surname>Dalla-Favera</surname><given-names>R</given-names></name></person-group>. <article-title>Roles of BCL6 in normal and transformed germinal center B cells</article-title>. <source>Immunol Rev</source>. (<year>2012</year>) <volume>247</volume>:<page-range>172&#x02013;83</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1111/j.1600-065X.2012.01112.x</pub-id>
</mixed-citation></ref><ref id="B153"><label>153</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Maddur</surname><given-names>MS</given-names></name><name><surname>Miossec</surname><given-names>P</given-names></name><name><surname>Kaveri</surname><given-names>SV</given-names></name><name><surname>Bayry</surname><given-names>J</given-names></name></person-group>. <article-title>Th17 cells: biology, pathogenesis of autoimmune and inflammatory diseases, and therapeutic strategies</article-title>. <source>Am J Pathol</source>. (<year>2012</year>) <volume>181</volume>:<fpage>8</fpage>&#x02013;<lpage>18</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.ajpath.2012.03.044</pub-id>
<pub-id pub-id-type="pmid">22640807</pub-id>
</mixed-citation></ref><ref id="B154"><label>154</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jones</surname><given-names>SA</given-names></name><name><surname>Hunter</surname><given-names>CA</given-names></name></person-group>. <article-title>Is IL-6 a key cytokine target for therapy in COVID-19</article-title>? <source>Nat Rev Immunol</source>. (<year>2021</year>) <volume>21</volume>:<page-range>337&#x02013;9</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41577-021-00553-8</pub-id>
</mixed-citation></ref><ref id="B155"><label>155</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Martonik</surname><given-names>D</given-names></name><name><surname>Parfieniuk-Kowerda</surname><given-names>A</given-names></name><name><surname>Rogalska</surname><given-names>M</given-names></name><name><surname>Flisiak</surname><given-names>R</given-names></name></person-group>. <article-title>The role of th17 response in COVID-19</article-title>. <source>Cells</source>. (<year>2021</year>) <volume>10</volume>:<fpage>1550</fpage>. doi: <pub-id pub-id-type="doi">10.3390/cells10061550</pub-id>
<pub-id pub-id-type="pmid">34205262</pub-id>
</mixed-citation></ref><ref id="B156"><label>156</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sadeghi</surname><given-names>A</given-names></name><name><surname>Tahmasebi</surname><given-names>S</given-names></name><name><surname>Mahmood</surname><given-names>A</given-names></name><name><surname>Kuznetsova</surname><given-names>M</given-names></name><name><surname>Valizadeh</surname><given-names>H</given-names></name><name><surname>Taghizadieh</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Th17 and Treg cells function in SARS-CoV2 patients compared with healthy controls</article-title>. <source>J Cell Physiol</source>. (<year>2021</year>) <volume>236</volume>:<page-range>2829&#x02013;39</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1002/jcp.30047</pub-id>
</mixed-citation></ref><ref id="B157"><label>157</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rha</surname><given-names>MS</given-names></name><name><surname>Shin</surname><given-names>EC</given-names></name></person-group>. <article-title>Activation or exhaustion of CD8(+) T cells in patients with COVID-19</article-title>. <source>Cell Mol Immunol</source>. (<year>2021</year>) <volume>18</volume>:<page-range>2325&#x02013;33</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41423-021-00750-4</pub-id>
</mixed-citation></ref><ref id="B158"><label>158</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>THO</given-names></name><name><surname>Rowntree</surname><given-names>LC</given-names></name><name><surname>Petersen</surname><given-names>J</given-names></name><name><surname>Chua</surname><given-names>BY</given-names></name><name><surname>Hensen</surname><given-names>L</given-names></name><name><surname>Kedzierski</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>CD8(+) T cells specific for an immunodominant SARS-CoV-2 nucleocapsid epitope display high naive precursor frequency and TCR promiscuity</article-title>. <source>Immunity</source>. (<year>2021</year>) <volume>54</volume>:<fpage>1066</fpage>&#x02013;<lpage>82 e5</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.immuni.2021.04.009</pub-id>
<pub-id pub-id-type="pmid">33951417</pub-id>
</mixed-citation></ref><ref id="B159"><label>159</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Varchetta</surname><given-names>S</given-names></name><name><surname>Mele</surname><given-names>D</given-names></name><name><surname>Oliviero</surname><given-names>B</given-names></name><name><surname>Mantovani</surname><given-names>S</given-names></name><name><surname>Ludovisi</surname><given-names>S</given-names></name><name><surname>Cerino</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Unique immunological profile in patients with COVID-19</article-title>. <source>Cell Mol Immunol</source>. (<year>2021</year>) <volume>18</volume>:<page-range>604&#x02013;12</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41423-020-00557-9</pub-id>
</mixed-citation></ref><ref id="B160"><label>160</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Song</surname><given-names>JW</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Fan</surname><given-names>X</given-names></name><name><surname>Meng</surname><given-names>FP</given-names></name><name><surname>Xu</surname><given-names>Z</given-names></name><name><surname>Xia</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>Immunological and inflammatory profiles in mild and severe cases of COVID-19</article-title>. <source>Nat Commun</source>. (<year>2020</year>) <volume>11</volume>:<fpage>3410</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41467-020-17240-2</pub-id>
<pub-id pub-id-type="pmid">32641700</pub-id>
</mixed-citation></ref><ref id="B161"><label>161</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mathew</surname><given-names>D</given-names></name><name><surname>Giles</surname><given-names>JR</given-names></name><name><surname>Baxter</surname><given-names>AE</given-names></name><name><surname>Oldridge</surname><given-names>DA</given-names></name><name><surname>Greenplate</surname><given-names>AR</given-names></name><name><surname>Wu</surname><given-names>JE</given-names></name><etal/></person-group>. <article-title>Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications</article-title>. <source>Science</source>. (<year>2020</year>) <volume>369</volume>:<elocation-id>eabc8511</elocation-id>. doi: <pub-id pub-id-type="doi">10.1126/science.abc8511</pub-id>
<pub-id pub-id-type="pmid">32669297</pub-id>
</mixed-citation></ref><ref id="B162"><label>162</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Swadling</surname><given-names>L</given-names></name><name><surname>Diniz</surname><given-names>MO</given-names></name><name><surname>Schmidt</surname><given-names>NM</given-names></name><name><surname>Amin</surname><given-names>OE</given-names></name><name><surname>Chandran</surname><given-names>A</given-names></name><name><surname>Shaw</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>Pre-existing polymerase-specific T cells expand in abortive seronegative SARS-CoV-2</article-title>. <source>Nature</source>. (<year>2022</year>) <volume>601</volume>:<page-range>110&#x02013;7</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41586-021-04186-8</pub-id>
</mixed-citation></ref><ref id="B163"><label>163</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Grom</surname><given-names>AA</given-names></name><name><surname>Horne</surname><given-names>A</given-names></name><name><surname>De Benedetti</surname><given-names>F</given-names></name></person-group>. <article-title>Macrophage activation syndrome in the era of biologic therapy</article-title>. <source>Nat Rev Rheumatol</source>. (<year>2016</year>) <volume>12</volume>:<page-range>259&#x02013;68</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/nrrheum.2015.179</pub-id>
</mixed-citation></ref><ref id="B164"><label>164</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jung</surname><given-names>JH</given-names></name><name><surname>Rha</surname><given-names>MS</given-names></name><name><surname>Sa</surname><given-names>M</given-names></name><name><surname>Choi</surname><given-names>HK</given-names></name><name><surname>Jeon</surname><given-names>JH</given-names></name><name><surname>Seok</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>SARS-CoV-2-specific T cell memory is sustained in COVID-19 convalescent patients for 10 months with successful development of stem cell-like memory T cells</article-title>. <source>Nat Commun</source>. (<year>2021</year>) <volume>12</volume>:<fpage>4043</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41467-021-24377-1</pub-id>
<pub-id pub-id-type="pmid">34193870</pub-id>
</mixed-citation></ref><ref id="B165"><label>165</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wagner</surname><given-names>KI</given-names></name><name><surname>Mateyka</surname><given-names>LM</given-names></name><name><surname>Jarosch</surname><given-names>S</given-names></name><name><surname>Grass</surname><given-names>V</given-names></name><name><surname>Weber</surname><given-names>S</given-names></name><name><surname>Schober</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Recruitment of highly cytotoxic CD8(+) T cell receptors in mild SARS-CoV-2 infection</article-title>. <source>Cell Rep</source>. (<year>2022</year>) <volume>38</volume>:<fpage>110214</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.celrep.2021.110214</pub-id>
<pub-id pub-id-type="pmid">34968416</pub-id>
</mixed-citation></ref><ref id="B166"><label>166</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Adamo</surname><given-names>S</given-names></name><name><surname>Michler</surname><given-names>J</given-names></name><name><surname>Zurbuchen</surname><given-names>Y</given-names></name><name><surname>Cervia</surname><given-names>C</given-names></name><name><surname>Taeschler</surname><given-names>P</given-names></name><name><surname>Raeber</surname><given-names>ME</given-names></name><etal/></person-group>. <article-title>Signature of long-lived memory CD8(+) T cells in acute SARS-CoV-2 infection</article-title>. <source>Nature</source>. (<year>2022</year>) <volume>602</volume>:<page-range>148&#x02013;55</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41586-021-04280-x</pub-id>
</mixed-citation></ref><ref id="B167"><label>167</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Buggert</surname><given-names>M</given-names></name><name><surname>Vella</surname><given-names>LA</given-names></name><name><surname>Nguyen</surname><given-names>S</given-names></name><name><surname>Wu</surname><given-names>VH</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Sekine</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>The identity of human tissue-emigrant CD8(+) T cells</article-title>. <source>Cell</source>. (<year>2020</year>) <volume>183</volume>:<fpage>1946</fpage>&#x02013;<lpage>61 e15</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.cell.2020.11.019</pub-id>
<pub-id pub-id-type="pmid">33306960</pub-id>
</mixed-citation></ref><ref id="B168"><label>168</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Redd</surname><given-names>AD</given-names></name><name><surname>Nardin</surname><given-names>A</given-names></name><name><surname>Kared</surname><given-names>H</given-names></name><name><surname>Bloch</surname><given-names>EM</given-names></name><name><surname>Pekosz</surname><given-names>A</given-names></name><name><surname>Laeyendecker</surname><given-names>O</given-names></name><etal/></person-group>. <article-title>CD8+ T-cell responses in COVID-19 convalescent individuals target conserved epitopes from multiple prominent SARS-coV-2 circulating variants</article-title>. <source>Open Forum Infect Dis</source>. (<year>2021</year>) <volume>8</volume>:<fpage>ofab143</fpage>. doi: <pub-id pub-id-type="doi">10.1093/ofid/ofab143</pub-id>
<pub-id pub-id-type="pmid">34322559</pub-id>
</mixed-citation></ref><ref id="B169"><label>169</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Keeton</surname><given-names>R</given-names></name><name><surname>Tincho</surname><given-names>MB</given-names></name><name><surname>Ngomti</surname><given-names>A</given-names></name><name><surname>Baguma</surname><given-names>R</given-names></name><name><surname>Benede</surname><given-names>N</given-names></name><name><surname>Suzuki</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>T cell responses to SARS-CoV-2 spike cross-recognize Omicron</article-title>. <source>Nature</source>. (<year>2022</year>) <volume>603</volume>:<page-range>488&#x02013;92</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41586-022-04460-3</pub-id>
</mixed-citation></ref><ref id="B170"><label>170</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lu</surname><given-names>LL</given-names></name><name><surname>Suscovich</surname><given-names>TJ</given-names></name><name><surname>Fortune</surname><given-names>SM</given-names></name><name><surname>Alter</surname><given-names>G</given-names></name></person-group>. <article-title>Beyond binding: antibody effector functions in infectious diseases</article-title>. <source>Nat Rev Immunol</source>. (<year>2018</year>) <volume>18</volume>:<fpage>46</fpage>&#x02013;<lpage>61</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/nri.2017.106</pub-id>
<pub-id pub-id-type="pmid">29063907</pub-id>
</mixed-citation></ref><ref id="B171"><label>171</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dan</surname><given-names>JM</given-names></name><name><surname>Mateus</surname><given-names>J</given-names></name><name><surname>Kato</surname><given-names>Y</given-names></name><name><surname>Hastie</surname><given-names>KM</given-names></name><name><surname>Yu</surname><given-names>ED</given-names></name><name><surname>Faliti</surname><given-names>CE</given-names></name><etal/></person-group>. <article-title>Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection</article-title>. <source>Science</source>. (<year>2021</year>) <volume>371</volume>:<elocation-id>eabf4063</elocation-id>. doi: <pub-id pub-id-type="doi">10.1126/science.abf4063</pub-id>
<pub-id pub-id-type="pmid">33408181</pub-id>
</mixed-citation></ref><ref id="B172"><label>172</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lau</surname><given-names>EHY</given-names></name><name><surname>Tsang</surname><given-names>OTY</given-names></name><name><surname>Hui</surname><given-names>DSC</given-names></name><name><surname>Kwan</surname><given-names>MYW</given-names></name><name><surname>Chan</surname><given-names>WH</given-names></name><name><surname>Chiu</surname><given-names>SS</given-names></name><etal/></person-group>. <article-title>Neutralizing antibody titres in SARS-CoV-2 infections</article-title>. <source>Nat Commun</source>. (<year>2021</year>) <volume>12</volume>:<fpage>63</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41467-020-20247-4</pub-id>
<pub-id pub-id-type="pmid">33397909</pub-id>
</mixed-citation></ref><ref id="B173"><label>173</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Roltgen</surname><given-names>K</given-names></name><name><surname>Boyd</surname><given-names>SD</given-names></name></person-group>. <article-title>Antibody and B cell responses to SARS-CoV-2 infection and vaccination</article-title>. <source>Cell Host Microbe</source>. (<year>2021</year>) <volume>29</volume>:<page-range>1063&#x02013;75</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.chom.2021.06.009</pub-id>
</mixed-citation></ref><ref id="B174"><label>174</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Embong</surname><given-names>AK</given-names></name><name><surname>Nguyen-Contant</surname><given-names>P</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Kanagaiah</surname><given-names>P</given-names></name><name><surname>Chaves</surname><given-names>FA</given-names></name><name><surname>Fitzgerald</surname><given-names>TF</given-names></name><etal/></person-group>. <article-title>Formation and expansion of memory B cells against coronavirus in acutely infected COVID-19 individuals</article-title>. <source>Pathogens</source>. (<year>2022</year>) <volume>11</volume>:<fpage>186</fpage>. doi: <pub-id pub-id-type="doi">10.3390/pathogens11020186</pub-id>
<pub-id pub-id-type="pmid">35215130</pub-id>
</mixed-citation></ref><ref id="B175"><label>175</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Morgenlander</surname><given-names>WR</given-names></name><name><surname>Henson</surname><given-names>SN</given-names></name><name><surname>Monaco</surname><given-names>DR</given-names></name><name><surname>Chen</surname><given-names>A</given-names></name><name><surname>Littlefield</surname><given-names>K</given-names></name><name><surname>Bloch</surname><given-names>EM</given-names></name><etal/></person-group>. <article-title>Antibody responses to endemic coronaviruses modulate COVID-19 convalescent plasma functionality</article-title>. <source>J Clin Invest</source>. (<year>2021</year>) <volume>131</volume>:<elocation-id>e146927</elocation-id>. doi: <pub-id pub-id-type="doi">10.1172/JCI146927</pub-id>
<pub-id pub-id-type="pmid">33571169</pub-id>
</mixed-citation></ref><ref id="B176"><label>176</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Breiman</surname><given-names>A</given-names></name><name><surname>Ruven-Clouet</surname><given-names>N</given-names></name><name><surname>Le Pendu</surname><given-names>J</given-names></name></person-group>. <article-title>Harnessing the natural anti-glycan immune response to limit the transmission of enveloped viruses such as SARS-CoV-2</article-title>. <source>PloS Pathog</source>. (<year>2020</year>) <volume>16</volume>:<elocation-id>e1008556</elocation-id>. doi: <pub-id pub-id-type="doi">10.1371/journal.ppat.1008556</pub-id>
<pub-id pub-id-type="pmid">32437478</pub-id>
</mixed-citation></ref><ref id="B177"><label>177</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pendu</surname><given-names>JL</given-names></name><name><surname>Breiman</surname><given-names>A</given-names></name><name><surname>Rocher</surname><given-names>J</given-names></name><name><surname>Dion</surname><given-names>M</given-names></name><name><surname>Ruvoen-Clouet</surname><given-names>N</given-names></name></person-group>. <article-title>ABO blood types and COVID-19: spurious, anecdotal, or truly important relationships? A reasoned review of available data</article-title>. <source>Viruses</source>. (<year>2021</year>) <volume>13</volume>:<fpage>160</fpage>. doi: <pub-id pub-id-type="doi">10.3390/v13020160</pub-id>
<pub-id pub-id-type="pmid">33499228</pub-id>
</mixed-citation></ref><ref id="B178"><label>178</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Severe Covid</surname><given-names>GG</given-names></name><name><surname>Ellinghaus</surname><given-names>D</given-names></name><name><surname>Degenhardt</surname><given-names>F</given-names></name><name><surname>Bujanda</surname><given-names>L</given-names></name><name><surname>Buti</surname><given-names>M</given-names></name><name><surname>Albillos</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Genomewide association study of severe covid-19 with respiratory failure</article-title>. <source>N Engl J Med</source>. (<year>2020</year>) <volume>383</volume>:<page-range>1522&#x02013;34</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1056/NEJMoa2020283</pub-id>
</mixed-citation></ref><ref id="B179"><label>179</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Roberts</surname><given-names>GHL</given-names></name><name><surname>Partha</surname><given-names>R</given-names></name><name><surname>Rhead</surname><given-names>B</given-names></name><name><surname>Knight</surname><given-names>SC</given-names></name><name><surname>Park</surname><given-names>DS</given-names></name><name><surname>Coignet</surname><given-names>MV</given-names></name><etal/></person-group>. <article-title>Expanded COVID-19 phenotype definitions reveal distinct patterns of genetic association and protective effects</article-title>. <source>Nat Genet</source>. (<year>2022</year>) <volume>54</volume>:<page-range>374&#x02013;81</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41588-022-01042-x</pub-id>
</mixed-citation></ref><ref id="B180"><label>180</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Boechat</surname><given-names>JL</given-names></name><name><surname>Chora</surname><given-names>I</given-names></name><name><surname>Morais</surname><given-names>A</given-names></name><name><surname>Delgado</surname><given-names>L</given-names></name></person-group>. <article-title>The immune response to SARS-CoV-2 and COVID-19 immunopathology - Current perspectives</article-title>. <source>Pulmonology</source>. (<year>2021</year>) <volume>27</volume>:<page-range>423&#x02013;37</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.pulmoe.2021.03.008</pub-id>
</mixed-citation></ref><ref id="B181"><label>181</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Woodruff</surname><given-names>MC</given-names></name><name><surname>Ramonell</surname><given-names>RP</given-names></name><name><surname>Nguyen</surname><given-names>DC</given-names></name><name><surname>Cashman</surname><given-names>KS</given-names></name><name><surname>Saini</surname><given-names>AS</given-names></name><name><surname>Haddad</surname><given-names>NS</given-names></name><etal/></person-group>. <article-title>Extrafollicular B cell responses correlate with neutralizing antibodies and morbidity in COVID-19</article-title>. <source>Nat Immunol</source>. (<year>2020</year>) <volume>21</volume>:<page-range>1506&#x02013;16</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41590-020-00814-z</pub-id>
</mixed-citation></ref><ref id="B182"><label>182</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Long</surname><given-names>QX</given-names></name><name><surname>Liu</surname><given-names>BZ</given-names></name><name><surname>Deng</surname><given-names>HJ</given-names></name><name><surname>Wu</surname><given-names>GC</given-names></name><name><surname>Deng</surname><given-names>K</given-names></name><name><surname>Chen</surname><given-names>YK</given-names></name><etal/></person-group>. <article-title>Antibody responses to SARS-CoV-2 in patients with COVID-19</article-title>. <source>Nat Med</source>. (<year>2020</year>) <volume>26</volume>:<page-range>845&#x02013;8</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41591-020-0897-1</pub-id>
</mixed-citation></ref><ref id="B183"><label>183</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Iyer</surname><given-names>AS</given-names></name><name><surname>Jones</surname><given-names>FK</given-names></name><name><surname>Nodoushani</surname><given-names>A</given-names></name><name><surname>Kelly</surname><given-names>M</given-names></name><name><surname>Becker</surname><given-names>M</given-names></name><name><surname>Slater</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients</article-title>. <source>Sci Immunol</source>. (<year>2020</year>) <volume>5</volume>:<elocation-id>eabe0367</elocation-id>. doi: <pub-id pub-id-type="doi">10.1126/sciimmunol.abe0367</pub-id>
<pub-id pub-id-type="pmid">33033172</pub-id>
</mixed-citation></ref><ref id="B184"><label>184</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Laidlaw</surname><given-names>BJ</given-names></name><name><surname>Ellebedy</surname><given-names>AH</given-names></name></person-group>. <article-title>The germinal centre B cell response to SARS-CoV-2</article-title>. <source>Nat Rev Immunol</source>. (<year>2022</year>) <volume>22</volume>:<fpage>7</fpage>&#x02013;<lpage>18</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41577-021-00657-1</pub-id>
<pub-id pub-id-type="pmid">34873279</pub-id>
</mixed-citation></ref><ref id="B185"><label>185</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Muecksch</surname><given-names>F</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Cho</surname><given-names>A</given-names></name><name><surname>Gaebler</surname><given-names>C</given-names></name><name><surname>Ben Tanfous</surname><given-names>T</given-names></name><name><surname>DaSilva</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Increased memory B cell potency and breadth after a SARS-CoV-2 mRNA boost</article-title>. <source>Nature</source>. (<year>2022</year>) <volume>607</volume>:<page-range>128&#x02013;34</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41586-022-04778-y</pub-id>
</mixed-citation></ref><ref id="B186"><label>186</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Victora</surname><given-names>GD</given-names></name><name><surname>Nussenzweig</surname><given-names>MC</given-names></name></person-group>. <article-title>Germinal centers</article-title>. <source>Annu Rev Immunol</source>. (<year>2022</year>) <volume>40</volume>:<page-range>413&#x02013;42</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1146/annurev-immunol-120419-022408</pub-id>
</mixed-citation></ref><ref id="B187"><label>187</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pusnik</surname><given-names>J</given-names></name><name><surname>Richter</surname><given-names>E</given-names></name><name><surname>Schulte</surname><given-names>B</given-names></name><name><surname>Dolscheid-Pommerich</surname><given-names>R</given-names></name><name><surname>Bode</surname><given-names>C</given-names></name><name><surname>Putensen</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Memory B cells targeting SARS-CoV-2 spike protein and their dependence on CD4(+) T cell help</article-title>. <source>Cell Rep</source>. (<year>2021</year>) <volume>35</volume>:<fpage>109320</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.celrep.2021.109320</pub-id>
<pub-id pub-id-type="pmid">34146478</pub-id>
</mixed-citation></ref><ref id="B188"><label>188</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Turner</surname><given-names>JS</given-names></name><name><surname>Kim</surname><given-names>W</given-names></name><name><surname>Kalaidina</surname><given-names>E</given-names></name><name><surname>Goss</surname><given-names>CW</given-names></name><name><surname>Rauseo</surname><given-names>AM</given-names></name><name><surname>Schmitz</surname><given-names>AJ</given-names></name><etal/></person-group>. <article-title>SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans</article-title>. <source>Nature</source>. (<year>2021</year>) <volume>595</volume>:<page-range>421&#x02013;5</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41586-021-03647-4</pub-id>
</mixed-citation></ref><ref id="B189"><label>189</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Halliley</surname><given-names>JL</given-names></name><name><surname>Tipton</surname><given-names>CM</given-names></name><name><surname>Liesveld</surname><given-names>J</given-names></name><name><surname>Rosenberg</surname><given-names>AF</given-names></name><name><surname>Darce</surname><given-names>J</given-names></name><name><surname>Gregoretti</surname><given-names>IV</given-names></name><etal/></person-group>. <article-title>Long-lived plasma cells are contained within the CD19(-)CD38(hi)CD138(+) subset in human bone marrow</article-title>. <source>Immunity</source>. (<year>2015</year>) <volume>43</volume>:<page-range>132&#x02013;45</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.immuni.2015.06.016</pub-id>
</mixed-citation></ref><ref id="B190"><label>190</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Heinz</surname><given-names>FX</given-names></name><name><surname>Stiasny</surname><given-names>K</given-names></name></person-group>. <article-title>Distinguishing features of current COVID-19 vaccines: knowns and unknowns of antigen presentation and modes of action</article-title>. <source>NPJ Vaccines</source>. (<year>2021</year>) <volume>6</volume>:<fpage>104</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41541-021-00369-6</pub-id>
<pub-id pub-id-type="pmid">34400651</pub-id>
</mixed-citation></ref><ref id="B191"><label>191</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Walsh</surname><given-names>EE</given-names></name><name><surname>Frenck</surname><given-names>RW</given-names><suffix>Jr.</suffix></name><name><surname>Falsey</surname><given-names>AR</given-names></name><name><surname>Kitchin</surname><given-names>N</given-names></name><name><surname>Absalon</surname><given-names>J</given-names></name><name><surname>Gurtman</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Safety and immunogenicity of two RNA-based covid-19 vaccine candidates</article-title>. <source>N Engl J Med</source>. (<year>2020</year>) <volume>383</volume>:<page-range>2439&#x02013;50</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1056/NEJMoa2027906</pub-id>
</mixed-citation></ref><ref id="B192"><label>192</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Goel</surname><given-names>RR</given-names></name><name><surname>Painter</surname><given-names>MM</given-names></name><name><surname>Apostolidis</surname><given-names>SA</given-names></name><name><surname>Mathew</surname><given-names>D</given-names></name><name><surname>Meng</surname><given-names>W</given-names></name><name><surname>Rosenfeld</surname><given-names>AM</given-names></name><etal/></person-group>. <article-title>mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern</article-title>. <source>Science</source>. (<year>2021</year>) <volume>374</volume>:<fpage>abm0829</fpage>. doi: <pub-id pub-id-type="doi">10.1126/science.abm0829</pub-id>
<pub-id pub-id-type="pmid">34648302</pub-id>
</mixed-citation></ref><ref id="B193"><label>193</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wherry</surname><given-names>EJ</given-names></name><name><surname>Barouch</surname><given-names>DH</given-names></name></person-group>. <article-title>T cell immunity to COVID-19 vaccines</article-title>. <source>Science</source>. (<year>2022</year>) <volume>377</volume>:<page-range>821&#x02013;2</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1126/science.add2897</pub-id>
</mixed-citation></ref><ref id="B194"><label>194</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chandrashekar</surname><given-names>A</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>McMahan</surname><given-names>K</given-names></name><name><surname>Jacob-Dolan</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>He</surname><given-names>X</given-names></name><etal/></person-group>. <article-title>Vaccine protection against the SARS-CoV-2 Omicron variant in macaques</article-title>. <source>Cell</source>. (<year>2022</year>) <volume>185</volume>:<fpage>1549</fpage>&#x02013;<lpage>55 e11</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.cell.2022.03.024</pub-id>
<pub-id pub-id-type="pmid">35427477</pub-id>
</mixed-citation></ref><ref id="B195"><label>195</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Chandrashekar</surname><given-names>A</given-names></name><name><surname>Sellers</surname><given-names>D</given-names></name><name><surname>Barrett</surname><given-names>J</given-names></name><name><surname>Jacob-Dolan</surname><given-names>C</given-names></name><name><surname>Lifton</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Vaccines elicit highly conserved cellular immunity to SARS-CoV-2 Omicron</article-title>. <source>Nature</source>. (<year>2022</year>) <volume>603</volume>:<page-range>493&#x02013;6</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41586-022-04465-y</pub-id>
</mixed-citation></ref><ref id="B196"><label>196</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wong</surname><given-names>CKH</given-names></name><name><surname>Wong</surname><given-names>JYH</given-names></name><name><surname>Tang</surname><given-names>EHM</given-names></name><name><surname>Au</surname><given-names>CH</given-names></name><name><surname>Wai</surname><given-names>AKC</given-names></name></person-group>. <article-title>Clinical presentations, laboratory and radiological findings, and treatments for 11,028 COVID-19 patients: a systematic review and meta-analysis</article-title>. <source>Sci Rep</source>. (<year>2020</year>) <volume>10</volume>:<fpage>19765</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41598-020-74988-9</pub-id>
<pub-id pub-id-type="pmid">33188232</pub-id>
</mixed-citation></ref><ref id="B197"><label>197</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ho</surname><given-names>HT</given-names></name><name><surname>Peischard</surname><given-names>S</given-names></name><name><surname>Strutz-Seebohm</surname><given-names>N</given-names></name><name><surname>Klingel</surname><given-names>K</given-names></name><name><surname>Seebohm</surname><given-names>G</given-names></name></person-group>. <article-title>Myocardial damage by SARS-coV-2: emerging mechanisms and therapies</article-title>. <source>Viruses</source>. (<year>2021</year>) <volume>13</volume>:<fpage>1880</fpage>. doi: <pub-id pub-id-type="doi">10.3390/v13091880</pub-id>
<pub-id pub-id-type="pmid">34578462</pub-id>
</mixed-citation></ref><ref id="B198"><label>198</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cui</surname><given-names>H</given-names></name><name><surname>Su</surname><given-names>S</given-names></name><name><surname>Cao</surname><given-names>Y</given-names></name><name><surname>Ma</surname><given-names>C</given-names></name><name><surname>Qiu</surname><given-names>W</given-names></name></person-group>. <article-title>The altered anatomical distribution of ACE2 in the brain with alzheimer&#x02019;s disease pathology</article-title>. <source>Front Cell Dev Biol</source>. (<year>2021</year>) <volume>9</volume>:<fpage>684874</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3389/fcell.2021.684874</pub-id>
<pub-id pub-id-type="pmid">34249938</pub-id>
</mixed-citation></ref><ref id="B199"><label>199</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jackson</surname><given-names>CB</given-names></name><name><surname>Farzan</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>B</given-names></name><name><surname>Choe</surname><given-names>H</given-names></name></person-group>. <article-title>Mechanisms of SARS-CoV-2 entry into cells</article-title>. <source>Nat Rev Mol Cell Biol</source>. (<year>2022</year>) <volume>23</volume>:<fpage>3</fpage>&#x02013;<lpage>20</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41580-021-00418-x</pub-id>
<pub-id pub-id-type="pmid">34611326</pub-id>
</mixed-citation></ref><ref id="B200"><label>200</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Thakur</surname><given-names>V</given-names></name><name><surname>Ratho</surname><given-names>RK</given-names></name><name><surname>Kumar</surname><given-names>P</given-names></name><name><surname>Bhatia</surname><given-names>SK</given-names></name><name><surname>Bora</surname><given-names>I</given-names></name><name><surname>Mohi</surname><given-names>GK</given-names></name><etal/></person-group>. <article-title>Multi-organ involvement in COVID-19: beyond pulmonary manifestations</article-title>. <source>J Clin Med</source>. (<year>2021</year>) <volume>10</volume>:<fpage>446</fpage>. doi: <pub-id pub-id-type="doi">10.3390/jcm10030446</pub-id>
<pub-id pub-id-type="pmid">33498861</pub-id>
</mixed-citation></ref><ref id="B201"><label>201</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hikmet</surname><given-names>F</given-names></name><name><surname>Mear</surname><given-names>L</given-names></name><name><surname>Edvinsson</surname><given-names>A</given-names></name><name><surname>Micke</surname><given-names>P</given-names></name><name><surname>Uhlen</surname><given-names>M</given-names></name><name><surname>Lindskog</surname><given-names>C</given-names></name></person-group>. <article-title>The protein expression profile of ACE2 in human tissues</article-title>. <source>Mol Syst Biol</source>. (<year>2020</year>) <volume>16</volume>:<elocation-id>e9610</elocation-id>. doi: <pub-id pub-id-type="doi">10.15252/msb.20209610</pub-id>
<pub-id pub-id-type="pmid">32715618</pub-id>
</mixed-citation></ref><ref id="B202"><label>202</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Chu</surname><given-names>M</given-names></name><name><surname>Zhong</surname><given-names>F</given-names></name><name><surname>Tan</surname><given-names>X</given-names></name><name><surname>Tang</surname><given-names>G</given-names></name><name><surname>Mai</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Digestive symptoms of COVID-19 and expression of ACE2 in digestive tract organs</article-title>. <source>Cell Death Discovery</source>. (<year>2020</year>) <volume>6</volume>:<fpage>76</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41420-020-00307-w</pub-id>
<pub-id pub-id-type="pmid">32818075</pub-id>
</mixed-citation></ref><ref id="B203"><label>203</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Albini</surname><given-names>A</given-names></name><name><surname>Calabrone</surname><given-names>L</given-names></name><name><surname>Carlini</surname><given-names>V</given-names></name><name><surname>Benedetto</surname><given-names>N</given-names></name><name><surname>Lombardo</surname><given-names>M</given-names></name><name><surname>Bruno</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Preliminary evidence for IL-10-induced ACE2 mRNA expression in lung-derived and endothelial cells: implications for SARS-cov-2 ARDS pathogenesis</article-title>. <source>Front Immunol</source>. (<year>2021</year>) <volume>12</volume>:<fpage>718136</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fimmu.2021.718136</pub-id>
<pub-id pub-id-type="pmid">34646263</pub-id>
</mixed-citation></ref><ref id="B204"><label>204</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Guney</surname><given-names>C</given-names></name><name><surname>Akar</surname><given-names>F</given-names></name></person-group>. <article-title>Epithelial and endothelial expressions of ACE2: SARS-coV-2 entry routes</article-title>. <source>J Pharm Pharm Sci</source>. (<year>2021</year>) <volume>24</volume>:<fpage>84</fpage>&#x02013;<lpage>93</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.18433/jpps31455</pub-id>
<pub-id pub-id-type="pmid">33626315</pub-id>
</mixed-citation></ref><ref id="B205"><label>205</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Maccio</surname><given-names>U</given-names></name><name><surname>Zinkernagel</surname><given-names>AS</given-names></name><name><surname>Shambat</surname><given-names>SM</given-names></name><name><surname>Zeng</surname><given-names>X</given-names></name><name><surname>Cathomas</surname><given-names>G</given-names></name><name><surname>Ruschitzka</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>SARS-CoV-2 leads to a small vessel endotheliitis in the heart</article-title>. <source>EBioMedicine</source>. (<year>2021</year>) <volume>63</volume>:<fpage>103182</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.ebiom.2020.103182</pub-id>
<pub-id pub-id-type="pmid">33422990</pub-id>
</mixed-citation></ref><ref id="B206"><label>206</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bois</surname><given-names>MC</given-names></name><name><surname>Boire</surname><given-names>NA</given-names></name><name><surname>Layman</surname><given-names>AJ</given-names></name><name><surname>Aubry</surname><given-names>MC</given-names></name><name><surname>Alexander</surname><given-names>MP</given-names></name><name><surname>Roden</surname><given-names>AC</given-names></name><etal/></person-group>. <article-title>COVID-19-associated nonocclusive fibrin microthrombi in the heart</article-title>. <source>Circulation</source>. (<year>2021</year>) <volume>143</volume>:<page-range>230&#x02013;43</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.120.050754</pub-id>
</mixed-citation></ref><ref id="B207"><label>207</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Varga</surname><given-names>Z</given-names></name><name><surname>Flammer</surname><given-names>AJ</given-names></name><name><surname>Steiger</surname><given-names>P</given-names></name><name><surname>Haberecker</surname><given-names>M</given-names></name><name><surname>Andermatt</surname><given-names>R</given-names></name><name><surname>Zinkernagel</surname><given-names>AS</given-names></name><etal/></person-group>. <article-title>Endothelial cell infection and endotheliitis in COVID-19</article-title>. <source>Lancet</source>. (<year>2020</year>) <volume>395</volume>:<page-range>1417&#x02013;8</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/S0140-6736(20)30937-5</pub-id>
</mixed-citation></ref><ref id="B208"><label>208</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ackermann</surname><given-names>M</given-names></name><name><surname>Verleden</surname><given-names>SE</given-names></name><name><surname>Kuehnel</surname><given-names>M</given-names></name><name><surname>Haverich</surname><given-names>A</given-names></name><name><surname>Welte</surname><given-names>T</given-names></name><name><surname>Laenger</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in covid-19</article-title>. <source>N Engl J Med</source>. (<year>2020</year>) <volume>383</volume>:<page-range>120&#x02013;8</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1056/NEJMoa2015432</pub-id>
</mixed-citation></ref><ref id="B209"><label>209</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ackermann</surname><given-names>M</given-names></name><name><surname>Mentzer</surname><given-names>SJ</given-names></name><name><surname>Kolb</surname><given-names>M</given-names></name><name><surname>Jonigk</surname><given-names>D</given-names></name></person-group>. <article-title>Inflammation and intussusceptive angiogenesis in COVID-19: everything in and out of flow</article-title>. <source>Eur Respir J</source>. (<year>2020</year>) <volume>56</volume>:<fpage>2003147</fpage>. doi: <pub-id pub-id-type="doi">10.1183/13993003.03147-2020</pub-id>
<pub-id pub-id-type="pmid">33008942</pub-id>
</mixed-citation></ref><ref id="B210"><label>210</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kichloo</surname><given-names>A</given-names></name><name><surname>Dettloff</surname><given-names>K</given-names></name><name><surname>Aljadah</surname><given-names>M</given-names></name><name><surname>Albosta</surname><given-names>M</given-names></name><name><surname>Jamal</surname><given-names>S</given-names></name><name><surname>Singh</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>COVID-19 and hypercoagulability: A review</article-title>. <source>Clin Appl Thromb Hemost</source>. (<year>2020</year>) <volume>26</volume>:<fpage>1076029620962853</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1177/1076029620962853</pub-id>
<pub-id pub-id-type="pmid">33074732</pub-id>
</mixed-citation></ref><ref id="B211"><label>211</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lowenstein</surname><given-names>CJ</given-names></name><name><surname>Solomon</surname><given-names>SD</given-names></name></person-group>. <article-title>Severe COVID-19 is a microvascular disease</article-title>. <source>Circulation</source>. (<year>2020</year>) <volume>142</volume>:<page-range>1609&#x02013;11</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.120.050354</pub-id>
</mixed-citation></ref><ref id="B212"><label>212</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Norooznezhad</surname><given-names>AH</given-names></name><name><surname>Mansouri</surname><given-names>K</given-names></name></person-group>. <article-title>Endothelial cell dysfunction, coagulation, and angiogenesis in coronavirus disease 2019 (COVID-19)</article-title>. <source>Microvasc Res</source>. (<year>2021</year>) <volume>137</volume>:<fpage>104188</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.mvr.2021.104188</pub-id>
<pub-id pub-id-type="pmid">34022205</pub-id>
</mixed-citation></ref><ref id="B213"><label>213</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Middleton</surname><given-names>EA</given-names></name><name><surname>He</surname><given-names>XY</given-names></name><name><surname>Denorme</surname><given-names>F</given-names></name><name><surname>Campbell</surname><given-names>RA</given-names></name><name><surname>Ng</surname><given-names>D</given-names></name><name><surname>Salvatore</surname><given-names>SP</given-names></name><etal/></person-group>. <article-title>Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome</article-title>. <source>Blood</source>. (<year>2020</year>) <volume>136</volume>:<page-range>1169&#x02013;79</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1182/blood.2020007008</pub-id>
</mixed-citation></ref><ref id="B214"><label>214</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wu</surname><given-names>C</given-names></name><name><surname>Lu</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>G</given-names></name><name><surname>Shi</surname><given-names>X</given-names></name><name><surname>Hisada</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Inflammasome activation triggers blood clotting and host death through pyroptosis</article-title>. <source>Immunity</source>. (<year>2019</year>) <volume>50</volume>:<fpage>1401</fpage>&#x02013;<lpage>11 e4</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.immuni.2019.04.003</pub-id>
<pub-id pub-id-type="pmid">31076358</pub-id>
</mixed-citation></ref><ref id="B215"><label>215</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gedefaw</surname><given-names>L</given-names></name><name><surname>Ullah</surname><given-names>S</given-names></name><name><surname>Leung</surname><given-names>PHM</given-names></name><name><surname>Cai</surname><given-names>Y</given-names></name><name><surname>Yip</surname><given-names>SP</given-names></name><name><surname>Huang</surname><given-names>CL</given-names></name></person-group>. <article-title>Inflammasome activation-induced hypercoagulopathy: impact on cardiovascular dysfunction triggered in COVID-19 patients</article-title>. <source>Cells</source>. (<year>2021</year>) <volume>10</volume>:<fpage>916</fpage>. doi: <pub-id pub-id-type="doi">10.3390/cells10040916</pub-id>
<pub-id pub-id-type="pmid">33923537</pub-id>
</mixed-citation></ref><ref id="B216"><label>216</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Grover</surname><given-names>SP</given-names></name><name><surname>Mackman</surname><given-names>N</given-names></name></person-group>. <article-title>Tissue factor: an essential mediator of hemostasis and trigger of thrombosis</article-title>. <source>Arterioscler Thromb Vasc Biol</source>. (<year>2018</year>) <volume>38</volume>:<page-range>709&#x02013;25</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1161/ATVBAHA.117.309846</pub-id>
</mixed-citation></ref><ref id="B217"><label>217</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Patra</surname><given-names>T</given-names></name><name><surname>Ray</surname><given-names>R</given-names></name></person-group>. <article-title>IL-6 induction and signaling: horizons of COVID-19-related pathogenesis</article-title>. <source>DNA Cell Biol</source>. (<year>2021</year>) <volume>40</volume>:<page-range>639&#x02013;42</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1089/dna.2021.0152</pub-id>
</mixed-citation></ref><ref id="B218"><label>218</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Popescu</surname><given-names>NI</given-names></name><name><surname>Lupu</surname><given-names>C</given-names></name><name><surname>Lupu</surname><given-names>F</given-names></name></person-group>. <article-title>Disseminated intravascular coagulation and its immune mechanisms</article-title>. <source>Blood</source>. (<year>2022</year>) <volume>139</volume>:<page-range>1973&#x02013;86</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1182/blood.2020007208</pub-id>
</mixed-citation></ref><ref id="B219"><label>219</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Torres Acosta</surname><given-names>MA</given-names></name><name><surname>Singer</surname><given-names>BD</given-names></name></person-group>. <article-title>Pathogenesis of COVID-19-induced ARDS: implications for an ageing population</article-title>. <source>Eur Respir J</source>. (<year>2020</year>) <volume>56</volume>:<fpage>2002049</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1183/13993003.02049-2020</pub-id>
<pub-id pub-id-type="pmid">32747391</pub-id>
</mixed-citation></ref><ref id="B220"><label>220</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fuehner</surname><given-names>T</given-names></name><name><surname>Renger</surname><given-names>I</given-names></name><name><surname>Welte</surname><given-names>T</given-names></name><name><surname>Freundt</surname><given-names>T</given-names></name><name><surname>Gottlieb</surname><given-names>J</given-names></name></person-group>. <article-title>Silent hypoxia in COVID-19: A case series</article-title>. <source>Respiration</source>. (<year>2022</year>) <volume>101</volume>:<page-range>376&#x02013;80</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1159/000520083</pub-id>
</mixed-citation></ref><ref id="B221"><label>221</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Simonson</surname><given-names>TS</given-names></name><name><surname>Baker</surname><given-names>TL</given-names></name><name><surname>Banzett</surname><given-names>RB</given-names></name><name><surname>Bishop</surname><given-names>T</given-names></name><name><surname>Dempsey</surname><given-names>JA</given-names></name><name><surname>Feldman</surname><given-names>JL</given-names></name><etal/></person-group>. <article-title>Silent hypoxaemia in COVID-19 patients</article-title>. <source>J Physiol</source>. (<year>2021</year>) <volume>599</volume>:<page-range>1057&#x02013;65</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1113/JP280769</pub-id>
</mixed-citation></ref><ref id="B222"><label>222</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Karagiannidis</surname><given-names>C</given-names></name><name><surname>Hentschker</surname><given-names>C</given-names></name><name><surname>Westhoff</surname><given-names>M</given-names></name><name><surname>Weber-Carstens</surname><given-names>S</given-names></name><name><surname>Janssens</surname><given-names>U</given-names></name><name><surname>Kluge</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Observational study of changes in utilization and outcomes in mechanical ventilation in COVID-19</article-title>. <source>PloS One</source>. (<year>2022</year>) <volume>17</volume>:<fpage>e0262315</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0262315</pub-id>
<pub-id pub-id-type="pmid">35030205</pub-id>
</mixed-citation></ref><ref id="B223"><label>223</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Monteil</surname><given-names>V</given-names></name><name><surname>Kwon</surname><given-names>H</given-names></name><name><surname>Prado</surname><given-names>P</given-names></name><name><surname>Hagelkruys</surname><given-names>A</given-names></name><name><surname>Wimmer</surname><given-names>RA</given-names></name><name><surname>Stahl</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Inhibition of SARS-coV-2 infections in engineered human tissues using clinical-grade soluble human ACE2</article-title>. <source>Cell</source>. (<year>2020</year>) <volume>181</volume>:<fpage>905</fpage>&#x02013;<lpage>13 e7</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.cell.2020.04.004</pub-id>
<pub-id pub-id-type="pmid">32333836</pub-id>
</mixed-citation></ref><ref id="B224"><label>224</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hsu</surname><given-names>CY</given-names></name><name><surname>Lai</surname><given-names>CC</given-names></name><name><surname>Yeh</surname><given-names>YP</given-names></name><name><surname>Chang-Chuan</surname><given-names>C</given-names></name><name><surname>Chen</surname><given-names>HH</given-names></name></person-group>. <article-title>Progression from pneumonia to ARDS as a predictor for fatal COVID-19</article-title>. <source>J Infect Public Health</source>. (<year>2021</year>) <volume>14</volume>:<page-range>504&#x02013;7</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.jiph.2020.12.026</pub-id>
</mixed-citation></ref><ref id="B225"><label>225</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Elicker</surname><given-names>BM</given-names></name></person-group>. <article-title>What are the long-term pulmonary sequelae of COVID-19 infection</article-title>? <source>Radiology</source>. (<year>2022</year>) <volume>304</volume>:<page-range>193&#x02013;4</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1148/radiol.220449</pub-id>
</mixed-citation></ref><ref id="B226"><label>226</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gattinoni</surname><given-names>L</given-names></name><name><surname>Chiumello</surname><given-names>D</given-names></name><name><surname>Caironi</surname><given-names>P</given-names></name><name><surname>Busana</surname><given-names>M</given-names></name><name><surname>Romitti</surname><given-names>F</given-names></name><name><surname>Brazzi</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>COVID-19 pneumonia: different respiratory treatments for different phenotypes</article-title>? <source>Intensive Care Med</source>. (<year>2020</year>) <volume>46</volume>:<page-range>1099&#x02013;102</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1007/s00134-020-06033-2</pub-id>
</mixed-citation></ref><ref id="B227"><label>227</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bos</surname><given-names>LDJ</given-names></name><name><surname>Sjoding</surname><given-names>M</given-names></name><name><surname>Sinha</surname><given-names>P</given-names></name><name><surname>Bhavani</surname><given-names>SV</given-names></name><name><surname>Lyons</surname><given-names>PG</given-names></name><name><surname>Bewley</surname><given-names>AF</given-names></name><etal/></person-group>. <article-title>Longitudinal respiratory subphenotypes in patients with COVID-19-related acute respiratory distress syndrome: results from three observational cohorts</article-title>. <source>Lancet Respir Med</source>. (<year>2021</year>) <volume>9</volume>:<page-range>1377&#x02013;86</page-range>. doi: <pub-id pub-id-type="doi">10.1016/S2213-2600(21)00365-9</pub-id>
</mixed-citation></ref><ref id="B228"><label>228</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Haudebourg</surname><given-names>AF</given-names></name><name><surname>Perier</surname><given-names>F</given-names></name><name><surname>Tuffet</surname><given-names>S</given-names></name><name><surname>de Prost</surname><given-names>N</given-names></name><name><surname>Razazi</surname><given-names>K</given-names></name><name><surname>Mekontso Dessap</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Respiratory mechanics of COVID-19- versus non-COVID-19-associated acute respiratory distress syndrome</article-title>. <source>Am J Respir Crit Care Med</source>. (<year>2020</year>) <volume>202</volume>:<page-range>287&#x02013;90</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1164/rccm.202004-1226LE</pub-id>
</mixed-citation></ref><ref id="B229"><label>229</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bain</surname><given-names>W</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Shah</surname><given-names>FA</given-names></name><name><surname>Suber</surname><given-names>T</given-names></name><name><surname>Drohan</surname><given-names>C</given-names></name><name><surname>Al-Yousif</surname><given-names>N</given-names></name><etal/></person-group>. <article-title>COVID-19 versus non-COVID-19 acute respiratory distress syndrome: comparison of demographics, physiologic parameters, inflammatory biomarkers, and clinical outcomes</article-title>. <source>Ann Am Thorac Soc</source>. (<year>2021</year>) <volume>18</volume>:<page-range>1202&#x02013;10</page-range>. doi: <pub-id pub-id-type="doi">10.1513/AnnalsATS.202008-1026OC</pub-id>
</mixed-citation></ref><ref id="B230"><label>230</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bos</surname><given-names>LDJ</given-names></name></person-group>. <article-title>COVID-19-related acute respiratory distress syndrome: not so atypical</article-title>. <source>Am J Respir Crit Care Med</source>. (<year>2020</year>) <volume>202</volume>:<page-range>622&#x02013;4</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1164/rccm.202004-1423LE</pub-id>
</mixed-citation></ref><ref id="B231"><label>231</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Konopka</surname><given-names>KE</given-names></name><name><surname>Nguyen</surname><given-names>T</given-names></name><name><surname>Jentzen</surname><given-names>JM</given-names></name><name><surname>Rayes</surname><given-names>O</given-names></name><name><surname>Schmidt</surname><given-names>CJ</given-names></name><name><surname>Wilson</surname><given-names>AM</given-names></name><etal/></person-group>. <article-title>Diffuse alveolar damage (DAD) resulting from coronavirus disease 2019 Infection is Morphologically Indistinguishable from Other Causes of DAD</article-title>. <source>Histopathology</source>. (<year>2020</year>) <volume>77</volume>:<page-range>570&#x02013;8</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1111/his.14180</pub-id>
</mixed-citation></ref><ref id="B232"><label>232</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Group</surname><given-names>RC</given-names></name><name><surname>Horby</surname><given-names>P</given-names></name><name><surname>Lim</surname><given-names>WS</given-names></name><name><surname>Emberson</surname><given-names>JR</given-names></name><name><surname>Mafham</surname><given-names>M</given-names></name><name><surname>Bell</surname><given-names>JL</given-names></name><etal/></person-group>. <article-title>Dexamethasone in hospitalized patients with covid-19</article-title>. <source>N Engl J Med</source>. (<year>2021</year>) <volume>384</volume>:<fpage>693</fpage>&#x02013;<lpage>704</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1056/NEJMoa2021436</pub-id>
<pub-id pub-id-type="pmid">32678530</pub-id>
</mixed-citation></ref><ref id="B233"><label>233</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Villar</surname><given-names>J</given-names></name><name><surname>Ferrando</surname><given-names>C</given-names></name><name><surname>Martinez</surname><given-names>D</given-names></name><name><surname>Ambros</surname><given-names>A</given-names></name><name><surname>Munoz</surname><given-names>T</given-names></name><name><surname>Soler</surname><given-names>JA</given-names></name><etal/></person-group>. <article-title>Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial</article-title>. <source>Lancet Respir Med</source>. (<year>2020</year>) <volume>8</volume>:<page-range>267&#x02013;76</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/S2213-2600(19)30417-5</pub-id>
</mixed-citation></ref><ref id="B234"><label>234</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hattori</surname><given-names>Y</given-names></name><name><surname>Hattori</surname><given-names>K</given-names></name><name><surname>Machida</surname><given-names>T</given-names></name><name><surname>Matsuda</surname><given-names>N</given-names></name></person-group>. <article-title>Vascular endotheliitis associated with infections: Its pathogenetic role and therapeutic implication</article-title>. <source>Biochem Pharmacol</source>. (<year>2022</year>) <volume>197</volume>:<fpage>114909</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.bcp.2022.114909</pub-id>
<pub-id pub-id-type="pmid">35021044</pub-id>
</mixed-citation></ref><ref id="B235"><label>235</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Haberecker</surname><given-names>M</given-names></name><name><surname>Schwarz</surname><given-names>EI</given-names></name><name><surname>Steiger</surname><given-names>P</given-names></name><name><surname>Frontzek</surname><given-names>K</given-names></name><name><surname>Scholkmann</surname><given-names>F</given-names></name><name><surname>Zeng</surname><given-names>X</given-names></name><etal/></person-group>. <article-title>Autopsy-based pulmonary and vascular pathology: pulmonary endotheliitis and multi-organ involvement in COVID-19 associated deaths</article-title>. <source>Respiration</source>. (<year>2022</year>) <volume>101</volume>:<page-range>155&#x02013;65</page-range>. doi: <pub-id pub-id-type="doi">10.1159/000518914</pub-id>
</mixed-citation></ref><ref id="B236"><label>236</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Abou-Ismail</surname><given-names>MY</given-names></name><name><surname>Diamond</surname><given-names>A</given-names></name><name><surname>Kapoor</surname><given-names>S</given-names></name><name><surname>Arafah</surname><given-names>Y</given-names></name><name><surname>Nayak</surname><given-names>L</given-names></name></person-group>. <article-title>The hypercoagulable state in COVID-19: Incidence, pathophysiology, and management</article-title>. <source>Thromb Res</source>. (<year>2020</year>) <volume>194</volume>:<page-range>101&#x02013;15</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.thromres.2020.06.029</pub-id>
</mixed-citation></ref><ref id="B237"><label>237</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><collab>Investigators A</collab><collab>Investigators AC-a</collab><collab>Investigators R-C</collab><name><surname>Lawler</surname><given-names>PR</given-names></name><name><surname>Goligher</surname><given-names>EC</given-names></name><name><surname>Berger</surname><given-names>JS</given-names></name><etal/></person-group>. <article-title>Therapeutic anticoagulation with heparin in noncritically ill patients with covid-19</article-title>. <source>N Engl J Med</source>. (<year>2021</year>) <volume>385</volume>:<fpage>790</fpage>&#x02013;<lpage>802</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1056/NEJMoa2105911</pub-id>
<pub-id pub-id-type="pmid">34351721</pub-id>
</mixed-citation></ref><ref id="B238"><label>238</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Langner</surname><given-names>RO</given-names></name><name><surname>Fuller</surname><given-names>GC</given-names></name></person-group>. <article-title>Collagen synthesis in thoracic aortas of rabbits with epinephrine-thyroxine induced arteriosclerosis</article-title>. <source>Atherosclerosis</source>. (<year>1973</year>) <volume>17</volume>:<page-range>463&#x02013;9</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/0021-9150(73)90036-1</pub-id>
</mixed-citation></ref><ref id="B239"><label>239</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gong</surname><given-names>X</given-names></name><name><surname>Yuan</surname><given-names>B</given-names></name><name><surname>Yuan</surname><given-names>Y</given-names></name></person-group>. <article-title>Incidence and prognostic value of pulmonary embolism in COVID-19: A systematic review and meta-analysis</article-title>. <source>PloS One</source>. (<year>2022</year>) <volume>17</volume>:<elocation-id>e0263580</elocation-id>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0263580</pub-id>
<pub-id pub-id-type="pmid">35286316</pub-id>
</mixed-citation></ref><ref id="B240"><label>240</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fraser</surname><given-names>M</given-names></name><name><surname>Agdamag</surname><given-names>ACC</given-names></name><name><surname>Maharaj</surname><given-names>VR</given-names></name><name><surname>Mutschler</surname><given-names>M</given-names></name><name><surname>Charpentier</surname><given-names>V</given-names></name><name><surname>Chowdhury</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>COVID-19-associated myocarditis: an evolving concern in cardiology and beyond</article-title>. <source>Biol (Basel)</source>. (<year>2022</year>) <volume>11</volume>:<fpage>520</fpage>. doi: <pub-id pub-id-type="doi">10.3390/biology11040520</pub-id>
</mixed-citation></ref><ref id="B241"><label>241</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Peretto</surname><given-names>G</given-names></name><name><surname>Villatore</surname><given-names>A</given-names></name><name><surname>Rizzo</surname><given-names>S</given-names></name><name><surname>Esposito</surname><given-names>A</given-names></name><name><surname>De Luca</surname><given-names>G</given-names></name><name><surname>Palmisano</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>The spectrum of COVID-19-associated myocarditis: A patient-tailored multidisciplinary approach</article-title>. <source>J Clin Med</source>. (<year>2021</year>) <volume>10</volume>:<fpage>1974</fpage>. doi: <pub-id pub-id-type="doi">10.3390/jcm10091974</pub-id>
<pub-id pub-id-type="pmid">34064463</pub-id>
</mixed-citation></ref><ref id="B242"><label>242</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Haussner</surname><given-names>W</given-names></name><name><surname>DeRosa</surname><given-names>AP</given-names></name><name><surname>Haussner</surname><given-names>D</given-names></name><name><surname>Tran</surname><given-names>J</given-names></name><name><surname>Torres-Lavoro</surname><given-names>J</given-names></name><name><surname>Kamler</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>COVID-19 associated myocarditis: A systematic review</article-title>. <source>Am J Emerg Med</source>. (<year>2022</year>) <volume>51</volume>:<page-range>150&#x02013;5</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.ajem.2021.10.001</pub-id>
</mixed-citation></ref><ref id="B243"><label>243</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Oleszak</surname><given-names>F</given-names></name><name><surname>Maryniak</surname><given-names>A</given-names></name><name><surname>Botti</surname><given-names>E</given-names></name><name><surname>Abrahim</surname><given-names>C</given-names></name><name><surname>Salifu</surname><given-names>MO</given-names></name><name><surname>Youssef</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Myocarditis associated with COVID-19</article-title>. <source>Am J Med Case Rep</source>. (<year>2020</year>) <volume>8</volume>:<fpage>498</fpage>&#x02013;<lpage>502</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.12691/ajmcr-8-12-19</pub-id>
</mixed-citation></ref><ref id="B244"><label>244</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Boehmer</surname><given-names>TK</given-names></name><name><surname>Kompaniyets</surname><given-names>L</given-names></name><name><surname>Lavery</surname><given-names>AM</given-names></name><name><surname>Hsu</surname><given-names>J</given-names></name><name><surname>Ko</surname><given-names>JY</given-names></name><name><surname>Yusuf</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Association between COVID-19 and myocarditis using hospital-based administrative data - United States, march 2020-january 2021</article-title>. <source>MMWR Morb Mortal Wkly Rep</source>. (<year>2021</year>) <volume>70</volume>:<page-range>1228&#x02013;32</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.15585/mmwr.mm7035e5</pub-id>
</mixed-citation></ref><ref id="B245"><label>245</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gauchotte</surname><given-names>G</given-names></name><name><surname>Venard</surname><given-names>V</given-names></name><name><surname>Segondy</surname><given-names>M</given-names></name><name><surname>Cadoz</surname><given-names>C</given-names></name><name><surname>Esposito-Fava</surname><given-names>A</given-names></name><name><surname>Barraud</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>SARS-Cov-2 fulminant myocarditis: an autopsy and histopathological case study</article-title>. <source>Int J Legal Med</source>. (<year>2021</year>) <volume>135</volume>:<page-range>577&#x02013;81</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1007/s00414-020-02500-z</pub-id>
</mixed-citation></ref><ref id="B246"><label>246</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wenzel</surname><given-names>P</given-names></name><name><surname>Kopp</surname><given-names>S</given-names></name><name><surname>Gobel</surname><given-names>S</given-names></name><name><surname>Jansen</surname><given-names>T</given-names></name><name><surname>Geyer</surname><given-names>M</given-names></name><name><surname>Hahn</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>Evidence of SARS-CoV-2 mRNA in endomyocardial biopsies of patients with clinically suspected myocarditis tested negative for COVID-19 in nasopharyngeal swab</article-title>. <source>Cardiovasc Res</source>. (<year>2020</year>) <volume>116</volume>:<page-range>1661&#x02013;3</page-range>. doi: <pub-id pub-id-type="doi">10.1093/cvr/cvaa160</pub-id>
</mixed-citation></ref><ref id="B247"><label>247</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Katsoularis</surname><given-names>I</given-names></name><name><surname>Fonseca-Rodriguez</surname><given-names>O</given-names></name><name><surname>Farrington</surname><given-names>P</given-names></name><name><surname>Lindmark</surname><given-names>K</given-names></name><name><surname>Fors Connolly</surname><given-names>AM</given-names></name></person-group>. <article-title>Risk of acute myocardial infarction and ischaemic stroke following COVID-19 in Sweden: a self-controlled case series and matched cohort study</article-title>. <source>Lancet</source>. (<year>2021</year>) <volume>398</volume>:<fpage>599</fpage>&#x02013;<lpage>607</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0140-6736(21)00896-5</pub-id>
<pub-id pub-id-type="pmid">34332652</pub-id>
</mixed-citation></ref><ref id="B248"><label>248</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Talanas</surname><given-names>G</given-names></name><name><surname>Dossi</surname><given-names>F</given-names></name><name><surname>Parodi</surname><given-names>G</given-names></name></person-group>. <article-title>Type 2 myocardial infarction in patients with coronavirus disease 2019</article-title>. <source>J Cardiovasc Med (Hagerstown)</source>. (<year>2021</year>) <volume>22</volume>:<page-range>603&#x02013;5</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.2459/JCM.0000000000001136</pub-id>
</mixed-citation></ref><ref id="B249"><label>249</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Stefanini</surname><given-names>GG</given-names></name><name><surname>Montorfano</surname><given-names>M</given-names></name><name><surname>Trabattoni</surname><given-names>D</given-names></name><name><surname>Andreini</surname><given-names>D</given-names></name><name><surname>Ferrante</surname><given-names>G</given-names></name><name><surname>Ancona</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>ST-elevation myocardial infarction in patients with COVID-19: clinical and angiographic outcomes</article-title>. <source>Circulation</source>. (<year>2020</year>) <volume>141</volume>:<page-range>2113&#x02013;6</page-range>. doi: <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.120.047525</pub-id>
</mixed-citation></ref><ref id="B250"><label>250</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Arhontoulis</surname><given-names>DC</given-names></name><name><surname>Kerr</surname><given-names>C</given-names></name><name><surname>Richards</surname><given-names>D</given-names></name><name><surname>Tjen</surname><given-names>K</given-names></name><name><surname>Hyams</surname><given-names>N</given-names></name><name><surname>Jones</surname><given-names>JA</given-names></name><etal/></person-group>. <article-title>Human cardiac organoids to model COVID-19 cytokine storm induced cardiac injuries</article-title>. <source>bioRxiv</source>. (<year>2022</year>) <volume>16</volume>:<page-range>799&#x02013;811</page-range>. doi: <pub-id pub-id-type="doi">10.1101/2022.01.31.478497</pub-id>
</mixed-citation></ref><ref id="B251"><label>251</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Beghi</surname><given-names>E</given-names></name><name><surname>Giussani</surname><given-names>G</given-names></name><name><surname>Westenberg</surname><given-names>E</given-names></name><name><surname>Allegri</surname><given-names>R</given-names></name><name><surname>Garcia-Azorin</surname><given-names>D</given-names></name><name><surname>Guekht</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Acute and post-acute neurological manifestations of COVID-19: present findings, critical appraisal, and future directions</article-title>. <source>J Neurol</source>. (<year>2022</year>) <volume>269</volume>:<page-range>2265&#x02013;74</page-range>. doi: <pub-id pub-id-type="doi">10.1007/s00415-021-10848-4</pub-id>
</mixed-citation></ref><ref id="B252"><label>252</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chou</surname><given-names>SH</given-names></name><name><surname>Beghi</surname><given-names>E</given-names></name><name><surname>Helbok</surname><given-names>R</given-names></name><name><surname>Moro</surname><given-names>E</given-names></name><name><surname>Sampson</surname><given-names>J</given-names></name><name><surname>Altamirano</surname><given-names>V</given-names></name><etal/></person-group>. <article-title>Global incidence of neurological manifestations among patients hospitalized with COVID-19-A report for the GCS-neuroCOVID consortium and the ENERGY consortium</article-title>. <source>JAMA Netw Open</source>. (<year>2021</year>) <volume>4</volume>:<elocation-id>e2112131</elocation-id>. doi: <pub-id pub-id-type="doi">10.1001/jamanetworkopen.2021.12131</pub-id>
<pub-id pub-id-type="pmid">33974053</pub-id>
</mixed-citation></ref><ref id="B253"><label>253</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Merkler</surname><given-names>AE</given-names></name><name><surname>Parikh</surname><given-names>NS</given-names></name><name><surname>Mir</surname><given-names>S</given-names></name><name><surname>Gupta</surname><given-names>A</given-names></name><name><surname>Kamel</surname><given-names>H</given-names></name><name><surname>Lin</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>Risk of ischemic stroke in patients with coronavirus disease 2019 (COVID-19) vs patients with influenza</article-title>. <source>JAMA Neurol</source>. (<year>2020</year>) <volume>77</volume>:<fpage>1</fpage>&#x02013;<lpage>7</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1001/jamaneurol.2020.2730</pub-id>
<pub-id pub-id-type="pmid">32614385</pub-id>
</mixed-citation></ref><ref id="B254"><label>254</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nersesjan</surname><given-names>V</given-names></name><name><surname>Amiri</surname><given-names>M</given-names></name><name><surname>Christensen</surname><given-names>HK</given-names></name><name><surname>Benros</surname><given-names>ME</given-names></name><name><surname>Kondziella</surname><given-names>D</given-names></name></person-group>. <article-title>Thirty-Day Mortality and Morbidity in COVID-19 Positive vs. COVID-19 Negative Individuals and vs. Individuals Tested for Influenza A/B: A Population-Based Study</article-title>. <source>Front Med (Lausanne)</source>. (<year>2020</year>) <volume>7</volume>:<fpage>598272</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fmed.2020.598272</pub-id>
<pub-id pub-id-type="pmid">33330562</pub-id>
</mixed-citation></ref><ref id="B255"><label>255</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Varatharaj</surname><given-names>A</given-names></name><name><surname>Thomas</surname><given-names>N</given-names></name><name><surname>Ellul</surname><given-names>MA</given-names></name><name><surname>Davies</surname><given-names>NWS</given-names></name><name><surname>Pollak</surname><given-names>TA</given-names></name><name><surname>Tenorio</surname><given-names>EL</given-names></name><etal/></person-group>. <article-title>Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UK-wide surveillance study</article-title>. <source>Lancet Psychiatry</source>. (<year>2020</year>) <volume>7</volume>:<page-range>875&#x02013;82</page-range>. doi: <pub-id pub-id-type="doi">10.1016/S2215-0366(20)30287-X</pub-id>
</mixed-citation></ref><ref id="B256"><label>256</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Han</surname><given-names>Y</given-names></name><name><surname>Yuan</surname><given-names>K</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>WJ</given-names></name><name><surname>Lu</surname><given-names>ZA</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Neuropsychiatric manifestations of COVID-19, potential neurotropic mechanisms, and therapeutic interventions</article-title>. <source>Transl Psychiatry</source>. (<year>2021</year>) <volume>11</volume>:<fpage>499</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41398-021-01629-8</pub-id>
<pub-id pub-id-type="pmid">34593760</pub-id>
</mixed-citation></ref><ref id="B257"><label>257</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Heming</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Rauber</surname><given-names>S</given-names></name><name><surname>Mausberg</surname><given-names>AK</given-names></name><name><surname>Borsch</surname><given-names>AL</given-names></name><name><surname>Hartlehnert</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Neurological manifestations of COVID-19 feature T cell exhaustion and dedifferentiated monocytes in cerebrospinal fluid</article-title>. <source>Immunity</source>. (<year>2021</year>) <volume>54</volume>:<fpage>164</fpage>&#x02013;<lpage>75 e6</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.immuni.2020.12.011</pub-id>
<pub-id pub-id-type="pmid">33382973</pub-id>
</mixed-citation></ref><ref id="B258"><label>258</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Franceschi</surname><given-names>AM</given-names></name><name><surname>Ahmed</surname><given-names>O</given-names></name><name><surname>Giliberto</surname><given-names>L</given-names></name><name><surname>Castillo</surname><given-names>M</given-names></name></person-group>. <article-title>Hemorrhagic posterior reversible encephalopathy syndrome as a manifestation of COVID-19 infection</article-title>. <source>AJNR Am J Neuroradiol</source>. (<year>2020</year>) <volume>41</volume>:<page-range>1173&#x02013;6</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3174/ajnr.A6595</pub-id>
</mixed-citation></ref><ref id="B259"><label>259</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hartzell</surname><given-names>S</given-names></name><name><surname>Bin</surname><given-names>S</given-names></name><name><surname>Cantarelli</surname><given-names>C</given-names></name><name><surname>Haverly</surname><given-names>M</given-names></name><name><surname>Manrique</surname><given-names>J</given-names></name><name><surname>Angeletti</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Kidney failure associates with T cell exhaustion and imbalanced follicular helper T cells</article-title>. <source>Front Immunol</source>. (<year>2020</year>) <volume>11</volume>:<fpage>583702</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3389/fimmu.2020.583702</pub-id>
<pub-id pub-id-type="pmid">33117396</pub-id>
</mixed-citation></ref><ref id="B260"><label>260</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cantarelli</surname><given-names>C</given-names></name><name><surname>Angeletti</surname><given-names>A</given-names></name><name><surname>Perin</surname><given-names>L</given-names></name><name><surname>Russo</surname><given-names>LS</given-names></name><name><surname>Sabiu</surname><given-names>G</given-names></name><name><surname>Podesta</surname><given-names>MA</given-names></name><etal/></person-group>. <article-title>Immune responses to SARS-CoV-2 in dialysis and kidney transplantation</article-title>. <source>Clin Kidney J</source>. (<year>2022</year>) <volume>15</volume>:<page-range>1816&#x02013;28</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1093/ckj/sfac174</pub-id>
</mixed-citation></ref><ref id="B261"><label>261</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Banham</surname><given-names>GD</given-names></name><name><surname>Godlee</surname><given-names>A</given-names></name><name><surname>Faustini</surname><given-names>SE</given-names></name><name><surname>Cunningham</surname><given-names>AF</given-names></name><name><surname>Richter</surname><given-names>A</given-names></name><name><surname>Harper</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Hemodialysis patients make long-lived antibodies against SARS-coV-2 that may be associated with reduced reinfection</article-title>. <source>J Am Soc Nephrol</source>. (<year>2021</year>) <volume>32</volume>:<page-range>2140&#x02013;2</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1681/ASN.2021020188</pub-id>
</mixed-citation></ref><ref id="B262"><label>262</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Clarke</surname><given-names>CL</given-names></name><name><surname>Prendecki</surname><given-names>M</given-names></name><name><surname>Dhutia</surname><given-names>A</given-names></name><name><surname>Gan</surname><given-names>J</given-names></name><name><surname>Edwards</surname><given-names>C</given-names></name><name><surname>Prout</surname><given-names>V</given-names></name><etal/></person-group>. <article-title>Longevity of SARS-CoV-2 immune responses in hemodialysis patients and protection against reinfection</article-title>. <source>Kidney Int</source>. (<year>2021</year>) <volume>99</volume>:<page-range>1470&#x02013;7</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.kint.2021.03.009</pub-id>
</mixed-citation></ref><ref id="B263"><label>263</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shankar</surname><given-names>S</given-names></name><name><surname>Beckett</surname><given-names>J</given-names></name><name><surname>Tipton</surname><given-names>T</given-names></name><name><surname>Ogbe</surname><given-names>A</given-names></name><name><surname>Kasanyinga</surname><given-names>M</given-names></name><name><surname>Dold</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>SARS-coV-2-specific T cell responses are not associated with protection against reinfection in hemodialysis patients</article-title>. <source>J Am Soc Nephrol</source>. (<year>2022</year>) <volume>33</volume>:<page-range>883&#x02013;7</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1681/ASN.2021121587</pub-id>
</mixed-citation></ref><ref id="B264"><label>264</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Aguilar-Bretones</surname><given-names>M</given-names></name><name><surname>den Hartog</surname><given-names>Y</given-names></name><name><surname>van Dijk</surname><given-names>LLA</given-names></name><name><surname>Malahe</surname><given-names>SRK</given-names></name><name><surname>Dieterich</surname><given-names>M</given-names></name><name><surname>Mora</surname><given-names>HT</given-names></name><etal/></person-group>. <article-title>SARS-CoV-2-specific immune responses converge in kidney disease patients and controls with hybrid immunity</article-title>. <source>NPJ Vaccines</source>. (<year>2024</year>) <volume>9</volume>:<fpage>93</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41541-024-00886-0</pub-id>
<pub-id pub-id-type="pmid">38806532</pub-id>
</mixed-citation></ref><ref id="B265"><label>265</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pei</surname><given-names>G</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Peng</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Yu</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Renal involvement and early prognosis in patients with COVID-19 pneumonia</article-title>. <source>J Am Soc Nephrol</source>. (<year>2020</year>) <volume>31</volume>:<page-range>1157&#x02013;65</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1681/ASN.2020030276</pub-id>
</mixed-citation></ref><ref id="B266"><label>266</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Faour</surname><given-names>WH</given-names></name><name><surname>Choaib</surname><given-names>A</given-names></name><name><surname>Issa</surname><given-names>E</given-names></name><name><surname>Choueiry</surname><given-names>FE</given-names></name><name><surname>Shbaklo</surname><given-names>K</given-names></name><name><surname>Alhajj</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Mechanisms of COVID-19-induced kidney injury and current pharmacotherapies</article-title>. <source>Inflammation Res</source>. (<year>2022</year>) <volume>71</volume>:<fpage>39</fpage>&#x02013;<lpage>56</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1007/s00011-021-01520-8</pub-id>
</mixed-citation></ref><ref id="B267"><label>267</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Legrand</surname><given-names>M</given-names></name><name><surname>Bell</surname><given-names>S</given-names></name><name><surname>Forni</surname><given-names>L</given-names></name><name><surname>Joannidis</surname><given-names>M</given-names></name><name><surname>Koyner</surname><given-names>JL</given-names></name><name><surname>Liu</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Pathophysiology of COVID-19-associated acute kidney injury</article-title>. <source>Nat Rev Nephrol</source>. (<year>2021</year>) <volume>17</volume>:<page-range>751&#x02013;64</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41581-021-00452-0</pub-id>
</mixed-citation></ref><ref id="B268"><label>268</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sullivan</surname><given-names>MK</given-names></name><name><surname>Lees</surname><given-names>JS</given-names></name><name><surname>Drake</surname><given-names>TM</given-names></name><name><surname>Docherty</surname><given-names>AB</given-names></name><name><surname>Oates</surname><given-names>G</given-names></name><name><surname>Hardwick</surname><given-names>HE</given-names></name><etal/></person-group>. <article-title>Acute kidney injury in patients hospitalized with COVID-19 from the ISARIC WHO CCP-UK Study: a prospective, multicentre cohort study</article-title>. <source>Nephrol Dial Transplant</source>. (<year>2022</year>) <volume>37</volume>:<page-range>271&#x02013;84</page-range>. doi: <pub-id pub-id-type="doi">10.1093/ndt/gfab303</pub-id>
</mixed-citation></ref><ref id="B269"><label>269</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Oetjens</surname><given-names>MT</given-names></name><name><surname>Luo</surname><given-names>JZ</given-names></name><name><surname>Chang</surname><given-names>A</given-names></name><name><surname>Leader</surname><given-names>JB</given-names></name><name><surname>Hartzel</surname><given-names>DN</given-names></name><name><surname>Moore</surname><given-names>BS</given-names></name><etal/></person-group>. <article-title>Electronic health record analysis identifies kidney disease as the leading risk factor for hospitalization in confirmed COVID-19 patients</article-title>. <source>PloS One</source>. (<year>2020</year>) <volume>15</volume>:<elocation-id>e0242182</elocation-id>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0242182</pub-id>
<pub-id pub-id-type="pmid">33180868</pub-id>
</mixed-citation></ref><ref id="B270"><label>270</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>May</surname><given-names>RM</given-names></name><name><surname>Cassol</surname><given-names>C</given-names></name><name><surname>Hannoudi</surname><given-names>A</given-names></name><name><surname>Larsen</surname><given-names>CP</given-names></name><name><surname>Lerma</surname><given-names>EV</given-names></name><name><surname>Haun</surname><given-names>RS</given-names></name><etal/></person-group>. <article-title>A multi-center retrospective cohort study defines the spectrum of kidney pathology in Coronavirus 2019 Disease (COVID-19)</article-title>. <source>Kidney Int</source>. (<year>2021</year>) <volume>100</volume>:<page-range>1303&#x02013;15</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.kint.2021.07.015</pub-id>
</mixed-citation></ref><ref id="B271"><label>271</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nasr</surname><given-names>SH</given-names></name><name><surname>Kopp</surname><given-names>JB</given-names></name></person-group>. <article-title>COVID-19-associated collapsing glomerulopathy: an emerging entity</article-title>. <source>Kidney Int Rep</source>. (<year>2020</year>) <volume>5</volume>:<page-range>759&#x02013;61</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.ekir.2020.04.030</pub-id>
</mixed-citation></ref><ref id="B272"><label>272</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hassler</surname><given-names>L</given-names></name><name><surname>Batlle</surname><given-names>D</given-names></name></person-group>. <article-title>Potential SARS-CoV-2 kidney infection and paths to injury</article-title>. <source>Nat Rev Nephrol</source>. (<year>2022</year>) <volume>18</volume>:<page-range>275&#x02013;6</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41581-022-00551-6</pub-id>
</mixed-citation></ref><ref id="B273"><label>273</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Velez</surname><given-names>JCQ</given-names></name><name><surname>Caza</surname><given-names>T</given-names></name><name><surname>Larsen</surname><given-names>CP</given-names></name></person-group>. <article-title>COVAN is the new HIVAN: the re-emergence of collapsing glomerulopathy with COVID-19</article-title>. <source>Nat Rev Nephrol</source>. (<year>2020</year>) <volume>16</volume>:<page-range>565&#x02013;7</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41581-020-0332-3</pub-id>
</mixed-citation></ref><ref id="B274"><label>274</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Guimaraes Sousa</surname><given-names>S</given-names></name><name><surname>Kleiton de Sousa</surname><given-names>A</given-names></name><name><surname>Maria Carvalho Pereira</surname><given-names>C</given-names></name><name><surname>Sofia Miranda Loiola Araujo</surname><given-names>A</given-names></name><name><surname>de Aguiar Magalhaes</surname><given-names>D</given-names></name><name><surname>Vieira de Brito</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>SARS-CoV-2 infection causes intestinal cell damage: Role of interferon&#x02019;s imbalance</article-title>. <source>Cytokine</source>. (<year>2022</year>) <volume>152</volume>:<fpage>155826</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.cyto.2022.155826</pub-id>
<pub-id pub-id-type="pmid">35158258</pub-id>
</mixed-citation></ref><ref id="B275"><label>275</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Zhu</surname><given-names>B</given-names></name><name><surname>Liang</surname><given-names>H</given-names></name><name><surname>Fang</surname><given-names>C</given-names></name><name><surname>Gong</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding</article-title>. <source>Nat Med</source>. (<year>2020</year>) <volume>26</volume>:<page-range>502&#x02013;5</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41591-020-0817-4</pub-id>
</mixed-citation></ref><ref id="B276"><label>276</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Feng</surname><given-names>Y</given-names></name><name><surname>Zeng</surname><given-names>D</given-names></name><name><surname>Hu</surname><given-names>L</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Song</surname><given-names>S</given-names></name><name><surname>Shi</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Case report: histopathology and molecular pathology analysis on enteric tissue of a COVID-19 patient</article-title>. <source>Diagn Pathol</source>. (<year>2021</year>) <volume>16</volume>:<fpage>40</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s13000-021-01082-7</pub-id>
<pub-id pub-id-type="pmid">33952310</pub-id>
</mixed-citation></ref><ref id="B277"><label>277</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Blanco-Melo</surname><given-names>D</given-names></name><name><surname>Nilsson-Payant</surname><given-names>BE</given-names></name><name><surname>Liu</surname><given-names>WC</given-names></name><name><surname>Uhl</surname><given-names>S</given-names></name><name><surname>Hoagland</surname><given-names>D</given-names></name><name><surname>Moller</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Imbalanced host response to SARS-coV-2 drives development of COVID-19</article-title>. <source>Cell</source>. (<year>2020</year>) <volume>181</volume>:<fpage>1036</fpage>&#x02013;<lpage>45 e9</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.cell.2020.04.026</pub-id>
<pub-id pub-id-type="pmid">32416070</pub-id>
</mixed-citation></ref><ref id="B278"><label>278</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lamers</surname><given-names>MM</given-names></name><name><surname>Beumer</surname><given-names>J</given-names></name><name><surname>van der Vaart</surname><given-names>J</given-names></name><name><surname>Knoops</surname><given-names>K</given-names></name><name><surname>Puschhof</surname><given-names>J</given-names></name><name><surname>Breugem</surname><given-names>TI</given-names></name><etal/></person-group>. <article-title>SARS-CoV-2 productively infects human gut enterocytes</article-title>. <source>Science</source>. (<year>2020</year>) <volume>369</volume>:<page-range>50&#x02013;4</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1126/science.abc1669</pub-id>
</mixed-citation></ref><ref id="B279"><label>279</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Saithong</surname><given-names>S</given-names></name><name><surname>Worasilchai</surname><given-names>N</given-names></name><name><surname>Saisorn</surname><given-names>W</given-names></name><name><surname>Udompornpitak</surname><given-names>K</given-names></name><name><surname>Bhunyakarnjanarat</surname><given-names>T</given-names></name><name><surname>Chindamporn</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Neutrophil extracellular traps in severe SARS-coV-2 infection: A possible impact of LPS and (1&#x02013;&#x0003e;3)-beta-D-glucan in blood from gut translocation</article-title>. <source>Cells</source>. (<year>2022</year>) <volume>11</volume>:<fpage>1103</fpage>. doi: <pub-id pub-id-type="doi">10.3390/cells11071103</pub-id>
<pub-id pub-id-type="pmid">35406667</pub-id>
</mixed-citation></ref><ref id="B280"><label>280</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kruglikov</surname><given-names>IL</given-names></name><name><surname>Scherer</surname><given-names>PE</given-names></name></person-group>. <article-title>Preexisting and inducible endotoxemia as crucial contributors to the severity of COVID-19 outcomes</article-title>. <source>PloS Pathog</source>. (<year>2021</year>) <volume>17</volume>:<elocation-id>e1009306</elocation-id>. doi: <pub-id pub-id-type="doi">10.1371/journal.ppat.1009306</pub-id>
<pub-id pub-id-type="pmid">33600486</pub-id>
</mixed-citation></ref><ref id="B281"><label>281</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sun</surname><given-names>Z</given-names></name><name><surname>Song</surname><given-names>ZG</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Tan</surname><given-names>S</given-names></name><name><surname>Lin</surname><given-names>S</given-names></name><name><surname>Zhu</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Gut microbiome alterations and gut barrier dysfunction are associated with host immune homeostasis in COVID-19 patients</article-title>. <source>BMC Med</source>. (<year>2022</year>) <volume>20</volume>:<fpage>24</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1186/s12916-021-02212-0</pub-id>
<pub-id pub-id-type="pmid">35045853</pub-id>
</mixed-citation></ref><ref id="B282"><label>282</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>Lau</surname><given-names>RI</given-names></name><name><surname>Liu</surname><given-names>Q</given-names></name><name><surname>Su</surname><given-names>Q</given-names></name><name><surname>Chan</surname><given-names>FKL</given-names></name><name><surname>Ng</surname><given-names>SC</given-names></name></person-group>. <article-title>Gut microbiota in COVID-19: key microbial changes, potential mechanisms and clinical applications</article-title>. <source>Nat Rev Gastroenterol Hepatol</source>. (<year>2023</year>) <volume>20</volume>:<page-range>323&#x02013;37</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41575-022-00698-4</pub-id>
</mixed-citation></ref><ref id="B283"><label>283</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Haupert</surname><given-names>SR</given-names></name><name><surname>Zimmermann</surname><given-names>L</given-names></name><name><surname>Shi</surname><given-names>X</given-names></name><name><surname>Fritsche</surname><given-names>LG</given-names></name><name><surname>Mukherjee</surname><given-names>B</given-names></name></person-group>. <article-title>Global prevalence of post-coronavirus disease 2019 (COVID-19) condition or long COVID: A meta-analysis and systematic review</article-title>. <source>J Infect Dis</source>. (<year>2022</year>) <volume>226</volume>:<page-range>1593&#x02013;607</page-range>. doi: <pub-id pub-id-type="doi">10.1093/infdis/jiac136</pub-id>
</mixed-citation></ref><ref id="B284"><label>284</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ayoubkhani</surname><given-names>D</given-names></name><name><surname>Khunti</surname><given-names>K</given-names></name><name><surname>Nafilyan</surname><given-names>V</given-names></name><name><surname>Maddox</surname><given-names>T</given-names></name><name><surname>Humberstone</surname><given-names>B</given-names></name><name><surname>Diamond</surname><given-names>I</given-names></name><etal/></person-group>. <article-title>Post-covid syndrome in individuals admitted to hospital with covid-19: retrospective cohort study</article-title>. <source>BMJ</source>. (<year>2021</year>) <volume>372</volume>:<fpage>n693</fpage>. doi: <pub-id pub-id-type="doi">10.1136/bmj.n693</pub-id>
<pub-id pub-id-type="pmid">33789877</pub-id>
</mixed-citation></ref><ref id="B285"><label>285</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Su</surname><given-names>Y</given-names></name><name><surname>Yuan</surname><given-names>D</given-names></name><name><surname>Chen</surname><given-names>DG</given-names></name><name><surname>Ng</surname><given-names>RH</given-names></name><name><surname>Wang</surname><given-names>K</given-names></name><name><surname>Choi</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Multiple early factors anticipate post-acute COVID-19 sequelae</article-title>. <source>Cell</source>. (<year>2022</year>) <volume>185</volume>:<fpage>881</fpage>&#x02013;<lpage>95 e20</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.cell.2022.01.014</pub-id>
<pub-id pub-id-type="pmid">35216672</pub-id>
</mixed-citation></ref><ref id="B286"><label>286</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Groff</surname><given-names>D</given-names></name><name><surname>Sun</surname><given-names>A</given-names></name><name><surname>Ssentongo</surname><given-names>AE</given-names></name><name><surname>Ba</surname><given-names>DM</given-names></name><name><surname>Parsons</surname><given-names>N</given-names></name><name><surname>Poudel</surname><given-names>GR</given-names></name><etal/></person-group>. <article-title>Short-term and long-term rates of postacute sequelae of SARS-coV-2 infection: A systematic review</article-title>. <source>JAMA Netw Open</source>. (<year>2021</year>) <volume>4</volume>:<elocation-id>e2128568</elocation-id>. doi: <pub-id pub-id-type="doi">10.1001/jamanetworkopen.2021.28568</pub-id>
<pub-id pub-id-type="pmid">34643720</pub-id>
</mixed-citation></ref><ref id="B287"><label>287</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Russell</surname><given-names>CD</given-names></name><name><surname>Lone</surname><given-names>NI</given-names></name><name><surname>Baillie</surname><given-names>JK</given-names></name></person-group>. <article-title>Comorbidities, multimorbidity and COVID-19</article-title>. <source>Nat Med</source>. (<year>2023</year>) <volume>29</volume>:<page-range>334&#x02013;43</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41591-022-02156-9</pub-id>
</mixed-citation></ref><ref id="B288"><label>288</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Klein</surname><given-names>J</given-names></name><name><surname>Wood</surname><given-names>J</given-names></name><name><surname>Jaycox</surname><given-names>JR</given-names></name><name><surname>Dhodapkar</surname><given-names>RM</given-names></name><name><surname>Lu</surname><given-names>P</given-names></name><name><surname>Gehlhausen</surname><given-names>JR</given-names></name><etal/></person-group>. <article-title>Distinguishing features of Long COVID identified through immune profiling</article-title>. <source>Nature</source>. (<year>2023</year>) <volume>623</volume>:<fpage>139</fpage>&#x02013;<lpage>48</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41586-023-06651-y</pub-id>
<pub-id pub-id-type="pmid">37748514</pub-id>
</mixed-citation></ref><ref id="B289"><label>289</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Stein</surname><given-names>SR</given-names></name><name><surname>Ramelli</surname><given-names>SC</given-names></name><name><surname>Grazioli</surname><given-names>A</given-names></name><name><surname>Chung</surname><given-names>JY</given-names></name><name><surname>Singh</surname><given-names>M</given-names></name><name><surname>Yinda</surname><given-names>CK</given-names></name><etal/></person-group>. <article-title>SARS-CoV-2 infection and persistence in the human body and brain at autopsy</article-title>. <source>Nature</source>. (<year>2022</year>) <volume>612</volume>:<page-range>758&#x02013;63</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41586-022-05542-y</pub-id>
</mixed-citation></ref><ref id="B290"><label>290</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Swank</surname><given-names>Z</given-names></name><name><surname>Senussi</surname><given-names>Y</given-names></name><name><surname>Manickas-Hill</surname><given-names>Z</given-names></name><name><surname>Yu</surname><given-names>XG</given-names></name><name><surname>Li</surname><given-names>JZ</given-names></name><name><surname>Alter</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>Persistent circulating SARS-CoV-2 spike is associated with post-acute COVID-19 sequelae</article-title>. <source>Clin Infect Dis</source>. (<year>2022</year>) <volume>76</volume>:<elocation-id>e487-90</elocation-id>. doi: <pub-id pub-id-type="doi">10.1101/2022.06.14.22276401</pub-id>
</mixed-citation></ref><ref id="B291"><label>291</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mantovani</surname><given-names>A</given-names></name><name><surname>Morrone</surname><given-names>MC</given-names></name><name><surname>Patrono</surname><given-names>C</given-names></name><name><surname>Santoro</surname><given-names>MG</given-names></name><name><surname>Schiaffino</surname><given-names>S</given-names></name><name><surname>Remuzzi</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>Long Covid: where we stand and challenges ahead</article-title>. <source>Cell Death Differ</source>. (<year>2022</year>) <volume>29</volume>:<page-range>1891&#x02013;900</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41418-022-01052-6</pub-id>
</mixed-citation></ref><ref id="B292"><label>292</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Davis</surname><given-names>HE</given-names></name><name><surname>McCorkell</surname><given-names>L</given-names></name><name><surname>Vogel</surname><given-names>JM</given-names></name><name><surname>Topol</surname><given-names>EJ</given-names></name></person-group>. <article-title>Long COVID: major findings, mechanisms and recommendations</article-title>. <source>Nat Rev Microbiol</source>. (<year>2023</year>) <volume>21</volume>:<page-range>133&#x02013;46</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41579-023-00896-0</pub-id>
</mixed-citation></ref><ref id="B293"><label>293</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Griffin</surname><given-names>DE</given-names></name></person-group>. <article-title>Why does viral RNA sometimes persist after recovery from acute infections</article-title>? <source>PloS Biol</source>. (<year>2022</year>) <volume>20</volume>:<elocation-id>e3001687</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1371/journal.pbio.3001687</pub-id>
<pub-id pub-id-type="pmid">35648781</pub-id>
</mixed-citation></ref><ref id="B294"><label>294</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kuhl</surname><given-names>U</given-names></name><name><surname>Pauschinger</surname><given-names>M</given-names></name><name><surname>Seeberg</surname><given-names>B</given-names></name><name><surname>Lassner</surname><given-names>D</given-names></name><name><surname>Noutsias</surname><given-names>M</given-names></name><name><surname>Poller</surname><given-names>W</given-names></name><etal/></person-group>. <article-title>Viral persistence in the myocardium is associated with progressive cardiac dysfunction</article-title>. <source>Circulation</source>. (<year>2005</year>) <volume>112</volume>:<page-range>1965&#x02013;70</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.105.548156</pub-id>
</mixed-citation></ref><ref id="B295"><label>295</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gold</surname><given-names>JE</given-names></name><name><surname>Okyay</surname><given-names>RA</given-names></name><name><surname>Licht</surname><given-names>WE</given-names></name><name><surname>Hurley</surname><given-names>DJ</given-names></name></person-group>. <article-title>Investigation of long COVID prevalence and its relationship to epstein-barr virus reactivation</article-title>. <source>Pathogens</source>. (<year>2021</year>) <volume>10</volume>:<fpage>763</fpage>. doi: <pub-id pub-id-type="doi">10.3390/pathogens10060763</pub-id>
<pub-id pub-id-type="pmid">34204243</pub-id>
</mixed-citation></ref><ref id="B296"><label>296</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bernal</surname><given-names>KDE</given-names></name><name><surname>Whitehurst</surname><given-names>CB</given-names></name></person-group>. <article-title>Incidence of Epstein-Barr virus reactivation is elevated in COVID-19 patients</article-title>. <source>Virus Res</source>. (<year>2023</year>) <volume>334</volume>:<fpage>199157</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.virusres.2023.199157</pub-id>
<pub-id pub-id-type="pmid">37364815</pub-id>
</mixed-citation></ref><ref id="B297"><label>297</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sepulveda</surname><given-names>N</given-names></name><name><surname>Malato</surname><given-names>J</given-names></name><name><surname>Sotzny</surname><given-names>F</given-names></name><name><surname>Grabowska</surname><given-names>AD</given-names></name><name><surname>Fonseca</surname><given-names>A</given-names></name><name><surname>Cordeiro</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Revisiting igG antibody reactivity to epstein-barr virus in myalgic encephalomyelitis/chronic fatigue syndrome and its potential application to disease diagnosis</article-title>. <source>Front Med (Lausanne)</source>. (<year>2022</year>) <volume>9</volume>:<fpage>921101</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fmed.2022.921101</pub-id>
<pub-id pub-id-type="pmid">35814774</pub-id>
</mixed-citation></ref><ref id="B298"><label>298</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Falzon</surname><given-names>D</given-names></name><name><surname>Zignol</surname><given-names>M</given-names></name><name><surname>Bastard</surname><given-names>M</given-names></name><name><surname>Floyd</surname><given-names>K</given-names></name><name><surname>Kasaeva</surname><given-names>T</given-names></name></person-group>. <article-title>The impact of the COVID-19 pandemic on the global tuberculosis epidemic</article-title>. <source>Front Immunol</source>. (<year>2023</year>) <volume>14</volume>:<fpage>1234785</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3389/fimmu.2023.1234785</pub-id>
<pub-id pub-id-type="pmid">37795102</pub-id>
</mixed-citation></ref><ref id="B299"><label>299</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Habib</surname><given-names>S</given-names></name><name><surname>Hamza</surname><given-names>E</given-names></name><name><surname>El-Gamal</surname><given-names>R</given-names></name><name><surname>Nosser</surname><given-names>NA</given-names></name><name><surname>Aboukamar</surname><given-names>WA</given-names></name><name><surname>Abdelsalam</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Clinical and immunological impacts of latent toxoplasmosis on COVID-19 patients</article-title>. <source>Cureus</source>. (<year>2023</year>) <volume>15</volume>:<fpage>e45989</fpage>. doi: <pub-id pub-id-type="doi">10.7759/cureus.45989</pub-id>
<pub-id pub-id-type="pmid">37900421</pub-id>
</mixed-citation></ref><ref id="B300"><label>300</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hasichaolu</surname></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>D</given-names></name></person-group>. <article-title>Circulating cytokines and lymphocyte subsets in patients who have recovered from COVID-19</article-title>. <source>BioMed Res Int</source>. (<year>2020</year>) <volume>2020</volume>:<fpage>7570981</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1155/2020/7570981</pub-id>
<pub-id pub-id-type="pmid">33274223</pub-id>
</mixed-citation></ref><ref id="B301"><label>301</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Phetsouphanh</surname><given-names>C</given-names></name><name><surname>Darley</surname><given-names>DR</given-names></name><name><surname>Wilson</surname><given-names>DB</given-names></name><name><surname>Howe</surname><given-names>A</given-names></name><name><surname>Munier</surname><given-names>CML</given-names></name><name><surname>Patel</surname><given-names>SK</given-names></name><etal/></person-group>. <article-title>Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection</article-title>. <source>Nat Immunol</source>. (<year>2022</year>) <volume>23</volume>:<page-range>210&#x02013;6</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41590-021-01113-x</pub-id>
</mixed-citation></ref><ref id="B302"><label>302</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schultheiss</surname><given-names>C</given-names></name><name><surname>Willscher</surname><given-names>E</given-names></name><name><surname>Paschold</surname><given-names>L</given-names></name><name><surname>Gottschick</surname><given-names>C</given-names></name><name><surname>Klee</surname><given-names>B</given-names></name><name><surname>Henkes</surname><given-names>SS</given-names></name><etal/></person-group>. <article-title>The IL-1beta, IL-6, and TNF cytokine triad is associated with post-acute sequelae of COVID-19</article-title>. <source>Cell Rep Med</source>. (<year>2022</year>) <volume>3</volume>:<fpage>100663</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.xcrm.2022.100663</pub-id>
<pub-id pub-id-type="pmid">35732153</pub-id>
</mixed-citation></ref><ref id="B303"><label>303</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Low</surname><given-names>RN</given-names></name><name><surname>Low</surname><given-names>RJ</given-names></name><name><surname>Akrami</surname><given-names>A</given-names></name></person-group>. <article-title>A review of cytokine-based pathophysiology of Long COVID symptoms</article-title>. <source>Front Med (Lausanne)</source>. (<year>2023</year>) <volume>10</volume>:<fpage>1011936</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3389/fmed.2023.1011936</pub-id>
<pub-id pub-id-type="pmid">37064029</pub-id>
</mixed-citation></ref><ref id="B304"><label>304</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhao</surname><given-names>N</given-names></name><name><surname>Di</surname><given-names>B</given-names></name><name><surname>Xu</surname><given-names>LL</given-names></name></person-group>. <article-title>The NLRP3 inflammasome and COVID-19: Activation, pathogenesis and therapeutic strategies</article-title>. <source>Cytokine Growth Factor Rev</source>. (<year>2021</year>) <volume>61</volume>:<fpage>2</fpage>&#x02013;<lpage>15</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.cytogfr.2021.06.002</pub-id>
<pub-id pub-id-type="pmid">34183243</pub-id>
</mixed-citation></ref><ref id="B305"><label>305</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shen</surname><given-names>HH</given-names></name><name><surname>Yang</surname><given-names>YX</given-names></name><name><surname>Meng</surname><given-names>X</given-names></name><name><surname>Luo</surname><given-names>XY</given-names></name><name><surname>Li</surname><given-names>XM</given-names></name><name><surname>Shuai</surname><given-names>ZW</given-names></name><etal/></person-group>. <article-title>NLRP3: A promising therapeutic target for autoimmune diseases</article-title>. <source>Autoimmun Rev</source>. (<year>2018</year>) <volume>17</volume>:<fpage>694</fpage>&#x02013;<lpage>702</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.autrev.2018.01.020</pub-id>
<pub-id pub-id-type="pmid">29729449</pub-id>
</mixed-citation></ref><ref id="B306"><label>306</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Potere</surname><given-names>N</given-names></name><name><surname>Del Buono</surname><given-names>MG</given-names></name><name><surname>Caricchio</surname><given-names>R</given-names></name><name><surname>Cremer</surname><given-names>PC</given-names></name><name><surname>Vecchie</surname><given-names>A</given-names></name><name><surname>Porreca</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>Interleukin-1 and the NLRP3 inflammasome in COVID-19: Pathogenetic and therapeutic implications</article-title>. <source>EBioMedicine</source>. (<year>2022</year>) <volume>85</volume>:<fpage>104299</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ebiom.2022.104299</pub-id>
<pub-id pub-id-type="pmid">36209522</pub-id>
</mixed-citation></ref><ref id="B307"><label>307</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Yu</surname><given-names>F</given-names></name><name><surname>Chang</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>P</given-names></name></person-group>. <article-title>Inflammasomes: a rising star on the horizon of COVID-19 pathophysiology</article-title>. <source>Front Immunol</source>. (<year>2023</year>) <volume>14</volume>:<fpage>1185233</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3389/fimmu.2023.1185233</pub-id>
<pub-id pub-id-type="pmid">37251383</pub-id>
</mixed-citation></ref><ref id="B308"><label>308</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chang</surname><given-names>SE</given-names></name><name><surname>Feng</surname><given-names>A</given-names></name><name><surname>Meng</surname><given-names>W</given-names></name><name><surname>Apostolidis</surname><given-names>SA</given-names></name><name><surname>Mack</surname><given-names>E</given-names></name><name><surname>Artandi</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>New-onset IgG autoantibodies in hospitalized patients with COVID-19</article-title>. <source>Nat Commun</source>. (<year>2021</year>) <volume>12</volume>:<fpage>5417</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41467-021-25509-3</pub-id>
<pub-id pub-id-type="pmid">34521836</pub-id>
</mixed-citation></ref><ref id="B309"><label>309</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bastard</surname><given-names>P</given-names></name><name><surname>Rosen</surname><given-names>LB</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Michailidis</surname><given-names>E</given-names></name><name><surname>Hoffmann</surname><given-names>HH</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Autoantibodies against type I IFNs in patients with life-threatening COVID-19</article-title>. <source>Science</source>. (<year>2020</year>) <volume>370</volume>:<elocation-id>eabd4585</elocation-id>. doi: <pub-id pub-id-type="doi">10.1126/science.abd4585</pub-id>
<pub-id pub-id-type="pmid">32972996</pub-id>
</mixed-citation></ref><ref id="B310"><label>310</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ahamed</surname><given-names>J</given-names></name><name><surname>Laurence</surname><given-names>J</given-names></name></person-group>. <article-title>Long COVID endotheliopathy: hypothesized mechanisms and potential therapeutic approaches</article-title>. <source>J Clin Invest</source>. (<year>2022</year>) <volume>132</volume>:<elocation-id>e161167</elocation-id>. doi: <pub-id pub-id-type="doi">10.1172/JCI161167</pub-id>
<pub-id pub-id-type="pmid">35912863</pub-id>
</mixed-citation></ref><ref id="B311"><label>311</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>De Biasi</surname><given-names>S</given-names></name><name><surname>Meschiari</surname><given-names>M</given-names></name><name><surname>Gibellini</surname><given-names>L</given-names></name><name><surname>Bellinazzi</surname><given-names>C</given-names></name><name><surname>Borella</surname><given-names>R</given-names></name><name><surname>Fidanza</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Marked T cell activation, senescence, exhaustion and skewing towards TH17 in patients with COVID-19 pneumonia</article-title>. <source>Nat Commun</source>. (<year>2020</year>) <volume>11</volume>:<fpage>3434</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41467-020-17292-4</pub-id>
<pub-id pub-id-type="pmid">32632085</pub-id>
</mixed-citation></ref><ref id="B312"><label>312</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cao</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Lei</surname><given-names>G</given-names></name><name><surname>Xu</surname><given-names>K</given-names></name><name><surname>Zhao</surname><given-names>N</given-names></name><etal/></person-group>. <article-title>Integrated gut virome and bacteriome dynamics in COVID-19 patients</article-title>. <source>Gut Microbes</source>. (<year>2021</year>) <volume>13</volume>:<fpage>1</fpage>&#x02013;<lpage>21</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1080/19490976.2021.1887722</pub-id>
</mixed-citation></ref><ref id="B313"><label>313</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Molloy</surname><given-names>EJ</given-names></name><name><surname>Nakra</surname><given-names>N</given-names></name><name><surname>Gale</surname><given-names>C</given-names></name><name><surname>Dimitriades</surname><given-names>VR</given-names></name><name><surname>Lakshminrusimha</surname><given-names>S</given-names></name></person-group>. <article-title>Multisystem inflammatory syndrome in children (MIS-C) and neonates (MIS-N) associated with COVID-19: optimizing definition and management</article-title>. <source>Pediatr Res</source>. (<year>2023</year>) <volume>93</volume>:<page-range>1499&#x02013;508</page-range>. doi: <pub-id pub-id-type="doi">10.1038/s41390-022-02263-w</pub-id>
</mixed-citation></ref><ref id="B314"><label>314</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ahmad</surname><given-names>F</given-names></name><name><surname>Ahmed</surname><given-names>A</given-names></name><name><surname>Rajendraprasad</surname><given-names>SS</given-names></name><name><surname>Loranger</surname><given-names>A</given-names></name><name><surname>Gupta</surname><given-names>S</given-names></name><name><surname>Velagapudi</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Multisystem inflammatory syndrome in adults: A rare sequela of SARS-CoV-2 infection</article-title>. <source>Int J Infect Dis</source>. (<year>2021</year>) <volume>108</volume>:<page-range>209&#x02013;11</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.ijid.2021.05.050</pub-id>
</mixed-citation></ref><ref id="B315"><label>315</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Godfred-Cato</surname><given-names>S</given-names></name><name><surname>Bryant</surname><given-names>B</given-names></name><name><surname>Leung</surname><given-names>J</given-names></name><name><surname>Oster</surname><given-names>ME</given-names></name><name><surname>Conklin</surname><given-names>L</given-names></name><name><surname>Abrams</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>COVID-19-associated multisystem inflammatory syndrome in children - United States, march-july 2020</article-title>. <source>MMWR Morb Mortal Wkly Rep</source>. (<year>2020</year>) <volume>69</volume>:<page-range>1074&#x02013;80</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.15585/mmwr.mm6932e2</pub-id>
</mixed-citation></ref><ref id="B316"><label>316</label><mixed-citation publication-type="webpage">Available online at: <uri xlink:href="https://www.cdc.gov/mis/mis-a/hcp.html">https://www.cdc.gov/mis/mis-a/hcp.html</uri> (Accessed <date-in-citation content-type="access-date">December 02, 2022</date-in-citation>).</mixed-citation></ref><ref id="B317"><label>317</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vogel</surname><given-names>TP</given-names></name><name><surname>Top</surname><given-names>KA</given-names></name><name><surname>Karatzios</surname><given-names>C</given-names></name><name><surname>Hilmers</surname><given-names>DC</given-names></name><name><surname>Tapia</surname><given-names>LI</given-names></name><name><surname>Moceri</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>Multisystem inflammatory syndrome in children and adults (MIS-C/A): Case definition &#x00026; guidelines for data collection, analysis, and presentation of immunization safety data</article-title>. <source>Vaccine</source>. (<year>2021</year>) <volume>39</volume>:<page-range>3037&#x02013;49</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.vaccine.2021.01.054</pub-id>
</mixed-citation></ref><ref id="B318"><label>318</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sperotto</surname><given-names>F</given-names></name><name><surname>Friedman</surname><given-names>KG</given-names></name><name><surname>Son</surname><given-names>MBF</given-names></name><name><surname>VanderPluym</surname><given-names>CJ</given-names></name><name><surname>Newburger</surname><given-names>JW</given-names></name><name><surname>Dionne</surname><given-names>A</given-names></name></person-group>. <article-title>Cardiac manifestations in SARS-CoV-2-associated multisystem inflammatory syndrome in children: a comprehensive review and proposed clinical approach</article-title>. <source>Eur J Pediatr</source>. (<year>2021</year>) <volume>180</volume>:<page-range>307&#x02013;22</page-range>. doi: <pub-id pub-id-type="doi">10.1007/s00431-020-03766-6</pub-id>
</mixed-citation></ref><ref id="B319"><label>319</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shen</surname><given-names>M</given-names></name><name><surname>Milner</surname><given-names>A</given-names></name><name><surname>Foppiano Palacios</surname><given-names>C</given-names></name><name><surname>Ahmad</surname><given-names>T</given-names></name></person-group>. <article-title>Multisystem inflammatory syndrome in adults (MIS-A) associated with SARS-CoV-2 infection with delayed-onset myocarditis: case report</article-title>. <source>Eur Heart J Case Rep</source>. (<year>2021</year>) <volume>5</volume>:<fpage>ytab470</fpage>. doi: <pub-id pub-id-type="doi">10.1093/ehjcr/ytab470</pub-id>
<pub-id pub-id-type="pmid">35047731</pub-id>
</mixed-citation></ref><ref id="B320"><label>320</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kaufmann</surname><given-names>CC</given-names></name><name><surname>Simon</surname><given-names>A</given-names></name><name><surname>Reinhart-Mikocki</surname><given-names>D</given-names></name><name><surname>Publig</surname><given-names>S</given-names></name><name><surname>Huber</surname><given-names>K</given-names></name><name><surname>Freynhofer</surname><given-names>MK</given-names></name></person-group>. <article-title>Multisystem inflammatory syndrome in adults in a young male following severe acute respiratory syndrome coronavirus-2 infection: a case report</article-title>. <source>Eur Heart J Case Rep</source>. (<year>2022</year>) <volume>6</volume>:<fpage>ytab521</fpage>. doi: <pub-id pub-id-type="doi">10.1093/ehjcr/ytab521</pub-id>
<pub-id pub-id-type="pmid">35028501</pub-id>
</mixed-citation></ref><ref id="B321"><label>321</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Aldeghaither</surname><given-names>S</given-names></name><name><surname>Qutob</surname><given-names>R</given-names></name><name><surname>Assanangkornchai</surname><given-names>N</given-names></name><name><surname>Issa-Chergui</surname><given-names>B</given-names></name><name><surname>Tam</surname><given-names>M</given-names></name><name><surname>Larotondo</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Clinical and histopathologic features of myocarditis in multisystem inflammatory syndrome (Adult)-associated COVID-19</article-title>. <source>Crit Care Explor</source>. (<year>2022</year>) <volume>10</volume>:<elocation-id>e0630</elocation-id>. doi: <pub-id pub-id-type="doi">10.1097/CCE.0000000000000630</pub-id>
<pub-id pub-id-type="pmid">35211680</pub-id>
</mixed-citation></ref><ref id="B322"><label>322</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>McGrath</surname><given-names>LJ</given-names></name><name><surname>Scott</surname><given-names>AM</given-names></name><name><surname>Surinach</surname><given-names>A</given-names></name><name><surname>Chambers</surname><given-names>R</given-names></name><name><surname>Benigno</surname><given-names>M</given-names></name><name><surname>Malhotra</surname><given-names>D</given-names></name></person-group>. <article-title>Use of the postacute sequelae of COVID-19 diagnosis code in routine clinical practice in the US</article-title>. <source>JAMA Netw Open</source>. (<year>2022</year>) <volume>5</volume>:<elocation-id>e2235089</elocation-id>. doi: <pub-id pub-id-type="doi">10.1001/jamanetworkopen.2022.35089</pub-id>
<pub-id pub-id-type="pmid">36201207</pub-id>
</mixed-citation></ref><ref id="B323"><label>323</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tsampasian</surname><given-names>V</given-names></name><name><surname>Elghazaly</surname><given-names>H</given-names></name><name><surname>Chattopadhyay</surname><given-names>R</given-names></name><name><surname>Debski</surname><given-names>M</given-names></name><name><surname>Naing</surname><given-names>TKP</given-names></name><name><surname>Garg</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>Risk factors associated with post-COVID-19 condition: A systematic review and meta-analysis</article-title>. <source>JAMA Intern Med</source>. (<year>2023</year>) <volume>183</volume>:<page-range>566&#x02013;80</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1001/jamainternmed.2023.0750</pub-id>
</mixed-citation></ref><ref id="B324"><label>324</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Xie</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>E</given-names></name><name><surname>Bowe</surname><given-names>B</given-names></name><name><surname>Al-Aly</surname><given-names>Z</given-names></name></person-group>. <article-title>Long-term cardiovascular outcomes of COVID-19</article-title>. <source>Nat Med</source>. (<year>2022</year>) <volume>28</volume>:<page-range>583&#x02013;90</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41591-022-01689-3</pub-id>
</mixed-citation></ref><ref id="B325"><label>325</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wan</surname><given-names>EYF</given-names></name><name><surname>Mathur</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>R</given-names></name><name><surname>Yan</surname><given-names>VKC</given-names></name><name><surname>Lai</surname><given-names>FTT</given-names></name><name><surname>Chui</surname><given-names>CSL</given-names></name><etal/></person-group>. <article-title>Association of COVID-19 with short- and long-term risk of cardiovascular disease and mortality: a prospective cohort in UK Biobank</article-title>. <source>Cardiovasc Res</source>. (<year>2023</year>) <volume>119</volume>:<page-range>1718&#x02013;27</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1093/cvr/cvac195</pub-id>
</mixed-citation></ref><ref id="B326"><label>326</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Han</surname><given-names>L</given-names></name><name><surname>Zhao</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Gu</surname><given-names>S</given-names></name><name><surname>Deng</surname><given-names>X</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Excess cardiovascular mortality across multiple COVID-19 waves in the United States from March 2020 to March 2022</article-title>. <source>Nat Cardiovasc Res</source>. (<year>2023</year>) <volume>2</volume>:<page-range>322&#x02013;33</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s44161-023-00220-2</pub-id>
</mixed-citation></ref><ref id="B327"><label>327</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Daugherty</surname><given-names>SE</given-names></name><name><surname>Guo</surname><given-names>Y</given-names></name><name><surname>Heath</surname><given-names>K</given-names></name><name><surname>Dasmarinas</surname><given-names>MC</given-names></name><name><surname>Jubilo</surname><given-names>KG</given-names></name><name><surname>Samranvedhya</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Risk of clinical sequelae after the acute phase of SARS-CoV-2 infection: retrospective cohort study</article-title>. <source>BMJ</source>. (<year>2021</year>) <volume>373</volume>:<fpage>n1098</fpage>. doi: <pub-id pub-id-type="doi">10.1136/bmj.n1098</pub-id>
<pub-id pub-id-type="pmid">34011492</pub-id>
</mixed-citation></ref><ref id="B328"><label>328</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Abbasi</surname><given-names>J</given-names></name></person-group>. <article-title>The COVID heart-one year after SARS-coV-2 infection, patients have an array of increased cardiovascular risks</article-title>. <source>JAMA</source>. (<year>2022</year>) <volume>327</volume>:<page-range>1113&#x02013;4</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1001/jama.2022.2411</pub-id>
</mixed-citation></ref><ref id="B329"><label>329</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Scudiero</surname><given-names>F</given-names></name><name><surname>Silverio</surname><given-names>A</given-names></name><name><surname>Muraca</surname><given-names>I</given-names></name><name><surname>Russo</surname><given-names>V</given-names></name><name><surname>Di Maio</surname><given-names>M</given-names></name><name><surname>Silvestro</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Long-term prognostic impact of right ventricular dysfunction in patients with COVID-19</article-title>. <source>J Pers Med</source>. (<year>2022</year>) <volume>12</volume>:<fpage>162</fpage>. doi: <pub-id pub-id-type="doi">10.3390/jpm12020162</pub-id>
<pub-id pub-id-type="pmid">35207651</pub-id>
</mixed-citation></ref><ref id="B330"><label>330</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ruffenach</surname><given-names>G</given-names></name><name><surname>Hong</surname><given-names>J</given-names></name><name><surname>Vaillancourt</surname><given-names>M</given-names></name><name><surname>Medzikovic</surname><given-names>L</given-names></name><name><surname>Eghbali</surname><given-names>M</given-names></name></person-group>. <article-title>Pulmonary hypertension secondary to pulmonary fibrosis: clinical data, histopathology and molecular insights</article-title>. <source>Respir Res</source>. (<year>2020</year>) <volume>21</volume>:<fpage>303</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12931-020-01570-2</pub-id>
<pub-id pub-id-type="pmid">33208169</pub-id>
</mixed-citation></ref><ref id="B331"><label>331</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Simonneau</surname><given-names>G</given-names></name><name><surname>Galie</surname><given-names>N</given-names></name><name><surname>Rubin</surname><given-names>LJ</given-names></name><name><surname>Langleben</surname><given-names>D</given-names></name><name><surname>Seeger</surname><given-names>W</given-names></name><name><surname>Domenighetti</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>Clinical classification of pulmonary hypertension</article-title>. <source>J Am Coll Cardiol</source>. (<year>2004</year>) <volume>43</volume>:<fpage>5S</fpage>&#x02013;<lpage>12S</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jacc.2004.02.037</pub-id>
<pub-id pub-id-type="pmid">15194173</pub-id>
</mixed-citation></ref><ref id="B332"><label>332</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Klok</surname><given-names>FA</given-names></name><name><surname>van der Hulle</surname><given-names>T</given-names></name><name><surname>den Exter</surname><given-names>PL</given-names></name><name><surname>Lankeit</surname><given-names>M</given-names></name><name><surname>Huisman</surname><given-names>MV</given-names></name><name><surname>Konstantinides</surname><given-names>S</given-names></name></person-group>. <article-title>The post-PE syndrome: a new concept for chronic complications of pulmonary embolism</article-title>. <source>Blood Rev</source>. (<year>2014</year>) <volume>28</volume>:<page-range>221&#x02013;6</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.blre.2014.07.003</pub-id>
</mixed-citation></ref><ref id="B333"><label>333</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cho</surname><given-names>JL</given-names></name><name><surname>Villacreses</surname><given-names>R</given-names></name><name><surname>Nagpal</surname><given-names>P</given-names></name><name><surname>Guo</surname><given-names>J</given-names></name><name><surname>Pezzulo</surname><given-names>AA</given-names></name><name><surname>Thurman</surname><given-names>AL</given-names></name><etal/></person-group>. <article-title>Quantitative chest CT assessment of small airways disease in post-acute SARS-coV-2 infection</article-title>. <source>Radiology</source>. (<year>2022</year>) <volume>304</volume>:<page-range>185&#x02013;92</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1148/radiol.212170</pub-id>
</mixed-citation></ref><ref id="B334"><label>334</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lewis</surname><given-names>KL</given-names></name><name><surname>Helgeson</surname><given-names>SA</given-names></name><name><surname>Tatari</surname><given-names>MM</given-names></name><name><surname>Mallea</surname><given-names>JM</given-names></name><name><surname>Baig</surname><given-names>HZ</given-names></name><name><surname>Patel</surname><given-names>NM</given-names></name></person-group>. <article-title>COVID-19 and the effects on pulmonary function following infection: A retrospective analysis</article-title>. <source>EClinicalMedicine</source>. (<year>2021</year>) <volume>39</volume>:<fpage>101079</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.eclinm.2021.101079</pub-id>
<pub-id pub-id-type="pmid">34405138</pub-id>
</mixed-citation></ref><ref id="B335"><label>335</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Faverio</surname><given-names>P</given-names></name><name><surname>Luppi</surname><given-names>F</given-names></name><name><surname>Rebora</surname><given-names>P</given-names></name><name><surname>D&#x02019;Andrea</surname><given-names>G</given-names></name><name><surname>Stainer</surname><given-names>A</given-names></name><name><surname>Busnelli</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>One-year pulmonary impairment after severe COVID-19: a prospective, multicenter follow-up study</article-title>. <source>Respir Res</source>. (<year>2022</year>) <volume>23</volume>:<fpage>65</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12931-022-01994-y</pub-id>
<pub-id pub-id-type="pmid">35313890</pub-id>
</mixed-citation></ref><ref id="B336"><label>336</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wild</surname><given-names>JM</given-names></name><name><surname>Porter</surname><given-names>JC</given-names></name><name><surname>Molyneaux</surname><given-names>PL</given-names></name><name><surname>George</surname><given-names>PM</given-names></name><name><surname>Stewart</surname><given-names>I</given-names></name><name><surname>Allen</surname><given-names>RJ</given-names></name><etal/></person-group>. <article-title>Understanding the burden of interstitial lung disease post-COVID-19: the UK Interstitial Lung Disease-Long COVID Study (UKILD-Long COVID)</article-title>. <source>BMJ Open Respir Res</source>. (<year>2021</year>) <volume>8</volume>:<elocation-id>e001049</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1136/bmjresp-2021-001049</pub-id>
</mixed-citation></ref><ref id="B337"><label>337</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ambardar</surname><given-names>SR</given-names></name><name><surname>Hightower</surname><given-names>SL</given-names></name><name><surname>Huprikar</surname><given-names>NA</given-names></name><name><surname>Chung</surname><given-names>KK</given-names></name><name><surname>Singhal</surname><given-names>A</given-names></name><name><surname>Collen</surname><given-names>JF</given-names></name></person-group>. <article-title>Post-COVID-19 pulmonary fibrosis: novel sequelae of the current pandemic</article-title>. <source>J Clin Med</source>. (<year>2021</year>) <volume>10</volume>:<fpage>2452</fpage>. doi: <pub-id pub-id-type="doi">10.3390/jcm10112452</pub-id>
<pub-id pub-id-type="pmid">34205928</pub-id>
</mixed-citation></ref><ref id="B338"><label>338</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tale</surname><given-names>S</given-names></name><name><surname>Ghosh</surname><given-names>S</given-names></name><name><surname>Meitei</surname><given-names>SP</given-names></name><name><surname>Kolli</surname><given-names>M</given-names></name><name><surname>Garbhapu</surname><given-names>AK</given-names></name><name><surname>Pudi</surname><given-names>S</given-names></name></person-group>. <article-title>Post-COVID-19 pneumonia pulmonary fibrosis</article-title>. <source>QJM</source>. (<year>2020</year>) <volume>113</volume>:<page-range>837&#x02013;8</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1093/qjmed/hcaa255</pub-id>
</mixed-citation></ref><ref id="B339"><label>339</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Melms</surname><given-names>JC</given-names></name><name><surname>Biermann</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Nair</surname><given-names>A</given-names></name><name><surname>Tagore</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>A molecular single-cell lung atlas of lethal COVID-19</article-title>. <source>Nature</source>. (<year>2021</year>) <volume>595</volume>:<page-range>114&#x02013;9</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41586-021-03569-1</pub-id>
</mixed-citation></ref><ref id="B340"><label>340</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Li</surname><given-names>F</given-names></name><name><surname>Deng</surname><given-names>J</given-names></name><name><surname>Song</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>C</given-names></name><name><surname>Yu</surname><given-names>B</given-names></name><name><surname>Wang</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>Pulmonary fibrosis in patients with COVID-19: A retrospective study</article-title>. <source>Front Cell Infect Microbiol</source>. (<year>2022</year>) <volume>12</volume>:<fpage>1013526</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3389/fcimb.2022.1013526</pub-id>
<pub-id pub-id-type="pmid">36619759</pub-id>
</mixed-citation></ref><ref id="B341"><label>341</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Davis</surname><given-names>HE</given-names></name><name><surname>Assaf</surname><given-names>GS</given-names></name><name><surname>McCorkell</surname><given-names>L</given-names></name><name><surname>Wei</surname><given-names>H</given-names></name><name><surname>Low</surname><given-names>RJ</given-names></name><name><surname>Re&#x02019;em</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Characterizing long COVID in an international cohort: 7 months of symptoms and their impact</article-title>. <source>EClinicalMedicine</source>. (<year>2021</year>) <volume>38</volume>:<fpage>101019</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.eclinm.2021.101019</pub-id>
<pub-id pub-id-type="pmid">34308300</pub-id>
</mixed-citation></ref><ref id="B342"><label>342</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Haider</surname><given-names>S</given-names></name><name><surname>Janowski</surname><given-names>AJ</given-names></name><name><surname>Lesnak</surname><given-names>JB</given-names></name><name><surname>Hayashi</surname><given-names>K</given-names></name><name><surname>Dailey</surname><given-names>DL</given-names></name><name><surname>Chimenti</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>A comparison of pain, fatigue, and function between post-COVID-19 condition, fibromyalgia, and chronic fatigue syndrome: a survey study</article-title>. <source>Pain</source>. (<year>2023</year>) <volume>164</volume>:<fpage>385</fpage>&#x02013;<lpage>401</lpage>. doi: <pub-id pub-id-type="doi">10.1097/j.pain.0000000000002711</pub-id>
<pub-id pub-id-type="pmid">36006296</pub-id>
</mixed-citation></ref><ref id="B343"><label>343</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hellgren</surname><given-names>L</given-names></name><name><surname>Birberg Thornberg</surname><given-names>U</given-names></name><name><surname>Samuelsson</surname><given-names>K</given-names></name><name><surname>Levi</surname><given-names>R</given-names></name><name><surname>Divanoglou</surname><given-names>A</given-names></name><name><surname>Blystad</surname><given-names>I</given-names></name></person-group>. <article-title>Brain MRI and neuropsychological findings at long-term follow-up after COVID-19 hospitalisation: an observational cohort study</article-title>. <source>BMJ Open</source>. (<year>2021</year>) <volume>11</volume>:<elocation-id>e055164</elocation-id>. doi: <pub-id pub-id-type="doi">10.1136/bmjopen-2021-055164</pub-id>
</mixed-citation></ref><ref id="B344"><label>344</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Xu</surname><given-names>E</given-names></name><name><surname>Xie</surname><given-names>Y</given-names></name><name><surname>Al-Aly</surname><given-names>Z</given-names></name></person-group>. <article-title>Long-term neurologic outcomes of COVID-19</article-title>. <source>Nat Med</source>. (<year>2022</year>) <volume>28</volume>:<page-range>2406&#x02013;15</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41591-022-02001-z</pub-id>
</mixed-citation></ref><ref id="B345"><label>345</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Spudich</surname><given-names>S</given-names></name><name><surname>Nath</surname><given-names>A</given-names></name></person-group>. <article-title>Nervous system consequences of COVID-19</article-title>. <source>Science</source>. (<year>2022</year>) <volume>375</volume>:<page-range>267&#x02013;9</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1126/science.abm2052</pub-id>
</mixed-citation></ref><ref id="B346"><label>346</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Klein</surname><given-names>J</given-names></name><name><surname>Wood</surname><given-names>J</given-names></name><name><surname>Jaycox</surname><given-names>JR</given-names></name><name><surname>Dhodapkar</surname><given-names>RM</given-names></name><name><surname>Lu</surname><given-names>P</given-names></name><name><surname>Gehlhausen</surname><given-names>JR</given-names></name><etal/></person-group>. <article-title>Distinguishing features of long COVID identified through immune profiling</article-title>. <source>Nature</source>. (<year>2023</year>) <volume>623</volume>:<page-range>139&#x02013;48</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41586-023-06651-y</pub-id>
</mixed-citation></ref><ref id="B347"><label>347</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wong</surname><given-names>AC</given-names></name><name><surname>Devason</surname><given-names>AS</given-names></name><name><surname>Umana</surname><given-names>IC</given-names></name><name><surname>Cox</surname><given-names>TO</given-names></name><name><surname>Dohnalova</surname><given-names>L</given-names></name><name><surname>Litichevskiy</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Serotonin reduction in post-acute sequelae of viral infection</article-title>. <source>Cell</source>. (<year>2023</year>) <volume>186</volume>:<fpage>4851</fpage>&#x02013;<lpage>67 e20</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.cell.2023.09.013</pub-id>
<pub-id pub-id-type="pmid">37848036</pub-id>
</mixed-citation></ref><ref id="B348"><label>348</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mina</surname><given-names>Y</given-names></name><name><surname>Enose-Akahata</surname><given-names>Y</given-names></name><name><surname>Hammoud</surname><given-names>DA</given-names></name><name><surname>Videckis</surname><given-names>AJ</given-names></name><name><surname>Narpala</surname><given-names>SR</given-names></name><name><surname>O&#x02019;Connell</surname><given-names>SE</given-names></name><etal/></person-group>. <article-title>Deep phenotyping of neurologic postacute sequelae of SARS-coV-2 infection</article-title>. <source>Neurol Neuroimmunol Neuroinflamm</source>. (<year>2023</year>) <volume>10</volume>:<elocation-id>e200097</elocation-id>. doi: <pub-id pub-id-type="doi">10.1212/NXI.0000000000200097</pub-id>
<pub-id pub-id-type="pmid">37147136</pub-id>
</mixed-citation></ref><ref id="B349"><label>349</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Greer</surname><given-names>N</given-names></name><name><surname>Bart</surname><given-names>B</given-names></name><name><surname>Billington</surname><given-names>CJ</given-names></name><name><surname>Diem</surname><given-names>SJ</given-names></name><name><surname>Ensrud</surname><given-names>KE</given-names></name><name><surname>Kaka</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>COVID-19 postacute care major organ damage: a systematic review</article-title>. <source>BMJ Open</source>. (<year>2022</year>) <volume>12</volume>:<elocation-id>e061245</elocation-id>. doi: <pub-id pub-id-type="doi">10.1136/bmjopen-2022-061245</pub-id>
</mixed-citation></ref><ref id="B350"><label>350</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Al-Aly</surname><given-names>Z</given-names></name><name><surname>Xie</surname><given-names>Y</given-names></name><name><surname>Bowe</surname><given-names>B</given-names></name></person-group>. <article-title>High-dimensional characterization of post-acute sequelae of COVID-19</article-title>. <source>Nature</source>. (<year>2021</year>) <volume>594</volume>:<page-range>259&#x02013;64</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41586-021-03553-9</pub-id>
</mixed-citation></ref><ref id="B351"><label>351</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vanholder</surname><given-names>R</given-names></name><name><surname>Ringoir</surname><given-names>S</given-names></name></person-group>. <article-title>Infectious morbidity and defects of phagocytic function in end-stage renal disease: a review</article-title>. <source>J Am Soc Nephrol</source>. (<year>1993</year>) <volume>3</volume>:<page-range>1541&#x02013;54</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1681/ASN.V391541</pub-id>
</mixed-citation></ref><ref id="B352"><label>352</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vaziri</surname><given-names>ND</given-names></name><name><surname>Pahl</surname><given-names>MV</given-names></name><name><surname>Crum</surname><given-names>A</given-names></name><name><surname>Norris</surname><given-names>K</given-names></name></person-group>. <article-title>Effect of uremia on structure and function of immune system</article-title>. <source>J Ren Nutr</source>. (<year>2012</year>) <volume>22</volume>:<page-range>149&#x02013;56</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1053/j.jrn.2011.10.020</pub-id>
</mixed-citation></ref><ref id="B353"><label>353</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yoon</surname><given-names>JW</given-names></name><name><surname>Pahl</surname><given-names>MV</given-names></name><name><surname>Vaziri</surname><given-names>ND</given-names></name></person-group>. <article-title>Spontaneous leukocyte activation and oxygen-free radical generation in end-stage renal disease</article-title>. <source>Kidney Int</source>. (<year>2007</year>) <volume>71</volume>:<page-range>167&#x02013;72</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/sj.ki.5002019</pub-id>
</mixed-citation></ref><ref id="B354"><label>354</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yuan</surname><given-names>Q</given-names></name><name><surname>Tang</surname><given-names>B</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name></person-group>. <article-title>Signaling pathways of chronic kidney diseases, implications for therapeutics</article-title>. <source>Signal Transduct Target Ther</source>. (<year>2022</year>) <volume>7</volume>:<fpage>182</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41392-022-01036-5</pub-id>
<pub-id pub-id-type="pmid">35680856</pub-id>
</mixed-citation></ref><ref id="B355"><label>355</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Verkade</surname><given-names>MA</given-names></name><name><surname>van Druningen</surname><given-names>CJ</given-names></name><name><surname>Op de Hoek</surname><given-names>CT</given-names></name><name><surname>Weimar</surname><given-names>W</given-names></name><name><surname>Betjes</surname><given-names>MG</given-names></name></person-group>. <article-title>Decreased antigen-specific T-cell proliferation by moDC among hepatitis B vaccine non-responders on haemodialysis</article-title>. <source>Clin Exp Med</source>. (<year>2007</year>) <volume>7</volume>:<fpage>65</fpage>&#x02013;<lpage>71</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1007/s10238-007-0127-x</pub-id>
<pub-id pub-id-type="pmid">17609878</pub-id>
</mixed-citation></ref><ref id="B356"><label>356</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schiffl</surname><given-names>H</given-names></name><name><surname>Lang</surname><given-names>SM</given-names></name></person-group>. <article-title>Long-term interplay between COVID-19 and chronic kidney disease</article-title>. <source>Int Urol Nephrol</source>. (<year>2023</year>) <volume>55</volume>:<page-range>1977&#x02013;84</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1007/s11255-023-03528-x</pub-id>
</mixed-citation></ref><ref id="B357"><label>357</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Uribarri</surname><given-names>A</given-names></name><name><surname>Nunez-Gil</surname><given-names>IJ</given-names></name><name><surname>Aparisi</surname><given-names>A</given-names></name><name><surname>Becerra-Munoz</surname><given-names>VM</given-names></name><name><surname>Feltes</surname><given-names>G</given-names></name><name><surname>Trabattoni</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Impact of renal function on admission in COVID-19 patients: an analysis of the international HOPE COVID-19 (Health Outcome Predictive Evaluation for COVID 19) Registry</article-title>. <source>J Nephrol</source>. (<year>2020</year>) <volume>33</volume>:<page-range>737&#x02013;45</page-range>. doi: <pub-id pub-id-type="doi">10.1007/s40620-020-00790-5</pub-id>
</mixed-citation></ref><ref id="B358"><label>358</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Coca</surname><given-names>SG</given-names></name><name><surname>Singanamala</surname><given-names>S</given-names></name><name><surname>Parikh</surname><given-names>CR</given-names></name></person-group>. <article-title>Chronic kidney disease after acute kidney injury: a systematic review and meta-analysis</article-title>. <source>Kidney Int</source>. (<year>2012</year>) <volume>81</volume>:<page-range>442&#x02013;8</page-range>. doi: <pub-id pub-id-type="doi">10.1038/ki.2011.379</pub-id>
</mixed-citation></ref><ref id="B359"><label>359</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sato</surname><given-names>Y</given-names></name><name><surname>Takahashi</surname><given-names>M</given-names></name><name><surname>Yanagita</surname><given-names>M</given-names></name></person-group>. <article-title>Pathophysiology of AKI to CKD progression</article-title>. <source>Semin Nephrol</source>. (<year>2020</year>) <volume>40</volume>:<page-range>206&#x02013;15</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.semnephrol.2020.01.011</pub-id>
</mixed-citation></ref><ref id="B360"><label>360</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Duffield</surname><given-names>JS</given-names></name></person-group>. <article-title>Cellular and molecular mechanisms in kidney fibrosis</article-title>. <source>J Clin Invest</source>. (<year>2014</year>) <volume>124</volume>:<page-range>2299&#x02013;306</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1172/JCI72267</pub-id>
</mixed-citation></ref><ref id="B361"><label>361</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Besschetnova</surname><given-names>TY</given-names></name><name><surname>Brooks</surname><given-names>CR</given-names></name><name><surname>Shah</surname><given-names>JV</given-names></name><name><surname>Bonventre</surname><given-names>JV</given-names></name></person-group>. <article-title>Epithelial cell cycle arrest in G2/M mediates kidney fibrosis after injury</article-title>. <source>Nat Med</source>. (<year>2010</year>) <volume>16</volume>:<page-range>535&#x02013;43</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/nm.2144</pub-id>
</mixed-citation></ref><ref id="B362"><label>362</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kramann</surname><given-names>R</given-names></name><name><surname>Schneider</surname><given-names>RK</given-names></name><name><surname>DiRocco</surname><given-names>DP</given-names></name><name><surname>MaChado</surname><given-names>F</given-names></name><name><surname>Fleig</surname><given-names>S</given-names></name><name><surname>Bondzie</surname><given-names>PA</given-names></name><etal/></person-group>. <article-title>Perivascular Gli1+ progenitors are key contributors to injury-induced organ fibrosis</article-title>. <source>Cell Stem Cell</source>. (<year>2015</year>) <volume>16</volume>:<fpage>51</fpage>&#x02013;<lpage>66</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.stem.2014.11.004</pub-id>
<pub-id pub-id-type="pmid">25465115</pub-id>
</mixed-citation></ref><ref id="B363"><label>363</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Maksimowski</surname><given-names>N</given-names></name><name><surname>Williams</surname><given-names>VR</given-names></name><name><surname>Scholey</surname><given-names>JW</given-names></name></person-group>. <article-title>Kidney ACE2 expression: Implications for chronic kidney disease</article-title>. <source>PloS One</source>. (<year>2020</year>) <volume>15</volume>:<elocation-id>e0241534</elocation-id>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0241534</pub-id>
<pub-id pub-id-type="pmid">33125431</pub-id>
</mixed-citation></ref><ref id="B364"><label>364</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Azinheira Nobrega Cruz</surname><given-names>N</given-names></name><name><surname>Goncalves de Oliveira</surname><given-names>LC</given-names></name><name><surname>Tedesco Silva Junior</surname><given-names>H</given-names></name><name><surname>Osmar Medina Pestana</surname><given-names>J</given-names></name><name><surname>Casarini</surname><given-names>DE</given-names></name></person-group>. <article-title>Angiotensin-converting enzyme 2 in the pathogenesis of renal abnormalities observed in COVID-19 patients</article-title>. <source>Front Physiol</source>. (<year>2021</year>) <volume>12</volume>:<fpage>700220</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3389/fphys.2021.700220</pub-id>
<pub-id pub-id-type="pmid">34497535</pub-id>
</mixed-citation></ref><ref id="B365"><label>365</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tarris</surname><given-names>G</given-names></name><name><surname>de Rougemont</surname><given-names>A</given-names></name><name><surname>Estienney</surname><given-names>MA</given-names></name><name><surname>Journet</surname><given-names>J</given-names></name><name><surname>Lariotte</surname><given-names>AC</given-names></name><name><surname>Aubignat</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Chronic kidney disease linked to SARS-CoV-2 infection: a case report</article-title>. <source>BMC Nephrol</source>. (<year>2021</year>) <volume>22</volume>:<fpage>278</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12882-021-02490-z</pub-id>
<pub-id pub-id-type="pmid">34376184</pub-id>
</mixed-citation></ref><ref id="B366"><label>366</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Petersen</surname><given-names>EL</given-names></name><name><surname>Gossling</surname><given-names>A</given-names></name><name><surname>Adam</surname><given-names>G</given-names></name><name><surname>Aepfelbacher</surname><given-names>M</given-names></name><name><surname>Behrendt</surname><given-names>CA</given-names></name><name><surname>Cavus</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>Multi-organ assessment in mainly non-hospitalized individuals after SARS-CoV-2 infection: The Hamburg City Health Study COVID programme</article-title>. <source>Eur Heart J</source>. (<year>2022</year>) <volume>43</volume>:<page-range>1124&#x02013;37</page-range>. doi: <pub-id pub-id-type="doi">10.1093/eurheartj/ehab914</pub-id>
</mixed-citation></ref><ref id="B367"><label>367</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nalbandian</surname><given-names>A</given-names></name><name><surname>Sehgal</surname><given-names>K</given-names></name><name><surname>Gupta</surname><given-names>A</given-names></name><name><surname>Madhavan</surname><given-names>MV</given-names></name><name><surname>McGroder</surname><given-names>C</given-names></name><name><surname>Stevens</surname><given-names>JS</given-names></name><etal/></person-group>. <article-title>Post-acute COVID-19 syndrome</article-title>. <source>Nat Med</source>. (<year>2021</year>) <volume>27</volume>:<page-range>601&#x02013;15</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41591-021-01283-z</pub-id>
</mixed-citation></ref><ref id="B368"><label>368</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Clarke</surname><given-names>SA</given-names></name><name><surname>Abbara</surname><given-names>A</given-names></name><name><surname>Dhillo</surname><given-names>WS</given-names></name></person-group>. <article-title>Impact of COVID-19 on the endocrine system: A mini-review</article-title>. <source>Endocrinology</source>. (<year>2022</year>) <volume>163</volume>:<fpage>bqab203</fpage>. doi: <pub-id pub-id-type="doi">10.1210/endocr/bqab203</pub-id>
<pub-id pub-id-type="pmid">34543404</pub-id>
</mixed-citation></ref><ref id="B369"><label>369</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Li</surname><given-names>K</given-names></name><name><surname>Chen</surname><given-names>G</given-names></name><name><surname>Hou</surname><given-names>H</given-names></name><name><surname>Liao</surname><given-names>Q</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Bai</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Analysis of sex hormones and menstruation in COVID-19 women of child-bearing age</article-title>. <source>Reprod BioMed Online</source>. (<year>2021</year>) <volume>42</volume>:<page-range>260&#x02013;7</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.rbmo.2020.09.020</pub-id>
</mixed-citation></ref><ref id="B370"><label>370</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sapra</surname><given-names>L</given-names></name><name><surname>Saini</surname><given-names>C</given-names></name><name><surname>Garg</surname><given-names>B</given-names></name><name><surname>Gupta</surname><given-names>R</given-names></name><name><surname>Verma</surname><given-names>B</given-names></name><name><surname>Mishra</surname><given-names>PK</given-names></name><etal/></person-group>. <article-title>Long-term implications of COVID-19 on bone health: pathophysiology and therapeutics</article-title>. <source>Inflammation Res</source>. (<year>2022</year>) <volume>71</volume>:<page-range>1025&#x02013;40</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1007/s00011-022-01616-9</pub-id>
</mixed-citation></ref><ref id="B371"><label>371</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zacharias</surname><given-names>H</given-names></name><name><surname>Dubey</surname><given-names>S</given-names></name><name><surname>Koduri</surname><given-names>G</given-names></name><name><surname>D&#x02019;Cruz</surname><given-names>D</given-names></name></person-group>. <article-title>Rheumatological complications of covid 19</article-title>. <source>Autoimmun Rev</source>. (<year>2021</year>) <volume>20</volume>:<fpage>102883</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.autrev.2021.102883</pub-id>
<pub-id pub-id-type="pmid">34237419</pub-id>
</mixed-citation></ref><ref id="B372"><label>372</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Beydon</surname><given-names>M</given-names></name><name><surname>Chevalier</surname><given-names>K</given-names></name><name><surname>Al Tabaa</surname><given-names>O</given-names></name><name><surname>Hamroun</surname><given-names>S</given-names></name><name><surname>Delettre</surname><given-names>AS</given-names></name><name><surname>Thomas</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Myositis as a manifestation of SARS-coV-2</article-title>. <source>Ann Rheum Dis</source>. (<year>2021</year>) <volume>80</volume>:<fpage>e42</fpage>. doi: <pub-id pub-id-type="doi">10.1136/annrheumdis-2020-217573</pub-id>
<pub-id pub-id-type="pmid">32327427</pub-id>
</mixed-citation></ref><ref id="B373"><label>373</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fiolet</surname><given-names>T</given-names></name><name><surname>Kherabi</surname><given-names>Y</given-names></name><name><surname>MacDonald</surname><given-names>CJ</given-names></name><name><surname>Ghosn</surname><given-names>J</given-names></name><name><surname>Peiffer-Smadja</surname><given-names>N</given-names></name></person-group>. <article-title>Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review</article-title>. <source>Clin Microbiol Infect</source>. (<year>2022</year>) <volume>28</volume>:<page-range>202&#x02013;21</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.cmi.2021.10.005</pub-id>
</mixed-citation></ref><ref id="B374"><label>374</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Forchette</surname><given-names>L</given-names></name><name><surname>Sebastian</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>T</given-names></name></person-group>. <article-title>A comprehensive review of COVID-19 virology, vaccines, variants, and therapeutics</article-title>. <source>Curr Med Sci</source>. (<year>2021</year>) <volume>41</volume>:<page-range>1037&#x02013;51</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1007/s11596-021-2395-1</pub-id>
</mixed-citation></ref><ref id="B375"><label>375</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mendiola-Pastrana</surname><given-names>IR</given-names></name><name><surname>Lopez-Ortiz</surname><given-names>E</given-names></name><name><surname>Rio de la Loza-Zamora</surname><given-names>JG</given-names></name><name><surname>Gonzalez</surname><given-names>J</given-names></name><name><surname>Gomez-Garcia</surname><given-names>A</given-names></name><name><surname>Lopez-Ortiz</surname><given-names>G</given-names></name></person-group>. <article-title>SARS-coV-2 variants and clinical outcomes: A systematic review</article-title>. <source>Life (Basel)</source>. (<year>2022</year>) <volume>12</volume>:<fpage>170</fpage>. doi: <pub-id pub-id-type="doi">10.3390/life12020170</pub-id>
<pub-id pub-id-type="pmid">35207458</pub-id>
</mixed-citation></ref><ref id="B376"><label>376</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Corriero</surname><given-names>A</given-names></name><name><surname>Ribezzi</surname><given-names>M</given-names></name><name><surname>Mele</surname><given-names>F</given-names></name><name><surname>Angrisani</surname><given-names>C</given-names></name><name><surname>Romaniello</surname><given-names>F</given-names></name><name><surname>Daleno</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>COVID-19 variants in critically ill patients: A comparison of the delta and omicron variant profiles</article-title>. <source>Infect Dis Rep</source>. (<year>2022</year>) <volume>14</volume>:<fpage>492</fpage>&#x02013;<lpage>500</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3390/idr14030052</pub-id>
<pub-id pub-id-type="pmid">35735762</pub-id>
</mixed-citation></ref><ref id="B377"><label>377</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Du</surname><given-names>M</given-names></name><name><surname>Ma</surname><given-names>Y</given-names></name><name><surname>Deng</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name></person-group>. <article-title>Comparison of long COVID-19 caused by different SARS-coV-2 strains: A systematic review and meta-analysis</article-title>. <source>Int J Environ Res Public Health</source>. (<year>2022</year>) <volume>19</volume>:<fpage>16010</fpage>. doi: <pub-id pub-id-type="doi">10.3390/ijerph192316010</pub-id>
<pub-id pub-id-type="pmid">36498103</pub-id>
</mixed-citation></ref><ref id="B378"><label>378</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Notarte</surname><given-names>KI</given-names></name><name><surname>Catahay</surname><given-names>JA</given-names></name><name><surname>Velasco</surname><given-names>JV</given-names></name><name><surname>Pastrana</surname><given-names>A</given-names></name><name><surname>Ver</surname><given-names>AT</given-names></name><name><surname>Pangilinan</surname><given-names>FC</given-names></name><etal/></person-group>. <article-title>Impact of COVID-19 vaccination on the risk of developing long-COVID and on existing long-COVID symptoms: A systematic review</article-title>. <source>EClinicalMedicine</source>. (<year>2022</year>) <volume>53</volume>:<fpage>101624</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.eclinm.2022.101624</pub-id>
<pub-id pub-id-type="pmid">36051247</pub-id>
</mixed-citation></ref><ref id="B379"><label>379</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Byambasuren</surname><given-names>O</given-names></name><name><surname>Stehlik</surname><given-names>P</given-names></name><name><surname>Clark</surname><given-names>J</given-names></name><name><surname>Alcorn</surname><given-names>K</given-names></name><name><surname>Glasziou</surname><given-names>P</given-names></name></person-group>. <article-title>Effect of covid-19 vaccination on long covid: systematic review</article-title>. <source>BMJ Med</source>. (<year>2023</year>) <volume>2</volume>:<fpage>e000385</fpage>. doi: <pub-id pub-id-type="doi">10.1136/bmjmed-2022-000385</pub-id>
</mixed-citation></ref><ref id="B380"><label>380</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tyrkalska</surname><given-names>SD</given-names></name><name><surname>Martinez-Lopez</surname><given-names>A</given-names></name><name><surname>Arroyo</surname><given-names>AB</given-names></name><name><surname>Martinez-Morcillo</surname><given-names>FJ</given-names></name><name><surname>Candel</surname><given-names>S</given-names></name><name><surname>Garcia-Moreno</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Differential proinflammatory activities of Spike proteins of SARS-CoV-2 variants of concern</article-title>. <source>Sci Adv</source>. (<year>2022</year>) <volume>8</volume>:<elocation-id>eabo0732</elocation-id>. doi: <pub-id pub-id-type="doi">10.1126/sciadv.abo0732</pub-id>
<pub-id pub-id-type="pmid">36112681</pub-id>
</mixed-citation></ref><ref id="B381"><label>381</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nishijima</surname><given-names>Y</given-names></name><name><surname>Hader</surname><given-names>SN</given-names></name><name><surname>Hanson</surname><given-names>AJ</given-names></name><name><surname>Zhang</surname><given-names>DX</given-names></name><name><surname>Sparapani</surname><given-names>R</given-names></name><name><surname>Gutterman</surname><given-names>DD</given-names></name><etal/></person-group>. <article-title>Prolonged endothelial-dysfunction in human arterioles following infection with SARS-CoV-2</article-title>. <source>Cardiovasc Res</source>. (<year>2022</year>) <volume>118</volume>:<page-range>18&#x02013;9</page-range>. doi:&#x000a0;doi.org/10.1093/cvr/cvab339
</mixed-citation></ref><ref id="B382"><label>382</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nishijima</surname><given-names>Y</given-names></name><name><surname>Hader</surname><given-names>SN</given-names></name><name><surname>Beyer</surname><given-names>AM</given-names></name></person-group>. <article-title>Differential impacts of COVID-19 variants on human microvascular function</article-title>. <source>Cardiovasc Res</source>. (<year>2023</year>) <volume>119</volume>:<page-range>e115&#x02013;e7</page-range>. doi: <pub-id pub-id-type="doi">10.1093/cvr/cvad006</pub-id>
</mixed-citation></ref><ref id="B383"><label>383</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jiang</surname><given-names>Y</given-names></name><name><surname>Rubin</surname><given-names>L</given-names></name><name><surname>Peng</surname><given-names>T</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Xing</surname><given-names>X</given-names></name><name><surname>Lazarovici</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>Cytokine storm in COVID-19: from viral infection to immune responses, diagnosis and therapy</article-title>. <source>Int J Biol Sci</source>. (<year>2022</year>) <volume>18</volume>:<page-range>459&#x02013;72</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.7150/ijbs.59272</pub-id>
</mixed-citation></ref><ref id="B384"><label>384</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Henderson</surname><given-names>LA</given-names></name><name><surname>Canna</surname><given-names>SW</given-names></name><name><surname>Schulert</surname><given-names>GS</given-names></name><name><surname>Volpi</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>PY</given-names></name><name><surname>Kernan</surname><given-names>KF</given-names></name><etal/></person-group>. <article-title>On the alert for cytokine storm: immunopathology in COVID-19</article-title>. <source>Arthritis Rheumatol</source>. (<year>2020</year>) <volume>72</volume>:<page-range>1059&#x02013;63</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1002/art.41285</pub-id>
</mixed-citation></ref><ref id="B385"><label>385</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Zhao</surname><given-names>B</given-names></name><name><surname>Qu</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Xiong</surname><given-names>J</given-names></name><name><surname>Feng</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Detectable serum severe acute respiratory syndrome coronavirus 2 viral load (RNAemia) is closely correlated with drastically elevated interleukin 6 level in critically ill patients with coronavirus disease 2019</article-title>. <source>Clin Infect Dis</source>. (<year>2020</year>) <volume>71</volume>:<page-range>1937&#x02013;42</page-range>. doi: <pub-id pub-id-type="doi">10.1093/cid/ciaa449</pub-id>
</mixed-citation></ref><ref id="B386"><label>386</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Luporini</surname><given-names>RL</given-names></name><name><surname>Rodolpho</surname><given-names>JMA</given-names></name><name><surname>Kubota</surname><given-names>LT</given-names></name><name><surname>Martin</surname><given-names>A</given-names></name><name><surname>Cominetti</surname><given-names>MR</given-names></name><name><surname>Anibal</surname><given-names>FF</given-names></name><etal/></person-group>. <article-title>IL-6 and IL-10 are associated with disease severity and higher comorbidity in adults with COVID-19</article-title>. <source>Cytokine</source>. (<year>2021</year>) <volume>143</volume>:<fpage>155507</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.cyto.2021.155507</pub-id>
<pub-id pub-id-type="pmid">33839002</pub-id>
</mixed-citation></ref><ref id="B387"><label>387</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bekele</surname><given-names>Y</given-names></name><name><surname>Sui</surname><given-names>Y</given-names></name><name><surname>Berzofsky</surname><given-names>JA</given-names></name></person-group>. <article-title>IL-7 in SARS-coV-2 infection and as a potential vaccine adjuvant</article-title>. <source>Front Immunol</source>. (<year>2021</year>) <volume>12</volume>:<fpage>737406</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3389/fimmu.2021.737406</pub-id>
<pub-id pub-id-type="pmid">34603318</pub-id>
</mixed-citation></ref><ref id="B388"><label>388</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ma</surname><given-names>A</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Ye</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Zhuang</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>High levels of circulating IL-8 and soluble IL-2R are associated with prolonged illness in patients with severe COVID-19</article-title>. <source>Front Immunol</source>. (<year>2021</year>) <volume>12</volume>:<fpage>626235</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fimmu.2021.626235</pub-id>
<pub-id pub-id-type="pmid">33584733</pub-id>
</mixed-citation></ref><ref id="B389"><label>389</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kedor</surname><given-names>C</given-names></name><name><surname>Freitag</surname><given-names>H</given-names></name><name><surname>Meyer-Arndt</surname><given-names>L</given-names></name><name><surname>Wittke</surname><given-names>K</given-names></name><name><surname>Hanitsch</surname><given-names>LG</given-names></name><name><surname>Zoller</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>A prospective observational study of post-COVID-19 chronic fatigue syndrome following the first pandemic wave in Germany and biomarkers associated with symptom severity</article-title>. <source>Nat Commun</source>. (<year>2022</year>) <volume>13</volume>:<fpage>5104</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41467-022-32507-6</pub-id>
<pub-id pub-id-type="pmid">36042189</pub-id>
</mixed-citation></ref><ref id="B390"><label>390</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shabgah</surname><given-names>AG</given-names></name><name><surname>Navashenaq</surname><given-names>JG</given-names></name><name><surname>Shabgah</surname><given-names>OG</given-names></name><name><surname>Mohammadi</surname><given-names>H</given-names></name><name><surname>Sahebkar</surname><given-names>A</given-names></name></person-group>. <article-title>Interleukin-22 in human inflammatory diseases and viral infections</article-title>. <source>Autoimmun Rev</source>. (<year>2017</year>) <volume>16</volume>:<page-range>1209&#x02013;18</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.autrev.2017.10.004</pub-id>
</mixed-citation></ref><ref id="B391"><label>391</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fang</surname><given-names>S</given-names></name><name><surname>Ju</surname><given-names>D</given-names></name><name><surname>Lin</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>W</given-names></name></person-group>. <article-title>The role of interleukin-22 in lung health and its therapeutic potential for COVID-19</article-title>. <source>Front Immunol</source>. (<year>2022</year>) <volume>13</volume>:<fpage>951107</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3389/fimmu.2022.951107</pub-id>
<pub-id pub-id-type="pmid">35967401</pub-id>
</mixed-citation></ref><ref id="B392"><label>392</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Muller</surname><given-names>U</given-names></name><name><surname>Steinhoff</surname><given-names>U</given-names></name><name><surname>Reis</surname><given-names>LF</given-names></name><name><surname>Hemmi</surname><given-names>S</given-names></name><name><surname>Pavlovic</surname><given-names>J</given-names></name><name><surname>Zinkernagel</surname><given-names>RM</given-names></name><etal/></person-group>. <article-title>Functional role of type I and type II interferons in antiviral defense</article-title>. <source>Science</source>. (<year>1994</year>) <volume>264</volume>:<page-range>1918&#x02013;21</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1126/science.8009221</pub-id>
</mixed-citation></ref><ref id="B393"><label>393</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lee</surname><given-names>JS</given-names></name><name><surname>Shin</surname><given-names>EC</given-names></name></person-group>. <article-title>The type I interferon response in COVID-19: implications for treatment</article-title>. <source>Nat Rev Immunol</source>. (<year>2020</year>) <volume>20</volume>:<page-range>585&#x02013;6</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41577-020-00429-3</pub-id>
</mixed-citation></ref><ref id="B394"><label>394</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Karki</surname><given-names>R</given-names></name><name><surname>Sharma</surname><given-names>BR</given-names></name><name><surname>Tuladhar</surname><given-names>S</given-names></name><name><surname>Williams</surname><given-names>EP</given-names></name><name><surname>Zalduondo</surname><given-names>L</given-names></name><name><surname>Samir</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>Synergism of TNF-alpha and IFN-gamma triggers inflammatory cell death, tissue damage, and mortality in SARS-coV-2 infection and cytokine shock syndromes</article-title>. <source>Cell</source>. (<year>2021</year>) <volume>184</volume>:<fpage>149</fpage>&#x02013;<lpage>68 e17</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.cell.2020.11.025</pub-id>
<pub-id pub-id-type="pmid">33278357</pub-id>
</mixed-citation></ref><ref id="B395"><label>395</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rubtsova</surname><given-names>K</given-names></name><name><surname>Rubtsov</surname><given-names>AV</given-names></name><name><surname>Cancro</surname><given-names>MP</given-names></name><name><surname>Marrack</surname><given-names>P</given-names></name></person-group>. <article-title>Age-associated B cells: A T-bet-dependent effector with roles in protective and pathogenic immunity</article-title>. <source>J Immunol</source>. (<year>2015</year>) <volume>195</volume>:<page-range>1933&#x02013;7</page-range>. doi: <pub-id pub-id-type="doi">10.4049/jimmunol.1501209</pub-id>
</mixed-citation></ref><ref id="B396"><label>396</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ferreira-Gomes</surname><given-names>M</given-names></name><name><surname>Kruglov</surname><given-names>A</given-names></name><name><surname>Durek</surname><given-names>P</given-names></name><name><surname>Heinrich</surname><given-names>F</given-names></name><name><surname>Tizian</surname><given-names>C</given-names></name><name><surname>Heinz</surname><given-names>GA</given-names></name><etal/></person-group>. <article-title>SARS-CoV-2 in severe COVID-19 induces a TGF-beta-dominated chronic immune response that does not target itself</article-title>. <source>Nat Commun</source>. (<year>2021</year>) <volume>12</volume>:<fpage>1961</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41467-021-22210-3</pub-id>
<pub-id pub-id-type="pmid">33785765</pub-id>
</mixed-citation></ref><ref id="B397"><label>397</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Witkowski</surname><given-names>M</given-names></name><name><surname>Tizian</surname><given-names>C</given-names></name><name><surname>Ferreira-Gomes</surname><given-names>M</given-names></name><name><surname>Niemeyer</surname><given-names>D</given-names></name><name><surname>Jones</surname><given-names>TC</given-names></name><name><surname>Heinrich</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>Untimely TGFbeta responses in COVID-19 limit antiviral functions of NK cells</article-title>. <source>Nature</source>. (<year>2021</year>) <volume>600</volume>:<fpage>295</fpage>&#x02013;<lpage>301</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41586-021-04142-6</pub-id>
<pub-id pub-id-type="pmid">34695836</pub-id>
</mixed-citation></ref><ref id="B398"><label>398</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wilk</surname><given-names>AJ</given-names></name><name><surname>Rustagi</surname><given-names>A</given-names></name><name><surname>Zhao</surname><given-names>NQ</given-names></name><name><surname>Roque</surname><given-names>J</given-names></name><name><surname>Martinez-Colon</surname><given-names>GJ</given-names></name><name><surname>McKechnie</surname><given-names>JL</given-names></name><etal/></person-group>. <article-title>A single-cell atlas of the peripheral immune response in patients with severe COVID-19</article-title>. <source>Nat Med</source>. (<year>2020</year>) <volume>26</volume>:<page-range>1070&#x02013;6</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41591-020-0944-y</pub-id>
</mixed-citation></ref><ref id="B399"><label>399</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Parrot</surname><given-names>T</given-names></name><name><surname>Gorin</surname><given-names>JB</given-names></name><name><surname>Ponzetta</surname><given-names>A</given-names></name><name><surname>Maleki</surname><given-names>KT</given-names></name><name><surname>Kammann</surname><given-names>T</given-names></name><name><surname>Emgard</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>MAIT cell activation and dynamics associated with COVID-19 disease severity</article-title>. <source>Sci Immunol</source>. (<year>2020</year>) <volume>5</volume>:<elocation-id>eabe1670</elocation-id>. doi: <pub-id pub-id-type="doi">10.1101/2020.08.27.20182550</pub-id>
<pub-id pub-id-type="pmid">32989174</pub-id>
</mixed-citation></ref><ref id="B400"><label>400</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Townsend</surname><given-names>L</given-names></name><name><surname>Dyer</surname><given-names>AH</given-names></name><name><surname>Naughton</surname><given-names>A</given-names></name><name><surname>Imangaliyev</surname><given-names>S</given-names></name><name><surname>Dunne</surname><given-names>J</given-names></name><name><surname>Kiersey</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Severe COVID-19 is characterised by inflammation and immature myeloid cells early in disease progression</article-title>. <source>Heliyon</source>. (<year>2022</year>) <volume>8</volume>:<fpage>e09230</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.heliyon.2022.e09230</pub-id>
<pub-id pub-id-type="pmid">35386227</pub-id>
</mixed-citation></ref><ref id="B401"><label>401</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>George</surname><given-names>PM</given-names></name><name><surname>Reed</surname><given-names>A</given-names></name><name><surname>Desai</surname><given-names>SR</given-names></name><name><surname>Devaraj</surname><given-names>A</given-names></name><name><surname>Faiez</surname><given-names>TS</given-names></name><name><surname>Laverty</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>A persistent neutrophil-associated immune signature characterizes post-COVID-19 pulmonary sequelae</article-title>. <source>Sci Transl Med</source>. (<year>2022</year>) <volume>14</volume>:<elocation-id>eabo5795</elocation-id>. doi: <pub-id pub-id-type="doi">10.1126/scitranslmed.abo5795</pub-id>
<pub-id pub-id-type="pmid">36383686</pub-id>
</mixed-citation></ref><ref id="B402"><label>402</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name></person-group>. <article-title>NETosis and neutrophil extracellular traps in COVID-19: immunothrombosis and beyond</article-title>. <source>Front Immunol</source>. (<year>2022</year>) <volume>13</volume>:<fpage>838011</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3389/fimmu.2022.838011</pub-id>
<pub-id pub-id-type="pmid">35309344</pub-id>
</mixed-citation></ref><ref id="B403"><label>403</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Newell</surname><given-names>KL</given-names></name><name><surname>Clemmer</surname><given-names>DC</given-names></name><name><surname>Cox</surname><given-names>JB</given-names></name><name><surname>Kayode</surname><given-names>YI</given-names></name><name><surname>Zoccoli-Rodriguez</surname><given-names>V</given-names></name><name><surname>Taylor</surname><given-names>HE</given-names></name><etal/></person-group>. <article-title>Switched and unswitched memory B cells detected during SARS-CoV-2 convalescence correlate with limited symptom duration</article-title>. <source>PloS One</source>. (<year>2021</year>) <volume>16</volume>:<elocation-id>e0244855</elocation-id>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0244855</pub-id>
<pub-id pub-id-type="pmid">33507994</pub-id>
</mixed-citation></ref><ref id="B404"><label>404</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Speletas</surname><given-names>M</given-names></name><name><surname>Dadouli</surname><given-names>K</given-names></name><name><surname>Syrakouli</surname><given-names>A</given-names></name><name><surname>Gatselis</surname><given-names>N</given-names></name><name><surname>Germanidis</surname><given-names>G</given-names></name><name><surname>Mouchtouri</surname><given-names>VA</given-names></name><etal/></person-group>. <article-title>MBL deficiency-causing B allele (rs1800450) as a risk factor for severe COVID-19</article-title>. <source>Immunobiology</source>. (<year>2021</year>) <volume>226</volume>:<fpage>152136</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.imbio.2021.152136</pub-id>
<pub-id pub-id-type="pmid">34628288</pub-id>
</mixed-citation></ref><ref id="B405"><label>405</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Terahara</surname><given-names>K</given-names></name><name><surname>Sato</surname><given-names>T</given-names></name><name><surname>Adachi</surname><given-names>Y</given-names></name><name><surname>Tonouchi</surname><given-names>K</given-names></name><name><surname>Onodera</surname><given-names>T</given-names></name><name><surname>Moriyama</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>SARS-CoV-2-specific CD4(+) T cell longevity correlates with Th17-like phenotype</article-title>. <source>iScience</source>. (<year>2022</year>) <volume>25</volume>:<fpage>104959</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.isci.2022.104959</pub-id>
<pub-id pub-id-type="pmid">35992306</pub-id>
</mixed-citation></ref><ref id="B406"><label>406</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ryan</surname><given-names>FJ</given-names></name><name><surname>Hope</surname><given-names>CM</given-names></name><name><surname>Masavuli</surname><given-names>MG</given-names></name><name><surname>Lynn</surname><given-names>MA</given-names></name><name><surname>Mekonnen</surname><given-names>ZA</given-names></name><name><surname>Yeow</surname><given-names>AEL</given-names></name><etal/></person-group>. <article-title>Long-term perturbation of the peripheral immune system months after SARS-CoV-2 infection</article-title>. <source>BMC Med</source>. (<year>2022</year>) <volume>20</volume>:<fpage>26</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1186/s12916-021-02228-6</pub-id>
<pub-id pub-id-type="pmid">35027067</pub-id>
</mixed-citation></ref><ref id="B407"><label>407</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Guo</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>G</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Ren</surname><given-names>L</given-names></name><name><surname>Gu</surname><given-names>X</given-names></name><etal/></person-group>. <article-title>SARS-CoV-2-specific antibody and T-cell responses 1 year after infection in people recovered from COVID-19: a longitudinal cohort study</article-title>. <source>Lancet Microbe</source>. (<year>2022</year>) <volume>3</volume>:<page-range>e348&#x02013;e56</page-range>. doi: <pub-id pub-id-type="doi">10.1016/S2666-5247(22)00036-2</pub-id>
</mixed-citation></ref><ref id="B408"><label>408</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Al-Saadi</surname><given-names>E</given-names></name><name><surname>Abdulnabi</surname><given-names>MA</given-names></name></person-group>. <article-title>Hematological changes associated with COVID-19 infection</article-title>. <source>J Clin Lab Anal</source>. (<year>2022</year>) <volume>36</volume>:<elocation-id>e24064</elocation-id>. doi: <pub-id pub-id-type="doi">10.1002/jcla.24064</pub-id>
<pub-id pub-id-type="pmid">34783405</pub-id>
</mixed-citation></ref><ref id="B409"><label>409</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Terpos</surname><given-names>E</given-names></name><name><surname>Ntanasis-Stathopoulos</surname><given-names>I</given-names></name><name><surname>Elalamy</surname><given-names>I</given-names></name><name><surname>Kastritis</surname><given-names>E</given-names></name><name><surname>Sergentanis</surname><given-names>TN</given-names></name><name><surname>Politou</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Hematological findings and complications of COVID-19</article-title>. <source>Am J Hematol</source>. (<year>2020</year>) <volume>95</volume>:<page-range>834&#x02013;47</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1002/ajh.25829</pub-id>
</mixed-citation></ref><ref id="B410"><label>410</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Halpert</surname><given-names>G</given-names></name><name><surname>Shoenfeld</surname><given-names>Y</given-names></name></person-group>. <article-title>SARS-CoV-2, the autoimmune virus</article-title>. <source>Autoimmun Rev</source>. (<year>2020</year>) <volume>19</volume>:<fpage>102695</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.autrev.2020.102695</pub-id>
<pub-id pub-id-type="pmid">33130000</pub-id>
</mixed-citation></ref><ref id="B411"><label>411</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pretorius</surname><given-names>E</given-names></name><name><surname>Vlok</surname><given-names>M</given-names></name><name><surname>Venter</surname><given-names>C</given-names></name><name><surname>Bezuidenhout</surname><given-names>JA</given-names></name><name><surname>Laubscher</surname><given-names>GJ</given-names></name><name><surname>Steenkamp</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Persistent clotting protein pathology in Long COVID/Post-Acute Sequelae of COVID-19 (PASC) is accompanied by increased levels of antiplasmin</article-title>. <source>Cardiovasc Diabetol</source>. (<year>2021</year>) <volume>20</volume>:<fpage>172</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12933-021-01359-7</pub-id>
<pub-id pub-id-type="pmid">34425843</pub-id>
</mixed-citation></ref><ref id="B412"><label>412</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Salisbury</surname><given-names>R</given-names></name><name><surname>Iotchkova</surname><given-names>V</given-names></name><name><surname>Jaafar</surname><given-names>S</given-names></name><name><surname>Morton</surname><given-names>J</given-names></name><name><surname>Sangha</surname><given-names>G</given-names></name><name><surname>Shah</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Incidence of symptomatic, image-confirmed venous thromboembolism following hospitalization for COVID-19 with 90-day follow-up</article-title>. <source>Blood Adv</source>. (<year>2020</year>) <volume>4</volume>:<page-range>6230&#x02013;9</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1182/bloodadvances.2020003349</pub-id>
</mixed-citation></ref><ref id="B413"><label>413</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Munipalli</surname><given-names>B</given-names></name><name><surname>Seim</surname><given-names>L</given-names></name><name><surname>Dawson</surname><given-names>NL</given-names></name><name><surname>Knight</surname><given-names>D</given-names></name><name><surname>Dabrh</surname><given-names>AMA</given-names></name></person-group>. <article-title>Post-acute sequelae of COVID-19 (PASC): a meta-narrative review of pathophysiology, prevalence, and management</article-title>. <source>SN Compr Clin Med</source>. (<year>2022</year>) <volume>4</volume>:<fpage>90</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1007/s42399-022-01167-4</pub-id>
<pub-id pub-id-type="pmid">35402784</pub-id>
</mixed-citation></ref><ref id="B414"><label>414</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jewell</surname><given-names>PD</given-names></name><name><surname>Bramham</surname><given-names>K</given-names></name><name><surname>Galloway</surname><given-names>J</given-names></name><name><surname>Post</surname><given-names>F</given-names></name><name><surname>Norton</surname><given-names>S</given-names></name><name><surname>Teo</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>COVID-19-related acute kidney injury; incidence, risk factors and outcomes in a large UK cohort</article-title>. <source>BMC Nephrol</source>. (<year>2021</year>) <volume>22</volume>:<fpage>359</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1186/s12882-021-02557-x</pub-id>
<pub-id pub-id-type="pmid">34719384</pub-id>
</mixed-citation></ref><ref id="B415"><label>415</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Credle</surname><given-names>JJ</given-names></name><name><surname>Gunn</surname><given-names>J</given-names></name><name><surname>Sangkhapreecha</surname><given-names>P</given-names></name><name><surname>Monaco</surname><given-names>DR</given-names></name><name><surname>Zheng</surname><given-names>XA</given-names></name><name><surname>Tsai</surname><given-names>HJ</given-names></name><etal/></person-group>. <article-title>Unbiased discovery of autoantibodies associated with severe COVID-19 via genome-scale self-assembled DNA-barcoded protein libraries</article-title>. <source>Nat Biomed Eng</source>. (<year>2022</year>) <volume>6</volume>(<issue>8</issue>):<page-range>992&#x02013;1003</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41551-022-00925-y</pub-id>
</mixed-citation></ref></ref-list></back></article>